

DUKE UNIVERSITY MEDICAL CENTER

CURRICULUM VITAE

Henry S. Friedman, M.D.

PRIMARY ACADEMIC APPOINTMENT: Surgery

SECONDARY ACADEMIC APPOINTMENTS: Pediatrics, Pathology, Medicine

PRESENT ACADEMIC RANK AND TITLE: James B. Powell, Jr. Professor of

Neuro-Oncology (Surgery)

Professor of Pediatrics

Associate Professor of Medicine

Assistant Professor of Pathology

DATE AND RANK OF FIRST DUKE July 1, 1983

FACULTY APPOINTMENT: Assistant Professor of Pediatrics

MEDICAL LICENSURE: New York, 1977

North Carolina, 1980

SPECIALTY CERTIFICATION AND DATES:

American Board of Pediatrics: May, 1982

Sub-Board of Hematology/Oncology: October, 1982

EDUCATION:

High School Stuyvesant High School 1969 Diploma

College University of Rochester 1973 B. A.

Rochester, NY

Graduate Upstate Medical Center 1977 M. D.

Syracuse, NY

PROFESSIONAL TRAINING AND ACADEMIC CAREER:

Upstate Medical Center 1977-1978 Internship Syracuse, NY Pediatrics

Upstate Medical Center 1978-1979 Residency Syracuse, NY Pediatrics

Upstate Medical Center 1979-1981 Research Fellow Syracuse, NY Pediatric Hematology-Oncology

Duke University Medical Center 1981-1983 Senior Research Fellow Durham, NC Pediatric Hematology Oncology

Duke University Medical Center 1983-1986 Assistant Professor Durham, NC Pediatrics

Duke University Medical Center 1984-present Assistant Professor Durham, NC Pathology

Duke University Medical Center 1986-1990 Associate Professor Durham, NC Pediatrics

Duke University Medical Center 1982-present Member - Cancer Center Durham, NC 1984-present Senior Investigator,

Module I, Cancer Center Isolation Facility

Duke University Medical Center 1987-1990 Associate Professor of Durham, NC Pediatrics with Tenure

Duke University Medical Center 1990-present Professor of Pediatrics Durham, NC with Tenure

Duke University Medical Center 1992-present Associate Chief of Durham, NC Preuss Laboratory for

Brain Tumor Research Duke University Medical Center 1992-present Graduate Faculty Durham, NC (Pathology) of the

Graduate School Duke University Medical Center 1995-present Chief, Division of Durham, NC Pediatric Neuro-Oncology

Duke University Medical Center 1996-present Associate Professor Durham, NC of Medicine

Duke University Medical Center 1997-present Associate Professor Durham, NC of Surgery

Duke University Medical Center 1997-present Co-Director, Clinical Durham, NC Neuro-Oncology Program

Duke University Medical Center 1999-present James B. Powell, Jr. Durham, NC Professor of Neuro-Oncology

Duke University Medical Center 2005-present Co-Deputy Director, Durham, NC The Preston Robert Tisch Brain Tumor Center at Duke

Duke University Medical Center 2010-present Associate Director for Durham, NC Clinical Research, Neuro-Oncology Program, Duke

Cancer Institute

PUBLICATIONS: REFEREED JOURNALS

1. Coleman, R.A., Sommerville, H.M., Friedman, H.S., Kinney, T.R., and Falletta, J.M.: Insulin therapy for ketolactic acidosis complicating malignancy. *J. Pediatr.* 100:584-587, 1982.
2. Frank, J.A., Friedman, H.S., Davidson, D.M., Falletta, J.M., and Kinney, T.R.: Propionibacterium shunt nephritis in two adolescents with medulloblastoma. *Cancer* 52:330-333, 1983.
3. Friedman, H.S., Bigner, S.H., McComb, R.D., Schold, S.C., Jr., Pasternack, J.F., Groothuis, D.R., and Bigner, D.D.: A model for human medulloblastoma - growth, morphology, and chromosomal analysis *in vitro* and in athymic mice. *J. Neuropathol. Exp. Neurol.* 42:485-503, 1983.
4. Friedman, H.S., Schold, S.C., Jr., Varia, M., and Bigner, D.D.: Chemotherapy and radiation therapy of human medulloblastoma in athymic nude mice. *Cancer Res.* 43:3088-3093, 1983.
5. Schold, S.C., Jr., Friedman, H.S., Bjornsson, T.D., and Falletta, J.M.: Treatment of patients with recurrent primary brain tumors with (AZQ). *Neurology* 34:615-619, 1984.
6. Friedman, H.S., Kurtzberg, J., Croker, B., Falletta, J.M., and Kinney, T.R.: Retinoblastoma metastatic to bone marrow. *Clin. Pediatr.* 23:184-187, 1984.
7. Schold, S.C., Jr., Friedman, H.S., Bjornsson, T.D., and Bigner, D.D.: Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone and diaziquone-based drug combinations. *Cancer Res.* 44:2352-2357, 1984.
8. Friedman, H.S., Schold, S.C., Jr., Muhlbaier, L.H., Bjornsson, T.D., and Bigner, D.D.: *In vitro* versus *in vivo* correlations of chemosensitivity of human medulloblastoma. *Cancer Res.* 44:5145-5159, 1984.
9. Becton, D.L., and Friedman, H.S.: Management of solid tumors in children. *Compr. Ther.* 10(11):58-66, 1984.

10. Becton, D.L., Kinney, T.R., Chaffee, S., Kurtzberg, J., Friedman, H.S., and Falletta, J.M.: High dose intravenous immunoglobulin for severe platelet alloimmunization. *Pediatrics* 74:1120-1122, 1984.

11. Glickman, L.T., Greene, R.B., DeGregory, K.T., Friedman, H.S., and Stockman, J.A.: Toxocara antigen and mitogen-induced lymphocyte blastogenesis for diagnosis of visceral larva migrans: clinical and experimental findings in macaques and human beings. *Am. J. Vet. Res.* 45:1235-1237, 1984.

5

12. Ambruso, D.R., McCabe, E.R.B., Anderson, D., Beaudet, A., Ballas, L.M., Brandt, I.K., Brown, B., Coleman, R., Dunger, D.R., Falletta, J.M., Friedman, H.S., Haymond, M.W., Keating, J.P., Kinney, T.R., Leonard, J.V., Mahoney, D.H., Matalon, R., Roe, T.F., Simmons, P., and Slonim, A.E.: Infectious and bleeding complications in patients with glycogenosis 1b. *Am. J. Dis. Child.* 139:691-697, 1985.

13. Dranoff, G., Elion, G.B., Friedman, H.S., Campbell, G.L., and Bigner, D.D.: Influence of glutamine on the growth of human glioma and medulloblastoma in culture. *Cancer Res.* 45:4077-4081, 1985.

14. Campbell, G.L., Bartel, R., Friedman, H.S., and Bigner, D.D.: Effect of glutamate analogues on brain tumor cell lines. *J. Neurochem.* 45:1186-1192, 1985.

15. Dranoff, G., Elion, G.B., Friedman, H.S., and Bigner, D.D.: Combination chemotherapy *in vitro* exploiting glutamine metabolism of human glioma and medulloblastoma. *Cancer Res.* 45:4082-4086, 1985.

16. Zeltzer, P.M., Friedman, H.S., Norris, D.G., and Ragab, A.: Criteria and definitions for response and relapse in children with brain tumors. *Cancer* 56:1824-1826, 1985.

17. Friedman, H.S., Burger, P.C., Bigner, S.H., Trojanowski, J., Halperin, E.C., and Bigner, D.D.: Establishment and characterization of the human medulloblastoma cell line and

transplantable xenograft D283 Med. J. Neuropathol. Exp. Neurol. 44:592-605, 1985.

18. Friedman, H.S., and Schold, S.C., Jr.: Rational approaches to the chemotherapy of medulloblastoma. Neurol. Clin. 3:843-853, 1985.

19. Bjornsson, T.D., Schold, S.C., Jr., Friedman, H.S., Schneider, D., and Falletta, J.M.: Pharmacokinetics of diaziquone after three different dosage regimens. Cancer Treat. Rep. 69:1383-1385, 1985.

20. Friedman, H.S., Schold, S.C., Jr., and Bigner, D.D.: Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice. Cancer Res. 46:224-228, 1986.

21. Friedman, H.S., Mahaley, M.S., Schold, S.C., Jr., Vick, N.A., Falletta, J.M., Bullard, D.E., D'Souza, B.J., Khandekar, J.D., Lew, S., Oakes, W.J., and Bigner, D.D.: The efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma. Neurosurgery 18:335-340, 1986.

22. Ware, R., Kinney, T.R., Friedman, H.S., and Falletta, J.: Prognostic implications for direct platelet associated IgG (PAIgG) in childhood ITP. Am. J. Pediatr. Hematol. Oncol. 8:32-37, 1986.

23. Bigner, D.D., Bigner, S.H., Burger, P.C., Shelburne, J.D., and Friedman, H.S.: Primary brain tumors in Fischer 344 rats chronically exposed to acrylonitrile in their drinking water. Food Chem. Toxicol. 24:129-137, 1986.

6

24. Bigner, S.H., Friedman, H.S., Kinney, T.R., Kurtzberg, J., Chaffee, S., Becton, D., and Falletta, J.M.: 9P- in a girl with acute lymphocytic leukemia (ALL) and sickle cell disease. Cancer Genet. Cytogenet. 21:267-269, 1986.

25. Friedman, H.S., Colvin, O.M., Ludeman, S.M., Schold, S.C., Jr., Boyd, V.L., Muhlbaier, L.H., and Bigner, D.D.: Experimental chemotherapy of human medulloblastoma with

classical alkylators. *Cancer Res.* 46:2827-2833, 1986.

26. Månsson, J.E., Fredman, P., Bigner, D.D., Molin, K., Rosengren, B., Friedman, H.S., and Svennerholm, L.: Characterization of new gangliosides of the lactotetraose series in murine xenografts of a human glioma cell line. *FEBS Lett.* 201:109-113, 1986.

27. Malik, R.K., Friedman, H.S., Djang, W.T., Falletta, J.M., Buckley, E., Kurtzberg, J., Kinney, T.R., Stine, K., Chaffee, S., Hayes, J., Halperin, E.C., and Oakes, W.J.: Treatment of trilateral retinoblastoma with vincristine and cyclophosphamide. *Am. J. Ophthalmol.* 102:650-656, 1986.

28. Bigner, S.H., Friedman, H.S., Biegel, J.A., Wikstrand, C.J., Mark, J., Gebhardt, R., Eng, L.F., and Bigner, D.D.: Specific chromosomal abnormalities characterize four established cell lines derived from malignant human gliomas. *Acta Neuropathol.* 72:86-97, 1986.

29. Becton, D.L., Friedman, H.S., Kurtzberg, J., Chaffee, S., Falletta, J.M., and Kinney, T.R.: Severe mycoplasma pneumonia in three sisters with sickle cell disease. *Pediatr. Hematol. Oncol.* 3:259-265, 1986.

30. Warnke, P.D., Friedman, H.S., Bigner, D.D., and Groothuis, D.R.: Simultaneous measurements of blood flow and blood-to-tissue transport in xenotransplanted medulloblastomas. *Cancer Res.* 47:1687-1690, 1987.

31. Schold, S.C., Jr., Mahaley, M.S., Jr., Vick, N.S., Friedman, H.S., Burger, P.C., DeLong, E.R., Bullard, D.E., Khandekar, J.D., and Falletta, J.M.: Phase II AZQ-based chemotherapy trials in patients with high-grade supratentorial gliomas. *J. Clin. Oncol.* 5:464-471, 1987.

32. Trojanowski, J.Q., Friedman, H.S., Burger, P.C., and Bigner, D.D.: A rapidly dividing human medulloblastoma cell line (D283 Med) expresses all three neurofilament subunits. *Am. J. Pathol.* 126:358-363, 1987.

33. Schold, S.C., Jr., Friedman, H.S., and Bigner, D.D.: Therapeutic evaluation of the human glioma line D-54 MG in athymic mice. *Cancer Treat. Rep.* 71:849-850, 1987.

34. Friedman, H.S., and Oakes, W.J.: The chemotherapy of posterior fossa tumors of childhood. *J. Neurooncol.* 5:217-229, 1987.

35. Becton, D.L., Kurtzberg, J., Kinney, T.R., Friedman, H.S., Chaffee, S., and Falletta, J.M.: Successful treatment of familial erythrophagocytic lymphohistiocytosis. *Med. Pediatr. Oncol.* 15:58-61, 1987.

7

36. Kurtzberg, J., Friedman, H.S., Kinney, T.R., Chaffee, S., and Falletta, J.M.: Treatment of platelet alloimmunization with intravenous immunoglobulin -two case reports and review of the literature. *Am. J. Med.* 83(4A):30-33, 1987.

37. Kurtzberg, J., Friedman, H.S., Chaffee, S., Falletta, J.M., Kinney T.R., Schwartz, R.S., Matthews, T.J., and Kurlander, M.D.: The efficacy of intravenous gammaglobulin in autoimmune mediated pediatric blood dyscrasias. *Am. J. Med.* 83(4A):4-9, 1987.

38. Kurtzberg, J., Friedman, H.S., Kinney, T.R., Chaffee, S., Stine, K., Falletta, J.M., and Weinhold, K.J.: Management of human immunodeficiency virus associated thrombocytopenia with intravenous gammaglobulin. *Am. J. Pediatr. Hematol. Oncol.* 9:299-301, 1987.

39. Becton, D.L., Armstrong, B., Friedman, H.S., Kurtzberg, J., Chaffee, S., Kinney, T.R., and Falletta, J.M.: Bacterial endocarditis associated with long term right atrial catheterization. *Pediatr. Hematol. Oncol.* 4:131-136, 1987.

40. Bigner, S.H., Mark, J., Friedman, H.S., Biegel, J.A., and Bigner, D.D.: Structural chromosomal abnormalities in human medulloblastoma. *Cancer Genet. Cytogenet.* 30:91-101, 1988.

41. Lee, Y., Bullard, D.E., Zalutsky, M.R., Coleman, R.E., Wikstrand, C.J., Friedman, H.S., Colapinto, E.V., and Bigner, D.D.: Therapeutic efficacy of anti glioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma

xenograft model. *Cancer Res.* 48:559-566, 1988.

42. Ware, R., Friedman, H.S., Filston, H.C., Chaffee, S., Kurtzberg, J., Kinney, T.R., and Falletta, J.M.: Childhood hepatic mesenchymoma: successful treatment with surgery and multiple agent chemotherapy. *Med. Pediatr. Oncol.* 16:62-65, 1988.

43. Friedman, H.S., Burger, P.C., Bigner, S.H., Trojanowski, J.Q., Brodeur, G.M., He, X., Wikstrand, C.J., Kurtzberg, J., Berens, M., Halperin, E.C., and Bigner, D.D.: Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of *c-myc*. *Am. J. Pathol.* 130:472-484, 1988.

44. Humphrey, P.A., Wong, A.J., Vogelstein, B., Friedman, H.S., Werner, M.H., Bigner, D.D., and Bigner, S.H.: Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. *Cancer Res.* 48:2231-2238, 1988.

45. Ware, R., Kurtzberg, J., Friedman, H.S., Falletta, J.M., and Kinney, T.R.: Chronic immune-mediated thrombocytopenia following varicella infection. *J. Pediatr.* 112:742-744, 1988.

46. Lee, Y.S., Bullard, D.E., Humphrey, P.A., Colapinto, E.V., Friedman, H.S., Zalutsky, M.R., Coleman, R.E., and Bigner, D.D.: Treatment of intracranial human glioma xenografts with 131I anti-tenascin monoclonal antibody (MAb) 81C6. *Cancer Res.* 48:2904-2910, 1988.

8

47. Skapek, S., Colvin, O.M., Griffith, O., Elion, G.B., Bigner, D.D., and Friedman, H.S.: Enhanced cytotoxicity of melphalan secondary to BSO-mediated depletion of glutathione in medulloblastoma xenografts in athymic nude mice. *Cancer Res.* 48:2764-2767, 1988.

48. Colapinto, E.V., Lee, Y.S., Humphrey, P.A., Zalutsky, M.R., Friedman, H.S., Bullard, D.E., and Bigner, D.D.: Localization of monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts. *Br. J. Neurosurg.* 2:179-191, 1988.

49. Friedman, H.S., Colvin, O.M., Skapek, S.X., Ludeman, S.M., Elion, G.B., Schold, S.C., Jr.,

Jacobsen, P.F., Muhlbaier, L.H., and Bigner, D.D.: Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. *Cancer Res.* 48:4189-4195, 1988.

50. Ware, R., Friedman, H.S., Gutman, L.T., Rourk, M.H., Shorter, N.A., and Filston, H.C.: Combined medical and surgical management of severe pseudo-membraneous colitis. *Pediatr. Infect. Dis. J.* 7:602-603, 1988.

51. Friedman, H.S., and Oakes, W.J.: Recurrent brain tumors in children. *Pediatr. Neurosci.* 13:233-241, 1988.

52. Longee, D.C., Friedman, H.S., Djang, W.T., Halperin, E.C., Schold, S.C., Jr., and Oakes, W.J.: Transient late MRI changes suggesting progression of brain stem glioma - implications for entry criteria for phase II trials. *Neurosurgery* 23:248-253, 1988.

53. Friedman, H.S., Skapek, S.X., Colvin, O.M., Elion, G.B., Blum, M.R., Savina, P.M., Hilton, J., Schold, S.C., Jr., Kurtzberg, J., and Bigner, D.D.: Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. *Cancer Res.* 48:5397-5402, 1988.

54. Colapinto, E.V., Humphrey, P.A., Zalutsky, M.R., Groothuis, D.R., Friedman, H.S., de Tribolet, N., Carrel, S., and Bigner, D.D.: Comparative localization of murine monoclonal antibody Me1-14 F(ab')₂ fragment and whole IgG2a in human glioma xenografts. *Cancer Res.* 48:5701-5707, 1988.

55. Skapek, S.X., Colvin, O.M., Griffith, O.W., Groothuis, D.R., Colapinto, E.V., Lee, Y.S., Hilton, J., Elion, G.B., Bigner, D.D., and Friedman, H.S.: Buthionine sulfoximine-mediated depletion of glutathione in intracranial human glioma-derived xenografts. *Biochem. Pharmacol.* 37:4313-4317, 1988.

56. He, X., Skapek, S.X., Wikstrand, C.J., Friedman, H.S., Kemshead, J.T., Coakham, H.B., Bigner, S.H., and Bigner, D.D.: Phenotypic analysis of four human medulloblastoma cell

lines and transplantable xenografts. *J. Neuropathol. Exp. Neurol.* 48:48-68, 1989.

57. Friedman, H.S., Schold, S.C., Jr., Djang, W.T., Kurtzberg, J., Longee, D.C., Halperin, E.C., Falletta, J.M., Coleman, R.E., and Oakes, W.J.: Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumors. *Neurology* 39:62-65, 1989.

9

58. Stine, K.C., Friedman, H.S., Kurtzberg, J., Filston, H., Lowe, J., Baker, M., and Falletta, J.M.: Pulmonary septic emboli mimicking metastatic rhabdomyosarcoma. *J. Pediatr. Surg.* 24:491-493, 1989.

59. Halperin, E.C., Weh, S.M., Scott, J.W., Djang, W.T., Oakes, W.J., and Friedman, H.S.: Selection of an optimum management strategy for pediatric brain tumors. *Med. Pediatr. Oncol.* 17:116-125, 1989.

60. Gottfries, J., Mansson, J.-E., Fredman, P., Wikstrand, C.J., Friedman, H.S., Bigner, D.D., and Svennerholm, L.: Ganglioside mapping of a human medulloblastoma xenograft. *Acta Neuropathol.* 77:283-288, 1989.

61. Friedman, H.S., Colvin, O.M., Griffith, O.W., Lippitz, B., Elion, G.B., Schold, S.C., Hilton, J., and Bigner, D.D.: Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion. *JNCI* 81:524-527, 1989.

62. Schold, S.C., Jr., Brant, T.P., von Hofe, E., Friedman, H.S., Mitro, S., Meer, L., Bigner, D.D., Swenberg, J.K., and Kleihues, P.: O6-Alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain tumor xenografts. *J. Neurosurg.* 70:573-577, 1989.

63. Friedman, H.S., Schold, S.C., Mahaley, M.S., Colvin, O.M., Oakes, W.J., Vick, N.A., Burger, P.C., Bigner, S.H., Borowitz, M., Halperin, E.C., Djang, W., Falletta, J.M., deLong,

R., Garvin, J.H., DeVivo, D.C., Norris, D., Golumbe, B., Winter, J., Bodziner, R.A., Sipahi, H., and Bigner, D.D.: Phase II treatment of medulloblastoma and pineoblastoma with melphalan: clinical therapy based on experimental models of human medulloblastoma. *J. Clin. Oncol.* 7:904-911, 1989.

64. Friedman, H.S., Kurtzberg, J., Schold, S.C., and Oakes, W.J.: Protein elevation secondary to a subdural fluid collection in a child receiving multiple lumbar punctures. *J. Pediatr.* 115:439-441, 1989.

65. Bigner, S.H., Schold, S.C., Jr., Friedman, H.S., Mark, J., and Bigner, D.D.: Chromosomal composition of malignant human gliomas through serial subcutaneous transplantation in athymic mice. *Cancer Genet. Cytogenet.* 40:111-120, 1989.

66. Zalutsky, M.R., Garg, P.K., Friedman, H.S., and Bigner, D.D.: Labeling monoclonal antibodies and F(ab')₂ fragments with the alpha-particle emitting nuclide astatine-211: preservation of immunoreactivity and *in vivo* localizing capacity. *Proc. Natl. Acad. Sci. USA* 86:7149-7153, 1989.

67. Gluckman, E., Broxmeyer, H.E., Auerbach, A.D., Friedman, H.S., Douglas, G.W., Devergie, A., Esperou, H., Thiery, D., Socie, G., Lehn, P., Cooper, S., English, D., Kurtzberg, J., Bard, J., and Boyse, E.A.: Hematopoietic reconstitution of a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. *N. Engl. J. Med.* 321:1174-1178, 1989.

10

68. Ibayashi, N., Herman, M.M., Boyd, J.C., Bigner, D.D., Friedman, H.S., Collins, V.P., Donoso, L.A., and Rubinstein, L.J.: Relationship of the demonstration of intermediate filament protein to kinetics of three human neuroepithelial tumor cell lines: lack of neural-related proteins in most cells in S-phase: a double-labeled immunohistochemical study on matrix cultures. *Lab. Invest.* 61:310-318, 1989.

69. Garg, P.K., Friedman, H., Slade, S., Bigner, D.D., and Zalutsky, M.R.: Astatine-211 labeled monoclonal antibody: a potential agent for radioimmunotherapy. *Nuklearmedizin. Suppl.* 25:663-666, 1989.
70. Rosenberg, M.C., Colvin, O.M., Griffith, O.W., Bigner, S.H., Elion, G.B., Horton, J.K., Lilley, E., Bigner, D.D., and Friedman, H.S.: Establishment of a melphalan-resistant human rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion. *Cancer Res.* 49:6917-6922, 1989.
71. Lilley, E.R., Rosenberg, M.C., Elion, G.B., Colvin, O.M., Bigner, D.D., and Friedman, H.S.: Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft. *Cancer Res.* 50:284-287, 1990.
72. Moncino, M.D., Friedman, H.S., Kurtzberg, J., and Pizzo, S.V.: Papillary adrenocarcinoma of the renal pelvis in a child: case report and brief review of the literature. *Med. Pediatr. Oncol.* 18:81-86, 1990.
73. Ware, R., Friedman, H.S., Kinney, T.R., Kurtzberg, J., Chaffee, S., and Falletta, J.M.: Familial erythrophagocytic lymphohistiocytosis: late relapse despite continuous high-dose VP-16 chemotherapy. *Med. Pediatr. Oncol.* 18:27-29, 1990.
74. Ibayashi, N., Herman, M.M., Boyd, J.C., Caccamo, D.V., Friedman, H.S., Bigner, D.D., and Rubinstein, L.J.: Kinetics and glial fibrillary acidic (GFA) protein production in a transplantable human giant cell glioblastoma (D-212 MG) of near haploid karyotype maintained in an organ culture system. An immunohistochemistry study. *Neuropathol. Appl. Neurobiol.* 16:27-37, 1990.
75. Lippitz, B., Halperin, E.C., Griffith, O.W., Colvin, O.M., Honore, G., Ostertag, C.B., Bigner, D.D., and Friedman, H.S.: L-Buthionine sulfoximine-mediated radiosensitization in experimental interstitial radiotherapy of intracerebral D-54 MG glioma xenografts in

athymic mice. *Neurosurgery* 26:255-260, 1990.

76. Fekete, I., Schlageter, M.S., Bigner, D.D., Griffith, O.W., Friedman, H.S., and Groothuis, D.R.: The rate of buthionine sulfoximine entry into brain and brain tumor. *Cancer Res.* 50:1251-1256, 1990.

77. Colapinto, E.V., Zalutsky, M.R., Archer, G.E., Noska, M.A., Friedman, H.S., and Bigner, D.D.: Radioimmunotherapy of intracerebral human glioma xenografts with ¹³¹I-labeled F(ab')₂ fragments of monoclonal antibody Me1-14. *Cancer Res.* 50:1822-1827, 1990.

78. Fuchs, F.H., Archer, G., Colvin, O.M., Bigner, S.H., Schuster, J.M., Fuller, G.N., Schold, S.C., Jr., Muhlbaier, L.H., Friedman, H.S., and Bigner, D.D.: A nude rat model of human
11

neoplastic meningitis: activity of intrathecal 4-hydroperoxycyclophosphamide. *Cancer Res.* 50:1954-1959, 1990.

79. Cope, D.A., Dewhirst, M.W., Friedman, H.S., Bigner, D.D., and Zalutsky, M.R.: Enhanced delivery of a monoclonal antibody F(ab')₂ fragment to subcutaneous human glioma xenografts using local hyperthermia. *Cancer Res.* 50:1803-1809, 1990.

80. Friedman, H.S., Colvin, O.M., Aisaka, K., Popp, J., Bossen, E.H., Reimer, K.A., Powell, J.B., Hillton, J., Gross, S.S., Levi, R., Bigner, D.D., and Griffith, O.W.: Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity. *Cancer Res.* 50:2455-2462, 1990.

81. Bigner, S.H., Friedman, H.S., Vogelstein, B., Oakes, W.J., and Bigner, D.D.: Amplification of the *c-myc* gene in medulloblastoma cell lines and xenografts. *Cancer Res.* 50:2347-2350, 1990.

82. Longee, D.C., Friedman, H.S., Albright, R.E., Burger, P.C., Oakes, W.J., and Schold, S.C.: Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. *J. Neurosurg.* 72:583-588, 1990.

83. Oakes, W.J., Friedman, H.S., Bigner, S.H., Bullock, N.H., and Bigner, D.D.: Successful laboratory growth and analysis of CUSA-obtained medulloblastoma samples. Technical note. *J. Neurosurg.* 72:821-823, 1990.
84. Wasson, J.C., Saylor, R.L., III, Zeltzer, P., Friedman, H.S., Bigner, S.H., Burger, P.C., Bigner, D.D., Look, A.T., Douglass, E.C., and Brodeur, G.M.: Oncogene amplification in pediatric brain tumors. *Cancer Res.* 50:2987-2990, 1990.
85. Humphrey, P.A., Wong, A.J., Vogelstein, B., Zalutsky, M.R., Fuller, G.N., Archer, G.E., Friedman, H.S., Kwatra, M.M., Bigner, S.H., and Bigner, D.D.: Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. *Proc. Natl. Acad. Sci. USA* 87:4207-4211, 1990.
86. Broxmeyer, H.E., Gluckman, E., Auerbach, A., Douglas, G.W., Friedman, H.S., Cooper, S., Hangoc, G., Kurtzberg, J., Bard, J., and Boyse, E.A.: Human umbilical cord blood: a clinically useful source of transplantable hematopoietic stem/progenitor cells. *Int. J. Cell Cloning* 8 (Suppl. 1):76-91, 1990.
87. Rippe, D.J., Boyko, O.B., Fuller, G.N., Friedman, H.S., Oakes, W.J., and Schold, S.C., Jr.: Gadopentetate-dimeglumine-enhanced MR imaging of gliomatosis cerebri: appearance mimicking leptomeningeal tumor dissemination. *Am. J. Neuroradiol.* 11:800-801, 1990.
88. Rippe, D.J., Boyko, O.B., Friedman, H.S., Oakes, W.J., Schold, S.C., Jr., DeLong, G.R., and Meisler, W.J.: Gd-DTPA-enhanced MR imaging of leptomeningeal spread of primary intracranial CNS tumor in children. *Am. J. Neuroradiol.* 11:329-332, 1990.
89. Wiener, M.D., Boyko, O.B., Friedman, H.S., Hockenberger, B., and Oakes, W.J.: False-positive spinal MRI findings for subarachoid spread of primary CNS tumor in postoperative pediatric patients. *Am. J. Neuroradiol.* 11:1100-1103, 1990.
- 12
90. Fishbein, J.D., Friedman, H.S., and Falletta, J.M.: Treatment of catheter-related sepsis with

- low dose urokinase infusion. *Pediatr. Infect. Dis.* 9:676-678, 1990.
91. Bigner, S.H., Humphrey, P.A., Wong, A.J., Vogelstein, B., Mark, J., Friedman, H.S., and Bigner, D.D.: Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. *Cancer Res.* 50:8017-8022, 1990.
92. Wang, A.M., Elion, G.B., Friedman, H.S., Bodell, W.J., Bigner, D.D., and Schold, S.C.: Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts. *Cancer Chemother. Pharmacol.* 27:278-284, 1991.
93. Rhodes, R.E., Friedman, H.S., Hatten, H.P., Jr., Hockenberger, B., Oakes, W.J., and Tomita, T.: Neurocutaneous melanosis: contrast-enhanced MR imaging. *Am. J. Neuroradiol.* 12:380-382, 1991.
94. Friedman, H.S., Horowitz, M. E., and Oakes, W.J.: CNS tumors: improvement in outcome through a multi-modality approach. *Pediatr. Clin. North Am.* 38:381-392, 1991.
95. Gottfries, J., Percy, A.K., Månsson, J.-E., Fredman, P., Wikstrand, C., Friedman, H.S., Bigner, D.D., and Svennerholm, L.: Glycolipids and glycosyltransferases in permanent cell lines established from human medulloblastomas. *Biochim. Biophys. Acta* 1081:253-261, 1991.
96. Brown, M.T., Friedman, H.S., Oakes, W.J., Boyko, O.B., and Schold, S.C., Jr.: Saggital sinus thrombosis and leptomeningeal medulloblastoma: a benign outcome without anticoagulation. *Neurology* 41:455-456, 1991.
97. Skapek, S.X., Van Dellen, A.F., McMahon, D.P., Postels, D.G., Griffith, O.W., Bigner, D.D., and Friedman, H.S.: Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine. *Cancer Chemother. Pharmacol.* 28:15-21, 1991.
98. He, X., Wikstrand, C.J., Friedman, H.S., Bigner, S.H., Pleasure, S., Trojanowski, J.W., and Bigner, D.D.: Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts. *Lab.*

Invest. 64:833-843, 1991.

99. Griebel, M., Friedman, H.S., Halperin, E.C., Wiener, M.D., Marks, L., Oakes, W.J., Hoffman, J.M., DeLong, G.R., Schold, S.C., Jr., Hockenberger, B., Freeman, C.R., and Kun, L.: Reversible neurotoxicity following hyperfractionated radiation therapy of brainstem glioma. *Med. Pediatr. Oncol.* 19:182-186, 1991.

100. Lilley, E.R., Elion, G.B., Dewhirst, M.W., Schold, Jr., S.C., Blum, M.R., Savina, P.M., Laskowitz, D.T., Bigner, D.D., and Friedman, H.S.: Therapeutic analysis of melphalan-resistant human rhabdomyosarcoma xenograft TE-671 MR. *Cancer Res.* 51:3906-3909, 1991.

101. Schuster, J.M., Friedman, H.S., and Bigner, D.D.: Therapeutic analysis of *in vitro* and *in vivo* brain tumor models. *Neurol. Clin.* 9:375-382, 1991.

13

102. Friedman, H.S., Oakes, W.J., Bigner, S.H., Wikstrand, C.J., and Bigner, D.D.: Medulloblastoma: tumor biological and clinical perspectives. *J. Neurooncol.* 11:1-15, 1991.

103. Longee, D.C., Friedman, H.S., Phillips, P.C., Burger, P.C., Oakes, W.J., Heffez, D., Wharam, M., Strauss, L., Fuller, G.N., and Schold, S.C., Jr.: Osteoblastic metastases from low-grade astrocytoma. *Med. Pediatr. Oncol.* 19:318-324, 1991.

104. Bruggers, C.S., Friedman, H.S., Phillips, P.C., Wiener, M.D., Hockenberger, B., Oakes, W.J., and Buckley, E.G.: Leptomeningeal dissemination of optic pathway gliomas in three pediatric patients. *Am. J. Ophthalmol.* 111:719-723, 1991.

105. Humphrey, P.A., Gangarosa, L.M., Wong, A.J., Archer, G.E., Lund-Johansen, M., Bjerkvig, R., Laerum, O.-D., Friedman, H.S., and Bigner, D.D.: Deletion-mutant epidermal growth factor receptor in human gliomas: effect of type II mutation on receptor function. *Biochem. Biophys. Res. Commun.* 178:1413-1420, 1991.

106. Bruggers, C.S., Kurtzberg, J., and Friedman, H.S.: Vincristine therapy for severe platelet alloimmunization. *Am. J. Pediatr. Hematol. Oncol.* 13:300-304, 1991.
107. Saylor, III, R.L., Sidransky, D., Friedman, H.S., Bigner, S.H., Bigner, D.D., Vogelstein, B., and Brodeur, G.M.: Infrequent p53 gene mutations in medulloblastomas. *Cancer Res.* 51:4721-4723, 1991.
108. Friedman, H.S., Touri, S.L., Hatten, H.P., Hockenberger, B., Vandersteenhoven, J.J., and Oakes, W.J.: Inflammatory lesion mimicking a metastatic ependymoma. *Neurosurgery* 29:617-620, 1991.
109. Wikstrand, C.J., Friedman, H.S., and Bigner, D.D.: Medulloblastoma cell-substrate interaction in vitro. *Invasion Metastasis* 11:310-324, 1991.
110. Laskowitz, D.T., Elion, G.B., Dewhirst, M.W., Griffith, O.W., Cattley, R.C., Bigner, D.D., and Friedman, H.S.: Enhancement of melphalan-induced gastrointestinal toxicity in mice treated with regional hyperthermia and BSO-mediated glutathione depletion. *Int. J. Hyperthermia* 8:111-120, 1992.
111. Laskowitz, D.T., Elion, G.B., Dewhirst, M.W., Griffith, O.W., Savina, P.M., Blum, M.R., Prescott, D.M., Bigner, D.D., and Friedman, H.S.: Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft. *Radiat. Res.* 129:218-223, 1992.
112. He, X., Ostrowski, L.E., von Wronski, M.A., Friedman, H.S., Wikstrand, C.J., Bigner, S.H., Rasheed, A., Batra, S.K., Mitra, S., Brent, T.P., and Bigner, D.D.: Expression of O⁶-methylguanine-DNA methyltransferase in six human medulloblastoma cell lines. *Cancer Res.* 52:1144-1148, 1992.
113. Hoffman, J.M., Hanson, M.W., Friedman, H.S., Hockenberger, B.M., Oakes, W.J., Halperin, E.C., and Coleman, R.E.: FDG-PET in pediatric posterior fossa brain tumors. *J. Comput. Assist. Tomogr.* 16:62-68, 1992.

114. Friedman, H.S., Krischer, J.P., Burger, P., Oakes, W.J., Hockenberger, B., Weiner, M.D., Falletta, J.M., Norris, D., Ragab, A.H., Mahoney, Jr., D.H., Whitehead, M.V., and Kun, L.E.: Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. *J. Clin. Oncol.* 10:249-256, 1992.
115. Laskowitz, D.T., Elion, G.B., Dewhirst, M.W., Griffith, O.W., Casero, R.A., Jr., Scott, P.A., Bullock, N., Bigner, D.D., and Friedman, H.S.: Effects of glutathione or polyamine depletion on *in vivo* thermosensitization. *Int. J. Hyperthermia* 8:199-208, 1992.
116. Dunsmore, K.P., Friedman, H. S., and Kurtzberg, J.: The uses of intravenous immunoglobulin in pediatrics, a review. *Crit. Rev. Oncol. Hematol.* 12:67-90, 1992.
117. Marks, L.B., Friedman, H.S., Kurtzberg, J., Oakes, W.J., and Hockenberger, B.M.: Reversal of radiation induced neutropenia by granulocyte colony-stimulating factor. *Med. Pediatr. Oncol.* 20:240-242, 1992.
118. Debatin, J.F., Nadel, S.N., Gray, L., Friedman, H.S., Trotter, P., Hockenberger, B., and Oakes, W.J.: Phase III clinical evaluation of gadoteridol injection: experience in pediatric neuro-oncologic MR imaging. *Pediatr. Radiol.* 22:93-98, 1992.
119. Friedman, H.S., and Oakes, W.J.: New therapeutic options in the management of childhood brain tumors. *Oncology* 6:27-44, 1992.
120. Nelson, S.C., Friedman, H.S., Oakes, W.J., Halperin, E.C., Tien, R., Fuller, G.N., Hockenberger, B., Scroggs, M.W., Moncino, M., Kurtzberg, J., and Buckley, E.G.: Successful therapy for trilateral retinoblastoma. *Am. J. Ophthalmol.* 114:23-29, 1992.
121. Halperin, E.C., Brizel, D.M., Honore, G., Sontag, M.R., Griffith, O.W., Bigner, D.D., and Friedman, H.S.: The radiation dose-response relationship in a human glioma xenograft and an evaluation of the influence of glutathione depletion by buthionine sulfoximine. *Int. J.*

Radiat. Oncol. Biol. Phys. 24:103-109, 1992.

122. Friedman, H.S., Colvin, O.M., Kaufman, S.H., Ludeman, S.M., Bullock, N., and Bigner, D.D., and Griffith, O.W.: Cyclophosphamide resistance in medulloblastoma. *Cancer Res.* 52:5373-5378, 1992.

123. Smith, D.C., Vick, N.A., Trump, D.L., Friedman, H.S., Friedman, A.H., Purvis, J., Gauspari, A., and Schold, S.C., Jr.: A phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas. *Cancer Chemother. Pharmacol.* 30:272-276, 1992.

124. Groothuis, D.R., Lippitz, B.E., Fekete, I., Schlageter, K.E., Molnar, P., Colvin, O.M., Roe, C.R., Bigner, D.D., and Friedman, H.S.: The effect of an amino acid-lowering diet on the rate of melphalan entry into brain and xenotransplanted glioma. *Cancer Res.* 52:5590-5596, 1992.

15

125. Malik, R.K., Fuller, G.N., Oakes, W.J., Tien, R., Hockenberger, B., Friedman, H.S., and Halperin, E.C.: Back pain and paraplegia in a fifteen-year-old male. *J. Pediatr.* 121:652-658, 1992.

126. Mulligan, K., Nelson, S., Friedman, H.S., and Andrews, P.I.: Shigellosis-associated encephalopathy. *Pediatr. Infect. Dis. J.* 11:889-890, 1992.

127. Friedman, H.S., Dolan, M.E., Moschel, R.C., Pegg, A.E., Felker, G.M., Rich, J., Bigner, D.D., and Schold, S.C., Jr.: Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. *JNCI* 84:1926-1931, 1992.

128. DeLong, R., Friedman, H., Friedman, N., Gustafson, K., Halperin, E., and Oakes, J.: Usefulness of methylphenidate for treatment of neuropsychological sequelae of radiotherapy and chemotherapy of childhood brain tumors and leukemia. *J. Child. Neurol.* 7:462-463, 1992.

129. Donnal, J., Halperin, E.C., Friedman, H.S., Boyko, O.B., Oakes, W.J., Heinz, E.R., Hockenberger, B., and Hershatter, B.W.: Subfrontal recurrence of medulloblastoma. *Am. J. Radiol.* 13:1617-1618, 1992.
130. Wikstrand, C.J., Longee, D.C., McLendon, R.E., Fuller, G.N., Friedman, H.S., Fredman, P., Svennerholm, L., and Bigner, D.D.: Lactotetraose series ganglioside 3',6'-isoLD1 in tumors of central nervous and other systems *in vitro* and *in vivo*. *Cancer Res.* 53:120-126, 1993.
131. Castellino, S., Elion, G.B., Griffith, O.W., Dewhirst, M., Kurtzberg, J., Cattley, R.C., Scott, P., Bigner, D.D., and Friedman, H.S.: Development of a model of melphalan-induced gastrointestinal toxicity in mice. *Cancer Chemother. Pharmacol.* 31:376-380, 1993.
132. Schuster, J.M., Friedman, H.S., Archer, G.E., Fuchs, H.E., McLendon, R.E., Colvin, O.M., and Bigner, D.D.: Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide. *Cancer Res.* 53:2338-2343, 1993.
133. Bruggers, C.S., Friedman, H.S., Fuller, G.N., Tien, R.D., Marks, L.B., Halperin, E.C., Hockenberger, B., and Oakes, W.J.: Comparison of serial PET and MRI scans in a pediatric patient with a brainstem glioma. *Med. Pediatr. Oncol.* 21:301-306, 1993.
134. Nelson, S.C., Friedman, H.S., Hockenberger, B., Vandersteenhoven, J.J., Gray, L., Touri, S.L., and Oakes, W.J.: False-positive MRI detection of recurrent or metastatic pediatric infratentorial tumors. *Med. Pediatr. Oncol.* 21:350-355, 1993.
135. Brown, M.T., Friedman, H.S., Oakes, W.J., Boyko, O.B., Hockenberger, B., and Schold, S.C., Jr.: Chemotherapy for pilocytic astrocytomas. *Cancer* 71:3166-3172, 1993.
136. Furie, D.M., Felsberg, G.J., Tien, R.D., Friedman, H.S., Fuchs, H., and McLendon, R.: MR imaging of gangliocytoma of the cerebellum and spinal cord. *J. Comput. Assist. Tomogr.* 17:488-491, 1993.
137. Duffner, P. K., Horowitz, M.E., Krischer, J., Friedman, H.S., Burger, P.C., Cohen, M.E., Sanford, R., Mulhern, R.K., Seidel, F.G., and Kun, L.: Post-operative chemotherapy and

- delayed radiation in children less than 3 years of age with malignant brain tumors: a Pediatric Oncology Group study. *New Engl. J. Med.* 328:1725-1731, 1993.
138. Strong, J., Hatten, P., Brown, M.T., Debatin, J.F., Friedman, H.S., Oakes, W.J., and Tien, R.D.: Pilocytic astrocytoma: correlation between the initial imaging features and clinical aggressiveness. *AJR* 161:369-372, 1993.
139. Levine, E.S., Friedman, H.S., Griffith, O.W., Colvin, O.M., Raynor, J., and Liberman, M.: Cardiac cell toxicity induced by 4-hydroperoxycyclophosphamide is modulated by perturbation of glutathione metabolism. *Cardiovasc. Res.* 27:1248-1253, 1993.
140. Moghrabi, A., Friedman, H.S., Burger, P.C., Tien, R.D., and Oakes, W.J.: Carboplatin treatment of progressive optic pathway gliomas to delay radiotherapy. *J. Neurosurg.* 79:223-227, 1993.
141. Garg, S., Garg, P.K., Zhao, X-G., Friedman, H.S., Bigner, D.D., and Zalutsky, M.R.: Radioiodination of a monoclonal antibody using N-succinimidyl 5-iodo-3-pyridinecarboxylate. *Nucl. Med. Biol.* 20:835-842, 1993.
142. Halperin, E.C., Friedman, H.S., Schold, S.C., Fuchs, H.E., Oakes, W.J., Hockenberger, B., and Burger, P.C.: Surgery, hyperfractionated craniospinal irradiation and adjuvant chemotherapy in the management of supratentorial embryonal neuroepithelial neoplasms in children. *Surg. Neurol.* 40:278-283, 1993.
143. Gravatt, L.C., Chaffee, S., Hebert, M.E., Halperin, E.C., Friedman, H.S., Hershfield, M.S., Elion, G.B., and Kurtzberg, J.: Efficacy and toxicity of 9-β-D-arabinofuranosylguanine (Ara-G) as an agent to purge malignant T cells from murine bone marrow: application to an *in vivo* T-leukemia model. *Leukemia* 7:1261-1267, 1993.
144. Soo, M.S., Tien, R.D., Gray, L., Friedman, H.S., Andrews, I., and Massey, W.: MR appearance in nine patients with mesenrhombencephalitis. *Am. J. Roentgenol.*

160:1089-1093, 1993.

145. Felker, G.M., Friedman, H.S., Dolan, M.E., Moschel, R.C., and Schold, S.C.: Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. *Cancer Chemother. Pharmacol.* 32:471-476, 1993.

146. Freeman, C.R., Krischer, J., Sanford, R.A., Cohen, M.E., Burger, P.C., Friedman, H.S., del Carpio, R., and Kun, L.: Final results of a Pediatric Oncology Group study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children. *Int. J. Biol. Phys.* 27:197-206, 1993.

147. Mosijczuk, A.D., Nigro, M.A., Thomas, P.R.M., Burger, P.C., Krischer, J.P., Morantz, R., Mulne, A.F., Towbin, R.B., Freeman, A.I., Kurdunowicz, B., Nigro, E.D., Friedman, H.S., and Kun, L.E.: Pre-radiation chemotherapy in advanced medulloblastoma: a Pediatric Oncology Group pilot study. *Cancer* 72:2755-2762, 1993.

17

148. Nelson, S.C., Bruggers, C.S., Kurtzberg, J., and Friedman, H.S.: Management of leukemic hyperleukocytosis with hydration, urinary alkalinization, and allopurinol. *Am. J. Ped. Hem. Oncol.* 15:351-355, 1993.

149. Ashdown, B.C., Boyko, O.B., Uglietta, J.P., Friedman, H.S., Hockenberger, B., Oakes, W.J., and Fuller, G.N.: Postradiation cerebellar necrosis mimicking tumor: MR appearance. *J. Comput. Assist. Tomogr.* 17:124-126, 1993.

150. Moghrabi, A., Friedman, H.S., McLendon, R., Hockenberger, B., Tien, R., Halperin, E.C., and Oakes, W.J.: Arteriovenous malformation following radiotherapy mimicking recurrent medulloblastoma. *Med. Pediatr. Oncol.* 22:140-143, 1994.

151. Nashold, J.R.B., Oakes, W.J., Friedman, H.S., Halperin, E.C., Soo, M., Hockenberger, B., Fuller, G.N., and Tien, R.: Successful treatment of pineal mixed germ cell tumor with residual progressive teratoma. *Med. Pediatr. Oncol.* 22:137-139, 1994.

152. Tien, R.D., Felsberg, G., Friedman, H.S., Brown M., and MacFall, L.: MR imaging of high-grade cerebral gliomas: value of diffusion-weighted echoplanar pulse sequences. *Am. J. Roentgenol.* 162:671-677, 1994.
153. Rasheed, B.K.A., McLendon, R.E., Herndon, J.E., Friedman, H.S., Friedman, A.H., Bigner, D.D., and Bigner, S.H.: Alterations of the TP53 gene in human gliomas. *Cancer Res.* 54:1324-1330, 1994.
154. Friedman, H.S., Houghton, P.J., Schold, S.C., Keir, S., and Bigner, D.D.: Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. *Cancer Chemother. Pharmacol.* 34:171-174, 1994.
155. Friedman, H.S., Dolan, M.E., Kaufmann, S.H., Colvin, O.M., Griffith, O.W., Moschel, R.C., Schold, S.C., Bigner, D.D., and Ali-Osman, F.: Elevated DNA polymerase- α , DNA polymerase- β , and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. *Cancer Res.* 54:3487-3493, 1994.
156. Kadota, R.P., Mandell, L.R., Fontanesi, J., Kanar, E.H., Krischer, J., Kun, L.E., and Friedman, H.S.: Hyperfractionated irradiation and concurrent cisplatin in brain stem tumors: a Pediatric Oncology Group study (9139). *Pediatr. Neurosurg.* 20:221-225, 1994.
157. Friedman, H.S., Archer, G.E., McLendon, R.E., Schuster, J.M., Colvin, O.M., Guaspari, A., Blum, R., Savina, P.A., Fuchs, H., and Bigner, D.D.: Intrathecal melphalan therapy of human neoplastic meningitis in athymic nude rats. *Cancer Res.* 54:4710-4714, 1994.
158. Schumacher, D.J., Tien, R.D., and Friedman, H.S.: Gadolinium enhancement of the leptomeninges caused by hydrocephalus: a potential mimic of leptomeningeal metastasis. *Am. J. Neuroradiol.* 15:639-641, 1994.
159. Bruggers, C.S., Friedman, H.S., Tien, R., and DeLong, R.: Cerebral atrophy in an infant following treatment with ifosfamide. *Med. Pediatr. Oncol.* 23:380-383, 1994.

160. Aaron, R.H., Elion, G.B., Colvin, O.M., Graham, M., Keir, S., Bigner, D.D., and Friedman, H.S.: Busulfan therapy of central nervous system xenografts in athymic mice. *Cancer Chemother. Pharmacol.* 35:127-131, 1994.
161. Dolan, M.E., Chae, M.-Y., Pegg, A.E., Mullen, J.H., Friedman, H.S., and Moschel, R.C.: Metabolism of O6-benzylguanine, an inactivator of O6-alkylguanine-DNA alkyltransferase. *Cancer Res.* 54:5123-5130, 1994.
162. Dolan, M.E., Pegg, A.E., Moschel, R.C., Vichnuvajjala, B.R., Flora, K.P., Grever, M.R., and Friedman, H.S.: Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when administered in polyethylene glycol or cremophor-el. *Cancer Chemo. Pharmacol.* 35:121-126, 1994.
163. Krishna, M.C., Dewhirst, M.W., Friedman, H.S., Cook, J.A., DeGraff, W., Samuni, A., and Mitchell, J.B.: Hyperthermic sensitization by the radical initiator 2,2'-azobis(2-amidinopropane) dihydrochloride (AAPH): I. *In vitro* studies. *Int. J. Hyperthermia* 10:271-281, 1994.
164. Osumi, A.K., McLendon, R.E., Tien, R.D., Friedman, H.S., Graham, M., Hockenberger, B., Halperin, E.C., and Oakes, W.J.: Well differentiated astrocytoma occurring nine years after radiation therapy for medulloblastoma. *Clin. Neuropathol.* 13:281-285, 1995.
165. Schuster, J., Zalutsky, M.R., Noska, M.A., Dodge, R., Friedman, H.S., Bigner, D.D., and Dewhirst, M.W.: Hyperthermic modulation of radiolabelled antibody uptake in a human glioma xenograft and normal tissues. *Int. J. Hyperthermia* 11:59-72, 1995.
166. Friedman, H.S. and Stewart, E.: Brain tumors in children: paradigm of an orphan disease. *Focus and Opinion: Pediatrics* 1:11-16, 1995.
167. Lachance, D.H., Oette, D., Schold, S.C., Jr., Brown, M., Kurtzberg, J., Graham, M.L., Tien, R., Felsberg, G., Colvin, O.M., Moghrabi, A., Browning, I., Hockenberger, B., Stewart, E.,

Ferrell, L., Kerby, T., Duncan-Brown, M., Golembe, B., Fuchs, H., Fredericks, R., Hayes, F.A., Rubin, A.S., Bigner, D.D., and Friedman, H.S.: Dose escalation trial of cyclophosphamide with sargamostim in the treatment of central nervous system (CNS) neoplasms. *Med. Pediatr. Oncol.* 24:241-247, 1995.

168. Pastan, I.H., Archer, G.E., McLendon, R.E., Friedman, H.S., Fuchs, H.E., Wang, Q-C., Pai, L.H., Herndon, J., and Bigner, D.D.: Intrathecal administration of single-chain immunotoxin, LMB-7 (B3(Fv)-PE38), produces cures of carcinomatous meningitis in a rat model. *Proc. Natl. Acad. Sci. USA* 93:2765-2769, 1995.

169. Foltz, R.M., McLendon, R.E., Friedman, H.S., Dodge, R.K., Bigner, D.D., and Dewhirst, M.W.: A pial window model for intracranial study of human glioma microvascular function. *Neurosurgery* 36:976-985, 1995.

170. Rasheed, B.K.A., McLendon, R.E., Friedman, H.S., Friedman, A.H., Fuchs, H.E., Bigner, D.D., and Bigner, S.H.: Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. *Oncogene* 10:2243-2246, 1995.

19

171. Castellino, S.M., Friedman, H.S., Elion, G.B., Ong, E.T., Marcelli, S.L., Page, R., Bigner, D.D., and Dewhirst, M.W.: Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma. *Br. J. Cancer* 71:1181-1187, 1995.

172. Friedman, H.S., Dolan, M.E., Pegg, A.E., Marcelli, S., Keir, S., Catino, J.J., Bigner, D.D., and Schold, S.C., Jr.: Activity of temozolomide in the treatment of central nervous system tumor xenografts. *Cancer Res.* 55:2853-2857, 1995.

173. Marks, L.B., and Friedman, H.S.: Hematologic toxicity during craniospinal irradiation: the impact of prior chemotherapy. *Med. Pediatr. Oncol.* 25:45-51, 1995.

174. Batra, S.K., McLendon, R.E., Koo, J.S., Castelino-Prabhu, S., Fuchs, H.E., Krischer, J.P., Friedman, H.S., Bigner, D.D., and Bigner, S.H. Prognostic implications of chromosome

- 17p deletions in human medulloblastomas. *J. Neurooncol.* 24:39-45, 1995.
175. Duffner, P., Cohen, M., Sanford, R., Morowitz, M., Krischer, J., Burger, P., Friedman, H., Kun, L., and the Pediatric Oncology Group: Lack of efficacy of postoperative chemotherapy and delayed radiation in very young children with pineoblastoma. *Med. Pediatr. Oncol.* 25:38-44, 1995.
176. Moghrabi, A., Fuchs, H., Brown, M., Schold, Jr., S.C., Graham, M., Kurtzberg, J., Tien, R., Felsberg, G., Lachance, D.H., Colvin, O.M., Oette, D., Allegretta, A., Hockenberger, B., Stewart, E., Ferrell, L., Kerby, T., Duncan-Brown, M., Bigner, D.D., and Friedman, H.S.: Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma. *Med. Pediatr. Oncol.* 25:190-196, 1995.
177. Bigner, D.D., Brown, M., Coleman, R.E., Friedman, A.H., Friedman, H.S., McLendon, R.E., Bigner, S.H., Zhao, X.-G. Wikstrand, C.J., Pegram, C.N., Kerby, T., and Zalutsky, M.R.: Phase I studies of treatment of malignant gliomas and neoplastic meningitis with ¹³¹I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F(ab')₂ - A preliminary report. *J. Neurooncol.* 24:109-122, 1995.
178. Duffner, P.K., Kun, L.E., Burger, P.C., Horowitz, M.E., Cohen, M.E., Sanford, R.A., Krischer, J.P., James, H.E., Reigate, H.L., Friedman, H.S., and the Pediatric Oncology Group: Postoperative chemotherapy and delayed radiation in infants and very young children with choroid plexus carcinomas. *Pediatr. Neurosurg.* 22:189-196, 1995.
179. Friedman, H.S., Bigner, S.H., and Bigner, D.D.: Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again). *J. Neurooncol.* 24:103-108, 1995.
180. Lirng, J.-F., Tien, R.D., Felsberg, G.J., Osumi, A.K., Moghrabi, A., and Friedman, H.S.: Clinical significance of contrast-enhanced MRI in brainstem gliomas. *Chin. J. Radiol.*

20:13-24, 1995.

181. Rich, J.N., Elion, G.B., Wellner, D., Colvin, O.M., Groothuis, D.R., Hilton, J.H.,

Schlageter, K.E., Bigner, D.D., Griffith, O.W., and Friedman, H.S.: The effect of *L*-amino

20

acid oxidase on activity of melphalan against an intracranial xenograft. *Cancer Chemother.*

Pharmacol. 36:379-384, 1995.

182. Kurpad, S.N., Friedman, H.S., Archer, G.E., McLendon, R.E., Petros, W.M., Fuchs, H.E.,

Guaspari, A., and Bigner, D.D.: Intraarterial administration of melphalan for treatment of

intracranial human glioma xenografts in athymic rats. *Cancer Res.* 55:3803-3809, 1995.

183. Batra, S.K., Castelino-Prabhu, S., Wikstrand, C.J., Zhu, X., Humphrey, P.A., Friedman,

H.S., and Bigner, D.D.: Epidermal growth factor receptor ligand-independent, unregulated,

cell-transforming potential of a naturally occurring human mutant *EGFRvIII* gene. *Cell*

Growth Differ. 6:1251-1259, 1995.

184. Heideman, R.L., Douglass, E.C., Langston, J.A., Krischer, J.P., Burger, P.C., Kovnar, E.H.,

Kun, L.E., Friedman, H.S., and Kadota, R.: A Phase II study of every other day high-dose

ifosfamide in pediatric brain tumors: A Pediatric Oncology Group Study. *J. Neurooncol.*

25:77-84 1995.

185. Houghton, P.J., Cheshire, P.J., Hallman, J.D., II, Lutz, L., Friedman, H.S., Danks, M.K.,

and Houghton, J.A.: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan,

administered at low dose levels in protracted schedules to mice bearing xenografts of

human tumors. *Cancer Chemother. Pharmacol.* 36:393-403, 1995.

186. Razzouk, B.I., Heideman, R.L., Horowitz, M.E., Friedman, H.S., Jenkins, J.J., and Kun,

L.E.: A Phase II evaluation of thiotepa followed by other multiagent chemotherapy in

infants and young children with malignant brain tumors. *Cancer* 75:2762-2767, 1995.

187. Dong, Q., Barsky, D., Colvin, M.E., Melius, C.F., Ludeman, S.M., Moravek, J.F., Colvin,

- O.M., Bigner, D.D., Modrich, P., and Friedman, H.S.: A structural basis for a phosphoramidate mustard-induced DNA interstrand cross-link at 5'-d (GAC). *Proc. Natl. Acad. Sci. USA* 92:12170-12174, 1995.
188. Bigner, D.D., Archer, G.E., McLendon, R.E., Friedman, H.S., Fuchs, H.E., Pai, L.H., Herndon, J.E., II, and Pastan, I.H.: Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis. *Clin. Cancer Res.* 1:1545-1555, 1995.
189. Moghrabi, A., Tien, R.D., Kerby, T., and Friedman, H.S.: Prognostic value of contrast-enhanced MRI in brainstem gliomas. *Pediatr. Neurosurg.* 23:293-298, 1995.
190. Strickland, D.K., Vaidyanathan, G., Friedman, H.S., and Zalutsky, M.R.: Meta-[¹³¹I]iodobenzylguanidine uptake and meta-[²¹¹At]astatobenzylguanidine treatment in human medulloblastoma cell lines. *J. Neurooncol.* 25:9-17, 1995.
191. Lirng, J.F., Enterline, D.S., Tien, R.D., Fuchs, H., Friedman, H.S., Ellington, K.S., and McLendon, R.E.: MRI of papillary meningiomas in children. *Pediatr. Radiol.* 25S1:9-13, 1995.
192. Broome, C., Schiff, R., and Friedman, H.S.: Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. *Med. Pediatr. Oncol.* 26:105-110, 1996.
- 21
193. Dong, Q., Bullock, N., Ali-Osman, F., Colvin, O.M., Bigner, D.D., and Friedman, H.S.: Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand cross-linking in the *c-myc* gene in 4-hydroperoxycyclophosphamide-sensitive and -resistant medulloblastoma cell lines. *Cancer Chemother. Pharmacol.* 37:242-246, 1996.
194. Blaeker, H., Rasheed, B.K.A., McLendon, R., Friedman, H.S., Batra, S.K., Fuchs, H.E., and Bigner, S.H.: Microsatellite analysis of childhood brain tumors. *Genes Chromosom. Cancer* 15:54-63, 1996.

195. Halperin, E., Samulski, T., Oakes, J., and Friedman, H.S.: Fabrication and testing of a device capable of reducing the incidence of ventricular shunt promoted metastasis. *J. Neurooncol.* 27:39-46, 1996.
196. Mahoney, D., Strother, D., Camitta, B., Bowen, T., Ghim, T., Pick, T., Wall, D. Yu, L., Shuster, J., and Friedman, H.: High dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: A Pilot Pediatric Oncology Group Study. *J. Clin. Oncol.* 14:382-388, 1996.
197. Freeman, C.R., Bourguoin, P.M., Sanford, R.A., Cohen, M.E., Friedman, H.S., and Kun, L.E.: Long term survivors of hyperfractionated radiotherapy in brain stem tumors in children: clinical characteristics and treatment-related toxicities. *Cancer* 77:555-562, 1996.
198. Kuyper, L.F., Baccanari, D.P., Jones, M.L., Hunter, R.N., Tansik, R.L., Joyner, S.S., Boytos, C.M., Rudolph, S.K., Knick, V., Wilson, R., Caddell, M., Friedman, H.S., Comley, J., and Stables, J.: High affinity inhibitors of dihydrofolate reductase: antifungal and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size. *J. Med. Chem.* 39:892-903, 1996.
199. Srivenugopal, K.S., Yuan, X.-H., Friedman, H.S., and Ali-Osman, F.: Ubiquitinationdependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. *Biochemistry* 35, 1328-1334, 1996.
200. McCowage, G., Tien, R., McLendon, R., Feisberg, G., Fuchs, H., Graham, M.L., Kurtzberg, J., Moghrabi, A., Ferrell, L., Kerby, T., Duncan-Brown, M., Stewart, E., Robertson, P.L., Colvin, O.M., Golembe, B., Bigner, D.D., and Friedman, H.S.: Successful treatment of childhood pilocytic astrocytomas metastatic to the leptomeninges with high-dose cyclophosphamide. *Med. Pediatr. Oncol.* 27:32-39, 1996.
201. McLendon, R.E., Fung, K.-M., Bentley, R.C., Rasheed, B.K.A., Trojanowski, J.Q., Bigner,

S.H., Bigner, D.D., and Friedman, H.S.: Production and characterization of two ependymoma xenografts. *J. Neuropathol. Exp. Neurol.* 55:540-548, 1996.

202. Brown, M.T., Coleman, R.E., Friedman, A.H., Friedman, H.S., McLendon, R.E., Reiman, R., Felsberg, G.J., Tien, R.D., Bigner, S.H., Zalutsky, M.R., Zhao, X.G., Wikstrand, C.J., Pegram, C.N., Herndon, II, J.E., Vick, N.A., Paleologos, N., Fredericks, R.K., Schold, Jr., S.C., and Bigner, D.D.: Intrathecal ¹³¹I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection
22

cavities with subarachnoid communication: Phase I trial results. *Clin. Cancer Res.* 2:963-972, 1996.

203. Duffner, P.K., Krischer, J.P., Burger, P.C., Cohen, M.E., Backstrom, J.W., Horowitz, M.E., Sanford, R.A., Friedman, H.S., Kun, L.E., and the Pediatric Oncology Group: Treatment of infants with malignant gliomas: The Pediatric Oncology Group Experience. *J. Neurooncol.* 28:245-256, 1996.

204. Ashley, D.M., Longee, D., Tien, R., Fuchs, H., Graham, M.L., Kurtzberg, J., Casey, J., Olson, J., Meier, L., Ferrell, L., Kerby, T., Duncan-Brown, M., Stewart, E., Colvin, O.M., Pipas, J.M., McCowage, G., McLendon, R., Bigner, D.D., and Friedman, H.S.: Treatment of patients with pineoblastoma with high dose cyclophosphamide. *Med. Pediatr. Oncol.* 26:387-392, 1996.

205. Vaidyanathan, G., Friedman, H.S., Keir, S.T., and Zalutsky, M.R.: Localization of [¹³¹I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity. *Br. J. Cancer* 73:1171-1177, 1996.

206. Ashley, D.M., Meier, L., Zalduondo, F.M., Friedman, H.S., and Longee, D.: Dramatic response to low dose oral VP 16 in disseminated, recurrent medulloblastoma. *J. Clin. Oncol.* 14:1922-1927, 1996.

207. Moynihan, K., Elion, G.B., Ali-Osman, F., Marcelli, S., Keir, S., Bigner, D.D., and Friedman, H.S.: Enhancement of melphalan activity by inhibition of DNA polymerase- α and DNA polymerase- β . *Cancer Chemother. Pharmacol.* 38:349-354, 1996.
208. Heinz, R., Wiener, D., Friedman, H.S., and Tien, R.: Detection of CSF metastases - CT myelography or MR? A prospective efficacy study. *Am. J. Neuroradiol.* 16:1147-1151, 1996.
209. Tonda, M.E., Heideman, R.L., Petros, W.P., Friedman, H.S., Murry, D.J., and Rodman, J.H.: Carboplatin pharmacokinetics in young children with brain tumors. *Cancer Chemother. Pharmacol.* 38:395-400, 1996.
210. Deutsch, M., Patrick, R.M., Thomas, M.D., Krischer, J., Boyett, J.M., Albright, L., Aronin, P., Langston, J., Allen, J.C., Finlay, J.L., Linggood, R., Mulhern, R., Stanley, P., Stehbens, J.A., Duffner, P., Kun, L., Rorke, L., Cherlow, J., Friedman, H., Packer, R.J., and Vietti, T. Results of a prospective randomized trial comparing standard dose neuraxis irradiation (3,600 cGy/20) with reduced neuraxis irradiation (2,340 cGy/13) in patients with low stage medulloblastoma: a combined Children's Cancer Group-Pediatric Oncology Group study. *Pediatr. Neurosurg.* 24:167-177, 1996.
211. Halperin, E.C., and Friedman, H.S.: Is there a correlation between duration of presenting symptoms at stage of diagnosis of medulloblastoma. *Cancer* 78:874-880, 1996.
212. Jones, D.N., McCowage, G., Sostman, P.D., Brizel, D.M., Layfield, L., Charles, H.C., Dewhurst, M.W., Prescott, D.M., Friedman, H.S., Harrelson, J.M., Scully, S.P., and Coleman, R.E.: Monitoring of neoadjuvant therapy response of soft tissue and musculoskeletal sarcomas using F18-FDG PET: initial evaluation. *J. Nucl. Med.* 37:1438-1444, 1996.
213. Vaidyanathan, G., Friedman, H.S., Keir, S.T., and Zalutsky, M.R.: Evaluation of *Meta-*

[211At] astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model.

Nucl. Med. Biol. 23:851-856, 1996.

214. Hare, C.B., Elion, G.B., Houghton, P.J., Houghton, J.A., Keir, S., Marcelli, S.L., Bigner, D.D., and Friedman, H.S.: Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. *Cancer Chemother. Pharmacol.* 39:187-191, 1997.

215. Moynihan, K., Elion, G.B., Pegram, C., Reist, C.J., Wellner, D., Bigner, D.D., Griffith, O.W., and Friedman, H.S.: *L*-amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma. *Cancer Chemother. Pharmacol.* 39:179-186, 1997.

216. Kurpad, S.N., Dolan, M.E., McLendon, R.E., Archer, G.E., Moschel, R.C., Pegg, A.E., Bigner, D.D., and Friedman, H.S.: Intraarterial O₆-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea. *Cancer Chemother. Pharmacol.* 39:307-316, 1997.

217. Moghrabi, A., Tien, R., Fuchs, H., Longee, D., McLendon, R., and Friedman, H.S.: False positive MRI images in the follow-up of patients with brain tumors. *Med. Pediatr. Oncol.* 28:127-131, 1997.

218. McLendon, R.E., Bentley, R.C., Parisi, J.E., Tien, R.D., Harrison, J.C., Tarbell, N.C., Billitt, A.L., Gualtieri, R.J., and Friedman, H.S.: Malignant supratentorial glial-neuronal neoplasms: report of two cases and review of the literature. *Arch. Pathol. Lab. Med.* 121:485-492, 1997.

219. Friedman, H.S., Johnson, S.P., Dong, Q., Schold, S.C., Rasheed, B.K.A., Bigner, S.H., Ali-Osman, F., Dolan, E., Colvin, O.M., Houghton, P., German, G., Drummond, J.T., Keir, S., Marcelli, S., Bigner, D.D., and Modrich, P.: Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. *Cancer Res.* 57:2933-2936, 1997.

220. Kupczyk-Subotkowska, L., Siahaan, T.J., Basile, A.S., Friedman, H.S., Higgins, P.E., and Gallo, J.M.: Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate. *J. Med. Chem.* 40:1726-1730, 1997.
221. Graham, M.L., Herndon, J.E., II, Casey, J.R., Chaffee, S., Ciocci, G.H., Krischer, J.P., Kurtzberg, J., Laughlin, M.J., Longee, D.C., Olson, J.F., Pennington, C.N., and Friedman, H.S.: High-dose chemotherapy with autologous stem cell rescue in patients with recurrent and high risk pediatric brain tumors. *J. Clin. Oncol.* 15:1814-1823, 1997.
222. Hare, C.B., Elion, G.B., Colvin, O.M., Ali-Osman, F., Griffith, O.W., Petros, W.P., Keir, S., Marcelli, S.L., Bigner, D.D., and Friedman, H.S.: Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft. *Cancer Chemother. Pharmacol.* 40:409-414, 1997.
- 24
223. Ashley, D.M., Coleman, E., Fuchs, H., Dear, G., Zalduondo, F.M., Friedman, H.S., and Longee, D.: Chronic CSF leak into the peritoneal cavity of an 8 year old demonstrated by radionuclide cisternography: successful treatment with an epidural blood patch. *Clin. Nucl. Med.* 22:390-392, 1997.
224. Rasheed, B.K.A., Stenzel, T.T., McLendon, R.E., Parsons, R., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Bigner, S.H.: *PTEN* gene mutations are seen in high-grade but not in low-grade gliomas. *Cancer Res.* 57:4187-4190, 1997.
225. Bigner, S.H., McLendon, R.E., Fuchs, H., McKeever, P.E., and Friedman, H.S.: Chromosomal characteristics of childhood brain tumors. *Cancer Genet. Cytogenet.* 97:125-134, 1997.
226. McCowage, G.B., Friedman, H.S., Moghrabi, A., Kerby, T., Ferrell, L., Stewart, E., Duncan-Brown, M., Fuchs, H.E., Tien, R., McLendon, R.E., Meier, L., Kurtzberg, J., Ashley, D., Colvin, O.M., and Longee, D.C.: Activity of high dose cyclophosphamide in

the treatment of childhood malignant gliomas. *Med. Pediatr. Oncol.* 30:75-80, 1998.

227. Mulhern, R.K., Armstrong, F.D., Aronin, P., Duffner, P., Friedman, H., Kepner, J., Krischer, J., Kun, L., Langston, J., Thomas, P.R.M., and Vietti, T.: Neurophysiological functioning of survivors of childhood medulloblastoma randomized to receive conventional (3,600 cGy/20) or reduced (2,340 cGy/13) dose craniospinal irradiation. A Pediatric Oncology Group Study. *J. Clin. Oncol.* 16:1723-1728, 1998.

228. Coggins, C.A., Elion, G.B., Houghton, P.J., Hare, C.B., Keir, S., Colvin, O.M., Bigner, D.D., and Friedman, H.S.: Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. *Cancer Chemother. Pharmacol.* 41:485-490, 1998.

229. Houghton, P.J., Stewart, C.F., Thompson, J., Santana, V.M., Furman, W.L., and Friedman, H.S.: Preclinical and clinical results with irinotecan: extending principles learned in model systems to clinical trials design. *Oncology (Supplement)* 12:1-10, 1998.

230. McLendon, R.E., Cleveland, L., Pegram, C., Bigner, S.H., Bigner, D.D., and Friedman, H.S.: Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin fixed paraffin embedded astrocytomas. *Lab. Invest.* 78:643-644, 1998.

231. Bigner, D.D., Brown, M.T., Friedman, A.H., Coleman, R.E., Akabani, G., Friedman, H.S., Thorstad, W.L., McLendon, R.E., Bigner, S.H., Zhao, X.-G., Pegram, C.N., Wikstrand, C.J., Herndon II, J.E., Vick, N.A., Paleologos, N., Cokgor, I., Provenzale, J.M., and Zalutsky, M.R.: Iodine-131-labeled anti-tenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results. *J. Clin. Oncol.* 16:2202-2212, 1998.

232. Lee, S.E., Johnson, S.P., Hale, L.P., Li, J., Bullock, N., Fuchs, H., Friedman, A., McLendon, R., Bigner, D.D., Modrich, P., and Friedman, H.S.: Analysis of DNA mismatch repair proteins in human medulloblastoma. *Clin. Cancer Res.* 4:1415-1419, 1998.

233. Burger, P.C., Yu, I.-T., Tihan, T., Friedman, H.S., Strother, D., Kepner, J.L., Duffner, P.K., Kun, L.E., and Perlman, E.J.: Atypical teratoid/rhabdoid tumor: a highly malignant tumor of infancy and childhood frequently mistaken for a medulloblastoma. A Pediatric Oncology Group Study. *Am. J. Surg. Pathol.* 22:1083-1092, 1998.
234. Duffner, P.K., Krischer, J.P., Horowitz, M.E., Cohen, M.E., Burger, P.C., Friedman, H.S., Kun, L.E., and The Pediatric Oncology Group: Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed radiation. A Pediatric Oncology Group Study. *Ann. Neurol.* 44:313-316, 1998.
235. Duffner, P.K., Krischer, J.P., Sanford, R.A., Horowitz, M.E., Burger, P.C., Cohen, M.E., Friedman, H.S., Kun, L.E., and the Pediatric Oncology Group: Prognostic factors in infants and very young children with intracranial ependymomas. *Pediatr. Neurosurg.* 28:215-222, 1998.
236. Friedman, H.S., Kokkinakis, D.M., Pluda, J., Friedman, A.H., Cokgor, I., Haglund, M.M., Ashley, D.M., Rich, J., Dolan, M.E., Pegg, A.E., Moschel, R.C., McLendon, R., Kerby, T., Herndon, J.E., Bigner, D.D., and Schold, S.C., Jr.: Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. *J. Clin. Oncol.* 16:3570-3575, 1998.
237. Hanley, M.L., Elion, G.B., Colvin, O.M., Modrich, P.L., Keir, S., Adams, D.J., Bigner, D.D., and Friedman, H.S.: Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors. *Cancer Chemother. Pharmacol.* 42:479-482, 1998.
238. Friedman, H.S., McLendon, R.E., Kerby, T., Dugan, M., Bigner, S.H., Henry, A.J., Ashley, D.M., Krischer, J., Lovell, S., Rasheed, K., Marchev, F., Semen, A.J., Cokgor, I., Rich, J., Stewart, E., Colvin, O.M., Provenzale, J.M., Bigner, D.D., Haglund, M.M., Friedman, A.H., and Modrich, P.L.: DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase

analysis and response to Temodal in newly diagnosed malignant glioma. *J. Clin. Oncol.* 16:3851-3857, 1998.

239. Moghrabi, A., Friedman, H.S., Ashley, D.M., Bottom, K.S., Kerby, T., Stewart, E., Bruggers, C., Provenzale, J.M., Champagne, M., Hershon, L., Watral, M., Ryan, J., Rasheed, K., Lovell, S., Korones, D., Fuchs, H., George, T., McLendon, R.E., Friedman, A.H., and Longee, D.C.: Phase II study of carboplatin (CBDCA) in progressive pediatric and adult low-grade gliomas. *Neurosurg. Focus* 4: article 4, 1998.

240. Cokgor, I., Friedman, A.H., and Friedman, H.S.: Gliomas. *Eur. J. Cancer* 34:1910-1918, 1998.

241. Friedman, H.S., Lovell, S., Rasheed, K., Friedman, A.H., and the Writing Committee for the Brain Tumor Center at Duke: Treatment of adults with progressive oligodendroglioma with carboplatin (CBDCA): preliminary results. *Med. Pediatr. Oncol.* 31:16-18, 1998.

242. Cokgor, I., Friedman, H.S., and Friedman, A.H.: Chemotherapy for adults with malignant glioma. *Cancer Invest.* 17:264-272, 1999.

26

243. Dong, Q., Johnson, S.P., Colvin, O.M., Bullock, N., Kilborn, C., Runyon, G., Sullivan, D.M., Easton, J., Bigner, D.D., Nahta, R., Marks, J., Modrich, P., and Friedman, H.S.: Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR). *Cancer Chemother. Pharmacol.* 43:73-79, 1999.

244. Friedman, H.S., Pegg, A.E., Johnson, S.P., Loktionova, N.A., Dolan, M.E., Modrich, P., Moschel, R.C., Struck, R., Brent, T.P., Ludeman, S., Bullock, N., Kilborn, C., Keir, S., Dong, Q., Bigner, D.D., and Colvin, O.M.: Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase. *Cancer Chemother. Pharmacol.* 43:80-85, 1999.

245. Akabani, G., Reist, C.J., Cokgor, I., Friedman, A.H., Friedman, H.S., Coleman, E., Zhao, X.-G., Bigner, D.D., and Zalutsky, M.R.: Dosimetry of ¹³¹I-labeled 81C6 monoclonal

antibody administered into surgically created resection cavities in malignant brain tumor patients. *J. Nucl. Med.* 40:631-638, 1999.

246. Friedman, H.S., Kerby, T., Fields, S., Zilisch, J.E., Graden, D., McLendon, R.E., Houghton, P.J., Arbuck, S., Cokgor, I., Friedman, A.H., Ashley, D.M., Lovell, S., Rasheed, K., Longee, D.C., Bottom, K.S., Stewart, E.S., Colvin, O.M., Provenzale, J.M., Bigner, D.D., Rich, J.N., Haglund, M., and Scurlock-Jones, M.: Topotecan treatment of adults with primary malignant glioma. *Cancer* 85:1160–1165, 1999.

247. Mandell, L.R., Kadota, R., Freeman, C., Douglass, E.C., Fontanesi, J., Cohen, M., Kovnar, E., Burger, P., Sanford, R.A., Kepner, J., Friedman, H., and Kun, L.E.: There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group Phase III trial comparing conventional vs. hyperfractionated radiotherapy. *Int. J. Radiat. Oncol. Biol. Phys.* 43:959-964, 1999.

248. Wu, M.H., Lohrbach, K.E., Olopade, O.I., Friedman, H.S., and Dolan, M.E.: Lack of evidence for a polymorphism at codon 160 of human *O6*-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer. *Clin. Cancer Res.* 5:209-213, 1999.

249. McLendon, R.E., Friedman, H.S., Fuchs, H.E., Kun, L.E., and Bigner, S.H.: Diagnostic markers in pediatric medulloblastoma. A Pediatric Oncology Group Study. *Histopathology* 34:154-162, 1999.

250. Friedman, H.S., Petros, W.P., Friedman, A.H., Schaaf, L.J., Kerby, T., Lawyer, J., Parry, M., Houghton, P.J., Lovell, S., Rasheed, K., Cloughsey, T., Stewart, E.S., Colvin, O.M., Provenzale, J.M., McLendon, R.E., Bigner, D.D., Cokgor, I., Haglund, M., Rich, J., Ashley, D., Malczyn, J., Elfring, G.L., and Miller, L.L.: Irinotecan therapy in adults with recurrent or progressive malignant glioma. *J. Clin. Oncol.* 17:1516-1525, 1999.

251. Sampson, J.H., Archer, G.E., Villavicencio, A.T., McLendon, R.E., Friedman, A.H.,

Bishop, W.R., Bigner, D.D., and Friedman, H.S.: Treatment of neoplastic meningitis with intrathecal temozolomide. *Clin. Cancer Res.* 5:1183-1188, 1999.

252. Bigner, S.H., Matthews, M.R., Rasheed, B.K.A., Wiltshire, R.N., Friedman, H.S., Friedman, A.H., Stenzel, T.T., Dawes, D.M., McLendon, R.E., and Bigner, D.D.:

27

Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. *Am. J. Pathol.* 155:375-386, 1999.

253. Kadota, R.P., Kun, L.E., Langston, J.W., Burger, P.C., Cohen, M.E., Mahoney, D.H., Walter, A.W., Rodman, J.H., Parent, A., Buckley, E., Kepner, J.L., and Friedman, H.S.:

Cyclophosphamide for the treatment of progressive astrocytoma - a Pediatric Oncology Group Phase II Study. *J. Pediatr. Hematol. Oncol.* 21:198-202, 1999.

254. Yung, A., Prados, M., Poisson, M., Rosenfeld, S., Brada, M., Friedman, H., Albright, R., Friedman, A.H., Olson, J., Bruner, J., Yue, N., Dugan, M., and Levin, V. for the Temodal Brain Tumor Group: Multicenter Phase II trial of temozolomide in patients with malignant astrocytoma at first relapse. *J. Clin. Oncol.* 17:2762-2769, 1999.

255. Duffner, P.K., Horowitz, M.E., Krischer, J.P., Burger, P.C., Cohen, M.E., Friedman, H.S., Kun, L.E., and the Pediatric Oncology Group: The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group Experience. *Neurooncol.* 1:152-161, 1999.

256. Archer, G.E., Sampson, J.H., Lorimer, I.A.J., McLendon, R.E., Kuan, C.T., Friedman, A.H., Friedman, H.S., Pastan, I.H., and Bigner, D.D.: Regional treatment of EGFRvIII expressing neoplastic meningitis with a single chain immunotoxin, MR-1. *Clin. Cancer Res.* 5:2646-2652, 1999.

257. Archer, G.E., Sampson, J.H., McLendon, R.E., Friedman, A.H., Colvin, O.M., Rose, M., Sands, H., McCullough, W., Fuchs, H., Bigner, D.D., and Friedman, H.S.: Intrathecal

busulfan treatment of human neoplastic meningitis in athymic nude rats. *J. Neurooncol.* 44(3):233-241, 1999.

258. Kadota, R.P., Stewart, C.F., Horn, M., Kuttesch, J.F., Jr., Burger, P.C., Kepner, J.L., Kun, L.E., Friedman, H.S., and Heideman, R.L.: Topotecan for the treatment of recurrent or progressive central nervous system tumors - a Pediatric Oncology Group Phase II Study. *J. Neurooncol.*, 43:43-47, 1999.

259. Mulne, A.F., Ducore, J.M., Elterman, R.D., Friedman, H.S., Krischer, J.P., Kun, L.E., Shuster, J.J., and Kadota, R.P.: Oral methotrexate for recurrent brain tumors in children - a Pediatric Oncology Group Study. *J. Pediatr. Hematol. Oncol.* 22:41-44, 2000.

260. Akabani, G., Cokgor, I., Coleman, R.E., Trotter, D.G., Wong, T.Z., Friedman, H.S., Garcia-Turner, A., Herndon II, J.E., DeLong, D., McLendon, R.E., Zhao, X.-G., Pegram, C.N., Bigner, D.D., and Zalutsky, M.R.: Dosimetry and dose-response relationships in newly diagnosed patients treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. *Int. J. Radiat. Oncol. Biol. Phys* 46:947-958, 2000.

261. Middlemas, D.S., Stewart, C.F., Kirstein, M.N., Poquette, C., Friedman, H.S., Houghton, P.J., and Brent, T.P.: Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. *Clin. Cancer Res.* 6:998-1007, 2000.

28

262. Aldosari, N., Rasheed, B.K.A., McLendon, R.E., Friedman, H.S., Bigner, D.D., and Bigner, S.H.: Characterization of chromosome 17 abnormalities in medulloblastomas. *Acta Neuropathol.* 99:345-351, 2000.

263. Castellino, R.C., Elion, G.B., Keir, S.T., Houghton, P.J., Johnson, S.P., Bigner, D.D., and Friedman, H.S.: Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. *Cancer Chemother. Pharmacol.* 45:345-349, 2000.

264. Sampson, J.H., Crotty, L.E., Lee, S., Archer, G.E., Ashley, D.M., Wikstrand, C.J., Hale,

L.P., Small, C., Dranoff, G., Friedman, A.H., Friedman, H.S., and Bigner, D.D.: Unarmed, tumor-specific, monoclonal antibody effectively treats brain tumors. Proc. Natl. Acad. Sci. USA 97(13):7503-7508, 2000.

265. Cokgor, I., Akabani, G., Wikstrand, C., Zalutsky, M.R., Friedman, H.S., Friedman, A.H., and Bigner, D.D.: Radiolabeled monoclonal antibodies for malignant glioma: an improvement over current therapy? Medscape Oncology 3(3), 2000.

266. Keir, S.T., Dolan, M.E., Pegg, A.E., Lawless, A., Moschel, R.C., Bigner, D.D., and Friedman, H.S.: O6-benzylguanine-mediated enhancement of nitrosourea activity in mercentral nervous system tumor xenografts – implications for clinical trials. Cancer Chemother. Pharmacol. 45:437-440, 2000.

267. Friedman, H.S.: Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. Semin. Oncol. 27(S6): 35-40, 2000.

268. Friedman, H.S., Kerby, T., and Calvert, H.: Temozolomide and treatment of malignant glioma. Clin. Cancer Res. 6:2585-2597, 2000.

269. Thomas, P.R.M., Deutsch, M., Kepner, J., Boyett, J.M., Krischer, J., Aronin, P., Albright, L., Allen, J.C., Packer, R.J., Linggood, R., Mulhern, R., Stehbens, J.A., Langston, J., Stanley, P., Duffner, P., Rorke, L., Kun, L., Cherlow, J., Friedman, H., Finlay, J.L., and Vietti, T.: Low stage medulloblastoma: Final analysis of trial comparing standard with reduced dosage neuraxis irradiation. J. Clin. Oncol. 18:3004-3011, 2000.

270. Wiltshire, R.N., Rasheed, B.K.A., Friedman, H.S., Friedman, A.H., and Bigner, S.H.: Comparative genetic patterns of glioblastoma multiforme: potential diagnostic tool for tumor classification. Neurooncol. 2:164-173, 2000.

271. Friedman, H.S., Pluda, J., Quinn, J.A., Ewesuedo, R.B., Long, L., Friedman, A.H., Cokgor, I., Colvin, O.M., Haglund, M.M., Ashley, D.M., Rich, J.R., Sampson, J., Pegg, A.E., Moschel, R.C., McLendon, R.E., Provenzale, J.M., Stewart, E.S., Tourt-Uhlig, S., Garcia-

Turner, A.M., Herndon, J.E., II, Bigner, D.D., and Dolan, M.E.: Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. *J. Clin. Oncol.* 18:3522-3528, 2000.

272. Cokgor, I., Akabani, G., Kuan, C.-T., Friedman, H.S., Friedman, A.H., Coleman, R.E., McLendon, R.E., Bigner, S.H., Zhao, X.-G., Garcia-Turner, A.M., Pegram, C.N., Wikstrand, C.J., Shafman, T.D., Herndon II, J.E., Provenzale, J.M., Zalutsky, M.R., and Bigner, D.D.: Phase I trial results of 131I-labeled antitenascin monoclonal antibody 81C6
29

treatment of patients with newly diagnosed malignant gliomas. *J. Clin. Oncol.* 18:3862-3872, 2000.

273. Bottom, K.S., Ashley, D.M., Friedman, H.S., Longee, D.C., and the Writing Committee for the Brain Tumor Center at Duke: Treatment of patients with glioblastoma multiforme with high-dose cyclophosphamide. *J. Neurooncol.* 46:151-156, 2000.

274. Brown, H.G., Kepner, J.L., Perlman, E.J., Friedman, H.S., Strother, D.R., Duffner, P.K., Kun, L.E., Goldthwaite, P.T., and Burger, P.C.: Large cell/anaplastic medulloblastomas: a Pediatric Oncology Group Study. *J. Neuropathol. Exp. Neurol.* 59:857-865, 2000.

275. Heimberger, A.B., Archer, G.E., McLendon, R.E., Hulette, C., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Sampson, J.H.: Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas. *Clin. Cancer Res.* 6:4148-4153, 2000.

276. Yung, A., Levin, V.A., Brada, M., Friedman, H., Osoba, D., Olson, J., Fink, K., Albright, R.E., and Fredericks, R.: Randomized, multicenter, open-label, Phase II, comparative study of temozolomide and procarbazine in the treatment of patients with glioblastoma multiforme at first relapse. *Br. J. Cancer* 83:588-593, 2000.

277. Mahoney, D.H., Jr., Cohen, M.E., Friedman, H.S., Kepner, J., Gemer, L., Langston, J.W.,

James, H.E., Duffner, P.K., Fontanesi, J., and Kun, L.E.: Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group Phase II Study. *Neurooncol.* 2:213-220, 2000.

278. Vaidyanathan, G., Affleck, D.J., Cavazos, C.M., Johnson, S.P., Shankar, S., Friedman, H.S., Colvin, M.O., and Zalutsky, M.R.: Radiolabeled guanine derivatives, 6-(4-[¹⁸F]fluorobenzyloxy)-9H-purin-2-ylamine and 6-(3-[¹³¹I]iodo-benzyloxy)-9H-purin-2-ylamine: potential tracers for the *in vivo* mapping of O⁶-alkylguanine-DNA alkyltransferase. *Bioconjug. Chem.* 11:868-875, 2000.

279. Houghton, P.J., Stewart, C.F., Kirstein, M.N., Poquette, C.A., Tan, M., Friedman, H.S., and Brent, T.P.: Antitumor activity of temozolomide combined with irinotecan is partly independent of MGMT and mismatch repair phenotypes in xenograft models. *Clin. Cancer Res.* 6:4110-4118, 2000.

280. Patel, V.J., Elion, G.B., Houghton, P.J., Keir, S., Pegg, A.E., Johnson, S.P., Dolan, M.E., Bigner, D.D., and Friedman, H.S.: Schedule dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. *Clin. Cancer Res.* 6:4154-4157, 2000.

281. Freeman, C.R., Kepner, J., Kun, L.E., Sanford, R.A., Kadota, R., Mandell, L., and Friedman, H.: A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas? *Int. J. Radiat. Oncol. Biol. Phys.* 47:561-564, 2000.

282. Cokgor, I., Akabani, G., Friedman, H.S., Friedman, A.H., Zalutsky, M.R., Zehngbot, L.M., Provenzale, J.M., Guy, C.D., Wikstrand, C.J., and Bigner, D.D.: Long term response in a

30

patient with neoplastic meningitis secondary to melanoma treated with ¹³¹I-radiolabeled anti-chondroitin proteoglycan sulfate Me1-14 F(ab')₂: a case study. *Cancer* 91(9):1809-

1813, 2001.

283. Keir, S.T., Hausheer, F., Lawless, A.A., Bigner, D.D., and Friedman, H.S.: Therapeutic activity of karenitecin (7-[(2-trimethylsilyl)ethyl])-20(S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice. *Cancer Chemother. Pharmacol.* 48:83-87, 2001.

284. Struck, R.F., Tiwari, A., Friedman, H.S., Keir, S., Morgan, L.R., and Waud, W.W.: Acyl derivatives of demethylpenclomedine, an antitumor-active, nonneurotoxic metabolite of penclomedine. *Cancer Chemother. Pharmacol.* 48:47-52, 2001.

285. Cavazos, C.M., Keir, S.T., Yoshinari, T., Bigner, D.D., and Friedman, H.S.: Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyl)-2-hydroxy)ethylamino-12,13-dihydro-13-(β -D-glucopyranosyl)5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione] against pediatric and adult central nervous system tumor xenografts. *Cancer Chemother. Pharmacol.* 48:250-254, 2001.

286. Friedman, H.S., Keir, S.T., Houghton, P.J., Lawless, A.A., Bigner, D.D., and Waters, S.J.: Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice. *Cancer Chemother. Pharmacol.* 48:413-416, 2001.

287. Gururangan, S., Cokgor, I., Rich, J.N., Edwards, S., Affronti, M.L., Quinn, J.A., Herndon, J.E., II, Provenzale, J.M., McLendon, R.E., Tourt-Uhlig, S., Sampson, J.H., Stafford-Fox, V., Zaknoen, S., Friedman, A.H., and Friedman, H.S.: Phase I study of Gliadel \bullet wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. *Neuro-Oncology* 3:246-250, 2001.

288. Hurwitz, C.A., Strauss, L.C., Kepner, J., Kretschmar, C., Harris, M.B., Friedman, H., Kun, L., and Kadota, R.: Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: A Pediatric Oncology Phase II Study. *J. Pediatr. Hematol. Oncol.* 23:277-281,

2001.

289. Ewesuedo, R.B., Wilson, L.R., Friedman, H.S., Moschel, R.C., and Dolan, M.E.: Inactivation of *O*6-alkylguanine-DNA alkyltransferase by 8-substituted *O*6-benzylguanine analogs in mice. *Cancer Chemother. Pharmacol.* 47:63-69, 2001.

290. DeGrado, T.R., Coleman, R.E., Wang, S., Baldwin, S.W., Orr, M.D., Friedman, H.S., Robertson, C., and Price, D.T.: Synthesis and evaluation of ¹⁸F-labeled choline as an oncologic PET tracer. *J. Nucl. Med.* 42:1804-1814, 2001.

291. Aldosari, N. Wiltshire, R.N., Dutra, A., Schrock E., McLendon, R.E., Friedman, H.S., Bigner, D.D., and Bigner, S.H.: Comprehensive molecular cytogenetic investigation of chromosomal abnormalities in human medulloblastoma cell lines and xenograft. *Neuro-Oncology* 4(2):75-85, 2002.

31

292. Heimberger, A.B., Archer, G.E., Crotty, L.E., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Sampson, J.H.: Dendritic cells pulsed with a tumor-specific peptide induces long-lasting immunity and is effective against murine intracerebral melanoma. *Neurosurgery* 50:158-166, 2002.

293. Reardon, D.A., Akabani, G., Coleman, R.E., Friedman, A.H., Friedman, H.S., Herndon, J.E., II, Cokgor, I., McLendon, R.E., Pegram, C.N., Provenzale, J.M., Quinn, J.A., Rich, J.N., Regalado, L.V., Sampson, J.H., Shafman, T.D., Wikstrand, C.J., Wong, T.Z., Zhao, X.-G., Zalutsky, M.R., and Bigner, D.D.: Phase II trial of murine ¹³¹I-labeled anti-tenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. *J. Clin. Oncol.* 20(5):1389-1397, 2002.

294. Rasheed, A., Herndon, J.E., Stenzel, T.T., Raetz, J.G.M., Kendelhardt, J., Friedman, H.S., Friedman, A.H., Bigner, D.D., Bigner, S.H., and McLendon, R.E.: Molecular markers of prognosis in astrocytic tumors. *Cancer* 94(10):2688-2697, 2002.

295. Quinn, J.A., Pluda, J., Dolan, M.E., Delaney, S., Kaplan, R., Rich, J.N., Friedman, A.H., Reardon, D.A., Sampson, J.H., Colvin, O.M., Haglund, M.M., Pegg, A.E., Moschel, R.C., McLendon, R.E., Provenzale, J.M., Gururangan, S., Tourt-Uhlig, S., Herndon, J.E., II, Bigner, D.D., and Friedman, H.S.: Phase II trial of carmustine plus O6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. *J. Clin. Oncol.* 20(9):2277-2283, 2002.
296. Turner, C.D., Gururangan, S., Eastwood, J., Bottom, K., Watral, M., Beason, R., McLendon, R.E., Friedman, A.H., Tourt-Uhlig, S., Miller, L.L., and Friedman, H.S.: Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. *Neuro-Oncology* 4:102-208, 2002.
297. Aldosari, N., Bigner, S.H., Burger, P.C., Becker, L., Kepner, J.L., Friedman, H.S., and McLendon, R.E.: MYCC and MYCN oncogene amplification in medulloblastoma: a FISH study on paraffin sections from the Children's Oncology Group. *Arch. Pathol. Lab. Med.* 126:540-544, 2002.
298. Gururangan, S., Cavazos, C.M., Herndon II, J.E., Ashley, D., Bruggers, C., Moghrabi, A., Watral, M., Tourt-Uhlig, S., Reardon, D., and Friedman, H.S.: A Phase II study of carboplatin in children with progressive low-grade gliomas. *J. Clin. Oncol.* 20:2951-2958, 2002.
299. Lal, A., Glazer, C.A., Martinson, H.E., Friedman, H.S., Archer, G.E., Sampson, J.H., and Riggins, G.J.: Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. *Cancer Res.* 62:3335-3339, 2002.
300. Cloughesy, T.F., Filka, E., Nelson, G., Kabbinnar, F., Friedman, H., Miller, L.L., Elfring, G.L.: Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. *Am. J. Clin. Oncol.* 25:204-208, 2002.

301. McGirt, M.J., Villavicencio, A.T., Friedman, H., and Friedman, A.H.: Non operative management of tumor bed cysts after BCNU wafer implantation: report of 3 cases. *J. Neurosurg.* 96:941-945, 2002.
302. Eberhart, C.G., Kepner, J.L., Goldthwaite, P.T., Kun, L.E., Duffner, P.K., Friedman, H.S., Strother, D.R., and Burger, P.C.: Histopathologic grading of medulloblastomas: a Pediatric Oncology Group Study. *Cancer* 94:552-560, 2002.
303. Bacolod, M.D., Johnson, S.P., Ali-Osman, F., Modrich, P., Bullock, N.S., Colvin, O.M., Bigner, D.D., and Friedman, H.S.: Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma. *Mol. Cancer Ther.* 1:727-736, 2002.
304. Friedman, H.S., Keir, S., Pegg, A.E., Houghton, P.J., Colvin, O.M., Moschel, R.C., Bigner, D.D., and Dolan, M.E.: O6-benzylguanine-mediated enhancement of chemotherapy. *Mol. Cancer Ther.* 1:943-948, 2002.
305. Gilbert, M.R., Friedman, H.S., Kuttesch, J.F., Prados, M.D., Olson, J.J., Reaman, G.H., and Zaknoen, S.L.: A Phase II study of temozolomide in patients with newly diagnosed, supratentorial malignant glioma before radiation therapy. *Neuro-oncology* 4:261-267, 2002.
306. Heimberger, A.B., Learn, C.A., Archer, G.E., McLendon, R.E., Chewning, T.A., Tuck, F.L., Pracyk, J.B., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Sampson, J.H.: Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 ('Iressa'). *Clin. Cancer Res.* 8:3496-3502, 2002.
307. Leggas, M., Stewart, C.F., Woo, M.H., Fouladi, M., Cheshire, P.J., Peterson, J.K., Friedman, H.S., Billups, C., and Houghton, P.J.: Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. *Clin. Cancer Res.*

8:3000-3007, 2002.

308. Friedman, H.S., Johnson, S.P., and Colvin, O.M.: Cellular mechanisms of Cyclophosphamide resistance: model studies in human medulloblastoma cell lines. *Cancer Treat Res.* 112:199-209, 2002.

309. Gururangan, S., and Friedman, H.S.: Innovations in design and delivery of chemotherapy for brain tumors. *Neuroimaging Clin N Am* 12:583-597, 2002.

310. Cokgor, I., Friedman, A.H., and Friedman, H.S.: Current options for the treatment of neoplastic meningitis. *J. Neurooncol.* 60:79-88, 2002.

311. Quinn, J.A., Reardon, D.A., Friedman, A.H., Rich, J.N., Sampson, J.H., Provenzale, J.M., McLendon, R.E., Gururangan, S., Bigner, D.D., Herndon II, J.E., Avgeropoulos, N., Finlay, J., Tourt-Uhlig, S., Affronti, M.L., Evans, B., Stafford-Fox, V., Zaknoen, S., and Friedman, H.S.: Phase II trial of Temozolomide in patients with progressive low grade glioma. *J. Clin. Oncol.* 21:646-651, 2003.

33

312. Vaidyanathan, G., Friedman, H.S., Wester, H.-J., Schottelium, M., and Zalutsky, M.R.: Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. *Clin. Cancer Res.* 9:1868-1876, 2003.

313. Korones, D.N., Benita-Weiss, M., Coyle, T.E., Mechtler, L., Bushunow, P., Evans, B., Reardon, D.A., Quinn, J.A., and Friedman, H.: Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. *Cancer* 97:1963-1968, 2003.

314. Friedman, H.S., Keir, S.T., and Houghton, P.J.: The emerging role of CPT-11 in the treatment of malignant glioma. *Cancer* 97 (9 Suppl.):2359-2362, 2003.

315. Gururangan, S., McLaughlin, C., Quinn, J., Rich, J., Reardon, D., Halperin, E.C., Herndon II, J., Fuchs, H., George, T., Provenzale, J., Watral, M., McLendon, R.E., Friedman, A.,

Friedman, H.S., Kurtzberg, J., Vredenbergh, J., and Martin, P.: High-dose chemotherapy with autologous stem cell rescue in children and adults with newly diagnosed pineoblastomas. *J. Clin. Oncol.* 21:2187-2191, 2003.

316. Flowers, J.L., Hoffman, R.M., Driscoll, T.A., Wall, M.E., Wani, M.C., Manikumar, G., Friedman, H.S., Dewhirst, M., Colvin, O.M., and Adams, D.J.: The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH. *Cancer Chemother. Pharmacol.* 52:253-265, 2003.

317. McGirt, M.J., Bulsara, K.R., Cummings, T.J., New, K.C., Little, K.M., Friedman, H.S., and Friedman, A.H.: Prognostic value of magnetic resonance imaging-guided stereotactic biopsy in the evaluation of recurrent malignant astrocytoma compared with a lesion due to radiation effect. *J. Neurosurg.* 98:14-20, 2003.

318. Friedman, H.S., and Szalavitz, M.: What is hope for a patient with a deadly brain tumor? *Cerebrum* 5:7-18, 2003.

319. Cloughesy, T.F., Filka, E., Kuhn, J., Nelson, G., Kabbinavar, F., Friedman, H., Miller, L.L., and Elfring, G.L.: Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. *Cancer* 97 (9 Suppl.):2381-2386, 2003.

320. Reardon, D.A., Friedman, H.S., Gilbert, M., and Yung, W.K.A.: Irinotecan: promising activity in the treatment of malignant glioma. *Oncology* 17 (Suppl) 9:14, 2003.

321. Sampson, J.H., Akabani, G., Archer, G.E., Bigner, D.D., Berger, M.S., Friedman, A.H., Friedman, H.S., Herndon, J.E., II, Kunwar, S., Marcus, S., McLendon, R.E., Paolino, A., Penne, K., Provenzale, J., Quinn, J., Reardon, D.A., Rich, J., Stenzel, T., Tourt-Uhlig, S., Wikstrand, C., Wong, T., Williams, R., Yuan, F., Zalutsky, M.R., and Pastan, I.: Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)- α and a mutated form of the

Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.

J. Neurooncol., 65:27-35, 2003.

34

322. Grossi, P.M., Ochiai, H., Archer, G.E., McLendon, R.E., Zalutsky, M.R., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Sampson, J.H. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin. Cancer Res. 9:5515-5520, 2003.

323. Heimberger, A.B., Crotty, L.E., Archer, G.E., Hess, K.R., Wikstrand, C.J., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Sampson, J.H.: Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin. Cancer Res. 9:4247-4254, 2003.

324. Dreyer, Z.E., Heideman, R.L., Cohen, H.J., Friedman, H.S., Mahoney, D.H., Kun, L.E., McCluggage, C., Stewart, C., Burger, P.C., Kepner, J., and Kadota, R.: A Phase II study of idarubicin in pediatric brain tumors: a Pediatric Oncology Group Study (POG 9237). Neuro-oncology 5:261-267, 2003.

325. Cheng, T.-Y., Grubbs, E., Abdul-Wahab, O., Leu, S.-Y., Hung, C.-F., Petros, W., Aloia, T., Fedrau, R., Pruitt, S., Colvin, M., Friedman, H., and Tyler, D.: Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion: implications for response and toxicity. Am. J. Surgery 186:460-467, 2003.

326. Rich, J.N., Reardon, D.A., Peery, T.L., Quinn, J.A., Penne, K.L., Wikstrand, C.J., Van Duyn, L.B., Dancey, J.E., McLendon, R.E., Kao, J.C., Stenzel, T.T., Rasheed, A.K, Tourt-Uhlig, S.E., Dowell, J.M., Herndon, J.E., II, Vredenburgh, J.J., Sampson, J.H., Friedman, A.H., Bigner, D.D., and Friedman, H.S.: Phase II trial of Gefitinib (ZD1839) in recurrent glioblastoma. J. Clin. Oncol. 22:133-142, 2004.

327. Wiltshire, R.N., Herndon, J.E., II, Lloyd, A., Friedman, H.S., Bigner, D.D., Bigner, S.H.,

and McLendon, R.E.: Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications. *J. Mol. Diagn.* 6:166-179, 2004.

328. Quinn, J.A., Reardon, D.A., Friedman, A.H., Rich, J.N., Sampson, J.H., Vredenburgh, J., Gururangan, S., Provenzale, J.M., Walker, A., Schweitzer, H., Bigner, D.D., Tourt-Uhlig, S., Herndon, II, J.E., Affronti, M.L., Jackson, S., Allen, D., Zeigler, K., Bohlin, C., Lentz, C., and Friedman, H.S.: Phase I trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. *Neuro-Oncology* 6:145-153, 2004.

329. Reardon, D.A., Quinn, J.A., Rich, J.N., Gururangan, S., Vredenburgh, J., Sampson, J.H., Provenzale, J.M., Walker, A., Perry, T., Badruddoja, M., Tourt-Uhlig, S., Herndon, J.E., II, Dowell, J.M., Affronti, M.L., Jackson, S., Allen, D., Ziegler, K., Houghton, P., Friedman, A.H., Bigner, D.D., and Friedman, H.S.: Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. *Neuro-Oncology* 6:134-144, 2004.

330. Learn, C.A., Hartzell, T.L., Wikstrand, C.J., Archer, G.E., Rich, J.N., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Sampson, J.H.: Resistance to tyrosine kinase inhibition by mutant EGFR variant III contributes to the neoplastic phenotype of glioblastoma multiforme. *Clin. Cancer Res.* 10:3216-3224, 2004.

35

331. Vaidyanathan, G., Affleck, D.J., Norman, J., Welsh, P., Liu, W., Johnson, S.P., Friedman, H.S., and Zalutsky, M.R.: O6-3-[131I]iodobenzylguanine ([131I]IBG: improved synthesis and further evaluation of a potential agent for imaging of alkylguanine-DNA alkyltransferase (AGT). *Bioconjug. Chem.* 15:402-408, 2004.

332. Hjelmeland, M.D., Hjelmeland, A.B., Sathornsumetee, S., Reese, E.D., Herbstreith, M.H., Laping, N.J., Friedman, H.S., Bigner, D.D., Wang, X.-F., and Rich, J.N.: SB-431542, a small molecule transforming growth factor- β -receptor antagonist, inhibits human glioma cell line proliferation and motility. *Mol. Cancer Ther.* 3(6):737-745, 2004.

333. Vaidyanathan, G., Affleck, D.J., Welsh, P., Vitorello, K.C., Snyder, S., Friedman, H.S., and Zalutsky, M.R.: A 4-methyl-substituted *meta*-iodobenzylguanidine analog with prolonged retention in human neuroblastoma cells. *Eur. J. Nucl. Med. Mol. Imaging* 31:1362-1370, 2004.
334. Grubbs, E.G., Abdel-Wahab, U.T., Cheng, T.Y., Pruitt, S.K., Colvin, O.M., Friedman, H.S., and Tyler, D.S.: Modulation of resistance to regional chemotherapy in the extremity melanoma model. *Surgery* 136(2):210-8, 2004.
335. Grubbs, E.G., Wahab-Abdel, O., Cheng, T.-Y., Wahab-Abdel., Z., Pruitt, S.K., Colvin, O.M., Friedman, H.S., and Tyler, D.S.: In-transit melanoma: the role of alkylating agent resistance in regional therapy. *J. Am. Coll. Surg.* 199:419-427, 2004.
336. Gururangan, S., and Friedman, H.S.: Recent advances in the treatment of pediatric brain tumors. *Oncology* 18:1649-1661, 2004.
337. Ueno, T., Ko, S.H., Grubbs, E., Abdel-Wahab, Z., Cheng, T.-Y., Abdel-Wahab, O.I., Bishop, W.R., Pruitt, S.K., Friedman, H.S., and Tyler, D.S.: Temozolomide: a novel regional infusion agent for the treatment of advanced extremity melanoma. *Am. J. Surg.* 188:532-537, 2004.
338. Bacolod, M.D., Johnson, S.P., Pegg, A.E., Dolan, M.E., Moschel, R.C., Bullock, N.S., Fang, Q., Colvin, O.M., Modrich, P., Bigner, D.D., and Friedman, H.S.: Brain tumor cell lines resistant to *O*⁶-benzylguanine/BCNU chemotherapy have *O*⁶-alkylguanine-DNA alkyltransferase (AGT) mutations. *Mol. Cancer Ther.* 3:1127-1135, 2005.
339. Sampson, J.H., Reardon, D.A., Friedman, A.H., Friedman, H.S., Coleman, R.E., McLendon, R.E., Pastan, I., and Bigner, D.D.: Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: Case study. *Neuro-Oncology* 7:90-96, 2005.
340. Shi, Q., Bao, S., Maxwell, J.A., Reese, E.D., Friedman, H.S., Bigner, D.D., Wang, X.-F.,

and Rich, J.N.: Secreted protein acidic, rich in cysteine (SPARC) mediates cellular survival of gliomas through AKT activation. *J. Biol. Chem.* 279:52200-52209, 2005.

341. Akabani, G., Reardon, D.A., Coleman, R.E., Wong, T.Z., Metzler, S.D., Bowsher, J.E., Barboriak, D.P., Provenzale, J.M., Greer, K.L., Delong, D., Friedman, H.S., Friedman, A.H., Zhao, X-G., Pegram, C.N., McLendon, R.E., Zalutsky, M.R., and Bigner, D.D.:

Dosimetry and radiographic analysis of iodine-131-labeled anti-tenascin 81C6 murine

36

monoclonal antibody in newly diagnosed patients with malignant gliomas: A phase II study.

J. Nuclear Med. 46:1042-1051, 2005.

342. Reardon, D.A., Quinn, J.A., Vredenburgh, J., Rich, J.N., Gururangan, S., Badruddoja, M., Herndon II, J.E., Dowell, J.M., Friedman, A.H., and Friedman, H.S.: Phase II trial of

irinotecan plus celecoxib in adults with recurrent malignant glioma. *Cancer* 103:329-338,

2005.

343. Blaney, S.M., Boyett, J., Friedman, H., Geyer, R., Horowitz, M., Hunt, D., Kieran, M., Kun, L., Packer, R., Phillips, P., Pollack, I., Prados, M., and Heideman, R.: Phase I clinical trial

of mafosfamide in infants and children • 3 years of age with newly diagnosed embryonal

tumors: A Pediatric Brain Tumor Consortium Study (PBTC-001). *J. Clin. Oncol.* 23:525-

531, 2005.

344. Goudar, R.K., Shi, Q., Hjelmeland, M.D., Keir, S.T., McLendon, R.E., Wikstrand, C.J.,

Reese, E.D., Conrad, C.A., Traxler, P., Lane, H.A., Reardon, D.A., Cavenee, W.K., Wang,

X-F., Bigner, D.D., Friedman, H.S., and Rich, J.N.: Combination therapy of inhibitors of

epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788)

and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor

growth inhibition. *Mol. Cancer Ther.* 4:101-112, 2005.

345. Desjardins A., Rich, J.N., Quinn, J.A., Vredenburgh, J., Gururangan, S., Sathornsumetee,

S., Reardon, D.A., Friedman, A.H., Bigner, D.D., Friedman, H.S.: Chemotherapy and novel therapeutic approaches in malignant glioma. *Front. Biosci.*10:2645-2668, 2005.

346. Quinn, J.A., Desjardins, A., Weingart, J., Brem, H., Dolan, M.E., Delaney, S.M., Vredenburgh, J., Rich, J., Friedman, A.H., Reardon, D.A., Sampson, J.H., Pegg, A.E., Moschel, R.C., Birch, R., McLendon, R.E., Provenzale, J.M., Gururangan, S., Dancey, J.E., Maxwell, J., Tourt-Uhlig, S., Herndon, J.E., II, Bigner, D.D., and Friedman, H.S.: Phase I trial of temozolomide (temodar) plus O6-benzylguanine (O6-BG) for patients with recurrent or progressive malignant glioma. *J. Clin. Oncol.* 23:7178-7187, 2005.

347. Cheng, C.L., Johnson, S.P., Keir, S.T., Quinn, J.A., Ali-Osman, F., Szabo, C., Li, H., Salzman, A.L., Dolan, M.E., Modrich, P., Bigner, D.D., and Friedman, H.S.: Poly (adribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair deficient malignant glioma xenograft. *Mol. Cancer Ther.* 4:1364-1381, 2005.

348. McLendon, R.E., Herndon II, J.E., West, B., Reardon, D., Wiltshire, R., Rasheed, B.K.A., Friedman, H.S., Friedman, A.H., and Bigner, D.D.: Survival analysis of presumptive prognostic markers among oligodendrogliomas. *Cancer* 104:1695-1699, 2005.

349. Reardon, D.A., Egorin, M.J., Quinn, J.A., Rich, J.N., Gururangan, S., Vredenburgh, J.J., Desjardins, A., Sathornsumetee, S., Provenzale, J.M., Tourt-Uhlig, S., Herndon II, J.E., Dowell, J.M., McLendon, R.E., Lagattuta, T.F., Kiczielinski, K.P., Dresemann, G., Salvado, A.J., Friedman, A.H., and Friedman, H.S.: Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. *J. Clin. Oncol.* 23:9359-9368, 2005.

37

350. Reardon, D.A., Quinn, J.A., Rich, J.N., Desjardins, A., Vredenburgh, J., Gururangan, S., Sathornsumetee, S., Badruddoja, M., McLendon, R., Provenzale, J., Herndon II, J.E., Dowell, J.M., Burkart, J.L., Newton, H.B., Friedman, A.H., and Friedman, H.S.: Phase 1

trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. *Cancer* 104:1478-1486, 2005.

351. Rich, J.N., Sathornsumetee, S., Keir, S.T., Kieran, M.W., Laforme, A., Kaipainen, A., McLendon, R.E., Graner, M.W., Rasheed, B.K.A., Wang, L., Reardon, D., Anderson, J.R., Wheeler, C., Dimery, I., Bigner, D.D., and Friedman, H.S.: ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple central nervous system tumors. *Clin. Cancer Res.* 11:8145-8157, 2005.

352. Greenberg, M.L., Fisher, P.G., Freeman, C., Korones, D.N., Bernstein, M., Friedman, H., Blaney, S., Hershon, L., Zhou, T., Chen, Z., and Kretschmar, C.: Etoposide, vincristine, and cyclosporine A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brain stem gliomas – A Pediatric Oncology Group Phase I Study. *Pediatr. Blood Cancer* 45:644-648, 2005.

353. Reardon, D.A., Akabani, G., Coleman, R.E., Friedman, A.H., Friedman, H.S., Herndon II, J.E., McLendon, R.E., Pegram, C.N., Provenzale, J.M., Quinn, J.A., Rich, J.N., Vredenburgh, J.J., Desjardins, A., Guruangan, S., Badruddoja, M., Dowell, J.M., Wong, T.Z., Zhao, X.-G., Zalutsky, M.R., and Bigner, D.D.: Salvage radioimmunotherapy with murine 131I-labeled anti-tenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results. *J. Clin. Oncol.* 24(1):115-122, 2006.

354. Jones, L.W., Guill, B., Keir, S.T., Carter, B.S.K., Friedman, H.S., Bigner, D.D., and Reardon, D.A.: Patterns of exercise across the cancer trajectory in brain tumor patients: a population-based survey. *Cancer* 106(10):2224-2232, 2006.

355. Chintagumpala, M.M., Friedman, H.S., Stewart, C.F., Kepner, J., McLendon, R.E., Modrich, P.L., McCluggage, C., Burger, P., Holmes, E., Thompson, S., Rutka, J.,

Michalski, J., Woo, S., Blaney, S.M., Kun, L., and Horowitz, M.E. A Phase II window trial of procarbazine and topotecan in children with high-grade glioma: a Pediatric Oncology Group Study. *J. Neurooncol.* 77:193-198, 2006.

356. Gururangan, S., Petros, W.P., Poussaint, T.Y., Hancock, M., Phillips, P.C., Friedman, H.S., Blaney, S.M., Rush, L., and Boyett, J.M.: Phase I trial of intrathecal Spartaject™ busulfan in children with neoplastic meningitis – a Pediatric Brain Tumor Consortium Study (PBTC-004). *Clin. Cancer Res.* 12:1540-1546, 2006.

357. Shankar, S., Zalutsky, M.R., Friedman, H., and Vaidyanathan, G.: Molecular imaging of alkylguanine-DNA alkyltransferase: further evaluation of radioiodinated derivatives of O6-benzylguanine. *Nucl. Med. Biol.* 33:399-407, 2006.

38

358. Vaidyanathan, G., Affleck, D.J., Schottelius, M., Wester, H., Friedman, H.S., and Zalutsky, M.R.: Synthesis and evaluation of glycosylated octreotate analogues labeled with radioiodine and ²¹¹At via a tin precursor. *Bioconjug. Chem.* 17:195-203, 2006.

359. Reardon, D.A., Rich, J.N., Friedman, H.S., and Bigner, D.D.: Recent advances in the treatment of malignant astrocytoma. *J. Clin. Oncol.* 24:1253-1265, 2006.

360. Gururangan, S., McLaughlin, C., Provenzale, J., Coleman, R.E., Halperin, E., Fuchs, H., George, T., Watral, M.A., Reardon, D., Quinn, J., Rich, J.N., Vredenburgh, J., and Friedman, H.S.: Incidence and patterns of neuraxis metastasis in children with diffuse pontine glioma. *J. Neurooncology.* 77:207-212, 2006.

361. Reardon, D.A., Quinn, J.A., Vredenburgh, J.J., Gururangan, S., Friedman, A.H., Desjardins, A., Sathornsumetee, S., Herndon II, J.E., Dowell, J.M., McLendon, R.E., Provenzale, J.M., Sampson, J.H., Smith, R.P., Swaisland, A.J., Ochs, J.S., Lyons, P., Tourt-Uhlig, S., Bigner, D.D., Friedman, H.S., and Rich, J.N.: Phase I trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. *Clin. Cancer Res.* 12:860-868, 2006.

362. Ueno, T., Ko, S.H., Grubbs, E., Yoshimoto, Y., Augustine, C., Abdel-Wahab, Z., Cheng, T.-Y., Abdel-Wahab, O.I., Pruitt, S.K., Friedman, H.S., and Tyler, D.S.: Modulation of chemotherapy resistance in regional therapy: A novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. *Mol. Cancer Ther.* 5(3):732-738, 2006.
363. Reardon, D.A., Zalutsky, M.R., Akabani, G., Coleman, R.E., Friedman, A.H., Friedman, H.S., Herndon, J.E., McLendon, R.E., Pegram, C.N., Provenzale, J.M., Quinn, J.A., Rich, J.N., Vredenburgh, J.J., Desjardins, A., Sampson, J.H., Gururangan, S., Wong, T.Z., Badruddoja, M.A., Zhao, X.-G., Dowell, J.M., and Bigner, D.D.: Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with iodine-131 and administered into the surgically created resection cavity of patients with malignant glioma: Phase I trial results. *J. Nucl. Med.* 47:912-918, 2006.
364. Ko, S.H., Ueno, T., Yoshimoto, Y., Yoo, J.S., Abdel-Wahab, O.I., Abdel-Wahab, Z., Chu, E., Pruitt, S.K., Friedman, H.S., Dewhirst, M.W., and Tyler, D.S.: Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. *Clin. Cancer Res.* 12:289-297, 2006.
365. Miralbell, R., Fitzgerald, T.J., Laurie, F., Kessel, S., Glicksman, A., Friedman, H.S., Urie, M., Kepner, J.L., Zhou, T., Chen, Z., Barnes, P., Kun, L., and Tarbell, N.J.: Radiotherapy in pediatric medulloblastoma: Quality assessment of Pediatric Oncology Group Trial 9031. *Int. J. Radiat. Oncol. Biol. Phys.* 64(5):1325-1330, 2006.
366. Keir, S.T., Guill, A.B., Carter, K.E., Boole, L.C., Gonzales, L., and Friedman, H.S.: Differential levels of stress in caregivers of brain tumor patients – observations from a pilot study. *Support Care Cancer* 14(12):1258-1261, 2006.
367. Keir, S.T., Guill, A.B., Carter, K.E., and Friedman, H.S.: Stress and intervention preferences of patients with brain tumors. *Support Care Cancer* 15(12):1213-1219, 2006.

368. Jones, L.W., Guill, B., Keir, S.T., Carter, K., Friedman, H.S., Bigner, D.D., and Reardon, D.A.: Exercise interest and preferences among patients diagnosed with primary brain cancer. *Supportive Care in Cancer*, published online July 4, 2006, 15(1):47-55, 2007.
369. Sathornsumetee, S., Hjelmeland, A.B., Keir, S.T., McLendon, R.E., Batt, D., Ramsey, T., Yusuff, N., Rasheed, B.K.A., Kieran, M.W., Laforme, A., Bigner, D.D., Friedman, H.S., and Rich, J.N.: AAL881, a novel small molecule inhibitor of RAF and VEGFR activities, blocks growth of malignant gliomas. *Cancer Res.* 66:8722-8730, 2006.
370. Maxwell, J.A., Johnson, S.P., Quinn, J.A., McLendon, R.E., Ali-Osman, F., Friedman, A.H., Herndon II, J.E., Bierau, K., Bigley, J., Bigner, D.D., and Friedman, H.S.: Quantitative analysis of O6-Alkylguanine-DNA Alkyltransferase in malignant glioma. *Mol. Cancer Therapy* 5:2531-2539, 2006.
371. Ochiai, H., Pernell, C.T., Archer, G.E., Chewing, T.A., McLendon, R.E., Friedman, H.S., and Sampson, J.H.: Treatment of neoplastic meningitis with intrathecal 9-nitro camptothecin. *Neurol. Med. Ch.* 46:485-489, discussion 489-490, 2006.
372. Houghton, P.J., Morton, C.L., Tucker, C., Payne, D., Favours, E., Cole, C., Gorlick, R., Kolb, E.A., Zhang, W., Lock, R., Carol, H., Tajbakhsh, M., Reynolds, C.P., Maris, J.M., Courtright, J., Keir, S.T., Friedman, H.S., Stopford, C., Zeidner, J., Wu, J., Liu, T., Billups, C.A., Khan, J., Ansher, S., Zhang, J., and Smith, M.A.: The pediatric preclinical testing program: Description of models and early testing results. *Pediatr. Blood Cancer* [Epub ahead of print], October 2006.
373. Badruddoja, M.A., Penne, K., Desjardins, A., Reardon, D.A., Rich, J.N., Quinn, J., Sathornsumetee, S., Friedman, A.H., Bigner, D.D., Herndon II, J.E., Cahill, A., Friedman, H.S., and Vredenburgh, J.J.: Phase II study of cloretazine for the treatment of adults with recurrent glioblastoma multiforme. *Neuro-Oncology* 9(1):70-74, 2007.

374. Jones, L.W., Guill, B., Keir, S.T., Carter, K., Friedman, H.S., Bigner, D.D., and Reardon, M.D. : Using the theory of planned behavior to understand the determinants of exercise in patients diagnosed with primary brain cancer. *Psycho-Oncology* 16:232-240, 2007.
375. Shi, Q., Hjelmeland, A.B., Keir, S.T., Song, L., Wickman, S., Jackson, D., Ohmori, O., Bigner, D.D., Friedman, H.S., and Rich, J.N.: A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. *Mol. Carcinog.* 46(6):488-496, 2007.
376. Sampson, J.H., Brady, M.L., Petry, N.A., Croteau, D., Friedman, A.H., Friedman, H.S., Wong, T., Bigner, D.D., Pastan, I., Puri, R.K., and Christoph Pedain, C.: Intracerebral Infusate Distribution by Convection-Enhanced Delivery in Humans with Malignant Gliomas: Descriptive Effects of Target Anatomy and Catheter Positioning. *Neurosurgery* 60 (2 Suppl 1), 89-99, 2007.
377. Badruddoja, M.A., Keir, S., King, I., Zeidner, J., Vredenburgh, J.J., Muhlbaier, L.H., Bigner, D.D., and Friedman, H.S.: Activity of VNP40101M (Clometazine) in the treatment of CNS tumor xenografts in athymic mice. Published online, May 23. *Neuro-Oncology* 9(3), 240-244, 2007.
378. Vredenburgh, J.J., Desjardins, A., Herndon, J.E. II, Dowell, J.M., Reardon, D.V., Quinn, J.A., Rich, J.N., Sathornsumetee, S., Gururangan, S., Wagner, M., Bigner, D.D., Friedman, A.H., and Friedman, H.S.: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. *Clin. Cancer Res.* 13 (4), 1253-1259, 2007.
379. McLendon, R.E., Akabani, G., Friedman, H.S., Reardon, D.A., Cleveland, L., Cokgor, I., Herndon, J.E., II, Wikstrand, C., Boulton, S.T., Friedman, A.H., Bigner, D.D., and Zalutsky, M.R.: Tumor resection cavity administered iodine-131-labeled anti-tenascin 81C6 radioimmunotherapy in malignant glioma: neuropathology aspects. Published online, March

30. Nucl. Med. Biol. 34(4), 405-413, 2007.
380. Johnson, S.P., Kamen, B.A., Bigner, D.D., and Friedman, H.S.: O4-benzylfolic acid inactivates O6-alkylguanine-DNA alkyltransferase in brain tumor cell lines. Cancer Chemother Pharmacol. Published online Feb 27. Cancer Chemother Pharmacol. 60(6):883-889, 2007.
381. Gururangan, S., Fisher, M., Allen, J.C., Herndon II, J., Quinn, J., Reardon, D.A., Vredenburgh, J., Desjardins, A., Phillips, P.C., Watral, M.A., Krauser, J., Friedman, A.H., and Friedman, H.S.: Temozolomide in children with progressive low-grade glioma. Neuro-Oncology 9:161-168, 2007.
382. Pollack, I.F., Jakacki, R.I., Blaney, S.M., Hancock, M.L., Kieran, M.W., Phillips, P., Kun, L., Friedman, H., Packer, R., Banerjee, A., Geyer, J.R., Goldman, S., Young Poussaint, T., Wang, Y., Hayes, M., Murgo, A., Weiner, S., and Boyett, J.M.: A Phase I trial of STI571 (Imatinib Mesylate) in children with newly diagnosed poor prognosis brainstem gliomas and recurrent intracranial malignant gliomas: A Pediatric Brain Tumor Consortium (PBTC) Report. Neuro-Oncology 9:145-160, 2007.
383. Yoshimoto, Y., Augustine, C.K., Yoo, J.S., Zipfel, P.A., Selim, A., Pruitt, S.K., Friedman, H.S., Ali-Osman, F., and Tyler, D.S.: Optimizing regional infusion treatment strategies for extremity melanoma: Utilizing drug resistance activity to predict tumor response to chemotherapy. Mol. Cancer Ther. 6:1492-1500, 2007.
384. Hjelmeland, A.B., Lattimore, K.P., Fee, B.E., Shi, Q., Wickman, S., Keir, S.T., Hjelmeland, M.D., Batt, D., Bigner, D.D., Friedman, H.S., and Rich, J.N.: The combination of novel low molecular weight inhibitors of RAF (LBT613) and TOR (RAD001) decreases glioma proliferation and invasion. (Epub Aug 31) Mol. Cancer Ther. 6(9):2449-2457, 2007.
385. Vredenburgh, J.J., Desjardins, A., Herndon II, J.E., Marcello, J., Reardon, D.A., Quinn, J.A., Rich, J.N., Sathornsumetee, S., Gururangan, S., Sampson, J., Wagner, M., Bailey, L.,

Bigner, D.D., Friedman, A.H., and Friedman, H.S.: Bevacizumab and Irinotecan: An active regimen against recurrent glioblastoma multiforme. *J. Clin. Oncol.* 25(30):4722-4729 2007.

386. Gururangan, S., Frankel, W., Broaddus, R., Senter, L, McDonald, M., Eastwood, J., Reardon, D., Vredenburgh, J., Quinn, J., and Friedman, H.S.: Multi-focal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, 41

agenesis of the corpus callosum, mental retardation, and inherited PMS-2 mutation.

Published online ahead of print Nov. 9, 2007, DOI: 10.1214/15228517-2007-037, *Neuro-Oncol.*, 2007.

387. Keir, S.T., Calhoun-Eagan, R.D., Swartz, J.J., Saleh, O.A., and Friedman, H.S.: Screening for distress in patients with brain cancer using the NCCN's rapid screening measure.

Published online ahead of print Aug. 2007, DOI: 10.1002/pon.1271, *Psycho-Oncol.* 17(6):621-625, 2008.

388. Keir, S.T., Swartz, J.J., and Friedman, H.S. Stress and long-term survivors of brain cancer. *Supportive Care Cancer* 15:1422-1428, 2007.

389. Nicholson, H.S., Kretschmar, C.S., Krailo, M., Bernstein, M., Kadota, R., Fort, D., Friedman, H., Harris, M., Tedeschi-Blok, N., Maziewski, C., Sato, J., and Reaman, G.H.:

Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: A report from the Children's Oncology Group. *Cancer* 110(7):1542-1550, 2007.

390. Broniscer, A., Gururangan, S., Goldman, S., MacDonald, T., Wallace, D., Stewart, C.F., Jakacki, R., Kieran, M.W., Chintagumpala, M.M., Banerjee, A., Geyer, J.R., Phillips, P.,

Friedman, H.S., and Gajjar, A.: Phase I trial of oral temozolomide and intravenous O6-benzylguanine (O6-BG), a methylguanine methyltransferase inhibitor in pediatric patients with recurrent brain tumors. *Clin. Can. Res.* 13:6712-6718, 2007.

391. Bota, D.A., Desjardins, A., Quinn, J.A., Affronti, M.L., and Friedman, H.S.: Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas. *Therapeutics and Clinical Risk Management* 3:707-715, 2007.
392. Desjardins, A., Quinn, J.A., Vredenburgh, J.J., Sathornsumetee, S., Friedman, A.H., Herndon, II, J.E., McLendon, R.E., Provenzale, J.M., Rich, J.N., Sampson, J.H., Gururangan, S., Dowell, J.M., Salvado, A., Friedman, H.S., and Reardon, D.A.: Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. *J. Neuro-Oncol.* 83:53-60, 2007.
393. Sathornsumetee, S., Cao, Y., Marcello, J.E., Herndon, J.E., McLendon, R.E., Desjardins, A., Friedman, H.S., Dewhirst, M.W., Vredenburgh, J.J., and Rich, J.N.: Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytomas patients treated with bevacizumab and irinotecan. *J. Clin. Oncol.* 26:271-278, 2008.
394. Zalutsky, M.R., Reardon, D.A., Akabani, G., Coleman, R.E., Friedman, A.H., Friedman, H.S., McLendon, R.E., Wong, T.Z., and Bigner, D.D.: Clinical experience with ^{211}At -particle-emitting 211At: Treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. Published online December 12, 2007. *J. Nucl. Med.* 49(1):30-38, 2008.
395. Reardon, D.A., Zalutsky, M.R., Akabani, G., Coleman, R.E., Friedman, A.H., Herndon, J.E., II, McLendon, R.E., Pegram, C.N., Quinn, J.A., Rich, J.N., Vredenburgh, J.J., Desjardins, A., Gururangan, S., Boulton, S., Raynor, R.H., Dowell, J.M., Wong, T.Z., Zhao, X.-G., Friedman, H.S., and Bigner, D.D.: A pilot study: 131I-anti-tenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Published online February 20. *Neuro-Oncology* 10(2):182, 2008.
396. Reardon, D.A., Desjardins, A., Vredenburgh, J.J., Sathornsumetee, S., Rich, J.N., Quinn,

J.A., Laguattuta, T.F., Egorin, M.J., Gururangan, S., McLendon, R., Herdon, II, J.E., Friedman, A.H., Salvado, A.J., and Friedman, H.S.: Safety and pharmacokinetics of doseintensive imatinib mesylate plus temozolomide: Phase I trial in adults with malignant glioma. Published online March 21 as DOI:10.1215/15228517-2008-003. *Neuro-Oncol.*, 10(3):330-340, 2008.

397. Bacolod, M.D., Fehdrau, R., Johnson, S.P., Bullock, N.S., Bigner, D.D., Colvin, M., and Friedman, H.S.: BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line. Published online July 17 ahead of print. *Cancer Chemother. Pharmacol.* 63(4):753-758, 2008.

398. Neale, G., Su, X., Morton, C.L., Phelps, D., Gorlick, R., Lock, R., Reynolds, C.P., Maris, J.M., Friedman, H.S., Dome, J., Khoury, J., Triche, T.J., Seeger, R.C., Gilbertson, R., Khan, J., Smith, M.A., and Houghton, P.J.: Molecular characterization of the pediatric preclinical testing panel. *Clin. Cancer Res.* 14:4572-4583, 2008.

399. Younis, I.R., Malone, S., Friedman, H.S., Schaaf, L.J., and Petros, W.P.: Enterohepatic recirculation model of irinotecan (CPT-11) & metabolite pharmacokinetics in patients with glioma. Published online ahead of print May 22. *Cancer Chemotherapy Pharmacol.*, 2008.

400. Bacolod, M.D., Lin, S.M., Johnson, S.P., Bullock, N.S., Colvin, M., Bigner, D.D., and Friedman, H.S.: The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide. *Curr. Cancer Drug Targets* 8(3):172-179, 2008.

401. Everson, R.G., Graner, M.W., Gromeier, M., Vredenburgh, J.J., Desjardins, A., Reardon, D.A., Friedman, H.S., Friedman, A.H., Bigner, D.D., and Sampson, J.H.: Immunotherapy against angiogenesis-associated targets: Evidence and implications for the treatment of malignant gliomas. *Exp. Rev. Anticancer Ther.* 8:717-732, 2008.

402. Sampson, J.H., Akabani, G., Berger, M.S., Coleman, R.E., Friedman, A.H., Friedman, H.S., Greer, K., Herndon, J.E., II, Kunwar, S., McLendon, R.E., Paolino, A., Petry, N.,

Provenzale, J.M., Reardon, D.A., Wong, T., Zalutsky, M.R., Pastan, I., and Bigner, D.D.
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.
Neuro-Oncol. 10:320-329, 2008.

403. Gururangan, S., Turner, C.D., Stewart, C.F., O'Shaughnessy, M., Kocak, M., Poussaint, T.Y., Phillips, P.C., Goldman, S., Packer, R., Pollack, I.F., Blaney, S.M., Karsten, V., Gerson, S.L., Boyett, J.M., Friedman, H.S., and Kun, L.E.: Phase I trial of VNP40101M (Clometazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. *Clin. Cancer Res.* 14(4):1124-1130, 2008.

404. Ashley, D.M., Riffkin, C.D., Lovric, M.M., Mikeska, T., Dobrovic, A., Maxwell, J.A., Friedman, H.S., Drummond, K.J., Kaye, A.H., Gan, H.K., Johns, T.G., and Hawkins, C.J. In 43

vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs. Published online ahead of print July 1. *Br J Cancer* 99:294-304, 2008.

405. Kadota, R.P., Mahoney, D.H., Doyle, J., Duerst, R., Friedman, H.S., Holmes, E.J., Kun, L.E., Zhou, T., and Pollack, I.F.: Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma. Published online ahead of print July 11. *Pediatr. Blood Cancer*, 2008.

406. Gururangan, S., Krauser, J., Watral, M.A., Driscoll, T., Larrier, N., Reardon, D.A., Rich, J.N., Quinn, J.A., Vredenburgh, J.J., Desjardins, A., McLendon, R.E., Fuchs, H., Kurtzberg, J., and Friedman, H.F.: Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Published online August 28. *Neuro-Oncol.* 10:745-751, 2008.

407. Maxwell, J.A., Johnson, S.P., McLendon, R.E., Lister, D.W., Horne, K.S., Rasheed, A., Quinn, J.A., Ali-Osman, F., Friedman, A.H., Modrich, P.L., Bigner, D.D., and Friedman, H.S.: Mismatch repair deficiency does not mediate clinical resistance to temozolomide in

malignant glioma. *Clin. Cancer Res.* 14:4859-4868, 2008.

408. Desjardins, A., Reardon, D.A., Herndon, J.E., II, Marcello, J., Quinn, J.A., Rich, J.N., Sathornsumetee, S., Gururangan, S., Sampson, J., Bailey, L., Bigner, D.D., Friedman, A.H., Friedman, H.S., and Vredenburgh, J.J.: Bevacizumab plus irinotecan in recurrent WHO grade III malignant gliomas. *Clin. Cancer Res.* 14:7068-7073, 2008.

409. Gururangan, S., Turner, C.D., Stewart, C.F., Kocak, M., Young Poussaint, T., Phillips, P.C., Goldman, S., Packer, R., Pollack, I., Blaney, S.M., Karsten, V., Gerson, S.L., Boyett, J.M., Friedman, H.S., and Kun, L.E.: Phase I trial of Cloretazine® (VNP40101M) in children with recurrent brain tumors – A Pediatric Brain Tumor Consortium (PBTC) study. *Clin. Cancer Res.* 14:1124-1130, 2008.

410. Keir, S.T., Farland, M.M., Lipp, E.S., and Friedman, H.S.: Distress persists in long-term brain tumor survivors with glioblastoma multiforme. Published online ahead of print October 29. *J. Cancer Surviv.* 2008.

411. Schmittling, R.J., Archer, G.E., Mitchell, D.A., Heimberger, A., Pegram, C., Herndon, J.E., II, Friedman, H.S., Bigner, D.D., and Sampson, J.H. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. *J. Immunol. Methods* 339(1):74-81, 2008.

412. Vredenburgh, J.J., Desjardins, A., Reardon, D.A., and Friedman, H.S.: Experience with irinotecan for the treatment of malignant glioma. *Neuro-Oncol.* 11(1):80-91, 2009.

413. Quinn, J.A., Jiang, S.X., Carter, J., Reardon, D.A., Desjardins, A., Vredenburgh, J.J., Rich, J.N., Friedman, A.H., Bigner, D.D., Sampson, J.H., McLendon, R.E., Herndon, J.E., II, Walker, A., and Friedman, H.S. Phase II trial of Gliadel® plus O6-benzylguanine (O6-BG) in adults with recurrent glioblastoma multiforme. *Clin. Cancer Res.* 15(3):1064-1068, 2009.

44

414. Yan, H., Parsons, D.W., McLendon, R., Rasheed, B.A., Jin, G., Yuan, W., Jones, S.,

Riggins, G.J., Friedman, H., Friedman, A., Kinzler, K.W., Velculescu, V.E., Vogelstein, B., and Bigner, D.D. IDH1 and IDH2 gene mutations play a fundamental role in astrocytoma and oligodendroglioma development. *New Engl. J. Med.* 360(8):765-773, 2009.

415. Quinn, J.A., Jiang, S.X., Reardon, D.A., Desjardins, A., Vredenburgh, J.J., Rich, J.N., Gururangan, S., Friedman, A.H., Bigner, D.D., Sampson, J.H., McLendon, R.E., Herndon, J.E., II, Walker, A., and Friedman, H.S. Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. *J. Clin. Oncol.* 27(8):1262-1267, 2009

416. Keir, S.T., Farland, M.M., Lipp, E.S., and Friedman, H.S.: Family appraisal of caregiving in a brain cancer model. *Journal of Hospice and Palliative Nursing*, January/February Volume 11(1):60-66, 2009.

417. Jones, L.W., Cohen, R-R., Mabe, S.K., West, M., Desjardins, A., Vredenburgh, J.J., Friedman, A.H., Reardon, D.A. Bigner, D.D., and Friedman, H.S.: Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing. *J. Neuro-Oncol.*, 94(1):79-85, 2009.

418. Okamura, T., Singh, S., Buolamwini, J., Haystead, T., Friedman, H.S., Bigner, D.D., and Ali-Osman, F.: Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor. *J. Biol. Chem.*, 284(25):16979-16989, 2009.

419. Paldino, M.J., Barboriak, D., Desjardins, A., Friedman, H.S., and Vredenburgh, J.J.: Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme. *J. Magn. Reson. Imaging* 29(5):1199-1205, 2009.

420. Reardon, D.A., Egorin, M.J., Desjardins, A., Vredenburgh, J.J., Sathornsumetee, S., Rich, J.N., Sampson, J.H., Quinn, J.A., Beumer, J.H., Lagattuta, T.F., Gururangan, S., Herndon, J.E., II, Marcello, J.E., Mathe, A.E., Friedman, A.H., Salvado., A.J., and Friedman, H.S.: Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine

kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. *Cancer* 115(10):2188-2198, 2009.

421. Quinn, J.A., Jiang, S.X., Reardon, D.A., Desjardins, A., Vredenburgh, J.J., Rich, J.N., Gururangan, S., Friedman, A.H., Bigner, D.D., Sampson, J.H., McLendon, R.E., Herndon, J.E., II, Walker, A., and Friedman, H.S. Phase 1 trial of temozolomide plus O6-benzylguanine 5-day regimen in adults with recurrent malignant glioma. *Neuro-Oncol.*, 11(5):556-561, 2009.

422. Quinn, J.A., Jiang, S.X., Reardon, D.A., Desjardins, A., Vredenburgh, J.J., Rich, J.N., Gururangan, S., Friedman, A.H., Bigner, D.D., Sampson, J.H., McLendon, R.E., Herndon, J.E., II, Walker, A., and Friedman, H.S. Phase 1 trial of temozolomide (TMZ) plus irinotecan (CPT-11) plus O6-benzylguanine (O6-BG) in adults with recurrent malignant glioma. *Cancer* 115(13):2964-2970, 2009.

45

423. Perry, S.L., Bohlin, C., Reardon, D.A., Desjardins, A., Friedman, A.H., and Friedman, H.S.: Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. *J. Neurooncol.*, 95(1):129-134, 2009.

424. Affronti, M.L., Heery, C.R., Herndon, J.E., II, Rich, J.N., Reardon, D.A., Desjardins, A., Vredenburgh, J.J., Friedman, A.H., Bigner, D.D., and Friedman, H.S.: Overall survival of newly diagnosed glioblastoma (GBM) patients receiving carmustine (BCNU) wafers followed by radiation (RT) and concurrent temozolomide (TMZ) plus rotational multi-agent chemotherapy. *Cancer* 115(15):3501-3511, 2009.

425. Quinn, J.A., Jiang, S.X., Reardon, D.A., Desjardins, A., Vredenburgh, J.J., Rich, J.N., Friedman, A.H., Bigner, D.D., Sampson, J.H., McLendon, R.E., Salacz, M., Herndon, J.E., II, Threatt, S., Quinn, K.A., and Friedman, H.S.: Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before

radiotherapy. *J. Neurooncol.*, 95(3):393-400, 2009.

426. Cui, B., Johnson, S.P., Bullock, N., Ali-Osman, F., Bigner, D.D., and Friedman, H.S.: Bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway. *Mol. Pharm.*, 75(6):1356-1363, 2009.

427. Reardon, D.A., Desjardins, A., Vredenburgh, J.J., Gururangan, S., Friedman, A.H., Herndon, J.E., II, Marcello, J., Norfleet, J.A., McLendon, R.E., Sampson, J.H., and Friedman, H.S.: Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. Published online ahead of print June 2009. *J. Neurooncol.*, 96(2):219-30, 2010.

428. Bektas, M., Johnson, S.P., Poe, W.E., Bigner, D.D., and Friedman, H.S.: A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells. *Cancer Chemother. Pharmacol.*, 64(5):1053-1058, 2009.

429. Friedman, H., Prados, M., Wen, P.Y., Mikkelsen, T., Schiff, D., Abrey, L., Yung, W.K., Paleologos, N., Nicholas, M.K., Jensen, R., Vredenburgh, J., Huang, J., Zheng, M., and Cloughesy, T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. *J. Clin. Oncol.*, 27(28):4733-4740, 2009.

430. Sampson, J.H., Archer, G.E., Mitchell, D.A., Heimberger, A.B., Herndon, II, J.E., Lally-Goss, D., McGehee-Norman, S., Paolino, A., Reardon, D.A., Friedman, A.H., Friedman, H.S., Bigner, D.D.: An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. *Mol. Cancer Ther.*, 8(10):2773-2779, 2009.

431. Reardon, D.A., Desjardins, A., Vredenburgh, J.J., Gururangan, S., Sampson, J.H., Sathornsumetee, S., McLendon, R.E., Herndon, J.E. II, Marcello, J.E., Norfleet, J., Friedman, A.H., Bigner, D.D., and Friedman, H.S.: Metronomic chemotherapy with daily,

oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. *Br. J. Cancer*, 101:1986-1994, 2009.

46

432. Gururangan, S., Hwang, E., Hawk, T.C., Fuchs, H., George, T., Quinn, J., Reardon, D., Rich, J., Watral, M.A., Halperin, E.C., Friedman, A., Friedman, H.S., and Coleman, R.E.: F-18 fluorodeoxyglucose positron emission tomography in patients with primitive neuroectodermal tumors of the brain. *Neurosurg.*, 55(6):1280-1289, 2009.

433. Jones LW, Friedman AH, West M, Mabe SK, Fraser J, Kraus WE, Friedman HS, Tresch MI, Major N, Reardon DA. Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma. *Cancer*, 116:695-704, 2010.

434. Augustine, C.K., Jung, S.H., Sohn, I., Yoo, J.S., Yoshimoto, Y., Olson, J.A., Jr., Friedman, H.S., Ali-Osman, F., and Tyler, D.S.: Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma. *Mol. Cancer Ther.*, 9(4):779-790, 2010.

435. Reardon, D.A., Vredenburgh, J.J., Desjardins, A., Peters, K.B., Gururangan, S., Sampson, J.H., Marcello, J., Herndon, J.E. II, McLendon, R.E., Janney, D., Friedman, A.H., Bigner, D.D., and Friedman, H.S.: Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma multiforme. *J. Neurooncol*, online May 5, 2010. *J. Neurooncol.*, 101(1):57-66, 2010.

436. Jones, L.W., Mourtzakis, M., Peters, K.B., Friedman, A.H., West, M.J., Mabe, S.K., Kraus, W.E., Friedman, H.S., and Reardon, D.A.: Changes in functional performance measures in adults undergoing chemoradiation for primary malignant glioma: a feasibility study. *Oncologist*, 15(6):636-647, 2010.

437. Peters, K.B., Coyle, T.E., Vredenburgh, J.J., Desjardins, A., Friedman, H.S., and Reardon,

D.A.: Ulceration of Striae Distensae in High-Grade Glioma Patients on Concurrent Systemic Corticosteroid and Bevacizumab Therapy. *J. Neurooncol*, online June 4, 2010.

438. Gururangan, S., Chi, S., Poussaint, T.Y., Onar-Thomas, A., Gilbertson, R., Vajapeyam, S., Friedman, H.S., Packer, R., Rood, B.R., Boyett, J.M., and Kun, L.: Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma – a Pediatric Brain Tumor Consortium Study (PBTC-022). *J. Clin. Oncol.*, online June 7, 2010.

439. Sampson, J.H., Archer, G.E., Pedain, C., Wembacher-Schroder, E., Westphal, M., Kunwar, S., Vogelbaum, M., Coan, A., Herndon, J.E., II, Raghavan, R., Brady, M., Reardon, D.A., Friedman, A.H., Friedman, H.S., Rodriguez-Ponce, I., Chang, S., Mittermeyer, S., Croteau, D., and Puri, R.: Poor drug distribution as a possible explanation for the results of the PRECISE trial. *J. Neurosurg.*, 113(2):301-309, 2010.

440. Aliabadi, H., Vredenburgh, J.J., Everson, R.G., Tucci, D.L., Desjardins, A., Friedman, H.S., and Sampson, J.: Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration. *J. Neurooncol.*, 98(3):427-430, 2010.

441. Toshimitsu, H., Yoshimoto, Y., Augustine, C.K., Padussis, J.C., Yoo, J.S., Selim, M.A., Pruitt, S.K., Friedman, H.S., Ali-Osman, F., and Tyler, D.S.: Inhibition of poly(ADP47 ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity melanoma. *Ann. Surg. Oncol.*, 17(8)2247-2254, 2010.

442. Vredenburgh, J.J., Desjardins, A., Kirkpatrick, J.P., Reardon, D.A., Peters, K.B., Herndon, J.E. II, Bailey, L., Threath, S., Sampson, J.H., Friedman, A.H., and Friedman, H.S.: Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. *Intl. J. Rad. Onc. Biol. Phys.*, online October 30, 2010.

443. Samspon, J.H., Heimberger, A.B., Archer, G.E., Aldape, K.D., Friedman, A.H., Friedman, H.S., Gilbert, M.R., Herndon, J.E. II, McLendon, R.E., Mitchell, D.A., Reardon, D.A., Sawaya, R., Schmittling, R., Shi, W., Vredenburgh, J., and Bigner, DD.: Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III (EGFRvIII) peptide vaccination in patients with newly-diagnosed glioblastoma. *J. Clin. Oncol.*, 28(31):4722-4729, 2010.
444. Vredenburgh, J.J., Cloughesy, T., Samant, M., Prados, M., Wen, P.Y., Mikkelsen, T., Schiff, D., Abrey, L.E., Yung, W.K.A., Paleologos, N., Nicholas, M.K., Jensen, R., Das, A., and Friedman, H.S.: Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Published online December 8, 2010. *Oncologist*, 15(12):1329-1334, 2010.
445. Sathornsumetee, S., Desjardins, A., Vredenburgh, J.J., McLendon, R.E., Marcello, J., Herndon, J.E. II, Mathe, A., Hamilton, M., Norfleet, J., Gururangan, S., Friedman, A.H., Friedman, H.S., and Reardon, D.A.: Phase II trial of bevacizumab plus erlotinib in patients with recurrent malignant glioma. *Neurooncol.*, 12(12):1300-1310, 2010.
446. Reardon, D.A., Desjardins, A., Peters, K., Gururangan, S., Sampson J., Rich, J.N., McLendon, R., Herndon, J.E. II, Marcello, J., Threath, S., Friedman, H.S., Vredenburgh, J.J.: Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after prior bevacizumab failure. *J. Neurooncol.*, online September 19, 2010. *J. Neurooncol.*, 103(2):371-379, 2011.
447. Prados, M., Cloughesy, T., Samant, M., Fang, L., Wen, P.Y., Mikkelsen, T., Schiff, D., Abrey, L.E., Yung, W.K.A., Paleologos, N., Nicholas, M.K., Jensen, R., Vredenburgh, J.J., Das, A., and Friedman, H.S.: Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. *Neurooncol.*, online November 17, 2010. *Neuro-Oncol.*, 13(1):143-151, 2011.

448. Parsons, D.W., Li, M., Zhang, S., Jones, S., Leary, R.J., Lin, J.C-H., Boca, S.M., Carter, H., Samayoa, J., Bettegowda, C., Galla, G.L., Jallo, G.I., Binder, Z.A., Nikolsky, Y., Hartigan, J., Smith, D.R., Gerhard, D.S., Fults, D.W., VandenBerg, S., Berger, M.S., Marie, S.K.N., Shinjo, S.M.O., Clara, C., Phillips, P.C., Minturn, J.E., Biegel, J.A., Judkins, A.R., Resnick, A.C., Storm, P.B., Curran, T., He, Y., Rasheed, B.A., Friedman, H.S., Keir, S.T., McLendon, R., Northcott, P.A., Taylor, M.D., Burger, P.C., Riggins, G.J., Karchin, R., Parmigiani, G., Bigner, D.D., Yan, H., Papadopoulos, N., Vogelstein, B., Kinzler, K.W.,
48

and Velculescu, V.E.: The genetic landscape of the childhood cancer medulloblastoma. *Science*, online December 16, 2010. *Science* 331(6016):435-439, 2011.

449. Paldino, M.J., Desjardins, A., Friedman, H.S., Vredenburgh, J.J., and Barboriak, D.P.: A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme. *Br. J. Radiol.*, online January 11, 2011.

450. Sampson, J.H., Aldape, K.D., Archer, G.E., Coan, A., Desjardins, A., Friedman, A.H., Friedman, H.S., Gilbert, M.R., Herndon, J.E. II, McLendon, R.E., Mitchell, D.A., Reardon, D.A., Sawaya, R., Schmittling, R., Shi, W., Vredenburgh, J.J., Bigner, D.D., and Heimberger, A.B.: Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. *Neuro-Oncol.*, 13(3):324-333, 2011.

451. Reardon, D.A., Turner, S., Peters, K., Desjardins, A., Gururangan, S., Sampson, J.H., McLendon, R., Herndon II, J.E., Friedman, A.H., Vredenburgh, J.J., Bigner, D.D., and Friedman, H.S.: A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. *J. Natl. Compr. Canc. Netw.*, 9(4):414-427, 2011.

452. Wefel, J.S., Cloughesy, T., Zazzali, J.L., Zheng, M., Prados, M., Wen, P.Y., Mikkelsen, T.,

Schiff, D., Abrey, L.E., Yung, W.K., Paleologos, N., Nicholas, M.K., Jensen, R., Vredenburgh, J., Das, A., and Friedman, H.S.: Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. *Neuro-Oncol.*, 13(6):660-668, 2011.

453. Vredenburgh, J.J., Desjardins, A., Reardon, D.A., Peters, K.B., Herndon, J.E. II, Marcello, J., Kirkpatrick, J.P., Sampson, J.H., Bailey, L., Threatt, S., Friedman, A.H., Bigner, D.D., and Friedman, H.S.: The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide and irinotecan for newly diagnosed glioblastoma. *Clin. Cancer Res.*, 17(12):4119-4124, 2011.

454. Ruden, E., Reardon, D.A., Coan, A.D., Herndon, J.E. II, Hornsby, W.E., West, M., Fels, D.R., Desjardins, A., Vredenburgh, J.J., Waner, E., Friedman, A.H., Friedman, H.S., Peters, K.B., and Jones, L.W.: Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma. *J. Clin. Oncol.*, online June 21, 2011.

455. Desjardins, A., Reardon, D.A., Peters, K.B., Threatt, S., Coan, A.D., Herndon II, J.E., Friedman, A.H., Friedman, H.S., and Vredenburgh, J.J.: A phase I trial of farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. *J. Neuro-Oncol.*, online July 7, 2011.

456. Reardon, D.A., Vredenburgh, J.J., Coan, A., Desjardins, A., Peters, K.B., Gururangan, S., Sathornsumetee, S., Rich, J.N., Herndon, J.E., and Friedman, H.S.: Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. *J. Neuro-Oncol.*, online July 9, 2011.

49

457. Lou, E., Turner, S., Sumrall, A., Reardon, D.A., Desjardins, A., Peters, K.B., Sampson, J.H., Friedman, H.S., and Vredenburgh, J.J.: Case Report; Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. *J. Clin. Oncol.*, 29(28):e739-e742, 2011.

458. Reardon, D.A., Desjardins, A., Peters, K., Vredenburgh, J.J., Gururangan, S., Sampson, J., McLendon, R., Herndon, J.E., II, Coan, A., Threatt, S., Friedman, A.H., and Friedman, H.S.: Phase 2 study of carboplatin, irinotecan and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. *Cancer*, online May 16, 2011.
459. Reardon, D.A., Vredenburgh, J.J., Coan, A., Desjardins, A., Peters, K.B., Gururangan, S., Sathornsumetee, S., Rich, J.N., Herndon, J.E. II, and Friedman, H.S.: Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. *J. Neurooncol.*, online July 9, 2011.
460. Desjardins, A., Reardon, D.A., Marcello, J., Herndon, J.E. II, Bailey, L., Peters, K.B., Friedman, H.S., and Vredenburgh, J.J.: Bevacizumab and daily temozolomide for recurrent glioblastoma. *Cancer*, online July 26, 2011.
461. Mitchell, D.A., Cui, X., Schmittling, R.J., Sanchez-Perez, L., Snyder, D.J., Congdon, K.L., Archer, G.E., Desjardins, A., Friedman, A.H., Friedman, H.S., Herndon II, J.E., McLendon, R.E., Reardon, D.A., Vredenburgh, J.J., Bigner, D.D., and Sampson, J.H.: Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. *Blood*, 118(11):3003-3012, 2011.
462. Turner, S., Peters, K.B., Vredenburgh, J.J., Desjardins, A., Friedman, H.S. and Reardon, D.A.: Everolimus tablets for patients with subependymal giant cell astrocytoma. *Expert Opin. Pharmacother.*, 12(14):2265-2269, 2011.
463. Reardon, D.A., Norden, A.D., Desjardins, A., Vredenburgh, J.J., Herndon, J.E. II, Coan, A., Sampson, J.H., Gururangan, S., Peters, K., McLendon, R.E., Norfleet, J., Lipp, E.S., Drappatz, J., Wen, P.Y., and Friedman, H.S.: Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. *J. Neurooncol.*, online September 22, 2011.

IN PRESS

464. Reardon, D.A., Desjardin, A., Vredenburgh, J.J., Herndon, J.E. II, Coan, A., Gururangan, S., Peters, K., McLendon, R., Sathornsumetee, S., Rich, J.N., Janney, D., and Friedman, H.S.: Phase II study of Gleevec® plus hydroxyurea in adults with progressive or recurrent low-grade glioma. *Cancer*, in press, 2011.

465. Reardon, D.A., Herndon, J.E. II, Peters, K., Desjardins, A., Lou, E., Sumrall, A., Turner, S., Gururangan, S., Sampson, J.H., Sathornsumetee, S., McLendon, R.E., Coan, A., Boulton, S., Friedman, A.H., Bigner, D.D., Friedman, H.S., and Vredenburgh, J.J.: Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. *J. Neurooncol.*, in press, 2011.

51

SUBMITTED FOR PUBLICATION

1. Reardon, D.A., Conrad, C.A., Cloughesy, T., Prados, M.D., Friedman, H.S., Aldape, K.D., Mischel, P., Xia, J., DiLea, C., Huang, J., Mietlowski, W., Dugan, M., and Yung, W.K.A.: Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Submitted, 2011.

2. Jiao, Y., Killela, P.J., Reitman, Z.J., Rasheed, B.A., Heaphy, C., de Wilde, R., Rodriguez, F.J., Rosemberg, S., Oba-Shinjo, S.M., Marie, S.K.N., Lipp, E., He, Y., Friedman, H., Friedman A.H., Riggins, G., Holdhoff, M., Burger, P, McLendon, R., Kinzler, K.W., Vogelstein, B., Bigner, D.D., Meeker, A.K., Papadopoulos, N., Diaz, L., and Yan, H.: Genetic signatures of grade II-III gliomas refine their classification. Submitted, 2011.

3. Kwatra, M.M., Reardon, D.A., Keir, S.T., Friedman, H.S., Sampson, J.H., Friedman, A.H., and Bigner, D.D.: Neurokinin 1 receptor: a potentially useful target in treating deadly glioblastomas. Submitted, 2011.

4. Ishimoto, T.M., Antoun, G., Friedman, H., Bigner, D., and Ali-Osman, F.: GSTP1-mediated

metabolism of cisplatin in human glioma cells and characterization of the rate-limiting metabolite, monoglutathionylplatinum, and its role in cisplatin resistance. Submitted, 2011.

5. Reardon, D.A., Vredenburgh, J.J., Desjardins, A., Peters, K.B., Gururangan, S., Sampson, J.H., Herndon, J.E. II, Coan, A., McLendon, R.E., and Friedman, H.S.: Phase I trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. Submitted, 2011.

6. Sampson, J.H., Schmittling, R.J., Archer, G.E., Congdon, K.L., Nair, S.K., Reap, E.A., Desjardins, A., Friedman, A.H., Friedman, H.S., Herndon, J.E. II, Coan, A., McLendon, R.E., Reardon, D.A., Vredenburgh, J.J., Bigner, D.D., and Mitchell, D.A.: IL-2R • blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced vaccine-induced responses in patients with glioblastoma. Submitted, 2011.

53

CHAPTERS

1. Schold, S.C., Jr., and Friedman, H.S.: Human brain tumor xenografts. In: Progress in Experimental Tumor Research. Rosenblum, M.L., Wilson, C.B., eds., Vol. 28, S. Karger, Basel, pp. 18-31, 1984.

2. Friedman, H.S., Bigner, S.H., Schold, S.C., Jr., and Bigner, D.D.: The use of experimental models of human medulloblastoma in the design of rational therapy. In: Biology of Brain Tumor. Walker, M.D., and Thomas, D.G.T., eds., Martinus Wihjoff Publications, Boston, MA, pp. 405-409, 1986.

3. Kurtzberg, J., and Friedman, H.S.: Stridor. In: Principles of Pediatrics: Health Care of the Young. Hockelman, et al., eds., 2nd Edition, McGraw-Hill Book Co., New York, NY, 1987.

4. Friedman, H.S., and Kurtzberg, J.: Swollen abdomen. In: Principles of Pediatrics: Health Care of the Young. Hockelman et al., eds., 2nd Edition, McGraw-Hill Book Co., New York, NY, 1987.

5. Colapinto, E.V., Lee, Y.S., McLendon, R.D., Humphrey, P.A., Zalutsky, M., Friedman, H.S., Pegram, C.N., Bigner, S.H., Bullard, D.E., Wikstrand, C.J., and Bigner, D.D.: The applications of monoclonal antibodies in neuro-oncology. In: *Brain Oncology, Biology, Diagnosis and Therapy*. Chatel, M., Darcel, F., and Pecker, J., eds., Martinus Nijhoff Publishing, The Netherlands, pp. 121-124, 1987.
6. Bigner, S.H., Vogelstein, B., Mark, J., Friedman, H.S., and Bigner, D.D.: Cytogenetics and molecular genetics: their status and role in understanding the behavior of central nervous system neoplasms. In: *Neuropathology*. Cancilla, P.A., Vogel, F.S., and Kaufman, N., eds., *Monographs in Pathology No. 32*, Williams and Wilkins, Baltimore, MD, pp. 30-40, 1990.
7. Lee, Y.S., Wikstrand, C.J., Humphrey, P.A., Bigner, S.H., Friedman, H.S., Vrionis, F.D., and Bigner, D.D.: In vitro growth of brain tumors. In: *Neurology of Brain Tumors*. Vol. 4, Salcman, M., ed., Williams and Wilkins, Baltimore, MD, pp. 163-183, 1990.
8. Schold, S.C., Jr., and Friedman, H.S.: Chemotherapy for nervous system tumors. In: *Neurology in Clinical Practice*. Bradley, W.F., Daroff, R., Fenichel, G.M., and Marsden, C.D., eds., Butterworth Publishers, Stoneham, MA, pp. 1042-1045, 1990.
9. Horowitz, M.E., Friedman, H.S., and McGrath, I.C.: Malignancies in children with HIV. In: *Pediatric AIDS: The Challenge of HIV Infection in Infants, Children, and Adolescents*. Pizzo, P.A., and Wilfert, C.M., eds., Williams and Wilkins, New York, NY, pp. 438-456, 1990.
- 54
10. Griffith, O.W., and Friedman, H.S.: Inhibition of metabolic drug inactivation: modulation of drug activity and toxicity by perturbations of glutathione metabolism. In: *Synergism and Antagonism in Chemotherapy*. Chou, T.-C., and Rideout, D.C., eds., Academic Press, New York, NY, pp. 245-284, 1991.

11. Friedman, H.S., and Schold, S.C. Jr.: Tumor site effects: CNS tumors. In: Mechanisms of Drug Resistance in Oncology. Teicher, B.A., ed., Marcel Dekker, Inc., New York, NY, pp. 251-261, 1993.
12. Colvin, O.M., Friedman, H.S., and Hilton, J.: Role of glutathione in cellular resistance to alkylating agents. In: Advances in Enzyme Regulation, Vol. 33. Weber, G., ed., Pergamon Press, New York, NY, pp. 19-26, 1993.
13. Friedman, H.S.: Foreword. In: Brain Tumors in Children, Vol. 2. Duffner, P., and Cohen, M., eds., Raven Press, New York, NY, 1994.
14. Friedman, H.S., Auerbach, S.D., and Kurtzberg, J.: Nonclassical alkylators. In: Cancer Chemotherapy--Principles and Practice. Chabner, B.A., and Collins, J.M., eds., J.B. Lippincott Co., Philadelphia, PA, pp. 333-356, 1996.
15. Chamberlain, M.C., and Friedman, H.S.: Immunotherapy and radiotherapy of leptomeningeal neoplasia. In: Cancer in the Nervous System. Levin, V.A., ed., Churchill Livingstone, New York, pp. 281-290, 1996.
16. Packer, R.J., Hoffman, H.J., Friedman, H.S., Kun, L.E., and Fuller, G.N.: Presentation and chemotherapy of primitive neuroectodermal tumors. In: Cancer in the Nervous System. Levin, V.A., ed., Churchill Livingstone, New York, pp. 153-170, 1996.
17. Friedman, H.S., and Houghton, P.J.: Treatment of central nervous system xenografts with camptothecins. In: The Camptothecins: From Discovery to the Patient. Pantazis, P., Giovanella, B.C. and Rothenberg, M.L., eds., New York Academy of Sciences, New York, pp. 210-212, 1996.
18. Fuchs, H., Friedman, H.S., and Halperin, E.C.: Medulloblastomas. In: Cancer of the Nervous System. Black, P.N., and Loeffler, J.S., eds., Blackwell Science, Cambridge, MA, pp. 567-575, 1997.
19. Friedman, H.S., Dolan, E., Auerbach, S.D., and Kurtzberg, J.: Nonclassical alkylators. In:

Cancer Chemotherapy and Biotherapy: Principles and Practice, Chabner, B.A., and Longo, D.L., eds., Lippincott Williams and Wilkins, Philadelphia, PA, pp. _____, 2001.

20. Zalutsky, M.R., Reardon, D.A., Akabani, G., Friedman, A.H., Friedman, H.S., and Bigner, D.D.: Targeted irradiation of brain tumours. In: Targeted Cancer Therapies. Bruland, Ø.S., and Flagstad, T., eds., University of Tromso Press, pp. 155-159, 2003.

55

21. Gururangan, S., and Friedman, H.S.: Primitive neuroectodermal tumors of the central nervous system. In: Cancer of the Nervous System. Black, P.N., and Loeffler, eds., 2nd Edition, in press, 2005.

22. Zalutsky, M.R., Reardon, D.A., Akabani, G., Friedman, A.H., Friedman, H.S., and Bigner, D.D.: Targeted irradiation of brain tumors. In: Targeted Cancer Therapies. Bruland, Ø.S. and Flagstad, T., eds., Ravnetrykk, Tromso, 2005.

56

OTHER PUBLICATIONS

PUBLISHED SCIENTIFIC REVIEWS/LETTERS

1. Friedman, H.S., Pincus, J.K., and Falletta, J.M.: Central nervous system leukemia. Lancet ii:633, 1981.

2. Becton, D.L., Chaffee, S., Kurtzberg, J., Friedman, H.S., Kinney, T.R., and Falletta, J.M.: Frequency of bone marrow aspiration in childhood ALL. J. Pediatr. 105:509, 1984.

3. Friedman, H.S., Kurtzberg, J., and Bigner, D.D.: *In vitro/in vivo* chemosensitivity of a human medulloblastoma. Cancer Res. 45:6538, 1985.

4. Friedman, H.S.: Rationale for "eight-in-one" chemotherapy. J. Clin. Oncol. 6:393-394, 1988.

5. Friedman, H.S.: Commentary: Pediatric brain tumors. In: 1988 Yearbook of Pediatrics. Oski, F.A., and Stockman, J.A., eds., Year Book Medical Publishers, Chicago, pp. 375-376, 1988.

6. Friedman, H.S.: Commentary: Pediatric brain tumors. In: 1990 Yearbook of Pediatrics. Oski,

- F.A., and Stockman, J.A., eds., Year Book Medical Publishers, Chicago, pp. 393-394, 1990.
7. Friedman, H.S.: Commentary: Ependymomas. In: 1992 Yearbook of Pediatrics. Stockman, J.A., ed., Year Book Medical Publishers, Chicago, pp. 364-365, 1992.
 8. Friedman, H.S., Archer, G., and Bigner, D.D.: Letter to the editor. Re: Toxicity of intrathecal melphalan. *J. Natl. Cancer Inst.* 86:870-871, 1994.
 9. Friedman, H.S.: Commentary: Radiation toxicity in the therapy of brain tumors. In: 1994 Yearbook of Pediatrics. Stockman, J.A., ed., Year Book Medical Publishers, Chicago, in press, 1995.
 10. Friedman, H.S.: Commentary: Pediatric brain tumors. In: 1995 Yearbook of Pediatrics. Stockman, J.A., ed., Year Book Medical Publishers, Chicago, in press, 1995.
 11. Friedman, H.S.: Commentary: Alternative therapy of recurrent brain tumor. In: *Cancer Practice: A Multidisciplinary Journal of Cancer Care*. J.B. Lippincott, New York, in press, 1995.
 12. Friedman, H.S., and Kun, L.E.: Letter to the editor. Re: Surveillance of children with medulloblastoma. *New Eng. J. Med.* 332:191, 1995.
 13. Friedman, H.S.: Commentary: Second malignancies in young children with primary brain tumors. In: 1999 Yearbook of Pediatrics. Stockman, J.A., ed., Year Book Medical Publishers, Chicago, in press, 2002.
 14. Friedman, H.S., and Kun, L.E.: Commentary: Childhood brain tumors. *Neurooncol.* 1:138, 1999.
 15. Friedman, H.S., and Kun, L.E.: Commentary: Medulloblastoma. *Neurooncol.* 1:232, 1999.
 16. Friedman, H.S.: Commentary: Temozolomide – a viewpoint. *CNS Drugs* 12:1172, 1999.
 17. Friedman, H.S.: Editorial: AGT depletion and augmentation of nitrosourea activity. *Clin. Cancer Res.* 6:2967-2968, 2000.

18. Friedman, H.S., and Bigner, D.D.: Glioblastoma multiforme and the epidermal growth factor receptor. (Perspective No. 05-8186) *New Engl. J. Med.* 353(19):1997-1999, 2005.
19. Reardon, D.A., Rich, J.N., Friedman, H.S., and Bigner, D.D.: Recent advances in the treatment of malignant astrocytomas. *J. Clin. Oncol.*, 24: 1253-1265, 2006.
20. Friedman, H.S. and Maxwell, J.: Correspondence: The fallacy of single-agent chemotherapy for cancer. *J. Clin. Oncol.* 25:3550, 2007.
21. Friedman, H.S., Prados, M.D., Wen, P.Y., Mikkelsen, T., Schiff, D., Abrey, L., Yung, W.K.A., Paleologos, N., Nicholas, M.K., Jensen, R., Vredenburgh, J., Huang, J., Zheng, M., and Cloughesy, T.: Reply to W. Wick, et al. *J. Clin. Oncol.* 28(12):e190-e192, 2010.

58

SELECTED ABSTRACTS

1. Caspari, E., Friedman, H.S., and Young, E.M.: Genetic changes induced by DNA in ephestia. *Genetics* 80 (Suppl.), 1975.
2. Stuart, M., Friedman, H., Pincus, J., Coppe, D., and Spitzer, R.: Evaluation of vascular and platelet prostaglandin synthesis in hemolytic uremic syndrome. *Pediatr. Res.* 14:626, 1980.
3. Castella, A., Miller, J.L., Neuberger, R.W., and Friedman, H.S.: An inhibitor selectively directed against factor VIII-AHF in a patient with von Willebrand's disease (vWd). *Thromb. Haemost.* 46:138, 1981.
4. Friedman, H.S., Coleman, R.A., Kinney, T.R., Sommerville, H.M., and Falletta, J.M.: Insulin infusion in ketolactic acidosis complicating malignancy. *Clin. Res.*, Dec., 1981.
5. Friedman, H.S., Bigner, S.H., Schold, S.C., Jr., and Bigner, D.D.: Growth morphology and chemotherapeutic response of medulloblastoma (MBT) in athymic mice. *Pediatr. Res.* 16:204A, 1982.
6. Friedman, H.S., Wagner, J.E., Kinney, T.R., Falletta, J.M., Hannan, W., Newberg, R., and Stockman, J.A., III: Macrocytosis and Hodgkin's disease. *Pediatr. Res.* 16:204A, 1982.

7. Friedman, H.S., Schold, S.C., Jr., Bigner, S.H., and Bigner, D.D.: Chemotherapeutic response of medulloblastoma in athymic mice. Presentation: Child Neurology Society, 1982. *Ann. Neurol.* 12:212, 1982.
8. Schold, S.C., Jr., Bigner, S.H., Friedman, H.S., Rawlings, C., and Bigner, D.D.: Growth and treatment of human brain neoplasms in athymic mice. Proceedings IX International Congress of Neuropathology 22, 1982.
9. Grieve, R., DeGregory, K.T., Glickman, L.T., Friedman, H.S., and Stockman, J.A., III: Antigen and mitogen induced blastogenesis in experimentally and naturally acquired visceral larval migrans. Presentation: International Congress of Parasitology, 1982.
10. Ware, R., Kinney, T.R., Friedman, H., and Falletta, J.: Prognostic implications for direct platelet associated IgG (PAIgG) in childhood ITP. Presentation: American Society of Hematology, 1982.
11. Bjornsson, T.D., Falletta, J.M., Schold, S.C., Jr., Friedman, H.S., and Shand, D.G.: Pharmacokinetics of diaziquone (AZQ) after three different dosage regimens. Presentation: American Society for Clinical Pharmacology and Therapeutics, 1982.
12. Schold, S.C., Jr., Friedman, H.S., Bjornsson, T.D., Shand, D.G., and Bigner, D.D.: Treatment of human brain tumors in athymic mice with aziridinybenzoquinone (AZQ). *Proc. Am. Assoc. Cancer Res.* 23:176, 1982.

59

13. Schold, S.C., Jr., Friedman, H.S., Bjornsson, T.D., and Falletta, J.M.: Treatment of recurrent anaplastic brain tumors with diaziquone (AZQ). Presentation: American Association of Neurology, 1983. *Neurology* 33(Suppl. 2):108, 1983.
14. Friedman, H.S., Schold, S.C., Jr., Muhlbaier, L.H., and Bigner, D.D.: *In vitro* and *in vivo* chemosensitivity of human medulloblastoma. Presentation: American Association for Cancer Research, 1984. *Proc. Am. Assoc. Cancer Res.* 25:376, 1984.

15. Schold, S.C., Jr., Friedman, H.S., and Bigner, D.D.: A human glioma-athymic mouse system for evaluation of novel brain tumor chemotherapeutic agents. Presentation: American Association of Neurology, 1984. AAN Scientific Program 44:336, 1984. Neuropathol. 34(Suppl.):277, 1984.
16. Dranoff, G., Elion, G.B., Campbell, G.L., Friedman, H.S., and Bigner, D.D.: Influence of glutamine on growth of human medulloblastoma in culture. Presentation: American Association of Neuropathology, 1984. J. Neuropathol. Exp. Neurol. 43:336, 1984.
17. Friedman, H.S., Bigner, S.H., Schold, S.C., Jr., Burger, P.C., Bjornsson, T.D., Halperin, E.C., Varia, M.A., Muhlbaier, L.H., and Bigner, D.D.: The use of human medulloblastoma models to design rational therapy. Presentation: Second International Symposium on Biology of Brain Tumor, London, 1984. J. Neurooncol. 2:286, 1984.
18. Dranoff, G., Elion, G.B., Friedman, H.S., and Bigner, D.D.: Glutamine requirements of human glioma and medulloblastoma in culture. Presentation: Second International Symposium on Biology of Brain Tumor, London, 1984. J. Neurooncol. 2:264, 1984.
19. Schold, S.C., Jr., Friedman, H.S., Bullard, D.E., Falletta, J.M., McDonald, D.R., Cairncross, J.G., Mahaley, M.S., Jr., Khandekar, J.D., and Vick, N.A.: Clinical trials of diaziquone (AZQ) in patients with primary central nervous neoplasms. Presentation: Second International Symposium on Biology of Brain Tumor, London, 1984. J. Neurooncol. 2:289, 1984.
20. Friedman, H.S., Ludeman, S.M., Schold, S.C., Jr., Boyd, V.L., Muhlbaier, L.H., and Bigner, D.D.: Sensitivity of human medulloblastoma (MED) to classical alkylators. Proc. Am. Assoc. Cancer Res. 26:330, 1985.
21. Dranoff, G., Elion, G.B., Friedman, H.S., and Bigner, D.D.: Glutamine based combination chemotherapy in culture for human glioma and medulloblastoma. Presentation: American Association for Cancer Research, 1985. Proc. Am. Assoc. Cancer Res. 26:323, 1985.

22. Friedman, H.S., Burger, P.C., Bigner, S.H., Trojanowski, J.O., Halperin, E.D., and Bigner, D.D.: Establishment and preliminary characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med. Presentation: American Association of Neuropathology, 1985. *J. Neuropathol. Exp. Neurol.* 44:310, 1985.

23. Bigner, D.D., Bigner, S.H., Burger, P.C., Shelburne, J.D., and Friedman, H.S.: Acrylonitrile neurooncogenesis in F344 rats. Presentation: Sixth International Conference on Brain Tumor Research and Therapy, Asheville, NC, 1985. *J. Neurooncol.* 4:94, 1986.

60

24. Schold, S.C., Jr., Mahaley, M.S., Jr., Friedman, H.S., Vick, N.A., Bullard, D.E., Burger, P.C., Cairncross, J.G., Falletta, J.M., Halperin, E.C., Khandekar, J.D., Macdonald, D.R., and Bigner, D.D.: Cooperative studies of chemotherapy for gliomas and medulloblastomas. Presentation: Sixth International Conference on Brain Tumor Research and Therapy, Asheville, NC, 1985. *J. Neurooncol.* 4:108, 1986.

25. Friedman, H.S., Schold, S.C., Jr., Bigner, S.H., Colvin, O.M., Ludeman, G.B., Elion, G.B., Boyd, V.L., Burger, P.C., Wikstrand, C.J., Trojanowski, J.Q., Halperin, E.C., Jacobsen, P.F., Papadimitriou, P.A., and Bigner, D.D.: Experimental chemotherapy of human glioma and medulloblastoma. Presentation: Sixth International Conference on Brain Tumor Research and Therapy, Asheville, NC, 1985. *J. Neurooncol.* 4:109, 1986.

26. Friedman, H.S., Colvin, O.M., Ludeman, S.M., Schold, S.C., Jr., Boyd, V.L., Muhlbaier, L.H., and Bigner, D.D.: Chemotherapy of human medulloblastoma with classical alkylators. Presentation: American Association for Cancer Research, 1986. *Proc. Am. Assoc. Cancer Res.* 27:381, 1986.

27. Biegel, J.A., Bigner, S.H., Mark, J., Friedman, H.S., and Bigner, D.D.: Karyotypic findings in six cases of human medulloblastoma. Presentation: American Association for Cancer Research, 1986. *Proc. Am. Assoc. Cancer Res.* 27:36, 1986.

28. Wikstrand, C.J., Mach, J.P., Carrel, S., De Tribolet, N., Friedman, H.S., Bullard, D.E., Humphrey, P.A., and Bigner, D.D.: Localization of anti-human glioma monoclonal antibodies (MAbs) in subcutaneous (SC) and intracerebral (IC) glioma xenografts. Presentation: American Association for Cancer Research, 1986. Proc. Am. Assoc. Cancer Res. 27:330, 1986.

29. Trojanowski, J.Q., Friedman, H.S., and Bigner, D.D.: A rapidly dividing human medulloblastoma cell line (D283 Med) expresses isoforms of all three neurofilament subunits. Presentation: X International Congress of Neuropathology (Stockholm) 10:63, 1986.

30. Duffner, P.K., Cohen, M.E., Horowitz, M., Friedman, H.S., Kun, L.E., Mahoney, D.H., Das, L., and Holbrook, C.J.: Postoperative chemotherapy and delayed irradiation in children less than 36 months of age with malignant brain tumors. Presentation: Child Neurology Society, 1986. Ann. Neurol. 20:424, 1986.

31. Kurtzberg, J., Friedman, H.S., Falletta, J.M., Kinney, T.R., Chaffee, S., Schwartz, R.S., and Kurlander, R.: The efficacy of IVIG in autoimmune mediated pediatric blood dyscrasias. Presentation: American Society of Hematology, 1986.

32. Schold, S.C., Jr., Mitra, S., Swenberg, J., Friedman, H.S., and Kleihues P.: Alkyl-transferase activity and alkylating DNG sensitivity in human glioma xenografts in athymic mice. Presentation: American Association of Neurology, 1987.

61

33. Friedman, H.S., Colvin, O.M., Hilton, J., Schold, S.C., Jr., Elion, G.B., Skapek, S.X., Blum, M.R., Savina, P.M., Muhlbaier, L.H., and Bigner, D.D.: Melphalan cytotoxicity and resistance in medulloblastoma. Presentation: American Association for Cancer Research, 1987. Proc. Am. Assoc. Cancer Res. 28:447, 1987.

34. Schold, S.C., Friedman, H.S., Elion, G.B., Mitra, S., and Bigner, D.D.: Therapeutic

synergy of thiopurines and alkylating drugs in a human glioma xenograft. Presentation: American Association for Cancer Research, 1987. Proc. Am. Assoc. Cancer Res. 28:416, 1987.

35. Humphrey, P.A., Wong, A.J., Friedman, H.S., Werner, M.H., Vogelstein, B., Bigner, D.D., and Bigner, S.H.: Amplification and expression of the epidermal growth factor receptor (EGFR) gene in human glioma (HGL) xenografts. Presentation: American Association for Cancer Research, 1987. Proc. Am. Assoc. Cancer Res. 28:23, 1987.

36. Lee, Y.S., Bullard, D.E., Friedman, H.S., Wikstrand, C.J., Coleman, R.E., Zalutsky, M., Muhlbaier, L.H., and Bigner, D.D.: Experimental radiotherapy of subcutaneous (SC) and intracranial (IC) human glioma (HGL) xenografts in rodents with ¹³¹I-monoclonal antibody (MAb) 81C6. Presentation: American Association for Cancer Research, 1987. Proc. Am. Assoc. Cancer Res. 28:392, 1987.

37. Humphrey, P.A., Wong, A.J., Vogelstein, B., Friedman, H.S., Bigner, D.D., and Bigner, S.H.: Loss of epidermal growth factor receptor gene amplification as malignant human gliomas establish in culture. Presentation: American Association for Cancer Research, 1988. Proc. Am. Assoc. Cancer Res. 29:78, 1988.

38. Skapek, S.X., Colvin, O.M., Griffith, O.W., Groothuis, D.R., Hilton, J., Elion, G.B., Bigner, D.D., and Friedman, H.S.: Selective buthionine sulfoximine (BSO)-mediated depletion of glutathione (GSH) in an intracranial human glioma-derived xenograft. Presentation: American Association for Cancer Research, 1988. Proc. Am. Assoc. Cancer Res. 29:357, 1988.

39. Winick, N., Friedman, H., Bigner, D., Peryea, X., Streckfuss, A., and Kamen, B.: Methotrexate (MTX), schedule dependent drug accumulation. Presentation: American Association for Cancer Research, 1988. Proc. Am. Assoc. Cancer Res. 29:288, 1988.

40. Ibayashi, N., Herman, M.M., Rubinstein, L.J., Bigner, D.D., Friedman, H.S., Collins, V.P.,

and Donoso, L.A.: Intermediate filament expression of three cultured human neuroepithelial tumor cell lines (medulloblastoma, retinoblastoma and malignant astrocytoma) in S phase. Presentation: American Association of Neuropathology, 1988. *J. Neuropathol. Exp. Neurol.* 47:349, 1988.

41. He, X., Wikstrand, C.J., Friedman, H.S., Trojanowski, J.Q., Bigner, S.H., and Bigner, D.D.: Antigenic phenotypes of four human medulloblastoma cell lines and xenografts. Presentation: American Association of Neuropathology, 1988. *J. Neuropathol. Exp. Neurol.* 47:349, 1988.

62

42. Boyko, O.B., Djang, W.T., Coleman, R.E., Burger, P.C., Friedman, H.S., and Schold, S.C., Jr.: Tumor versus edema: T1-201 and SPECT imaging in comparison to NMR in the follow-up of intracranial gliomas. Presentation: Society of Nuclear Medicine, 1988. *Am. J. Neuroradiol.* 9:1012, 1988.

43. Garg, P.K., Friedman, H.S., Slade, S., Bigner, D.D., and Zalutsky, M.R.: Astatine-211 labeled monoclonal antibody: a potential agent for radio-immunotherapy. *Eur. J. Nucl. Med.* 14:245, 1988.

44. Garg, P.K., Noska, M.A., Colapinto, E.V., Friedman, H.S., Bigner, D.D., and Zalutsky, M.R.: Labeling of a monoclonal antibody (MAb) with iodine and astatine using N-succinimidyl-3-(tri-n-butylstannyl)benzoate (ATE). Presentation: Society of Nuclear Medicine, 1988. *J. Nucl. Med.* 29:835, 1988.

45. Friedman, H.S., Colvin, O.M., Griffith, O.W., Elion, G.B., Schold, S.C., Jr., Hilton, J., Lippitz, B., and Bigner, D.D.: Enhanced melphalan or radiation sensitivity in intracranial human medulloblastoma or glioma xenografts following buthionine sulfoximine-mediated glutathione depletion. Presentation: American Association for Cancer Research, 1989. *Proc. Am. Assoc. Cancer Res.* 30:471, 1989.

46. Rosenberg, M.C., Colvin, O.M., Griffith, O.W., Bigner, S.H., Elion, G.B., Horton, J.K., Bigner, D.D., and Friedman, H.S.: Enhanced melphalan sensitivity in a melphalan-resistant human medulloblastoma xenograft secondary to buthionine sulfoximine-mediated glutathione depletion. Presentation: American Association for Cancer Research, 1989. Proc. Am. Assoc. Cancer Res. 30:461, 1989.
47. Friedman, H.S., Griffith, O.W., Popp, J., Colvin, O.M., Bossen, E.H., Reimer, K.A., Powell, J.B., and Bigner, D.D.: Acute toxicity resulting from combination therapy with cyclophosphamide and buthionine sulfoximine. Presentation: American Association for Cancer Research, 1989. Proc. Am. Assoc. Cancer Res. 30:464, 1989.
48. Fuchs, H.E., Archer, G.E., Colvin, O.M., Bigner, S.H., Muhlbaier, L.H., Friedman, H.S., and Bigner, D.D.: Activity of intrathecal 4-hydroperoxycyclophosphamide (4-HC) in a nude rat model of leptomeningeal dissemination of human medulloblastoma. Presentation: American Association for Cancer Research, 1989. Proc. Am. Assoc. Cancer Res. 30:464, 1989.
49. Fuchs, H.E., Archer, G.E., Friedman, H.S., Bigner, S.H., Colvin, O.M., and Bigner, D.D.: Establishment of a nude rat model of leptomeningeal dissemination of human medulloblastoma: activity of intrathecal 4-hydroperoxycyclophosphamide. Presentation: Association of Neurological Surgeons, 1989.
50. Fuchs, H.E., Archer, G.E., Schuster, J.M., Colvin, O.M., Bigner, S.H., Muhlbaier, L.H., Friedman, H.S., and Bigner, D.D.: A nude rat model of leptomeningeal tumor dissemination in medulloblastoma utilizing a chronic indwelling subarachnoid catheter: activity of intrathecal hydroperoxycyclophosphamide (4-HC). Presentation: American Association of Neuropathology, 1989. J. Neuropathol. Exp. Neurol. 48:356, 1989.
- 63
51. Garg, P.K., Slade, S., Harrison, C., Friedman, H.S., Bigner, D.D., and Zalutsky, M.R.:

Astatine-211 labeled F(ab')₂ fragment retains immunoreactivity and tumor uptake *in vivo*.

Presentation: Society of Nuclear Medicine, 1989. J. Nucl. Med. 30:778, 1989.

52. Than, T.T., Kooistra, K.L., Friedman, H.S., Phillips, P.C., Colvin, O.M., and Grochow, L.B.: Antitumor activity of intraventricular 4-hydroperoxycyclophosphamide in a rabbit VX2 meningeal carcinomatosis model. Presentation: American Association for Cancer Research, 1989. Proc. Am. Assoc. Cancer Res. 30:602, 1989.

53. Colapinto, E.V., Zalutsky, M.R., Noska, M.A., Archer, G.E., Friedman, H.S., and Bigner, D.D.: Radioimmunotherapy of intracerebral human glioma xenografts with ¹³¹I-labeled F(ab')₂ fragment of monoclonal antibody Me1-14. Presentation: Congress of Neurological Surgeons, 1989.

54. Cope, D.A., Slade, S.K., Dewhirst, M.W., Friedman, H.S., Bigner, D.D., Oleson, J.R., and Zalutsky, M.R.: Local hyperthermia at 42 degrees Celsius enhances monoclonal antibody fragment uptake in tumor. Presentation: American Society for Therapeutic Radiology and Oncology, 1989. Int. J. Radiat. Oncol. Biol. Phys. 17 (Suppl. 1):119-120, 1989.

55. Schold, S.C., Friedman, H.S., Bigner, S.H., Brent, T.P., and Bigner, D.D.: 06-Alkylguanine-DNA alkyltransferase in resected primary human central nervous system tumors. Presentation: Eighth Conference on Brain Tumor Research and Therapy, Zermatt, Switzerland, 1989. J. Neurooncol. 7 (Suppl.):S25, 1989.

56. Bigner, S.H., Mark, J., Vogelstein, B., Friedman, H.S., and Bigner, D.D.: Cytogenetics and molecular genetics of brain tumors: malignant gliomas and medulloblastomas. Presentation: Eighth Conference on Brain Tumor Research and Therapy, Zermatt, Switzerland, 1989. J. Neurooncol. 7 (Suppl.):S6, 1989.

57. Humphrey, P.A., Wong, A.J., Vogelstein, B., Friedman, H.S., Bigner, D.D., and Bigner, S.H.: Amplification and expression of mutant epidermal growth factor receptor genes in human gliomas. Presentation: Eighth Conference on Brain Tumor Research and Therapy,

Zermatt, Switzerland, 1989. J. Neurooncol. 7 (Suppl.):S15, 1989.

58. Fuchs, H.E., Archer, G.E., Schuster, J.M., Colvin, O.M., Bigner, S.H., Muhlbaier, L.H., Friedman, H.S., and Bigner, D.D.: A nude rat model of leptomeningeal tumor dissemination in medulloblastoma utilizing a chronic indwelling subarachnoid catheter: activity of intrathecal 4-hydroperoxycyclophosphamide. Presentation: Eighth Conference on Brain Tumor Research and Therapy, Zermatt, Switzerland, 1989. J. Neurooncol. 7 (Suppl.):S12, 1989.

59. Friedman, H.S., Griffith, O.W., Colvin, O.M., Elion, G.B., Bigner, S.H., Halperin, E.C., Lippitz, B., Schold, S.C., Ostertag, C.B., and Bigner, D.D.: Therapeutic consequences of glutathione depletion. Presentation: Eighth Conference on Brain Tumor Research and Therapy, Zermatt, Switzerland, 1989. J. Neurooncol. 7 (Suppl.):S12, 1989.

64

60. Lippitz, B.E., Halperin, E.C., Griffith, O.W., Colvin, O.M., Honore, G., Ostertag, B., Bigner, D.D., and Friedman, H.S.: L-BSO mediated radiosensitization in experimental interstitial radiotherapy of intracerebral D-54 MG xenografts in athymic mice. Presentation: Eighth Conference on Brain Tumor Research and Therapy, Zermatt, Switzerland, 1989. J. Neurooncol. 7 (Suppl.):S18, 1989.

61. Gluckman, E., Broxmeyer, H.E., Auerbach, A.D., Douglas, G., Friedman, H.S., Socie, G., Boyse, E.A.: Successful hematopoietic reconstitution by HLA identical umbilical cord blood in a case of fanconi anemia. Presentation: American Society of Hematology, 1989. Blood 74(Suppl.): 202a, 1989.

62. Fuchs, H.E., Oakes, W.J., Friedman, H.S., Schold, S.C., Hockenberger, B., and Halperin, E.: Therapy of cerebral primitive neuroectodermal tumors (PNETS) in childhood. Presentation: American Association of Neurological Surgeons, 1990.

63. Lilley, E., Rosenberg, M., Elion, G.B., Colvin, O.M., Bigner, D.D., and Friedman, H.S.:

Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft. Presentation: American Association for Cancer Research, 1990. Proc. Am. Assoc. Cancer Res. 31:447, 1990.

64. Lilley, E., Elion, G.B., Dewhirst, M.W., Schold, S.C., Griffith, O.W., Blum, M.R., Savina, P.M., Bigner, D.D., and Friedman, H.S.: Mechanistic and therapeutic analysis of the melphalan-resistant human rhabdomyosarcoma xenograft TE-671 MR. Presentation: American Association for Cancer Research, 1990. Proc. Am. Assoc. Cancer Res. 31:447, 1990.

65. Humphrey, P.A., Fuller, G.N., Archer, G., Zalutsky, M., Kwatra, M, Cook, S., Friedman, H., Vogelstein, B., Wong, A., Bigner, S.H., and Bigner, D.D.: Anti-synthetic peptide antibody reacting at the fusion junction of glioma deletion mutant EGF receptor (EGFR). Presentation: American Association for Cancer Research, 1990. Proc. Am. Assoc. Cancer Res. 31:257, 1990.

66. Kwatra, M., Humphrey, P., Bigner, S., Friedman, H., Vogelstein, B., Wong, A., Bigner, D.: Purification and characterization of a truncated, v-erb B-like, epidermal growth factor receptor from a human glioma xenograft. Proc. Am. Assoc. Cancer Res. 31:43, 1990.

67. Kurtzberg, J., Greenberg, M., Hebert, M., Gravatt, L., Chaffee, S., Friedman, H.S., Hershfield, M., Elion, G.B.: Pharmacologic purging of malignant T cells from human and murine bone marrow (BM) using 9-B-D-arabinofuranosyl guanine (Ara-G). Proc. Am. Assoc. Cancer Res. 31:173, 1990.

68. Kurtzberg, J., Friedman H, Asselin, B., Schultz, W., Krischer, J., Scudiery, D., Franklin, A., and Finkelberg, Z.: The use of polyethylene glycol-conjugated L-asparaginase (PEG-ASP) in pediatric patients with prior hypersensitivity to native L-asparaginase. ASCO Proceedings 9:219, 1990.

69. Lopes, M.B.S., Frankfurter, A., Zientek, G.M., Katsetos, C.D., Friedman, H.S., Bigner, D.D., and Herman, M.M.: Neuron-associated microtubule proteins in the U-251 malignant glioma cell line. Presentation: American Association of Neuropathologists, 1990. *J. Neuropathol. Exp. Neurol.* 49:272, 1990.
70. Skapek, S.X., Van Dellen, A.F., McMahon, D.P., Berg, S.T., Griffith, O.W., Bigner, D.D., and Friedman, H.S.: Melphalan (L-PAM)-induced toxicity in nude mice pretreated with buthionine sulfoximine (BSO). *Pediatr. Res.* 27:150A, 1990.
71. Levine, E.S., Walsh, C.M., Friedman, H.S., Griffith, O.W., and Lieberman, H.: Evaluation of antineoplastic agents on glutathione-depleted cultured heart cells. Presentation: Tissue Culture Association, 1990. *In Vitro* 26:61A, 1990.
72. Zalutsky, M.R., Garg, P.K., Friedman, H.S., and Bigner, D.D.: Enhancing tumor dose via improved antibody radiohalogenation methods and alpha-emitting AT-211. Presentation: Conference on Advances in the Clinical Application of Monoclonal Antibodies in Clinical Oncology, 1990.
73. Richter, C.B., Friedman, H.S., Klingenberg, K.L., Hughs, D., and Schenkman, D.I.: D2 corneforms as a cause of severe hyperkeratotic dermatitis in athymic nude mice. Presentation: American Association of Laboratory Animal Science, 1990. *Lab Animal Science* 40:545, 1990.
74. Brown, M., Cairncross, J.G., Vick, N.A., Macdonald, D.R., Friedman, H.S., Dropcho, E.J., and Schold, S.C.: Differential response of recurrent oligodendrogliomas vs. astrocytomas to intravenous melphalan. Presentation: American Association of Neurology, 1990. *Neurology* 40 (Suppl.) 397, 1990.
75. Hoffman, J.M., Hanson, M.W., Coleman, R.E., Oakes, J., Friedman, H.S.: FDG-PET in pediatric fossa brain tumors. Presentation: American Society of Nuclear Medicine. *J. Nucl. Med.* 31:878, 1990.

76. Duffner, P., Cohen, M., Horowitz, H., Kun, L., Burger, P., Sanford, R., Friedman, H.S., Freeman, C., and Krischer, J.: Post-operative chemotherapy and delayed radiotherapy in infants with intracranial ependymomas: a POG group wide protocol. Presentation: Child Neurology Association. *Ann. Neurol.* 28:442, 1990.

77. Laskowitz, D.T., Elion, G.B., Dewhirst, M.W., Griffith, O.W., Casero, R., Prescott, D.A., Bigner, D.D., and Friedman, H.S.: Therapeutic interaction between hyperthermia, melphalan, and perturbations of glutathione and polyamine levels in human rhabdomyosarcoma xenografts. Presentation: American Association for Cancer Research, 1991. *Proc. Am. Assoc. Cancer Res.* 32:372, 1991.

78. Friedman, H.S., Lippitz, B.E., Fekete, I., Schlageter, K.E., Molnar, P., Colvin, O.M., Roe, C.R., Bigner, D.D., and Groothuis, D.R.: Enhanced melphalan delivery to brain and xenotransplanted glioma following dietary induced depletion of large neutral amino acids. Presentation: American Association for Cancer Research, 1991. *Proc. Am. Assoc. Cancer Res.* 32:318, 1991.

66

79. Laskowitz, D.T., Elion, G.B., Dewhirst, M.W., Griffith, O.W., Cattley, R.C., Bigner, D.D., and Friedman, H.S.: Enhancement of melphalan induced gastrointestinal toxicity in mice treated with regional hyperthermia and BSO-mediated glutathione depletion. Presentation: American Association for Cancer Research, 1991. *Proc. Am. Assoc. Cancer Res.* 32:390, 1991.

80. Humphrey, P.A., Gangarosa, L.M., Lund-Johansen, M., Bjerkvig, R., Kwatra, M., Wong, A., Bigner, S.H., Archer, G.E., Friedman, H.S., Vogelstein, B., Laerum, O.-D., and Bigner, D.D.: Deletion mutant EGF receptor in malignant human glioma (MHG): effect of the mutation on receptor function. Presentation: American Association for Cancer Research, 1991. *Proc. Am. Assoc. Cancer Res.* 32:2, 1991.

81. Skapek, S.Z., VanDellen A.F., Postels, D.G., and Friedman, H.S.: Glutathione depletion in normal nude mouse tissues after the administration of buthionine sulfoximine.

Presentation: Uniformed Services Pediatric Research Seminar, 1991.

82. Levine, E.S., Friedman, H.S., Griffith, O.W., Colvin, O.M., Lieberman, M.: Glutathione modulation affects 4-hydroperoxycyclophosphamide cardiotoxicity. *FASEB J.* A554, 1991.

83. Brown, M.T., Friedman, H.S., Oakes, W.J., Vedanarayanan, V., and Schold, S.C.:

Clinically aggressive pilocytic astrocytomas. Presentation: American Association of Neurology, 1991. *Neurology* 41(3) (Suppl. 1):383, 1991.

84. Duffner, P., Horowitz, M., Krischer, J., Kun, L., Cohen, M., Friedman, H., Sanford, A.,

Burger, P., Freeman, C., and James, H.: Postoperative chemotherapy and delayed RT in infants with brain tumors: a pediatric oncology group study. Presentation: Child Neurology Society, 1991. *Ann. Neurol.* 30:484, 1991.

85. Cohen, M., Duffner, P., Horowitz, M., Friedman, H., and Kun, L.: Cisplatin ototoxicity in patients under 3 years of age (a pediatric oncology group study). Presentation: Child Neurology Society, 1991. *Ann. Neurol.* 30:459, 1991.

86. Fuchs, H.E., Archer, G.E., Schuster, J.M., Zalutsky, M.R., Colvin, O.M., Bigner, S.H.,

Muhlbaier, L.H., Friedman, H.S., and Bigner, D.D.: A nude rat model of neoplastic meningitis for evaluation of intrathecal chemotherapy and monoclonal antibody (MAb)-based radiotherapy. Presentation: Ninth International Conference on Brain Tumor Research and Therapy. *J. Neurooncol.* 12:278, 1992.

87. Humphrey, P.A., Wong, A.J., Gangarosa, M., Archer, G.E., Lund-Johansen, M., Bjerkvig,

R., Laerum, O.-D., Friedman, H.S., and Bigner, D.D.: Deletion-mutant epidermal growth factor receptors (EGFR) in human glioblastomas. Presentation: Ninth International Conference on Brain Tumor Research and Therapy. *J. Neurooncol.* 12:255, 1992.

88. Friedman, H.S., Kun, L.E., and the POG Brain Tumor Core Committee: Pediatric

Ongology Group (POG) Brain Tumor Progress Report. Presentation: Ninth International Conference on Brain Tumor Research and Therapy. *J. Neurooncol.* 12:239, 1992.

89. Duffner, P., Horowitz, M., Krischer, J., Kun, L., Cohen, M., Friedman, H., Sanford, A., Burger, P., Freeman, C., James, H., and the Brain Tumor Committee of POG:

67

Postoperative chemotherapy and delayed RT in infants with brain tumors: a Pediatric Oncology Group Study. Presentation: Ninth International Conference on Brain Tumor Research and Therapy. *J. Neurooncol.* 12:249, 1992.

90. Strong, J.A., Brown, M.T., Hatten, H.P., Jr., and Friedman, H.S.: Values of neuroimaging for predicting clinical behavior of pilocytic astrocytomas. *Am. J. Neuroradiol.*, in press, 1992.

91. Friedman, H.S., Lachance, D., Brown M.T., Fredericks, R., and Schold, S.C., Jr.: Dose escalation of cyclophosphamide (CPA) with recombinant human granulocyte macrophage colony stimulating factor (rhu-GM-CSF) in treatment of recurrent or persistent central nervous system (CNS) neoplasms. Presentation: American Association of Neurology. *Neurology* 42 (Suppl. 3):343, 1992.

92. Fredericks, R., Schifter, T, Hoffman, J.M., Friedman, H.S., Friedman, A.H., Coleman, R.E., Brown, M.T., and Schold, S.C., Jr.: FDG-PET imaging in meningiomas. Presentation: American Association of Neurology. *Neurology* 42 (Suppl. 3):235, 1992.

93. Gravatt, L.C., Richter, C., Friedman, H.S., and Kurtzberg, J.: Establishment of a model of a human stem cell leukemia in severe combined immunodeficient mice. Presentation: American Association for Cancer Research. *Proc. Am. Assoc. Cancer Res.* 33:557, 1992.

94. Friedman, H.S., Archer, G.E., Schuster, J.M., Fuchs, H.E., Bigner, S.H., and Bigner, D.D.: Intrathecal melphalan therapy in an athymic rat model of neoplastic meningitis. Presentation: American Association for Cancer Research. *Proc. Am. Assoc. Cancer Res.*

33:405, 1992.

95. Castellino, S., Elion, G.B., Griffith, O.W., Dewhirst, M., Kurtzberg, J., Cattley, R., Bigner, D.D., and Friedman, H.S.: Development and use of a model of melphalan-induced gastrointestinal toxicity in mice. Presentation: American Association for Cancer Research. Proc. Am. Assoc. Cancer Res. 33:426, 1992.

96. Schuster, J.M., Friedman, H.S., Colvin, O.M., Archer, G.E., Fuchs, H.E., and Bigner, D.D.: Intraarterial therapy of glioma xenografts with 4-HC. Presentation: American Association for Cancer Research. Proc. Am. Assoc. Cancer Res. 33:405, 1992.

97. Castellino, S., Friedman, H.S., Elion, G.E., Ong, E., Bigner, D.D., and Dewhirst, M.: Flunarizine enhancement of melphalan activity against rhabdomyosarcoma xenografts. Presentation: American Association for Cancer Research. Proc. Am. Assoc. Cancer Res. 33:426, 1992.

98. Nicholson, S., Mazawski, C., Vezina, G., Fitz, C., Phillips, P., Friedman, H.S., Hockenberger, B., Halperin, E., Ryan, J., and Packer, R.J.: Prognostic significance of magnetic resonance findings in children with brainstem gliomas. Ann. Neurol., in press, 1993.

99. Kurtzberg, J., Chaffee, S., Blow, B., Friedman, H.S., and Graham, M.L.: Acceleration of myeloid and platelet recovery after myeloblastive chemotherapy with G-CSF primed
68

peripheral stem cell augmentation of bone marrow transplantation in pediatric patients with malignant solid tumors. Blood 80 (Supp 1): 527a, 1992.

100. Rich, J.N., Elion, G.B., Griffith, O.W., Groothuis, D.R., Colvin, O.M., Wallner, D., Hilton, J.H., Bigner, D.D., and Friedman, H.S.: L-amino acid oxidase modulation of intracranial melphalan delivery. Presentation: American Association for Cancer Research. Proc. Am. Assoc. Cancer Res. 34:299, 1993.

101. Archer, G.E., Schuster, J.M., Fuchs, H.E., Bigner, S.H., McLendon, R.E., Guaspari, A., Bigner, D.D., and Friedman, H.S.: Multiple versus single dose melphalan in the treatment of neoplastic meningitis. Presentation: American Association for Cancer Research. Proc. Am. Assoc. Cancer Res. 34:269, 1993.
102. Friedman, H.S., Ochs, J., Finlay, J., Geyer, R., Arndt, C., Cohen, B., Phillips, P., Strauss, L.C., Hochberg, F., Schold, S.C., Bigner, D.D., and Colvin, O.M.: Phase I trial of intrathecal 4-hydroperoxycyclophosphamide for neoplastic meningitis. Presentation: American Association for Cancer Research. Proc. Am. Assoc. Cancer Res. 34:269, 1993.
103. Schuster, J.M., Friedman, H.S., Archer, G.E., Fuchs, H.E., McLendon, R.E., Colvin, O.M., and Bigner, D.D.: Intra-arterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide. Presentation: American Association for Cancer Research. Proc. Am. Assoc. Cancer Res. 34:269, 1993.
104. Friedman, H.S., Houghton, P.J., Schold, S.C., Jr., and Bigner, D.D.: Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against CNS xenografts. Presentation: American Association for Cancer Research. Proc. Am. Assoc. Cancer Res. 34:422, 1993.
105. Batra, S.K., Wei, S., McLendon, R.E., Friedman, H.S., Fuchs, H.E., Bigner, S.H., and Bigner, D.D.: Loss of heterozygosity of chromosome 17p and TP53 mutations in medulloblastomas. Proc. Am. Assoc. Cancer Res. 34:511, 1993.
106. Archer, G.E., Schuster, J.M., Fuchs, H.E., Guaspari, A., Bigner, D.D., Friedman, H.S., and McLendon, R.E.: Neuropathology of multiple versus single dose intrathecal melphalan in rats. J. Neuropathol. Exp. Neurol. 52:298, 1993.
107. McLendon, R.E., Batra, S.K., Friedman, H.S., Rasheed, B.K.A., Bigner, D.D., and Bigner, S.H.: Expression of *c-myc* in medulloblastoma xenografts. J. Neuropathol. Exp. Neurol. 52:267, 1993.
108. Levine, E.S., Moore, E.S., Friedman, H.S., and Lieberman, M.: Ion transporters in

cyclophosphamide-induced cardiotoxicity. *FASEB J.* 7(3):A112, 1993.

109. Pegg, A.E., Dolan, M.E., Friedman, H.S., and Moschel, R.C.: Inhibition of O6-alkylguanine-DNA alkyltransferase as a means to enhance the effectiveness of chemotherapeutic alkylating agents. Presentation: American Association for Cancer Research. *Proc. Am. Assoc. Cancer Res.* 34:565, 1993.

110. Tien, R.D., Moghrabi, A., and Friedman, H.: Clinical significance of contrast enhanced MR in brainstem glioma. Presentation: American Society of Neuroradiology, 1993.

69

111. Graham, M.L., Chaffee, S., Kurtzberg, J., Guaspari, A., and Friedman, H.S.: A phase I-II study of high-dose melphalan and cyclophosphamide with autologous bone marrow transplantation. *Proc. Am. Soc. Clin. Oncol.* 12:183, 1993.

112. Duffner, P., Cohen, M., Sanford, R., Horowitz, M., Krischer, J., Burger, P., Friedman, H., and Kun, L.: Lack of efficacy of postoperative chemotherapy and radiation in very young children with pineoblastoma. *Ann. Neurol.* 34:471, 1993.

113. Packer, R.J., Boyett, J., Zeltzer, P., Deutsch, M., Kun, L., Thomas, D., Krischer, J., Finlay, J., Allen, J.C., Friedman, H., and Bleyer, W.A.: Results of prospective randomized trials for children with primitive neuroectodermal tumors-medulloblastomas. *Ann. Neurol.* 34:480, 1993.

114. Duffner, P., Kun, L., Krischer, J., Cohen, M., Burger, P., Sanford, R., Friedman, H., and Horowitz, M.: Postoperative chemotherapy and delayed radiation in infants with malignant gliomas: a Pediatric Oncology Group study. *Ann. Neurol.* 34:480-481, 1993.

115. Brown, M.T., Friedman, H.S., Vick, N.A., Dropcho, E.J., MacDonald, D.R., Piepmeyer, J.M., Fredericks, R.K., and Bigner, D.D.: Clinical studies of the CNS Cancer Consortium (CNSCC). Presentation: Tenth International Conference on Brain Tumour Research and Therapy, Stalheim, Norway, 1993.

116. McLendon, R.E., Bradley, A., Parisi, J.E., Scheithauer, B.W., Felsberg, G., and Friedman, H.S.: Composite neuroblastoma-malignant glioma. Presentation: Meeting of the United States Canadian Academy of Pathology, San Francisco, March 13-15, 1994.

117. Batra, S.K., Castelino-Prabhu, S., Wikstrand, C.J., Friedman, H.S., Shibuya, M., and Bigner, D.D.: Mutant epidermal growth factor receptor gene: EGF independent transformation. Presentation: American Association for Cancer Research. Proc. Am. Assoc. Cancer Res. 35:584, 1994.

118. Archer, G., Dolan, E., DeLeon, M., Pegg, A., Moschel, R., Bigner, D., and Friedman, H.: Biodistribution and metabolism of O6-benzylguanine after intrathecal administration in athymic rats. Proc. Am. Assoc. Cancer Res. 35:355, 1994.

119. Aaron, R.H., Elion, G.B., Colvin, O.M., Graham, M., Bigner, D.D., and Friedman, H.S.: Busulfan therapy of central nervous system xenografts in athymic mice. Presentation: American Association for Cancer Research. Proc. Am. Assoc. Cancer Res. 35:298, 1994.

120. Friedman, H.S., Dolan, M.E., Kaufmann, S.H., Colvin, O.M., Griffith, O.W., Moschel, R.C., Schold, S.C., Bigner, D.D., and Ali-Osman, F.: Elevated DNA polymerase α , DNA polymerase β , and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. Presentation: American Association for Cancer Research. Proc. Am. Assoc. Cancer Res. 35:364, 1994.

121. Kurpad, S.N., Archer, G.E., McLendon, R.E., Guaspari, A., Friedman, H.S., and Bigner, D.D.: Treatment of intracranial human glioma xenografts in athymic rats with intra-arterial melphalan. Presentation: American Association for Cancer Research. Proc. Am. Assoc. Cancer Res. 35:298, 1994.

70

122. Dolan, M.E., Pegg, A.E., Moschel, R.C., Vishnuvajjala, B.R., Flora, K.P., Grever, M.R., and Friedman, H.S.: Biodistribution and effectiveness of O6-benzylguanine administered in

PEG 400 or cremophor vehicles in human brain tumor xenografts. Presentation: American Association for Cancer Research. Proc. Am. Assoc. Cancer Res. 35:319, 1994.

123. Mahoney, D., Strother, D., Bowen, T., Ghim, T., Pick, T., Wall, D., Yu, L., and Friedman, H.: High dose melphalan (MELP) and cyclophosphamide (CTX) with autologous bone marrow rescue (ABMR) for recurrent/progressive malignant brain tumors (BT) in children: a phase I-II pediatric oncology group study. Proc. Am. Soc. Clin. Oncol. 13:174, 1994.

124. Rodman, J., Tonda, M., Murry, D., Petros, W., Heideman, R., Kuttesch, J., and Friedman, H.: Systemic carboplatin (CP) pharmacokinetics (PK) and platinum-DNA (PtDNA) adduct formation in pediatric cancer patients. Proc. Am. Soc. Clin. Oncol. 13:140, 1994.

125. McLendon, R.E., Bentley, R.C., Bigner, S.H., Rasheed, B.K.A., Trojanowski, J.Q., Bigner, D.D., and Friedman, H.S.: Production and characterization of two childhood ependymoma xenografts. XIIth International Congress of Neuropathology, Ottawa, Canada, 1994.

126. McCowage, G., Friedman, H.S., and Fuchs, H.E.: Treatment of childhood high grade glioma with high dose cyclophosphamide. Presentation: American Association of Neurological Surgeons, St. Louis, MO, 1994.

127. Kurpad, S., Archer, G., Friedman, H.S., Bigner, D.D., and Fuchs, H.E.: Treatment of intracranial human glioma xenografts in athymic mice with intra-arterial melphalan. Presentation: Congress of Neurological Surgeons, Chicago IL, 1994.

128. McCowage, G., Friedman, H.S., and Fuchs, H.E.: Cyclophosphamide therapy of pilocytic astrocytoma metastatic to the leptomeninges. Presentation: Congress of Neurological Surgeons, Chicago, IL, 1994.

129. Cohen, M.E., Mahoney, D.H., Jr., Duffner, P.K., Gemer, L., James, H.E., Langston, J.W., Fontanesi, J., and Friedman, H.S.: Evaluation of optic pathway tumors: natural history and treatment. Pediatric Oncology Group Study (POG). Annal. Neurol. 36:505, 1994.

130. Bigner, D.D., Brown, M.T., Friedman, A.F., Friedman, H.S., McLendon, R.E., Bigner,

S.H., Zalutsky, M.R., Schold, S.C., Jr., and Coleman, R.E.: Phase I studies of radiolabeled 131I-Me1-14 F(ab')₂ monoclonal antibody in patients with malignant melanoma brain tumors or leptomeningeal metastases: Preliminary results. American Association of Neurological Surgeons. Neurology 45(Suppl.):A191, 1995.

131. Batra, S.K., McLendon, R.E., Friedman, H.S., Bigner, D.D., and Bigner, S.H.: Infrequent mutations of P53 gene in medulloblastoma: single-strand confirmation polymorphism (SSCP) analysis, sequencing, and immunohistochemistry. Presentation: Sixth International Conference on Pediatric Neuro-Oncology, Marseilles, France, 1995.

132. Thomas, P.R.M., Deutsch, M., Krischer, J.P., Boyett, J., Kun, L.E., Finlay, J.L., Friedman, H.S., Packer, R.J., Vrett, T.J., and Hammond, G.D.: Further evidence of superiority of standard dose compared with reduced dose neuraxis irradiation in low stage

71

medulloblastoma. Presentation: Int. Congress of Radiation Oncology. Int. J. Radiat. Oncol. Biol. Phys. 24:125, 1995.

133. McLendon, R.E., Archer, G.E., Schuster, J.M., Fuchs, H.E., Guaspari, A., Bigner, D.D., and Friedman, H.S.: Multiple vs. single dose intrathecal melphalan: toxicity and efficacy studies in rats. Tenth International Conference on Brain Tumour Research and Therapy, Stalheim, Norway, 1993. J. Neurooncol. 24:138, 1995.

134. Batra, S.K., McLendon, R.E., Friedman, H.S., Bigner, D.D., and Bigner, S.H.: Suppressor genes in medulloblastomas. Tenth International Conference on Brain Tumour Research and Therapy, Stalheim, Norway. J. Neurooncol. 24:195, 1995.

135. McLendon, R.E., Batra, S.K., Friedman, H.S., Rasheed, B.K.A., Bigner, D.D., and Bigner, S.H.: *C-myc* amplification in medulloblastoma biopsies (Bxs) and xenografts (Xgs). Tenth International Conference on Brain Tumour Research and Therapy, Stalheim, Norway. J. Neurooncol. 24:134, 1995.

136. Friedman, H.S., and Kun, L.E.: Pediatric oncology group brain tumor program, 1993. Presentation: Tenth International Conference on Brain Tumor Research and Therapy, Stalheim, Norway, 1993. *J. Neurooncol.* 24:102, 1995.
137. Bigner, D.D., Coleman, R.E., Brown, M., Friedman, H.S., and Zalutsky, M.R.: Current status of radiolabeled monoclonal antibodies (MAbs) for brain tumor (BT) and neoplastic meningitis (NM) treatment. Presentation: Tenth International Conference on Brain Tumour Research and Therapy, Stalheim, Norway, 1993. *J. Neurooncol.* 24:100, 1995.
138. Jones, D.N., Brizel, D.M., Charles, H.C., Dewhirst, M.W., Friedman, H.S., McCowage, G., Prescott, D.M., Sostman, H.D., and Coleman, R.E.: Monitoring of response to neoadjuvant therapy of soft tissue and musculoskeletal sarcomas using F18-FDG PET. *J. Nucl. Med.*, 1995.
139. Hoffman, J.M., Lowe, V.J., Friedman, H.S., Harris, L., and Coleman, R.E.: Metabolic characterization of pediatric primary brain tumors using FDG-PET. *J. Nucl. Med.*, 1995.
140. Cohen, M.E., Langston, J.W., Backstrom, J., Duffner, P.K., Friedman, H.S., Mahoney, D.H., Jr., Gemer, L., James, H.E., and Fontanesi, J.: Neuroimaging characteristics of progressive optic pathway tumors: Pediatric Oncology Group Study. *Pediatric Neurology*, 11:132, 1995.
141. Cohen, M.E., Mahoney, J., Gemer, L., James, H., Duffner, P., Fontanesi, J., Krischer, J., and Friedman, H.: Phase II study of carboplatin (CBDCA) in the treatment of children with progressive optic pathway tumors - a preliminary report from POG. Presentation: Vth International Symposium on Pediatric Neuro-oncology, Houston, TX. *Pediatric Neurosurgery*, 1995.
142. Bigner, D.D., Brown, M., Coleman, R.E., Friedman, A.H., Friedman, H.S., McLendon, R.E., Bigner, S.H., Zhao, X.-G., Wikstrand, C.J., Pegram, C.N., Kerby, T., and Zalutsky, M.R.: Phase I treatment study of locoregionally administered ¹³¹I-labeled antitenascin

81C6 in patients with malignant gliomas. Presentation: American Association for Cancer Research. Proc. Am. Assoc. Cancer Res. 36:482, 1995.

143. Batra, S.K., Castelino-Prabhu, S., Wikstrand, C.J., Zhu, X., Humphrey, P.A., Friedman, H.S., and Bigner, D.D.: Functional analysis of a mutant human epidermal growth factor receptor (EGFRvIII). Presentation: American Association for Cancer Research. Proc. Am. Assoc. Cancer Res. 36:170, 1995.

144. Kurpad, S.N., Archer, G.E., Colvin, O.M., Bullock, N., Guaspari, A., Bigner, D.D., and Friedman, H.S.: Improved therapeutic efficacy of IA melphalan administered with IP BSO in the treatment of intracranial human glioma xenografts. Presentation: American Association for Cancer Research. Proc. Am. Assoc. Cancer Res. 36:315, 1995.

145. Dong, Q., Colvin, M.E., Colvin, O.M., Bigner, D.D., Modrich, P., and Friedman, H.S.: Formation of a single phosphoramidate mustard-induced DNA interstrand cross-link in an oligonucleotide duplex. Presentation: American Association for Cancer Research. Proc. Am. Assoc. Cancer Res. 36:357, 1995.

146. Moynihan, M.K., Elion, G.B., Colvin, O.M., Ali-Osman, F., Bigner, D.D., and Friedman, H.S.: Treatment of rhabdomyosarcoma xenografts with melphalan and aphidicolin glycinate and/or ddC. Presentation: American Association for Cancer Research. Proc. Am. Assoc. Proc. Am. Assoc. Cancer Res. 36:374, 1995.

147. Moynihan, M.K., Elion, G.B., Griffith, O.W., Pegram, C., Colvin, O.M., Wellner, D., Bigner, D.D., and Friedman, H.S.: Treatment of intracranial xenografts with melphalan, L-amino acid oxidase and anti-LOX antibody. Presentation: American Association for Cancer Research. Proc. Am. Assoc. Proc. Am. Assoc. Cancer Res. 36:374, 1995.

148. Bigner, D.D., Archer, G.E., McLendon, R.E., Friedman, H.S., Fuchs, H.E., Pai, L.H., and Pastan, I.H.: Therapeutic efficacy of intrathecal immunotoxins in a rat model of neoplastic

meningitis. Presentation: American Association for Cancer Research. Proc. Am. Assoc. Cancer Res. 36:487, 1995.

149. Freeman, C.R., Bourgooin, P., Sanford, R.A., Cohen, M.E., Friedman, H.S., and Kun, L.E.: Long term survivors of hyperfractionated radiotherapy (HRT) in brain stem tumors in children: clinical characteristics and treatment-related toxicities. Presentation: International Society of Paediatric Oncology (SIOP) XXVIIth Meeting, 1995.

150. Needle, M.N., Molloy, P.T., Packer, R., Friedman, H.S., Cohen, B.H., Jakacki, R., Korf, B., Vaughan, S.N., and Phillips, P.C.: A Phase II randomized trial of 13-cis retinoic acid (CRA) and interferon ALFA-2A (IFN) in the treatment of plexiform neurofibroma (PN) in patients with neurofibromatosis Type 1 (NF1). Presentation: Society of Pediatric Research, 1995. Ped. Res. 37 151A, 1995.

151. Duffner, P.K., Kun, L., Krischer, J., Cohen, M., Sanford, R., Burger, P., Horowitz, M., and Friedman, H.S.: Prognostic factors in infants with ependymomas. Presentation: Eleventh International Conference on Brain Tumor Research and Therapy, Silverado Napa, CA, 1995.

73

152. Graham, M.L., Chaffee, S., Casey, J.R., Olson, J.F., Daeschner, C.W., Friedman, H.S., and Kurtzberg, J.A.: Busulfan/melphalan as preparative therapy for bone marrow transplantation. Presentation: Marrow Transplantation in Children, Hilton Head, SC, 1995.

153. McCowage, G.B., Longee, D., Fuchs, H., and Friedman, H.S.: Treatment of high-grade gliomas and metastatic pilocytic astrocytomas with high-dose cyclophosphamide. Presentation: American Society Clinical Oncology. Proc. Am. Soc. Clin. Oncol. 14:149, 1995.

154. Thomas, P.R.M., Deutsch, M., Mulhern, R., Stehbens, J., Krischer, J.P., Boyett, J.M., Shuster, J.J., Linggood, R.M., Kun, L.E., Finlay, J.L., Friedman, H.S., Packer, R.J., Aronin,

P.A., Albright, L.A., Vietti, T.J., and Hammond, G.D.: Reduced dose vs. standard dose neuraxis irradiation in low stage medulloblastoma: The POG and CCG Study. *Med. Pediatr. Oncol.* 25:277, 1995.

155. Freeman, C.R., Bourguin, P., Sanford, R.A., Cohen, M.E., Friedman, H.S., and Kun, L.E.: Long term survivors of hyperfractionated radiotherapy (HRT) in brain stem tumors in children: clinical characteristics and treatment-related toxicities. *Pediatric Oncology Group Study (POG)*. *Med. Pediatr. Oncol.* 25:235, 1995.

156. Duffner, P.K., Cohen, M.E., Kun, L., Krischer, J., Sanford, R., Burger, P., Horowitz, M., and Friedman, H.: Prognostic factors in infants with ependymomas. *Pediatric Oncology Group Study (POG)*. *Ann. Neurol.* 38:546, 1995.

157. McLendon, R.E., Friedman, H.S., Longee, D.C., Fuchs, H.E., and Hessler, R.B.: Synchronous ependymo-gliomas. *J. Neuropathol. Exp. Neurol.*, 54:422, 1995.

158. Longee, D.C., Ashley, D.M., Meier, L.L., Fuchs, H.E., and Friedman, H.S.: Activity of low-dose oral VP-16 in recurrent medulloblastoma. Presentation: Eleventh International Conference on Brain Tumor Research and Therapy, Silverado Napa, CA, 1995. *J. Neurooncol.* 28:96, 1996.

159. McLendon, R., Bruner, J.M., Friedman, H.S., Brown, M.T., Bigner, D.D., Rasheed, B.K.A., and Bigner, S.H.: Asynchronous primary brain tumors. Presentation: Eleventh International Conference on Brain Tumor Research and Therapy, Silverado-Napa, CA, 1995. *J. Neurooncol.* 28:99, 1996.

160. Brown, M.T., Coleman, R.E., Friedman, A.H., Friedman, H.S., McLendon, R.E., Zalutsky, M.R., and Bigner, D.D.: 131-Iodine (¹³¹I) labeled anti-tenascin monoclonal antibody (MAb) 81C6 treatment of patients with brain tumors (BT) and leptomeningeal metastases (LM). Presentation: Eleventh International Conference on Brain Tumor Research and Therapy, Silverado-Napa, CA, 1995. *J. Neurooncol.* 28:66, 1996.

161. Brown, M.T., Coleman, R.E., Friedman, A.H., Friedman, H.S., McLendon, R.E., Zalutsky, M.R., and Bigner, D.D.: 131-Iodine (¹³¹I) labeled Me1-14 F(ab')₂ monoclonal antibody (MAb) treatment of patients with brain tumors (BT) and leptomeningeal metastases (LM). Presentation: Eleventh International Conference on Brain Tumor Research and Therapy, Silverado-Napa, CA, 1995. *J. Neurooncol.* 28:66, 1996.

74

162. Longee, D.C., McCowage, G.B., Ashley, D.M., Moghrabi, A., Fuchs, H.E., Friedman, H.S., and Bigner, D.D.: Phase II study of high-dose cyclophosphamide in malignant tumors of the CNS. Presentation: Eleventh International Conference on Brain Tumor Research and Therapy, Silverado Napa, CA, 1995. *J. Neurooncol.* 28:72, 1996.

163. Kurpad, S.N., Dolan, M.E., Archer, G.E., Moschel, R.C., McLendon, R.E., Bigner, D.D., and Friedman, H.S.: Selective modulation of nitrosourea resistance by intraarterial O⁶-benzylguanine. Presentation: Eleventh International Conference on Brain Tumor Research and Therapy, Silverado Napa, CA, 1995. *J. Neurooncol.* 28:95, 1996.

164. Batra, S.K., Koo, J.S., McLendon, R.E., Friedman, H.S., Bigner, D.D., and Bigner, S.H.: Molecular markers of prognostic significance in human medulloblastomas. Presentation: Eleventh International Conference on Brain Tumor Research and Therapy, Silverado Napa, CA, 1995. *J. Neurooncol.* 28:81, 1996.

165. Vaidyanathan, G., Friedman, H.S., and Zalutsky, M.R.: Localization of *meta*-[²¹¹At]astatobenzylguanidine (MABG) in nude mice bearing SK-N-SH human neuroblastoma xenografts. Presentation: International Symposium on Advances in Neuroblastoma Research, 1996.

166. Coleman, R.E., Friedman, A.F., Friedman, H.S., Perry, J.R., McLendon, R.E., Bigner, S.H., Zalutsky, M.R., Schold, S.C., Jr., and Bigner, D.D.: Phase I studies of radiolabeled ¹³¹I 8136 anti-tenascin monoclonal antibody in patients with recurrent cystic gliomas or

surgically created brain tumor resection cavities: preliminary results. Presentation: Annual Meeting of the American Association of Neuropathologists, 1996.

167. Vaidyanathan, G., Friedman, H.S., Keir, S.T., and Zalutsky, M.R.: Meta-[211At]astatobenzylguanidine (MAbs): In vivo evaluation in an athymic mouse human neuroblastoma xenograft model. Presentation: Society of Nuclear Medicine, 1996.

168. Archer, G.E., Sampson, J.H., McLendon, R.E., Fuchs, H.E., Colvin, O.M., McCulloch, W., Parikh, I., Clement, M., Bigner, D.D., and Friedman, H.S.: Treatment of neoplastic meningitis with intrathecal Spartaject™-busulfan. Presentation: American Association for Cancer Research, 1996. Proc. Am. Assoc. Cancer Res. 37:298, 1996.

169. Hare, B.H., Elion, G.B., Ali-Osman, F., Colvin, O.M., Bigner, D.D., and Friedman, H.S.: Characterization of a busulfan-resistant human glioblastoma multiforme (GBM). Presentation: American Association for Cancer Research, 1996. Proc. Amer. Assoc. Cancer Res. 37:320, 1996.

170. Hare, C.B., Elion, G.B., Houghton, P., Houghton, J., Keir, S., Marcelli, S., Bigner, D.D., and Friedman, H.S.: Treatment of central nervous system xenografts with CPT-11. Presentation: American Association for Cancer Research, 1996.. Proc. Amer. Assoc. Cancer Res. 37:433, 1996.

171. Levin, V., Yung, A., Prados, M., Poisson, M., Rosenfeld, S., Brada, M., Friedman, H., Albright, R., Olson, J., Bruner, J., Yue, N., Dugan, M., and Temodal Brain Tumor Group: A Phase II study of temodal (TEM) in patients (PTS) with anaplastic astrocytoma (AA) at first relapse (FR). Presentation: American Society of Clinical Oncology, 1997. Proc. Am. Soc. Clin. Oncol. 16:384a, 1997.

172. Moghrabi, A., Friedman, H.S., Brugger, C., Kerby, T. and Longee, D.: Carboplatin for progressive low-grade glioma. Proc. Am. Soc. Clin. Oncol. 16:405a, 1997.

173. Dong, Q., Bullock, N., Johnson, S., Colvin, O.M., Bigner, D.D., Modrich, P., and Friedman, H.S.: A different DNA repair pathway confers drug resistance to 4-hydroperoxycyclophosphamide (4-HC) in human medulloblastoma D283. Presentation: American Association for Cancer Research, 1997. Proc. Amer. Assoc. Cancer Res. 38:523, 1997.

174. Friedman, H.S., Johnson, S., Dong, Q., Schold, S.C., Rasheed, A., Bigner, S., Ali-Osman, F., Dolan, M.E., Colvin, O.M., Houghton, P., Germaine, G., Drummond, J.T., Keir, S., Marcelli, S., Bigner, D.D., and Modrich, P.: Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Presentation: American Association for Cancer Research, 1997. Proc. Amer. Assoc. Cancer Res. 38:522, 1997.

175. Coggins, C., Elion, G.B., Keir, S., Marcelli, S., Bigner, D.D., Houghton, P.J., and Friedman, H.S.: CPT-11 plus alkylator combination therapy of central nervous system tumor xenografts. Presentation: American Association for Cancer Research, 1997. Proc. Amer. Assoc. Cancer Res. 38:76, 1997.

176. Song, D., Kupczyk-Subotkowska, L., Siahaan, T., Basile, A.S., Friedman, H.S., and Gallo, J.M.: A novel peripheral benzodiazepine receptor ligand-melphalan conjugate drug delivery system. Presentation: American Association for Cancer Research, 1997. Proc. Amer. Assoc. Cancer Res. 38:432, 1997.

177. Duffner, P., Horowitz, M., Krischer, J., Cohen, M., Burger, P., Friedman, H., and Kun, L.: Second malignancies in young children following treatment with POG 8633 (prolonged postoperative chemotherapy and delayed RT for malignant brain tumors in children < 3 years of age). Presentation: American Society of Clinical Oncology, 1997. Proc. Amer. Soc. Clin. Oncol. 16:524a, 1997.

178. Mandel, L., Kadota, R., Douglass, E.C., Fontanesi, J., Freeman, C., Cohen, M., Kovnar, E., Burger, P., Sanford, R.A., Kepner, J., Friedman, H., and Kun, L.: Is it time to rethink the

role of hyperfractionated radiotherapy in the management of children with newly-diagnosed brainstem glioma: results of a Pediatric Oncology Group Phase III trial comparing conventional vs hyperfractionated radiotherapy. Presentation: American Society of Therapeutic Radiation Oncology (ASTRO), 1997.

179. Mandel, L., Kadota, R., Douglass, E.C., Fontanesi, J., Freeman, C., Cohen, M., Kovnar, E., Burger, P., Sanford, R.A., Kepner, J., Friedman, H., Kun, L., and the Pediatric Oncology Group (POG): Results of a Pediatric Oncology Group Phase III trial comparing conventional vs hyperfractionated radiotherapy in children with brainstem glioma (BSG). Presentation: International Society of Paediatric Oncology (SIOP) XXVIXth Meeting, 1997.

76

180. Akabani, G., Friedman, A.H., Friedman, H.S., Coleman, R.E., Brown, M.T., Thorstad, W., Zalutsky, M.R., and Bigner, D.D.: Dosimetry of patients with recurrent brain tumors treated with ¹³¹I-labeled anti-tenascin monoclonal antibody 81C6 via surgically-created resection cavities. Presentation: Therapeutic Antibody Tech 97, 1997.

181. Friedman, H.S., Johnson, S., Dong, Q., Bullock, N., Kilborn, C., Dolan, E., Bigner, D.D., Modrich, P., and Colvin, O.M.: Multiple mechanisms of resistance to 4-hydroperoxycyclophosphamide in the human medulloblastoma cell line D-283 MED (4-HCR). Presentation: Society for Neuro-Oncology, 1997. Presented: Second Annual Meeting of the Society for Neuro-Oncology, Charlottesville, VA, October 31, 1997.

182. Friedman, H.S., Johnson, S., Dong, Q., Schold, S.C., Rasheed, A., Bigner, S., Ali-Osman, F., Dolan, M.E., Colvin, O.M., Houghton, P., Germaine, G., Drummond, J.T., Keir, S., Marcelli, S., Bigner, D.D., and Modrich, P.: Mismatch repair deficiency in central nervous system tumors. Presented: Second Annual Meeting of the Society for Neuro-Oncology, Charlottesville, VA, October 31, 1997.

183. Friedman, H.S., Johnson, S., Dong, Q., Schold, S.C., Rasheed, A., Bigner, S., Ali-Osman, F., Dolan, M.E., Colvin, O.M., Houghton, P., Germaine, G., Drummond, J.T., Keir, S., Marcelli, S., Bigner, D.D., and Modrich, P.: Mismatch repair deficiency in glioblastoma. 12th International Conference on Brain Tumor Research and Therapy, Oxford, U.K., September 20, 1997. *J. Neurooncol.* 35:S51, 1997.
184. Pegg, A.E., Dolan, M.E., Moschel, R.C., and Friedman, H.S.: Use of alkyltransferase inhibitors to enhance chemotherapy with BCNU or temozolomide. Presentation: 12th International Conference on Brain Tumor Research and Therapy, Oxford, U.K., September 20, 1997. *J. Neurooncol.* 35:S34, 1998.
185. Kun, L., Friedman, H., Kadota, R., and the Pediatric Oncology Group: Studies in the pediatric oncology group, 1997. Presentation: 12th International Conference on Brain Tumor Research and Therapy, Oxford, U.K., September 20, 1997. *J. Neurooncol.* S52, 1998.
186. Friedman, H.S., Dugan, M., Kerby, T., Henry, A., Lovell, M., Rasheed, K., Haglund, M., and Friedman, A.: Temodal • therapy of newly diagnosed high grade glioma. 12th International Conference on Brain Tumor Research and Therapy, Oxford, U.K., September 20, 1997. *J. Neurooncol.* 35:S51, 1998.
187. Mulne, A.F., Ducore, J.M., Elterman, R., Friedman, H.S., Krischer, J.P., Kun, L.E., Shuster, J.J., Kadota, R.P., and the Pediatric Oncology Group: Methotrexate (MTX) for recurrent or progressive childhood brain tumors - a Pediatric Oncology Group (POG) Study. 12th International Conference on Brain Tumor Research and Therapy, Oxford, U.K., September 20, 1997. *J. Neurooncol.* 35:S31, 1998.
188. Levin, V., Yung, A., Prados, M., Poisson, M., Rosenfeld, S., Brada, M., Friedman, H., Albright, R., Olson, J., Bruner, J., Yue, N., Sugano, D., Osoba, D., and Dugan, M.: Temodal® (temozolomide) at first relapse in anaplastic astrocytoma patients. 12th

International Conference on Brain Tumor Research and Therapy, Oxford, U.K., September 20, 1997. *J. Neurooncol.* 35:S51, 1998.

189. McLendon, R., Friedman, H., Fuchs, H. and Bigner, S.: Diagnostic markers in medulloblastoma. *J. Neurooncol.* 35:S30, 1998.

190. Friedman, H.S., Dugan, M., Kerby, T., Henry, M., Lovell, M., Rasheed, K., Haglund, M., and Friedman, A.: Temodal® therapy of newly diagnosed high grade glioma. Presentation: Society for Neuro-Oncology, 1997. *J. Neurooncol.*, 1998.

191. Friedman, H.S., Coleman, R.E., Friedman, A.H., Akabani, G., Brown, M.T., Fuchs, H.E., McLendon, R.E., Thorstad, W., Xhao, Z.G., Wikstrand, C.J., Pegram, C.N., Herndon II, J.E., Vick, N.A., Paleologus, N., Zalutsky, M.R., and Bigner, D.D.: ¹³¹Iodine-labeled antitenascin monoclonal antibody (MAB) 81C6 therapy of malignant glioma (MG).

Presentation: Twelfth International Conference on Brain Tumor Research and Therapy, Oxford, U.K., September 20, 1997. *J. Neurooncol.* 35:S52, 1998.

192. Heideman, R., Phillips, P., Friedman, H., Moghrabi, A., Gajjar, A., Rodman, J., Li, H., Walter, A., Jenkins, J., Sanford, R., Longee, D., Needle, M., Langston, J., and Kun, L.: Final results of a cooperative study of carboplatin (carbo) based primary chemotherapy (chemo) for infants and young children with CNS tumors. Presentation: American Society of Clinical Oncology, 1998. *Proc. Am. Soc. Clin. Oncol.* 51:534a, 1998.

193. Cokgor, I., Akabani, G., Brown, M.T., Friedman, A.H., Coleman, R.E., Friedman, H.S., Thorstad, W.L., McLendon, R.E., Bigner, S.H., Zhao, X.-G., Pegram, C.N., Wikstrand, C.J., Herndon, J.E., Vick, N.A., Paleologos, N., Zalutsky, M.R., and Bigner, D.D.: Phase I trial of patients with recurrent brain tumors and prior radiation therapy treated with ¹³¹I-labeled anti-tenascin monoclonal antibody 81C6 via surgically-created resection cavities.

Presentation: American Society of Clinical Oncology, 1998. *Proc. Am. Soc. Clin. Oncol.*

17:380a, 1998.

194. Friedman, A.H., Ashley, D.M., Kerby, T., Colvin, O.M., Fields, S., Zilisch, J., Graden, D., Provenzale, J., and Friedman, H.S.: Topotecan treatment of adults with primary malignant glioma. Presentation: American Society of Clinical Oncology, 1998. Proc. Am. Soc. Clin. Oncol. 17:390a, 1998.

195. Friedman, H.S., Dugan, M., Kerby, T., Henry, A.J., Ashley, D., Lovell, S., Rasheed, K., Cokgor, I., Friedman, A.H., and Modrich, P.: DNA mismatch repair analysis and response to Temodal® in newly diagnosed malignant glioma. Presentation: American Society of Clinical Oncology, 1998. Proc. Am. Soc. Clin. Oncol. 17:378a, 1998.

196. Colvin, O.M., Cokgor, I., Ashley, D.M., Kerby, T., Arbuck, S., Malczyn, J., Miller, L., Cloughesy, T., Houghton, P.J., Cokgor, I., Rich, J., Friedman, A.H., and Friedman, H.S.: Irinotecan treatment of adults with recurrent or progressive malignant glioma. Presentation: American Society of Clinical Oncology, 1998. Proc. Am. Soc. Clin. Oncol. 17:387a, 1998.

197. Horowitz, M.E., Duffner, P.K., Krischer, J.P., Sanford, R.A., Burger, P.C., Cohen, M.E., Friedman, H.S., Kun, L.E., and the Pediatric Oncology Group (POG): Postoperative

78

chemotherapy (CT) and delayed radiotherapy (RT) in children <3 years of age with malignant brain tumors (POG 8633/34): long-term follow-up. Presentation: 8th International Symposium on Pediatric Neuro-Oncology, 1998.

198. Strother, D., Kepner, J., Aronin, P., Langston, J., Constine, L., Burger, P., Duffner, P., Kun, L., Mulhern, R., Friedman, H., Horowitz, M., and the Pediatric Oncology Group: Preliminary results of the Pediatric Oncology Group baby-brain 2 protocol. Presentation: 8th International Symposium on Pediatric Neuro-Oncology, 1998.

199. Hanley, M., Elion, G., Colvin, O.M., Modrich, P., Keir, S., Adams, D., Bigner, D., and Friedman, H.: Therapeutic efficacy of vinorelbine against pediatric and adult central

nervous system (CNS) tumors. Presentation: American Association of Cancer Research, 1998. Proc. Amer. Assoc. Cancer Res. 39:588, 1998.

200. Friedman, H., Pegg, A., Johnson, S., Loktina, N., Dolan, E., Modrich, P., Moschel, R., Struck, R., Brent, T., Luderman, S., Bullock, N., Kilborn, C., Keir, S., Dong, Q., Bigner, D., and Colvin, O.M.: Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase. Presentation: American Association of Cancer Research, 1998. Proc. Amer. Assoc. Cancer Res. 39:219, 1998.

201. Friedman, H., Keir, S., Bigner, D., and Struck, R.: Treatment of CNS tumor xenografts with penclomedine (PEN) and 4-demethylpenclomedine (4-DM-PEN). Presentation: American Association of Cancer Research, 1998. Proc. Amer. Assoc. Cancer Res. 39:218, 1998.

202. McLendon, R.E., Friedman, H.S., Bigner, S.H., and Modrich, P.L.: DNA mismatch repair enzyme detection in adult glioblastoma by immunohistochemistry. Annual meeting of the United States-Canadian Academy of Pathology, March 3, 1998, Boston, MA. Lab. Invest., in press, 2002.

203. Sampson, J.H., Cokgor, I., Akabani, G., Friedman, A., Coleman, E., Friedman, H., McLendon, R., Zhou, X., Bigner, S., Pegram, C., Wikstrand, C., Vick, N., Paleologos, N., Zalutsky, M., and Bigner, D.: Radiolabeled anti-tenascin monoclonal antibody in recurrent malignant brain tumors. Presentation: American Association of Cancer Research, 1998. Proc. Amer. Assoc. Cancer Res. 39:324, 1998.

204. Friedman, H.S., Dugan, M., Kerby, T., Henry, A., Lovell, M., Rasheed, K., Parry, M., Hammond, C., Ashley, D., Haglund, M., McLendon, R., Johnson, S., Houghton, P.J., Bigner, D.D., Modrich, P., Colvin, O.M., and Friedman, A.H.: Laboratory and clinical therapy of central nervous system tumors with Temodal and Irinotecan (CPT-11). Cancer Invest. 16:S1:72, 1998.

205. Vaidyanathan, G., Friedman, H.S., and Zalutsky, M.R.: N.C.A. 5-iodo-1(2-deoxy, 2-fluoro-
• -D-arabinofuranosyl)uracil (fiu): tissue uptake in D-54 glioma xenograft mouse model
and cytotoxicity to D-247 glioma cells *in vitro*. Presentation: Society of Nuclear Medicine,
Toronto, June, 1998.

79

206. Kadota, R.P., Horn, M., Stewart, C.F., Kuttesch, J.F., Burger, P.C., Kepner, J., Kun, L.E.,
Friedman, H.S., and Heideman, R.L.: Topotecan for the treatment of recurrent or
progressive CNS tumors - a POG Phase II Study. Presentation: American Society of
Pediatric Hematology Oncology, Chicago, IL, September 11, 1998.

207. Friedman, A.H., Friedman, H.S., Kokkinakis, D.M., Pluda, J., Cokgor, I., Ashley, D.M.,
McLendon, R.E., Kerby, T., Bigner, D.D., and Schold, S.C., Jr.: Phase I trial of O6-
benzylguanine for patients undergoing surgery for malignant glioma. Presentation: Third
Annual European Association for Neuro-Oncology Congress, September 13-16, 1998,
Versailles, France. *J. Neurooncol.* 39:152, 1998.

208. Cokgor, I., Kerby, T., Houghton, P.J., Rich, J., Malczyn, J., Miller, L., Colvin, O.M.,
Friedman, A.H., Friedman, H.S.: Treatment of malignant glioma with irinotecan (CPT-11)
± BCNU. Presentation: Third Annual European Association for Neuro-Oncology
Congress, September 13-16, 1998, Versailles, France.

209. Friedman, H.S., Kokkinakis, D.M., Pluda, J., Friedman, A.H., Cokgor, I., Halund, M.M.,
Ashley, D.M., Rich, J.N., Dolan, E., Pegg, A.E., Moschel, R.M., McLendon, R.E., Kerby,
T., Herndon, J.E., Bigner, D.D., and Schold, S.C., Jr.: Phase I trial of O6-benzylguanine for
patients undergoing surgery for malignant glioma. Presentation: Third annual meeting of
the Society for Neuro-Oncology, November 13-15, 1998, San Francisco. *Neuro-Oncology*
1 (Suppl. 1): S18-S19, 1999.

210. Zalutsky, M.R., Akabani, G., Cokgor, I., Friedman, H.S., Coleman, R.E., Friedman, A.H.,

McLendon, R.E., Reist, C.J., Pegram, C.N., Zhao, X.-G., and Bigner, D.D.: Phase I trial of astatine-211 labeled human/mouse chimeric anti-tenascin antibody administered into malignant brain tumor resection cavities. Presentation: Third annual meeting of the Society for Neuro-Oncology, November 13-15, 1998, San Francisco. *Neuro-Oncology* 1 (Suppl. 1): S65-S66, 1999.

211. Akabani, G., Reist, C.J., Cokgor, I., Friedman, A.H., Friedman, H.S., Zhao, X.-G., Coleman, R.E., Bigner, D.D., and Zalutsky M.R.: Radiation dosimetry for patients with recurrent brain tumors treated with ¹³¹I- and ²¹¹At-labeled anti-tenascin monoclonal antibody 81C6. Presentation: Third annual meeting of the Society for Neuro-Oncology, November 13-15, 1998, San Francisco. *Neuro-Oncology* 1 (Suppl. 1): S1, 1999.

212. Sampson, J.H., Friedman, A.H., Coleman, R.E., Akabani, G., Friedman, H.S., Vick, N.A., Paleologos, N., Cokgor, I., Zalutsky, M.R., and Bigner, D.D.: Results of dose finding study for compartmental delivery of radiolabeled anti-tenascin monoclonal antibody 81C6 in patients with recurrent malignant gliomas with prior whole brain radiation. Presentation: Third annual meeting of the Society for Neuro-Oncology, November 13-15, 1998, San Francisco. *Neuro-Oncology* 1 (Suppl. 1): S53-S54, 1999.

213. Sampson, J.H., Archer, G.A., Villavicencio, A.T., Friedman, A.H., Bishop, W.R., Catino, J.J., Bigner, D.D., and Friedman, H.S.: Microcrystalline temozolomide for treatment of neoplastic meningitis. Presentation: Third annual meeting of the Society for Neuro-Oncology, November 13-15, 1998, San Francisco. *Neuro-Oncology* 1 (Suppl. 1): S54, 1999.

80

214. Provenzale, J.M., Rodriguez, D., Coleman, R.E., Friedman, H.S., Akabani, G., Cokgor, I., et al.: Worsening MR and PET findings do not necessarily indicate tumor progression in patients with resected primary brain tumors undergoing treatment with intracavitary iodine-

131I-labeled anti-tenascin monoclonal antibody. Presentation: Radiological Society of North America, 1998. Radiology 209(P), Abstract #256.

215. Cokgor, I., Akabani, G., Brown, M.T., Friedman, A.H., Coleman, R.E., Friedman, H.S., Thorstad, W.L., McLendon, R.E., Bigner, S.H., Zhao, X.-G., Pegram, C.N., Wikstrand, C.J., Herndon, J.E., Vick, N.A., Paleologos, N., Zalutsky, M.R., and Bigner, D.D.: Results of a phase I trial of patients with recurrent brain tumors and prior radiation therapy treated with 131I-labeled anti-tenascin monoclonal antibody 81C6 via surgically created resection cavities. Neurology 50, A354, 1998.

216. Friedman, H.S., Pegg, A.E., Johnson, S.P., Dolan, M.E., Modrich, P.C., Struck, R., Keir, S., Bigner, D.D., and Colvin, O.M.: Enhancement of cyclophosphamide (CY) activity following O6-benzylguanine (O6-BG) mediated depletion of O6-alkylguanine-DNA alkyltransferase (AGT). Presentation: American Association for Cancer Research, April 10-14, 1999, Philadelphia, PA. Proc. Am. Assoc. Cancer Res. 40:296-297, 1999.

217. Castellino, R.C., Elion, G.B., Keir, S., Houghton, P.J., Johnson, S.P., Bigner, D.D., and Friedman, H.S.: Combination chemotherapy with CPT-11 and BCNU displays schedule dependent activity against malignant glioma. Presentation: American Association for Cancer Research, April 10-14, 1999, Philadelphia, PA. Proc. Am. Assoc. Cancer Res. 40:109, 1999.

218. Colvin, O., Cokgor, I., Kerby, T., Lawless, A., Rich, J., Stewart, E., Rasheed, K., Affronti, M., Tourt-Uhlig, S., Provenzale, J., McLendon, R., Bigner, D., Zilisch, J., Graden, D., Fields, S.Z., Friedman, A., and Friedman, H.: Phase I trial of topotecan plus BCNU in malignant glioma. Proc. Am. Soc. Clin. Oncol. 18:150a, 1999.

219. Yung, A., Levin, V.A., Albright, R., Olson, J., Fredericks, R., Fink, K., Prados, M., Brada, M., Spence, A., Brunner, J., Yue, N., Dugan, M.H., and Zaknoen, S.: Randomized trial of Temoral (TEM) vs. procarbazine (PCB) in glioblastoma multiforme (GBM) at first relapse.

Proc. Am. Soc. Clin. Oncol. 18:139a, 1999.

220. Friedman, H., Cokgor, I., Kerby, T., Lawless, A., Rich, E., Stewart, E., Rasheed, K., Affronti, M., Tourt-Uhlig, S., Provenzale, J., McLendon, R., Colvin, O., Bigner, D., Malczyn, J., Friedman, A., and Miller, L.: Phase I trial of CPT-11 plus BCNU in malignant glioma. Proc. Am. Soc. Clin. Oncol. 18:150a, 1999.

221. Friedman, A., Cokgor, I., Kerby, T., Edwards, S., Rich, J., Stewart, E., McLendon, R., Affronti, M., Rasheed, K., Provenzale, J., Colvin, O., Bigner, D., Zaknoen, S., Fraass, U., Dugan, M., and Friedman, H.: Phase II treatment of anaplastic oligodendroglioma and low grade glioma with Temodal®. Proc. Am. Soc. Clin. Oncol. 18:150a, 1999.

222. Cohen, L., Friedman, H., Cokgor, I., Kerby, T., Rich, J., Stewart, E., McLendon, R., Provenzale, J., Malczyn, J., Miller, L., Zaknoen, S., Fraass, U., Dugan, M., Colvin, O.,

81

Bigner, D., Friedman, A., and Friedman, H.: Phase I trials of Gliadel™ plus CPT-11 or Temodal® (temozolomide). Proc. Am. Soc. Clin. Oncol. 18:149a, 1999.

223. Cokgor, I., Akabani, G., Friedman, A.H., Coleman, R.E., Zalutsky, M.R., McLendon, R.E., Bigner, S.H., Xiao-Guang, Z., Pegram, C.N., Wikstrand, C.J., Herndon, J.E. III, Provenzale, J.M., Friedman, H.S., and Bigner, D.D.: The treatment of newly diagnosed brain tumor patients with I131 anti-tenascin monoclonal antibody 81C6 *via* surgically created resection cavities: results of a Phase I trial. Presentation: American Society of Clinical Oncology, May 15-18, 1999, Atlanta, GA. Proc. Am. Soc. Clin. Oncol. 18:143a, 1999.

224. Chintagumpala, M., Burger, P., McCluggage, C., Kepner, J., Thompson, S., Michalski, J., Blaney, S., Woo, S., Friedman, H., and Horowitz, M.: Response to procarbazine in newly diagnosed patients with high-grade glioma - a Pediatric Oncology Group (POG) Study. Presentation: American Society of Clinical Oncology, May 15-18, 1998, Atlanta, GA. Proc. Am. Soc. Clin. Oncol. 18:558a, 1999.

225. Cloughesy, T.F., Nelson, G., Filka, E., Kabbinavar, F., Friedman, H., Selch, M., and Miller, L.: Irinotecan treatment for recurrent malignant glioma using every-three-week regimen. Proc. Am. Soc. Clin. Oncol. 18:144a, 1999.
226. Filka, E., Nelson, G., Friedman, H., Kabbinavar, F., Miller, L., Menco, H., and Cloughesy, T.: Inpatient dose escalation of irinotecan in patients with recurrent malignant glioma receiving anticonvulsants. Proc. Am. Soc. Clin. Oncol. 18:144a, 1999.
227. Provenzale, J.M., Rodriguez, D., Petrella, J.R., Wong, J., Wong, T., Friedman, H.S., Friedman, A., Akabani, G., Cokgor, I., McLendon, R.E., Bigner, D.D., and Coleman, R.E.: Test characteristics of MR and FDG PET in discriminating tumor progression from radiation necrosis after ¹³¹I-labeled monoclonal antibody treatment. Presentation: American Society of Neuroradiology, May 22-28, 1999, San Diego, CA. Am. J. Neuroradiol., in press, 2002.
228. Archer, G.E., Sampson, J.H., Villavicencio, A.T., McLendon, R.E., Friedman, A.H., Bishop, W.R., Bigner, D.D., and Friedman, H.S.: Regional delivery of microcrystalline temozolomide for the treatment of neoplastic meningitis. Presentation: American Association for Cancer Research, April 10-14, 1999, Philadelphia, PA. Proc. Am. Assoc. Cancer Res. 40:296, 1999.
229. Sampson, J.H., Cokgor, I., Akabani, G., Friedman, A.H., Coleman, R.E., Zalutsky, M.R., McLendon, R.E., Bigner, S.H., Xiao-Guang, A., Pegram, C.N., Wikstrand, C.J., Herndon, J.E., III, Provenzale, J.M., Friedman, H.S., and Bigner, D.D.: Phase I/II trial of newly diagnosed brain tumor patients treated with ¹³¹I-anti-tenascin MAb 81C6 *via* surgically created resection cavities. Presentation: American Association for Cancer Research, April 10-14, 1999, Philadelphia, PA. Proc. Am. Assoc. Cancer Res. 40:572, 1999.
230. Friedman, H.S., McLendon, R.E., Dolan, M.E., Pegg, A.E., Moschel, R.C., Colvin, O.M., Cokgor, I., Friedman, A.H., Schold, S.C., Bigner, D.D., and Modrich, P.L.: The biology of

sensitivity and resistance to the molecule (temozolomide). Presentation: American

82

Association for Cancer Research, April 10-14, 1999, Philadelphia, PA. Proc. Am. Assoc.

Cancer Res. 40:754, 1999.

231. Petros, W.P., Schaaf, L.J., Cokgor, I., Kerby, T.A., Colvin, O.M., Friedman, A.H., Knuth, D.W., Elfring, G.L., and Friedman, H.S.: Reduced systemic exposure to irinotecan and its active metabolite (SN-38) in patients with glioma receiving concurrent anticonvulsants and corticosteroids. Presentation: American College of Clinical Pharmacology. J.

Pharmacother., in press, 2002.

232. Provenzale, J.M., Sakurai, M., Bottom, K.S., Klintworth, G.K., Buckley, E.G., Friedman, H.S., et al: Patterns of CNS involvement and clinical outcome in trilateral retinoblastoma.

Presentation: Radiologic Society of North America, 1999.

233. Zalutsky, M.R., Akabani, G., Cokgor, I., Friedman, H.S., Coleman, R.E., Friedman, A.H., McLendon, R.E., Zhao, X.-G., Alston, K.L., and Bigner, D.D.: Dose escalation study of compartmental delivery of astatine-211 labeled human/mouse chimeric anti-tenascin monoclonal (mAb) antibody in patients with recurrent malignant gliomas. Presentation:

Thirteenth International Conference on Brain Tumor Research and Therapy, October 4-6, 1999, Sapporo, Japan. Neuro-Oncology 1:A2, S111, 1999.

234. Archer, G.E., Sampson, J.H., Lorimer, I.A.J., McLendon, R.E., Kuan, C.-T., Friedman, A.H., Friedman, H.S., Pastan, I.H., and Bigner, D.D.: EGFR deletion mutant specific immunotoxin MR1scFvPE38KDEL (MR-1) for regional therapy of neoplastic meningitis.

Presentation: Thirteenth International Conference on Brain Tumor Research and Therapy, October 4-6, 1999, Sapporo, Japan. Neuro-Oncology 1:A2, S103, 1999.

235. Archer, G.E., Heimberger, A.B., Villavicencio, A., Friedman, A., Friedman, H.S., Bigner, D.D., and Sampson, J.H.: Generation of peripheral blood-derived dendritic cells from the

immunosuppressive environment of patients with malignant gliomas. Presentation:

Thirteenth International Conference on Brain Tumor Research and Therapy, October 4-6, 1999, Sapporo, Japan. *Neuro-Oncology* 1:A2, S104, 1999.

236. Cokgor, I., Akabani, G., Friedman, A.H., Coleman, R.E., Zalutsky, M.R., McLendon, R.E., Bigner, S.H., Zhao, X.-G., Pegram, C.N., Wikstrand, C.J., Herndon, J.E. II, Provenzale, J.M., Friedman, H.S., and Bigner, D.D.: Newly diagnosed malignant glioma patients treated with ¹³¹I/anti-tenascin monoclonal antibody (MAb) 81C6 *via* surgically created resection cavities: results of a Phase I trial. Presentation: Thirteenth International Conference on Brain Tumor Research and Therapy, October 4-6, 1999, Sapporo, Japan. *Neuro-Oncology* [serial online], Doc 158-O, September 9, 1999, URL <http://neurooncology.mc.duke.edu>. *Neuro-Oncology* 1 (Suppl. 2), S107.

237. Sampson, J.H., Crotty, L.E., Lee, S., Archer, G.E., Wikstrand, C.J., Ashley, D.M., Friedman, A.H., Friedman, H.S., and Bigner, D.D.: Unarmed anti-EGFRvIII monoclonal antibody effectively treats EGFRvIII expressing intracranial tumors through antibody dependent macrophage cytotoxicity. Presentation: Thirteenth International Conference on Brain Tumor Research and Therapy, October 4-6, 1999, Sapporo, Japan. *Neuro-Oncology* [serial online], Doc 111-O, September 9, 1999, URL <http://neuro-oncology.mc.duke.edu>. *Neuro-Oncology* 1 (Suppl. 2), S98.

83

238. Sampson, J.H., Crotty, L.E., Archer, G.E., Friedman, A.H., Friedman, H.S., and Bigner, D.D.: An EGFRvIII specific peptide vaccine generates antitumor immunity through a humoral pathway. Presentation: Thirteenth International Conference on Brain Tumor Research and Therapy, October 4-6, 1999, Sapporo, Japan. *Neuro-Oncology* [serial online], Doc 135, September 9, 1999, URL <http://neuro-oncology.mc.duke.edu>. *Neuro-Oncology* 1 (Suppl. 2), S103.

239. Heimberger, A.B., Archer, G.E., Friedman, H.S., Bishop, W.R., Friedman, A.H., Bigner, D.D., and Sampson, J.H.: Intratumoral bulk flow microinfusion of temozolomide is efficacious against intracranial glioma. Presentation: Thirteenth International Conference on Brain Tumor Research and Therapy, October 4-6, 1999, Sapporo, Japan. Neuro-Oncology [serial online], Doc 200, September 9, 1999, URL <http://neurooncology.mc.duke.edu>. Neuro-Oncology 1 (Suppl. 2), S115.
240. Cokgor, I., Kokkinakis, D.M., Pluda, J., Friedman, A.H., Haglund, M.M., Ashley, D.M., Rich, J.N., Dolan, E., Pegg, A.E., Moschel, R.M., McLendon, R.E., Kerby, T., Herndon, J.E., Bigner, D.D., Schold, Jr., S.C., and Friedman, H.S.: Phase I trial of O6-benzylguanine plus bis(2-chloroethyl)nitrosourea for patients undergoing surgery for malignant glioma. 124th Annual Meeting of the American Neurological Association, October 10-13, 1999, Seattle, Washington. Ann. Neurol. 46(3):491, 1999.
241. Zalutsky, M.R., Akabani, G., Cokgor, I., Friedman, H.S., Coleman, R.E., Friedman, A.H., McLendon, R.E., Zhao, X.-G., Alston, K.L., and Bigner, D.D.: Compartmental administered astatine-211 labeled chimeric anti-tenascin monoclonal antibody (mAb) therapy in recurrent malignant glioma patients: current status of a Phase I study. Presentation: Fourth annual meeting of the Society for Neuro-Oncology, November 17-21, 1999, Scottsdale, Arizona. Neuro-Oncology [serial online], Doc 218, URL <http://neurooncology.mc.duke.edu>. Neuro-Oncology 1(4), 347-8.
242. Archer, G.E., Heimberger, A.B., Villavicencio, A., Friedman, A., Friedman, H.S., Bigner, D.D., and Sampson, J.H.: *In vitro* generation of dendritic cells from the peripheral blood of patients with malignant gliomas for antigen specific immunotherapy. Presentation: Fourth annual meeting of the Society for Neuro-Oncology, November 17-21, 1999, Scottsdale, Arizona. Neuro-Oncology [serial online], Doc. 10, URL <http://neurooncology.mc.duke.edu>. Neuro-Oncology 1(4), 296.

243. Cokgor, I., Akabani, G., Friedman, A.H., Coleman, R.E., Zalutsky, M.R., McLendon, R.E., Bigner, S.H., Zhao, X.-G., Pegram, C.N., Wikstrand, C.J., Herndon, J.E. II, Provenzale, J.M., Friedman, H.S., and Bigner, D.D.: Results of a Phase I trial in newly diagnosed malignant glioma patients treated with ¹³¹I-anti-tenascin monoclonal antibody 81C6. Presentation: Fourth annual meeting of the Society for Neuro-Oncology, November 17-21, 1999, Scottsdale, Arizona. Neuro-Oncology [serial online], Doc. 51, URL <http://neurooncology.mc.duke.edu>. Neuro-Oncology 1(4), 306.
244. Friedman, H., Cokgor, I., Kerby, T., Albergó, G., Rich, J., Stewart, E., Rasheed, K., Affronti, M., Tourt-Uhlig, S., Provenzale, J., McLendon, R., Bigner, D., Zilisch, J., Graden, D., Fields, S.Z., Colvin, O., and Friedman, A.: Phase I trial of topotecan plus BCNU in malignant glioma. Presentation: Fourth annual meeting of the Society for Neuro-Oncology, November 17-21, 1999, Scottsdale, Arizona. Neuro-Oncology [serial online], Doc. 72, URL <http://neuro-oncology.mc.duke.edu>. Neuro-Oncology 1(4), 311.
245. Friedman, H., Cokgor, I., Kerby, T., Lawless, J., Rich, J., Stewart, E., Rasheed, K., Affronti, M., Tourt-Uhlig, S., Provenzale, J., McLendon, R., Colvin, O., Bigner, D., Malczyn, J., Friedman, A., and Miller, L.: Phase I trial of CPT-11 plus BCNU in malignant glioma. Presentation: Fourth annual meeting of the Society for Neuro-Oncology, November 17-21, 1999, Scottsdale, Arizona. Neuro-Oncology [serial online], Doc. 71, URL <http://neurooncology.mc.duke.edu>. Neuro-Oncology 1(4), 310.
246. Friedman, A., Cokgor, I., Kerby, T., Edwards, S., Rich, J., Stewart, E., McLendon, R., Affronti, M., Rasheed, K., Provenzale, J., Colvin, O., Bigner, D., Zaknoen, S., Fraass, U., Dugan, M., and Friedman, H.: Phase II treatment of anaplastic oligodendro-glioma and low grade glioma with temodal®. Presentation: Fourth annual meeting of the Society for Neuro-Oncology, November 17-21, 1999, Scottsdale, Arizona. Neuro-Oncology [serial online], Doc. 70, URL <http://neuro-oncology.mc.duke.edu>. Neuro-Oncology 1(4), 310.

247. Friedman, H., Cokgor, I., Kerby, T., Edwards, S., Albergo, G., Tourt-Uhlig, S., Rich, J., Stewart, E., McLendon, R., Provenzale, J., Malczyn, J., Miller, L., Zaknoen, S., Fraass, U., Dugan, M., Colvin, O., Bigner, D., Friedman, A., and Cohen, L.: Phase I trials of gliadel™ plus CPT-11 or temodal® (temozolomide). Presentation: Fourth annual meeting of the Society for Neuro-Oncology, November 17-21, 1999, Scottsdale, Arizona. Neuro-Oncology [serial online], Doc. 73, URL <http://neuro-oncology.mc.duke.edu>. Neuro-Oncology 1(4), 311.

248. Akabani, G., Cokgor, I., Coleman, R.E., Gonzalez-Trotter, D., Wong, T.Z., Friedman, H.S., Garcia-Turner, A., Herndon II, J.E., McLendon, R.E., Zhao, X.-G., Pegram, C.N., Bigner, D.D., and Zalutsky, M.R.: Dosimetry of 131I-labeled anti-tenascin monoclonal antibody 81C6 in newly diagnosed patients with malignant gliomas. Presentation: Fourth Annual Meeting of the Society for Neuro-Oncology, November 17-21, 1999, Scottsdale, Arizona. Neuro-Oncology [serial online], Doc. 3, URL <http://neuro-oncology.mc.duke.edu>. Neuro-Oncology 1(4), 294.

249. Heimberger, A.B., Archer, G.E., Friedman, H.S., Bishop, W.R., Friedman, A., Bigner, D.D., and Sampson, J.H.: Intratumoral temozolomide via bulk flow microinfusion is efficacious against intracranial glioma. Presentation: Fourth Annual Meeting of the Society for Neuro-Oncology, November 17-21, 1999, Scottsdale, Arizona. Neuro-Oncology [serial online], Doc. 90, URL <http://neuro-oncology.mc.duke.edu>. Neuro-Oncology 1(4), 315.

250. Sampson, J.H., Crotty, L.E., Archer, G.E., Friedman, A.H., Friedman, H.S., and Bigner, D.D.: Tumoricidal humoral immunity induced by a peptide vaccination against the epidermal growth factor receptor mutation. Presentation: Fourth Annual Meeting of the Society for Neuro-Oncology, November 17-21, 1999, Scottsdale, Arizona. Neuro-Oncology [serial online], Doc. 176, URL <http://neuro-oncology.mc.duke.edu>. Neuro-

Oncology 1(4), 336-337.

85

251. Cloughesy, T., Filka, E., Nelson, G., Friedman, H., Kabbinavar, F., and Miller, L.L.:

Irinotecan (CPT-11, Camptosar®) shows variability in dose-limiting toxicity during inpatient dose escalation scheme in recurrent malignant glioma. Presentation: Fourth Annual Meeting of the Society for Neuro-Oncology, November 17-21, 1999, Scottsdale, Arizona. Neuro-Oncology [serial online], Doc. 49, URL <http://neurooncology.mc.duke.edu>. Neuro-Oncology 1(4), 305.

252. Patel, V.J., Elion, G., Keir, S., Bigner, D.D., Houghton, P.J., and Friedman, H.S.: Schedule dependent interaction of CPT-11 and temozolomide against central nervous system xenografts. Presentation: 91st Annual Meeting of the American Association of Cancer Research, April 1-5, 2000, San Francisco, CA. Proc. Amer. Assoc. Cancer Res. 41:410, 2000.

253. Friedman, H.S., Pluda, J., Bigner, D.D., Pegg, A.E., Moschel, R.C., Cokgor, I., Rich, J., Friedman, A.H., and Dolan, M.E.: Phase I trial of O6-benzylguanine plus BCNU for patients with recurrent malignant glioma. Presentation: 91st Annual Meeting of the American Association of Cancer Research, April 1-5, 2000, San Francisco, CA. Proc. Amer. Assoc. Cancer Res. 41:397, 2000.

254. Zalutsky, M.R., Cokgor, I., Akabani, G., Friedman, H.S., Coleman, R.E., Friedman, A.H., McLendon, R.E., Reist, C.J., Pegram, C.N., Zhao, X.-G., and Bigner, D.D.: Phase I trial of alpha-particle-emitting astatine-211 labeled chimeric anti-tenascin antibody in recurrent malignant glioma patients. Presentation: 91st Annual Meeting of the American Association of Cancer Research, April 1-5, 2000, San Francisco, CA. Proc. Amer. Assoc. Cancer Res. 41:544, 2000.

255. Heimberger, A.B., Archer, G., Crotty, L., Friedman, A., Friedman, H., Bigner, D., and

Sampson, J.: Induction of an anti-EGFRvIII immunological response with dendritic cells loaded with EGFRvIII-specific peptide which is curative for intracranial gliomas.

Presentation: 91st Annual Meeting of the American Association of Cancer Research, April 1-5, 2000, San Francisco, CA. Proc. Amer. Assoc. Cancer Res. 41:216, 2000.

256. Johnson, S.P., Miller, P.S., Colvin, O.M., Modrich, P., and Friedman, H.S.: In vitro repair of phosphoramidate mustard induced DNA interstrand crosslinks. Presentation: 91st Annual Meeting of the American Association of Cancer Research, April 1-5, 2000, San Francisco, CA. Proc. Amer. Assoc. Cancer Res. 41:98, 2000.

257. Flowers, J.L., Hoffman, R.M., Wall, M.E., Wani, M.C., Manikumar, G., Friedman, H.S., Dewhirst, M.W., Price, D.T., Colvin, O.M., and Adams, D.J.: Activity of camptothecin analogues in histocultures of human brain, breast, prostate, and colon tumors as a function of extracellular pH. Presentation: 91st Annual Meeting of the American Association of Cancer Research, April 1-5, 2000, San Francisco, CA. Proc. Amer. Assoc. Cancer Res. 41:213, 2000.

258. Archer, G.E., Crotty, L., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Sampson, J.H.: Peptide vaccination induces a therapeutic humoral response to mutant epidermal growth factor receptor expressing tumors. Presentation: 91st Annual Meeting of the American Association of Cancer Research, April 1-5, 2000, San Francisco, CA. Proc. Amer. Assoc. Cancer Res. 41:797, 2000.

259. Provenzale, J.M., Petrella, J.R., Holmes, T.M., Cruz, L.C.H., Jr., Cokgor, I., Friedman, H.S., and McLendon, R.E.: Evaluation of cerebral neoplasms using perfusion MR imaging. Presentation: 38th Annual Meeting of the American Society of Neuroradiology, April 2-8, 2000, Atlanta, GA.

260. Petrella, J.R., Luna, A., Provenzale, J.M., Holmes, T., McLendon, R.E., Cokgor, I., and

86

Friedman, H.S.: Distinguishing radiation treatment effects from tumor progression in patients with treated cerebral gliomas using cerebral blood volume mapping. Presentation: 38th Annual Meeting of the American Society of Neuroradiology, April 2-8, 2000, Atlanta, GA.

261. Cloughesy, T., Filka, E., Friedman, H., Kabbinavar, F., Kuhn, J., Selch, M., and Miller, L.: A Phase I (inpatient dose escalation) open-label study of irinotecan (CPT-11) in patients with recurrent or progressive malignant glioma. Presentation: 36th Annual Meeting of the American Society of Clinical Oncology, May 20-23, 2000, New Orleans, LA. Proc. Am. Soc. Clin. Oncol. 19:161a, 2000.

262. Cokgor, I., Akabani, G., Friedman, A., Coleman, R., Zalutsky, M., McLendon, R., Bigner, S., Xiao-Guang, Z., Pegram, C., Wikstrand, C., Herndon, J., III, Provenzale, J., Friedman, H., and Bigner, D.: Results of a Phase II trial in the treatment of recurrent patients with brain tumors treated with Iodine 131 anti-tenascin monoclonal antibody 81C6 via surgically created resection cavities. Presentation: 36th Annual Meeting of the American Society of Clinical Oncology, May 20-23, 2000, New Orleans, LA. Proc. Am. Soc. Clin. Oncol. 19:162a, 2000.

263. Quinn, J.A., Cokgor, I., Rich, J.N., Sands, H., Tourt-Uhlig, S., Garcia-Turner, A., Stewart, B.S., Sampson, J.H., Friedman, A.H., and Friedman, H.S.: Phase I trial of intrathecal busulfan for patients with neoplastic meningitis. Presentation: 36th Annual Meeting of the American Society of Clinical Oncology, May 20-23, 2000, New Orleans, LA. Proc. Am. Soc. Clin. Oncol. 19:163a, 2000.

264. Friedman, H.S., Cokgor, I., Tourt-Uhlig, S., Albergo, G., Rich, J.N., Quinn, J.A., Stewart, B., Rasheed, K., Affronti, M.L., Provenzale, J.M., McLendon, R.E., and Colvin, O.M.: Phase I trial of CPT-11 plus BCNU in malignant glioma. Presentation: 36th Annual Meeting of the American Society of Clinical Oncology, May 20-23, 2000, New Orleans,

LA. Proc. Am. Soc. Clin. Oncol. 19:170a, 2000.

265. Strother, D., Kepner, J., Aronin, P., Constine, L.S., Burger, P., Langston, J., Duffner, P., Kun, L., Friedman, H.S., Kupst, M.J., and Horowitz, M.: Dose-intensive (DI) chemotherapy (CT) prolongs event-free survival (EFS) for very young children with ependymoma (EP). Results of Pediatric Oncology Group (POG) Study 9233. Presentation: 36th Annual Meeting of the American Society of Clinical Oncology, May 20-23, 2000, New Orleans, LA. Proc. Am. Soc. Clin. Oncol. 19:585a, 2000.

87

266. Friedman, A.H., Cokgor, I., Edwards, S., Rich, J.N., Quinn, J.A., Stewart, B., McLendon, R.E., Affronti, M.L., Rasheed, K., Provenzale, J.M., Tourt-Uhlig, S., Sampson, J.H., and Friedman, H.S.: Phase II treatment of anaplastic oligodendroglioma and low grade glioma with temzolomide. Presentation: 36th Annual Meeting of the American Society of Clinical Oncology, May 20-23, 2000, New Orleans, LA. Proc. Am. Soc. Clin. Oncol. 19:169a, 2000.

267. Colvin, O.M., Cokgor, I., Edwards, S., Albergo, G., Tourt-Uhlig, S., Rich, J.N., Quinn, J.A., Stewart, B., McLendon, R.E., Provenzale, J.M., Sampson, J.H., Haglund, M.M., and Friedman, H.S.: Phase I trials of gliadel plus CPT-11 or temodar. Presentation: 36th Annual Meeting of the American Society of Clinical Oncology, May 20-23, 2000, New Orleans, LA. Proc. Am. Soc. Clin. Oncol. 19:172a, 2000.

268. Bigner, D., Akabani, A., Friedman, A., Coleman, R., Zalutsky, M., McLendon, R., Bigner, S., Xiao-Guang, Z., Shafman, T., Pegram, C., Wikstrand, C., Herndon, III, J., Provenzale, J., Friedman, H., and Cokgor, I.: Phase II clinical trial results of recurrent brain tumor patients treated with iodine-131 anti-tenascin monoclonal antibody 81C6. Presentation: Fourth Congress of the European Association of Neuro-Oncology, June 3-6, 2000, Copenhagen, Denmark. Neuro-Oncology [serial online], Doc. 83, URL <http://neurooncology>.

mc.duke.edu. Neuro-Oncology 2(1): S15, 2000.

269. Colvin, O., Cokgor, I., Edwards, S., Albergo, G., Tourt-Uhlig, S., Rich, J., Quinn, J., Stewart, E., McLendon, R., Provenzale, J., Sampson, J., Haglund, M., Beason, R., Miller, L., Zaknoen, S., Fraass U., Dugan, M., Bigner, D., Stafford-Fox, V., Cohen, L., Friedman, A., and Friedman, H.: Phase I trials of gliadel plus CPT-11 or Temodar. Presentation: Fourth Congress of the European Association of Neuro-Oncology, June 3-6, 2000, Copenhagen, Denmark. Neuro-Oncology [serial online], Doc. 343, URL <http://neurooncology.mc.duke.edu>.

mc.duke.edu. Neuro-Oncology 2(1): S56, 2000.

270. Chintagumpala, M., Stewart, C., Burger, P., Kepner, J., McCluggage, C., Thompson, S., Michalski, J., Blaney, S., Woo, S., Kun, L., Friedman, H., and Horowitz, M.: Responses to topotecan in newly-diagnosed patients with high-grade gliomas—a Pediatric Oncology Group (POG) Study. Presentation: Society of Neuro-oncology, June 11-14, 2000.

271. Heimberger, A.B., Archer, G.E., Price, D.T., McLendon, R.E., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Sampson, J.H.: The specific inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, "Iressa • " (ZD1839), is active against EGFR overexpressing intracranial tumors. Oral Poster Presentation: 50th Annual Meeting of the Congress of Neurological Surgeons, September 23-29, 2000, San Antonio, TX, 2000.

272. Hinman, J.M., Provenzale, J.M., Akabani, G., Zalutsky, M.R., Cokgor, I., Friedman, H.S., Coleman, R.E., and Bigner, D.D.: Patterns of recurrent tumor and radiation necrosis in astatine-labeled monoclonal antibody therapy. Presented at the 2000 meeting of the American Society of Neuroradiology, Atlanta, GA.

273. Vaidyanathan, G., Affleck, D., Cavazos, C., Johnson, S., Shankar, S., Friedman, H., Colvin, M., and Zalutsky, M.: O6-4-[18F]fluorobenzylguanine ([18F]FBG) and O6-3-[131I]iodobenzylguanine ([131I]IBG): potential tracers for the noninvasive mapping of O6-

alkylguanine-DNA alkyl transferase (AGT). Presentation: Pacifichem 2000, December 14-19, 2000, Honolulu, Hawaii.

274. Archer, G.E., Heimberger, A.B., McLendon, R.E., Price, D., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Sampson, J.H.: The EGFR-specific tyrosine kinase inhibitor, ZD1839 (Iressa •) is efficacious following oral administration against EGFRoverexpressing intracranial tumors. Presentation: Fifth Annual Meeting of the Society for Neuro-Oncology, November 9-12, 2000, Chicago, IL. Neuro-Oncology [serial online], Doc. 7, URL <http://neuro-oncology.mc.duke.edu>. Neuro-Oncology 2(4):247, 2000.

275. Friedman, H.S., Quinn, J.A., Tourt-Uhlig, S., Albergo, G., Rich, J.N., Cokgor, I., Stewart, E., Affronti, M.L., Provenzale, J.M., McLendon, R.E., Gururangan, S., Buchanan, W., Parker, R., Colvin, O.M., Bigner, D.D., Beason, R, Sampson, J., Haglund, M., Friedman, A.H., and Miller, L.: Phase I trial of CPT-11 plus BCNU in malignant glioma. Presentation: Fifth Annual Meeting of the Society for Neuro-Oncology, November 9-12, 2000, Chicago, IL. Neuro-Oncology [serial online], Doc. 71, URL <http://neurooncology.mc.duke.edu>. Neuro-Oncology 2(4):263, 2000.

276. Friedman, H.S., Quinn, J.A., Rich, J.N., Tourt-Uhlig, S., McLendon, R.E., Provenzale, J.M., Sampson, J., Haglund, M., Colvin, O.M., Cokgor, I., Gururangan, S., Affronti, M.L., Edwards, S., Albergo, G., Stewart, E., Beason, R., Zaknoen, S., Bigner, D.D., Stafford-Fox, V., Early, M., and Friedman, A.H.: Phase I trial of gliadel plus temodar. Presentation: Fifth Annual Meeting of the Society for Neuro-Oncology, November 9-12, 2000, Chicago, IL. Neuro-Oncology [serial online], Doc. 72, URL <http://neuro-oncology.mc.duke.edu>. Neuro-Oncology 2(4):263, 2000.

277. Quinn, J.A., Rich, J.N., Cokgor, I., Provenzale, J., McLendon, R., Edwards, S. Tourt-Uhlig, S., Gururangan, S., Affronti, M.L., Stewart, E., Parker, R., Buchanan, W., Bigner, D.D., Stafford-Fox, V., Zaknoen, S., Haglund, M., Friedman, A.H., and Friedman, H.S.: Phase II

trial of temodar for progressive low grade glioma. Presentation: Fifth Annual Meeting of the Society for Neuro-Oncology, November 9-12, 2000, Chicago, IL. Neuro-Oncology [serial online], Doc. 173, URL <http://neuro-oncology.mc.duke.edu>. Neuro-Oncology 2(4):288, 2000.

278. Quinn, J.A., Dolan, M.E., Pegg, A., Moschel, R.C., Pluda, J., McLendon, R., Provenzale, J., Petros, W., Tourt-Uhlig, S., Cokgor, I., Rich, J.N., Gururangan, S., Affronti, E., Parker, R., Buchanan, W., Colvin, O.M., Stewart, E., Friedman, A.H., Bigner, D.D., and Friedman, H.S.: Phase II trial of BCNU plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. Presentation: Fifth Annual Meeting of the Society for Neuro-Oncology, November 9-12, 2000, Chicago, IL. Neuro-Oncology [serial online], Doc. 175, URL <http://neuro-oncology.mc.duke.edu>. Neuro-Oncology 2(4):288, 2000.

279. Sampson, J.H., Crotty, L.E., Lee, S., Archer, G.E., Ashley, D.M., Wikstrand, C.J., Hale, L.P., Small, C., Dranoff, G., Friedman, A.H., Friedman, H.S., and Bigner, D.D.: Unarmed, tumor-specific antibody effectively treats brain tumors. Presentation: Fifth Annual Meeting of the Society for Neuro-Oncology, November 9-12, 2000, Chicago, IL. Neuro-Oncology [serial online], Doc. 193, URL <http://neuro-oncology.mc.duke.edu>. Neuro-Oncology 2(4):292-293, 2000.

89

280. Provenzale, J.M., Wang, G.R., Petrella, J.R., and Friedman, H.S.: Comparison of permeability measurements in high-grade and low-grade glial neoplasms. Presentation: 101st Annual Meeting of the American Roentgen Ray Society, April 29-May 4, 2001, Seattle, WA.

281. Provenzale, J.M., Wang, G.R., Petrella, J.R., and Friedman, H.S.: Serial changes in permeability in high grade glial neoplasms. Presentation: 101st Annual Meeting of the American Roentgen Ray Society, April 29-May 4, 2001, Seattle, WA.

282. Provenzale, J.M., Bottom, C., Buckley, E., Klintworth, G., and Friedman, H.S.: Time interval to development of leptomeningeal dissemination in trilateral retinoblastoma. Presentation: 101st Annual Meeting of the American Roentgen Ray Society, April 29-May 4, 2001, Seattle, WA.

283. Cavazos, C.M., Keir, S.T., Yoshinari, T., Bigner, D.D., and Friedman, H.S.: Therapeutic activity of topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyl-2-hydroxy)ethylamino-12,13-dihydro-13-(β -D-glucopyranosyl)-5H-indolo[2,3-A]-pyrrolo[3,4-C]-carbazole-5,7(6H)-dione] against pediatric and adult central nervous system tumor xenografts. . Presentation: 92nd Annual Meeting, American Association for Cancer Research, March 24-28, 2001, New Orleans, LA. Proc. Amer. Assoc. Cancer Res. 42:719, 2001.

284. Quinn, J.A., Rich, J.N., Reardon, D.A., Sampson, J.H., Provenzale, J.M., McLendon, R.E., Edwards, S.D., Tourt-Uhlig, S.E., Gururangan, S., Affronti, M.L., Stewart, E.S., Buchanan, M.W., Bigner, D.D., Stafford-Fox, V., Zaknoen, S., Haglund, M.M., Friedman, A.H., and Friedman, H.S.: Phase II trial of Temodar[®] for progressive low grade glioma. Presentation: 92nd Annual Meeting, American Association for Cancer Research, March 24-28, 2001, New Orleans, LA. Proc. Amer. Assoc. Cancer Res. 42:652, 2001.

285. Friedman, H.S., Keir, S.T., Houghton, P.J., Bigner, D.D., and Waters, S.J.: Activity of irifulven (6-hydroxymethylacylfulvene, MGI-114) in the treatment of human central nervous system tumors growing in athymic nude mice. Presentation: 92nd Annual Meeting, American Association for Cancer Research, March 24-28, 2001, New Orleans, LA. Proc. Amer. Assoc. Cancer Res. 42:324, 2001.

286. Reardon, D., Akabani, G., Friedman, A., Friedman, H. Herndon, J., III, Cokgor, I., McLendon, R., Quinn, J., Rich, J., Regalado, L., Sampson, J., Shafman, T., Wong, T., Zalutsky, M., and Bigner, D.: Results of a Phase II trial in the treatment of newly

diagnosed patients with high grade glioma treated with Iodine 131 murine anti-tenascin monoclonal antibody 81C6 via surgically created resection cavities. Presentation: 92nd Annual Meeting, American Association for Cancer Research, March 24-28, 2001, New Orleans, LA. Proc. Amer. Assoc. Cancer Res. 42:700, 2001.

287. Neville, K., Adams, D., Bottom, K., Blaney, S., Bernstein, M., Friedman, H., Kadota, R., and Berg, S.L.: Pharmacokinetics of O6-benzylguanine in children: A Pediatric Oncology Group Study. Presentation: 92nd Annual Meeting, American Association for Cancer Research, March 24-28, 2001, New Orleans, LA. Proc. Amer. Assoc. Cancer Res. 42:700, 2001.

90

288. Johnson, S.P., Colvin, O.M., and Friedman, H.S.: *In vitro* removal of a phosphoramidate mustard-induced interstrand DNA crosslink does not require the nucleotide excision repair proteins. Presentation: 92nd Annual Meeting, American Association for Cancer Research, March 24-28, 2001, New Orleans, LA. Proc. Amer. Assoc. Cancer Res. 42:555, 2001.

289. Vaidyanathan, G., Wester, H.-J., Schottelius, M., Friedman, H.S., and Zalutsky, M.R.: Specific and high-level targeting of a radiolabeled octreotide analogue to human medulloblastoma xenografts. Presentation: 92nd Annual Meeting, American Association for Cancer Research, March 24-28, 2001, New Orleans, LA. Proc. Amer. Assoc. Cancer Res. 42:700, 2001.

290. Reardon, D., Akabani, G., Friedman, A., Friedman, H., Herndon, J., II, Cokgor, I., McLendon, R., Quinn, J., Rich, J., Regalado, L., Sampson, J., Shafman, T., Wong, T., Zalutsky, M., and Bigner, D.: Outcome of newly diagnosed patients with high-grade glioma treated with Iodine-131 murine anti-tenascin monoclonal antibody 81C6 via surgically created resection cavities in a Phase II trial. Presentation: American Society of Clinical Oncology, 37th Annual Meeting, May 12-15, 2001, San Francisco, CA. Proc. Am.

Soc. Clin. Oncol. 20:54a, 2001.

291. Shafman, T., Friedman, H., Friedman, A., Akabani, G., Cokgor, I., Herndon, J., III, McLendon, R., Quinn, J., Reardon, D., Rich, J., Regalado, L., Sampson, J., Wong, T., Zalutsky, M., and Bigner, D.: Update of a phase II trial of iodine-131-labeled anti-tenascin monoclonal antibody treatment of patients with recurrent brain tumors.. Presentation: American Society of Clinical Oncology, 37th Annual Meeting, May 12-15, 2001, San Francisco, CA. Proc. Am. Soc. Clin. Oncol. 20:67a, 2001.

292. Rich, J., Reardon, D., Allen, D., Affronti, M.L., Carter, J., Edwards, S., Friedman, A., Gururangan, S., Herndon, J., Jackson, S., McLendon, R., Quinn, J., Tourt-Uhlig, S., Sampson, J., Bigner, D., Stafford-Fox, V., Zaknoen, S., and Friedman, H.: Phase I/II trial of gliadel plus temodar for adult patients with recurrent high-grade glioma. Presentation: American Society of Clinical Oncology, 37th Annual Meeting, May 12-15, 2001, San Francisco, CA. Proc. Am. Soc. Clin. Oncol. 20:75b, 2001.

293. Affronti, M., Reardon, D., Allen, D., Friedman, A., Gururangan, S., Herndon, J., Houghton, P., Jackson, S., McLendon, R., Quinn, J., Rich, J., Sampson, J., Tourt-Uhlig, S., Walker, A., Bigner, D., and Friedman, H.: Phase I trial of topotecan with BCNU in the treatment of adult patients with recurrent high grade glioma. Presentation: American Society of Clinical Oncology, 37th Annual Meeting, May 12-15, 2001, San Francisco, CA. Proc. Am. Soc. Clin. Oncol. 20:63a, 2001.

294. Friedman, H.S., Petros, W., Rich, J.N., Glantz, M.J., Sands, H., Tourt-Uhlig, S., Stewart, E.S., Gururangan, S., Sampson, J., Friedman, A.H., Colvin, M., and Quinn, J.: Phase I trial of intrathecal Spartaject™ busulfan for patients with neoplastic meningitis. Presentation: American Society of Clinical Oncology, 37th Annual Meeting, May 12-15, 2001, San Francisco, CA. Proc. Am. Soc. Clin. Oncol. 20:57a, 2001.

295. Cavazos, C.M., Gururangan, S., Herndon, J., II, Tourt-Uhlig, S., Moghrabi, A., Rich, J.N.,

Quinn, J.A., Reardon, D., Friedman, A.H., and Friedman, H.S.: A Phase II study of low-dose carboplatin (CBDCA) chemotherapy in adults with progressive low-grade gliomas. Presentation: American Society of Clinical Oncology, 37th Annual Meeting, May 12-15, 2001, San Francisco, CA. Proc. Am. Soc. Clin. Oncol. 20:63a, 2001.

296. Gururangan, S., Cavazos, C.M., Herndon, J.E., II, Longee, D.C., Bottom, K.S., Bruggers, C., Moghrabi, A., Watral, M., Tourt-Uhlig, S., Reardon, D.A., and Friedman, H.S.: A Phase II study of low-dose carboplatin (CBDCA) in children with progressive low-grade gliomas. Presentation: American Society of Clinical Oncology, 37th Annual Meeting, May 12-15, 2001, San Francisco, CA. Proc. Am. Soc. Clin. Oncol. 20:375a, 2001.

297. Quinn, J.A., Dolan, M., Pegg, A.E., Moschel, R.C., Pluda, J., McLendon, R.E., Provenzale, J., Petros, W., Tourt-Uhlig, S., Rich, J.N., Gururangan, S., Affronti, M.L., Buchanan, W., Colvin, O., Stewart, E.S., Friedman, A.H., Bigner, D.D., and Friedman, H.S.: Phase II trial of BCNU plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. Presentation: American Society of Clinical Oncology, 37th Annual Meeting, May 12-15, 2001, San Francisco, CA. Proc. Am. Soc. Clin. Oncol. 20:64a, 2001.

298. Tourt-Uhlig, S., Quinn, J.A., Rich, J.N., Reardon, D.A., Sampson, J.H., Provenzale, J.M., McLendon, R.E., Edwards, S., Gururangan, S., Affronti, M.L., Buchanan, W., Jackson, S., Allen, D., Penne, K., Lentz, C., Bigner, D.D., Haglund, M., Friedman, A.H., Avgeropoulos, N., Korones, D., Stafford-Fox, V., Zaknoen, S., and Friedman, H.S.: Phase II trial of temozolomide (Temodar®) in patients with progressive or recurrent low grade glioma. Presentation: American Society of Clinical Oncology, 37th Annual Meeting, May 12-15, 2001, San Francisco, CA. Proc. Am. Soc. Clin. Oncol. 20:76b, 2001.

299. Friedman, A.H., Quinn, J.A., Tourt-Uhlig, S., Rich, J.N., Stewart, E.S., Affronti, M.L., Provenzale, J., McLendon, R., Gururangan, S., Buchanan, W., Colvin, O., Bigner, D.D., Beason, R., Sampson, J., Haglund, M., Miller, L., and Friedman, H.S.: Phase I trial of CPT-

11 plus BCNU in malignant glioma. Presentation: American Society of Clinical Oncology, 37th Annual Meeting, May 12-15, 2001, San Francisco, CA. Proc. Am. Soc. Clin. Oncol. 20:64a, 2001.

300. Korones, D.N., Benita-Weiss, M., Mchtler, L., Bushunow, P., and Friedman, H.S.: A Phase I study of temozolomide (Temodar) and escalating doses of oral VP-16 for adults with recurrent malignant gliomas. Presentation: American Society of Clinical Oncology, 37th Annual Meeting, May 12-15, 2001, San Francisco, CA. Proc. Am. Soc. Clin. Oncol. 20:76b, 2001.

301. McLendon, R.E., Rasheed, A., Wiltshire, R., Herndon, J., Friedman, H., Friedman, A., Bigner, D., and Bigner, S.: Molecular profiling of astrocytomas. Presentation: Seventy-seventh Annual Meeting of the American Association of Neuropathologists, June 21-24, 2001, Chicago, IL. J. Neuropathol. Exp. Neurol. 60 (5):535, Abstract 127, 2001.

302. Provenzale, J.M., Wang, G.R., Petrella, J.R., and Friedman, H.S.: Permeability measurements in high-grade vs low-grade glial neoplasms. Presentation: 39th Annual Meeting of the American Society of Neuroradiology, April 23-27, 2001, Boston, MA.

92

303. Provenzale, J.M., Holmes, T., Petrella, J.R., Friedman, A.H., and Friedman, H.S.: Effect of reduction of MR perfusion imaging contrast dose on image quality. Presentation: 39th Annual Meeting of the American Society of Neuroradiology, April 23-27, 2001, Boston, MA.

304. Provenzale, J.M., Holmes, T., Petrella, J.R., Friedman, A.H., and Friedman, H.S.: Comparison of rCBV thresholds for distinguishing high-grade from low-grade tumors. Presentation: 39th Annual Meeting of the American Society of Neuroradiology, April 23-27, 2001, Boston, MA.

305. Provenzale, J.M., Holmes, T., Petrella, J.R., Friedman, A.H., and Friedman, H.S.: Effects

of various types of region of interest placement on measurement of relative cerebral blood volume. Presentation: 39th Annual Meeting of the American Society of Neuroradiology, April 23-27, 2001, Boston, MA.

306. Provenzale, J.M., Wang, G.R., Petrella, J.R., and Friedman, H.S.: Comparison of permeability measurements in enhancing and unenhancing brain neoplasms. Presentation: 39th Annual Meeting of the American Society of Neuroradiology, April 23-27, 2001, Boston, MA.

307. Kadota, R., Kepner, J., Friedman, H., and Kun, L.: Children with relapsed or progressive low grade astrocytoma (LGA) enrolled on Phase II chemotherapy trials have a high rate of disease progression: A Pediatric Oncology Group Analysis. Presentation: Fourteenth International Conference on Brain Tumor Research and Therapy, May 27-30, 2001, Asheville, NC. Neuro-Oncology [serial online], Doc. B78, URL <http://neurooncology.mc.duke.edu>. Neuro-Oncology 3 (Suppl 1):S20, 2001.

308. Reardon, D., Akabani, G., Friedman, A., Friedman, H., Herndon, II, J., Cokgor, I., McLendon, R., Quinn, J., Rich, J., Regalado, L., Sampson, J., Shafman, T., Wong, T., Zalutsky, M., and Bigner, D.: Phase II trial results of iodine-131 murine anti-tenascin monoclonal antibody 81C6 via surgically created resection cavities among newly diagnosed patients with high-grade glioma. Presentation: Fourteenth International Conference on Brain Tumor Research and Therapy, May 27-30, 2001, Asheville, NC. Neuro-Oncology [serial online], Doc. B141, URL <http://neuro-oncology.mc.duke.edu>. Neuro-Oncology 3 (Suppl 1):S34-35, 2001.

309. Reardon, D., Affronti, M.L., Allen, D., Friedman, A., Herndon, J., Houghton, P., Jackson, S., McLendon, R., Quinn, J., Rich, J., Walker, A., Sampson, J., Bigner, D., and Friedman, H.: Results of a Phase I trial of Topotecan with BCNU for adult patients with recurrent high grade glioma. Presentation: Fourteenth International Conference on Brain Tumor

Research and Therapy, May 27-30, 2001, Asheville, NC. Neuro-Oncology [serial online], Doc. B142, URL <http://neuro-oncology.mc.duke.edu>. Neuro-Oncology 3 (Suppl 1):S35, 2001.

310. Reardon, D., Edwards, S., Friedman, A., Herndon, J., McLendon, R., Quinn, J., Rich, J., Tourt-Uhlig, S., Sampson, J., Stafford-Fox, V., Zaknoen, S., Bigner, D., and Friedman, H.: Results of a Phase I/II trial of Gliadel plus Temodar for adult patients with recurrent highgrade glioma. Presentation: Fourteenth International Conference on Brain Tumor Research 93

and Therapy, May 27-30, 2001, Asheville, NC. Neuro-Oncology [serial online], Doc. B143, URL <http://neuro-oncology.mc.duke.edu>. Neuro-Oncology 3 (Suppl 1):S35, 2001.

311. Shafman, T., Friedman, H., Akabani, G., Cokgor, I., Herndon, J., McLendon, R., Quinn, J., Reardon, D., Rich, J., Regalado, L., Sampson, J., Wong, T., Zalutsky, M., and Bigner, D.: Iodine-131-labeled anti-tenascin monoclonal antibody for the treatment of patients with recurrent brain tumors: recent update of a Phase II trial. Presentation: Fourteenth International Conference on Brain Tumor Research and Therapy, May 27-30, 2001, Asheville, NC. Neuro-Oncology [serial online], Doc. B165, URL <http://neurooncology.mc.duke.edu>. Neuro-Oncology 3 (Suppl 1):S40, 2001.

312. Boon, K., Shoemaker, J., Johnson, S.P., Friedman, H.S., and Riggins, G.J.: A classification of medulloblastomas based on comprehensive gene expression analysis. Presentation: Fourteenth International Conference on Brain Tumor Research and Therapy, May 27-30, 2001, Asheville, NC. Neuro-Oncology [serial online], Doc. B20, URL <http://neurooncology.mc.duke.edu>. Neuro-Oncology 3 (Suppl 1):S6, 2001.

313. Quinn, J.A., Tourt-Uhlig, S., Rich, J.N., Reardon, D.A., Sampson, J.H., Provenzale, J.M., McLendon, R.E., Edwards, S., Gururangan, S., Affronti, M.L., Buchanan, W., Jackson, S., Allen, H., Penne, K., Lentz, C. Bigner, D.D., Haglund, M.M., Friedman, A.H.,

Avgeropoulos, N., Korones, D., Stafford-Fox, V., ZakNoen, S., and Friedman, H.S.: Phase II trial of Temodar® in patients with progressive low grade glioma. Presentation: Fourteenth International Conference on Brain Tumor Research and Therapy, May 27-30, 2001, Asheville, NC. Neuro-Oncology [serial online], Doc. B136, URL <http://neurooncology.mc.duke.edu>. Neuro-Oncology 3 (Suppl 1):S33, 2001.

314. Quinn, J.A., Friedman, H.S., Petros, W., Rich, J.N., Glantz, M.J., Sands, H., Tourt-Uhlig, S., Stewart, E., Gururangan, S., Sampson, J., Friedman, A.H., Colvin, O.M., and Quinn, J.A.: Phase I trial of intrathecal Spartaject™ busulfan for patients with leptomeningeal metastases. Presentation: Fourteenth International Conference on Brain Tumor Research and Therapy, May 27-30, 2001, Asheville, NC. Neuro-Oncology [serial online], Doc. B137, URL <http://neuro-oncology.mc.duke.edu>. Neuro-Oncology 3 (Suppl 1):S33, 2001.

315. Quinn, J.A., Dolan, M.E., Pegg, A., Moschel, R.C., Pluda, J., McLendon, R.E., Provenzale, J., Petros, W., Tourt-Uhlig, S., Rich, J.N., Gururangan, S., Affronti, M.L., Buchanan, W., Colvin, O.M., Stewart, E., Friedman, A.H., Bigner, D.D., and Friedman, H.S.: Phase II trial of O6-BG plus BCNU for patients with malignant glioma. Presentation: Fourteenth International Conference on Brain Tumor Research and Therapy, May 27-30, 2001, Asheville, NC. Neuro-Oncology [serial online], Doc. B138, URL <http://neurooncology.mc.duke.edu>. Neuro-Oncology 3 (Suppl 1):S34, 2001.

316. Reardon, D., Akabani, G., Friedman, A., Friedman, H., Herndon, J., McLendon, R., Quinn, J., Rich, J., Regalado, L., Sampson, J., Shafman, T., Wong, T., Bigner, D., and Zalutsky, M.: A Phase I study of Astatine-211 labeled human/murine chimeric antitenascin monoclonal antibody 81C6 via surgically created resection cavities for patients with high grade gliomas. Abstract 390. Sixth Annual Meeting of Society for Neuro-Oncology, November 15-18, 2001, Washington, DC. Neuro-Oncology [serial online], Doc. 390, URL <http://neuro-oncology.mc.duke.edu>. Neuro-Oncology 3(4):365, 2001.

317. Reardon, D., Affronti, M.L., Allen, D., Beason, R., Gururangan, S., Friedman, A., Herndon, J., Jackson, S., McLendon, R., Quinn, J., Rich, J., Sampson, J., Walker, A., Ziegler, K., Bigner, D., and Friedman, H.: A Phase II study of irinotecan plus BCNU for adults with high grade gliomas. Abstract 391. Sixth Annual Meeting of Society for Neuro-Oncology, November 15-18, 2001, Washington, DC. Neuro-Oncology [serial online], Doc. 391, URL <http://neuro-oncology.mc.duke.edu>. Neuro-Oncology 3(4):365, 2001.
318. Reardon, D., Affronti, M.L., Allen, D., Beason, R., Eveans, B., Gururangan, S., Friedman, A., Jackson, S., McLendon R., Quinn, J., Rich, J., Sampson, J., Stafford-Fox, V., Ziegler, K., Bigner, D., and Friedman, H.: A Phase I study of CPT-11 plus temozolomide for adults with recurrent malignant glioma. Abstract 392. Sixth Annual Meeting of Society for Neuro-Oncology, November 15-18, 2001, Washington, DC. Neuro-Oncology [serial online], Doc. 392, URL <http://neuro-oncology.mc.duke.edu>. Neuro-Oncology 3(4):365, 2001.
319. Wang, G.T., Chewning, T., Archer, G.A., McLendon, R.E., Bigner, D.D., Friedman, H.S., and Sampson, J.H.: SN-38G delivered via intratumoral microinfusion is effective against malignant glioma in athymic rats. Presentation: World Federation of Neuro-Oncology First Quadrennial Meeting and Society for Neuro-Oncology Sixth Annual Meeting, November 15-18, 2001, Washington, DC. Neuro-Oncology [serial online], Doc. A126, URL <http://neuro-oncology.mc.duke.edu>. Neuro-Oncology 3 (4):297, 2001.
320. Friedman, H. Quinn, J., Reardon, D., Rich, J., Friedman, A., Sampson, J., Evans, B., Tourt-Uhlig, S., Stafford-Fox, V., Bigner, D., and Zaknoen, S.: Phase II treatment of adults with brain metastases with Temodar. Presentation: World Federation of Neuro-Oncology First Quadrennial Meeting and Society for Neuro-Oncology Sixth Annual Meeting, November 15-18, 2001, Washington, DC. Neuro-Oncology [serial online], Doc. A362, URL

<http://neuro-oncology.mc.duke.edu>. Neuro-Oncology 3 (4):358, 2001.

321. Reardon, D., Sampson, J., Akabani, G., Archer, G., Coleman, R., Friedman, A., Friedman, H., Herndon, J., Kunwar, D., McLendon, R., Penne, K., Provenzale, J., Quinn, J., Rich, J., Marcus, S., Pastan, I., and Bigner, D.: A Phase 1 study of a recombinant chimeric protein composed of transforming growth factor (TCG)-alpha and a mutated form of the *Pseudomonas* exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. Abstract 393. Sixth Annual Meeting of Society for Neuro-Oncology, November 15-18, 2001, Washington, DC. Neuro-Oncology [serial online], Doc. 393, URL <http://neurooncology.mc.duke.edu>. Neuro-Oncology 3(4):366, 2001.

322. Friedman, H.S., Keir, S.T., Pegg, A.E., Houghton, P.J., Colvin, O.M., Moschel, R.C., Bigner, D.D., and Dolan, M.E.: O6-benzylguanine (O6-BG)-mediated enhancement of CPT-11 plus temozolomide combination therapy. Abstract #3934. Presentation: American Association for Cancer Research, 93rd Annual Meeting, April 6-10, 2002. San Francisco, CA. Proc. Am. Assoc. Cancer Res. 43:794, 2002.

323. Learn, C.A., Archer, G.E., Heimberger, A.B., McLendon, R.E., Chewning, T.A., Tuck, F.L., Pracyk, J.B., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Sampson, J.H.: Oral administration of the specific epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (Iressa) is efficacious against EGFR-overexpressing intracranial

95

tumors. Abstract #3890. Presentation: American Association for Cancer Research, 93rd Annual Meeting, April 6-10, 2002, San Francisco, CA. Proc. Am. Assoc. Cancer Res. 43:784, 2002.

324. Behin, A., Friedman, H., Faivre, S., Carpentier, A., Ould-Kaci, M., Delattre, J.Y., Lokiec, F., Weems, G., Smith, S., and Raymond, E.: Phase II clinical and pharmacokinetic (PK) trial of iriflufen in patients (pts) with recurrent malignant glioma: preliminary data.

Abstract #3708. Presentation: American Association for Cancer Research, 93rd Annual Meeting, April 6-10, 2002, San Francisco, CA. Proc. Am. Assoc. Cancer Res. 43:747, 2002.

325. Vaidyanathan, G., Liu, W., Welsh, P.C., Affleck, D.J., Norman, J.A., Johnson, S.P., Friedman, H.S., and Zalutsky, M.R.: Improved synthesis and further evaluation of O6-3-[131I]-iodobenzylguanine ([131I]-IBG), a potential agent for the noninvasive mapping of alkyl guanine-DNA-alkyltransferase (AGT). Abstract #1015. Presentation: American Association for Cancer Research, 93rd Annual Meeting, April 6-10, 2002, San Francisco, CA. Proc. Am. Assoc. Cancer Res. 43:202, 2002.

326. Provenzale, J.M., Wang, G.R., Petrella, J.R., and Friedman, H.S.: Measurement of MR permeability and corrected cerebral blood volume in high-grade and low-grade brain tumors. Presentation: Radiological Society of North America, 2001.

327. Provenzale, J.M., Wang, G.R., Petrella, J.R., and Friedman, H.S.: Correlation of maximum permeability and maximum corrected CBV values in brain neoplasms. Presentation: Radiological Society of North America, 2001.

328. Vaidyanathan, G., Liu, W., Welsh, P.C., Affleck, D.J., Norman, J.A., Johnson, S.P., Friedman, H.S., and Zalutsky, M.R.: Improved synthesis and further evaluation of O6-131Iiodobenzylguanine (131I-IBG), a potential agent for the noninvasive mapping of alkyl guanine-DNA alkyltransferase (AGT). Submitted, 2001.

329. Friedman, H.S., Yung, W.A., Jackson, E., Provenzale, J., Leeds, N., Conrad, C., Walker, A., Henry, A., Laurent, D. and Dugan, M.: A phase I trial of PTK787/ZK 222584 (PTK/ZK), a novel oral VEGF-R TK inhibitor in patients with recurrent GBM. Presentation: AACRNCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2001.

330. Reid, J.M., Cha, S., Buckner, J.C., Petros, W.P., Friedman, H.S., Tourt-Uhlig, S., Walker,

A., Kuhn, J.G., Prados, M., Supko, J.G., Gilbert, M.R., Batchelor, T.T., Schaaf, L., Gaylor, S.K., McGovren, J.P. and Gallo, J.M.: Pharmacokinetics of CPT-11 in glioma patients: pooler analysis of data from 4 NCI-sponsored trials (Duke University, NABTC, NABTT, NCCTG). Presentation: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2001.

331. Johnson, S.P., Noronha, A.M., Noll, D.M., Colvin, O.M., Friedman, H.S., and Miller, P.S.: Repair of N4C-ethyl-N4C crosslinked DNA by mammalian nuclear extracts. Abstract #5092. Presentation: American Association for Cancer Research, 93rd Annual Meeting, April 6-10, 2002, San Francisco, CA. Proc. Am. Assoc. Cancer Res. 43:1028, 2002.

96

332. Sampson, J.H., Grossi, P.M., Ocahai, H., Archer, G.E., Chewning, T., McLendon, R.E., Friedman, A.H., Friedman, H., and Bigner, D.D.: Intracerebral microinfusion of Herceptin® in an athymic rat model of intracranial metastatic breast cancer. Abstract #4578. Presentation: American Association for Cancer Research, 93rd Annual Meeting, April 6-10, 2002, San Francisco, CA. Proc. Am. Assoc. Cancer Res. 43:924, 2002.

333. Stenzel, T.T., Wikstrand, C.J., McLendon, R.E., Kuan, C.T., Wakiya, K., Friedman, H.S., and Bigner, D.D.: Development of real-time PCR assays for the proper selection of EGFR targeted small molecular and immunotoxin therapies for malignant gliomas. Abstract #3706. Poster Presentation: American Association for Cancer Research, 93rd Annual Meeting, April 6-10, 2002, San Francisco, CA. Proc. Am. Assoc. Cancer Res. 43:747, 2002.

334. Sampson, J.H., Reardon, D., Akabani, G., Archer, G., Friedman, A., Friedman, H., Herndon, J., McLendon, R., Penne, K., Paolino, A., Tourt-Uhlig, S., Quinn, J., Rich, J., Williams, R., Marcus, S., Wang, Q.-C., Pastan, I., and Bigner, D.: A Phase I study of intratumoral infusion of a recombinant chimeric protein composed of transforming growth

factor (TGF)- α and a mutated form of the pseudomonas exotoxin (TP-38) for the treatment of malignant brain tumors. Abstract #3703. Presentation: American Association for Cancer Research, 93rd Annual Meeting, April 6-10, 2002, San Francisco, CA. Proc. Am. Assoc. Cancer Res. 43:746, 2002.

335. Reardon, D., Akabani, G., Friedman, A., Friedman, H., Herndon, J., McLendon, R., Quinn, J., Rich, J., Penne, K., Sampson, J., Shafman, T., Wong, T., Zalutsky, M., and Bigner, D.: Phase I trial results: treatment of patients with newly diagnosed malignant gliomas using 131-iodine labeled human/murine chimeric antitenascin monoclonal antibody 81C6 via surgically created resection cavities. Abstract #2440. Presentation: American Association for Cancer Research, 93rd Annual Meeting, April 6-10, 2002, San Francisco, CA. Proc. Am. Assoc. Cancer Res. 43:491, 2002.

336. Hwang, E., Rich, J.N., Friedman, H.S., Keir, S.T., Bigner, D.D., Wakeling, A.E., Barge, A., and Sampson, J.H.: Antitumor activity of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TK1), in combination with temozolomide in human cancer. Abstract #3903. Presentation: American Association for Cancer Research, 93rd Annual Meeting, April 6-10, 2002, San Francisco, CA. Proc. Am. Assoc. Cancer Res. 43:787, 2002.

337. Korones, D.N., Benita-Weiss, M., Mechtler, L., Bushunow, P., Evans, B.L., and Friedman, H.S.: A phase I study of Temodar and escalating doses of oral VP-16 for adults with recurrent malignant glioma. Presentation: American Society of Clinical Oncology, 38th Annual Meeting, May 18-21, 2002, Orlando, FL. 21:67b, 2002.

338. Quinn, J.A., Glantz, M., Petros, W., Rich, J., Sands, H., Tourt-Uhlig, S., Walker, A., Reardon, D., Gururangan, S., Sampson, J., Friedman, A., Colvin, O.M., and Friedman, H.: Phase I trial of intrathecal Spartaject™ busulfan for patients with neoplastic meningitis. Presentation: American Society of Clinical Oncology, 38th Annual Meeting, May 18-21,

2002, Orlando, FL. 21:80a, 2002.

97

339. Friedman, A.H., Agarwal, S., Evans, B., Walker, A., Tourt-Uhlig, S., Reardon, D., Affronti, M.L., Allen, D., Beason, R., Gururangan, S., Jackson, S., McLendon, R., Quinn, J., Rich, J., Sampson, J., Stafford-Fox, V., Ziegler, K., Bigner, D., and Friedman, H.: Novel use of gliadel for gliomas. Presentation: American Society of Clinical Oncology, 38th Annual Meeting, May 18-21, 2002, Orlando, FL. 21:74b, 2002.

340. Friedman, H.S., Pluda, J., Weingart, J., Brem, H., Evans, B., Petros, W., Rich, J., Tourt-Uhlig, S., Gururangan, S., Reardon, D., Sampson, J., Friedman, A., Provenzale, J., McLendon, R., Colvin, O.M., Bigner, D., Dolan, E., Pegg, A., Moschel, R., and Quinn, J.: Phase I trial of temodar plus O6-benzylguanine in the treatment of patients with recurrent or progressive cerebral anaplastic gliomas. Presentation: American Society of Clinical Oncology, 38th Annual Meeting, May 18-21, 2002, Orlando, FL. 21:78a, 2002.

341. Yung, W.A., Friedman, H., Jackson, E., Provenzale, J., Leeds, N., Conrad, C., Walker, A., Henry, A., Huang, J., Laurent, D., and Dugan, M.: A phase I trial of PTK787/ZK 222584 (PTK/ZK), a novel oral VEGFR TK inhibitor in recurrent glioblastoma. Presentation: American Society of Clinical Oncology, 38th Annual Meeting, May 18-21, 2002, Orlando, FL. 21:79a, 2002.

342. Khatib, Z., Kadota, R., Buatti, J., Kaufman, B., Burger, P., Langston, J., Friedman, H., and Kun, L.: Phase II study of pre-irradiation topotecan in children with ependymoma: a Pediatric Oncology Group study. Presentation: American Society of Clinical Oncology, 38th Annual Meeting, May 18-21, 2002, Orlando, FL. 21:401a, 2002.

343. Sampson, J.H., Reardon, D., Akabani, G., Archer, G., Friedman, A., Friedman, H., Herndon, J., McLendon, R., Penne, K., Paolino, A., Tourt-Uhlig, S., Quinn, J., Rich, J., Williams, R., Marcus, S., Pastan, I., and Bigner, D.D.: A phase I study of intratumoral

infusion of a recombinant chimeric protein composed of transforming growth factor (TGF)- β and a mutated form of the Pseudomonas exotoxin (TP-38) for the treatment of malignant brain tumors. Presentation 1860: American Society of Clinical Oncology, 38th Annual Meeting, May 18-21, 2002, Orlando, FL. 21:13b, 2002.

344. Affronti, M.L., Reardon, D., Allen, D., Beason, R., Gururangan, S., Friedman, A., Herndon, J., Jackson, S., McLendon, R., Quinn, J., Rich, J., Sampson, J., Walker, A., Bigner, D.D., and Friedman, H.: A phase II study of CPT-11 plus BCNU for adults with high grade glioma. Presentation 2091: American Society of Clinical Oncology, 38th Annual Meeting, May 18-21, 2002, Orlando, FL. 21:70b, 2002.

345. Tourt-Uhlig, S., Reardon, D., Affronti, M.L., Allen, D., Beason, R., Evans, B., Gururangan, S., Friedman, A., Jackson, S., McLendon, R., Quinn, J., Rich, J., Sampson, J., Stafford-Fox, V., Ziegler, K, Bigner, D.D., and Friedman, H.: Treatment of adults with recurrent malignant glioma using temozolomide plus CPT-11: a phase I study. Presentation 2096: American Society of Clinical Oncology, 38th Annual Meeting, May 18-21, 2002, Orlando, FL. 21:71b, 2002.

98

346. Reardon, D., Akabani, G., Friedman, A., Friedman, H., Herndon, J., II, Cokgor, I., McLendon, R., Quinn, J., Rich, J., Penne, K., Sampson, J., Shafman, T., Wong, T., Zalutsky, M., and Bigner, D.D.: Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody treatment of patients with newly diagnosed malignant brain tumors following external beam radiotherapy. Presentation 2113: American Society of Clinical Oncology, 38th Annual Meeting, May 18-21, 2002, Orlando, FL. 21:75b, 2002.

347. Ngugen, T.B., Barbariak, D.P., Akabani, G., Friedman, H.S., and Provenzale, J.M.: Evaluation of changes in cerebral blood volume, cerebral blood flow and mean transit time after intracavitary radiation therapy for glioma. Presentation: American Society of

Neuroradiology, Vancouver, BC, 2002.

348. Reardon, D., Akabani, G., Friedman, A., Friedman, H., Herndon, J., McLendon, R., Quinn, J., Rich, J., Penne, K., Sampson, J., Shafman, T., Wong, T., Zalutsky, M., and Bigner, D.: Results of a phase I/II trial using iodine 131-labeled human–mouse chimeric antitenascin monoclonal antibody 81C6 via surgically created resection cavities in the treatment of patients with newly diagnosed malignant gliomas. Abstract 245. Society for Neuro-Oncology Seventh Annual Meeting, San Diego, CA, November 21-24, 2002. *Neuro-Oncology* 4:375, 2002.

349. Reardon, D., Sampson, J., Akabani, G., Archer, G., Coleman, R., Friedman, A., Friedman, H., Herndon, J., Kunwar, R., McLendon, R., Penne, K., Paolino, A., Quinn, J., Rich, J., Williams, R., Wong, T., Marcus, S., Bigner, D., and Pastan, I.: Preliminary phase I study results of a recombinant chimeric protein composed of transforming growth factor alpha (TGF)- α and a mutated form of the pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. Society for Neuro-Oncology Seventh Annual Meeting, San Diego, CA, November 21-24, 2002. *Neuro-Oncology* 4:376, 2002.

350. Provenzale, J.M., Liang, L., Petrella, J., and Friedman, H.S.: Comparison of T1-weighted perfusion measurements and relative cerebral blood volume measurements in high-grade gliomas. Presentation: Radiologic Society of North America, 2002.

351. Zalutsky, M., Reardon, D., Akabani, G., Friedman, A., Friedman, H., Herndon, J., McLendon, R., Quinn, J., Rich, J., Penne, K., Sampson, J., Shafman, T., Wong, T., and Bigner, D.: Astatine 211-labeled human-mouse chimeric antitenascin monoclonal antibody 81C6 via surgically created resection cavities for patients with recurrent malignant glioma: Phase I study results. Presentation: Fifth Congress of the European Association of Neuro-Oncology, September 7-10, 2002, Florence, Italy.

352. Reardon, D., Akabani, G., Friedman, A., Friedman, H., Herndon, J., McLendon, R., Quinn,

J., Rich, J., Penne, K., Sampson, J., Shafman, T., Wong, T., Zalutsky, M., and Bigner, D.: Treatment of patients with newly diagnosed malignant gliomas using iodine 131-labeled human-mouse chimeric antitenascin monoclonal antibody 81C6 via surgically created resection cavities: Phase I/II trial results. Presentation: Fifth Congress of the European Association of Neuro-Oncology, September 7-10, 2002, Florence, Italy.

99

353. Reardon, D., Akabani, G., Herndon, J., Wong, T., Coleman, E., Friedman, H., Friedman A., Zalutsky, M., and Bigner D.: Radiolabeled anti-tenascin monoclonal antibody 81C6 administered into surgical resection cavities in the treatment of patients with malignant brain tumors. Presentation, Keystone Symposium on Antibody-Based Therapeutics for Cancer (B4), February 4-9, 2003, Banff, Alberta.

354. Archer, G.E., Sampson, J.H., Friedman, H., Friedman, A., Reardon, D., Quinn, J., Paolino, A., and Bigner, D.D.: Immunologic monitoring of a dendritic cell based vaccine trial in glioma patients. Abstract #2000. Presentation, AACR 94th Annual Meeting, July 11-14, 2003, Washington, D.C. Proc. Am. Assoc. Cancer Res. 44:456, 2003.

355. Learn, C.A., Heimberger, A.B., Lal, A., Glazer, C.A., Martinson, H.E., Riggins, G.J., Archer, G.E., McLendon, R.E., Chewing, T.A., Tuck, F.L., Pracyk, J.B., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Sampson, J.H.: Brain tumor growth and invasion in mice are susceptible to inhibition by blockade of epidermal growth factor receptor (EGFR) with a selective EGFR-tyrosine kinase inhibitor. Presentation, AANS Annual Meeting, April 26-May 1, 2003, San Diego, California, 2003.

356. Sampson, J.H., Reardon, D., Akabani, G., Archer, G., Coleman, R., Friedman, A., Friedman, H., Herndon, J., Kunwar, S., McLendon, R., Penne, K., Paolino, A., Quinn, J., Rich, J., Williams, R., Marcus, S., Pastan, I., and Bigner, D.: Preliminary phase I study results of a recombinant chimeric protein composed of transforming growth factor (TGF)- α

and a mutated form of the *Pseudomonas* exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. Presentation, AANS Annual Meeting, April 26-May 1, 2003, San Diego, California, 2003.

357. Vaidyanathan, G., Affleck, D.J., Welsh, P., Peixoto, K.C., Snyder, S.A., Friedman, H.S., and Zalutsky, M.R.: A 4-methyl substituted MIGB analogue. Presentation: 15th International Symposium on Radiopharmaceutical Chemistry, 2003.

358. Provenzale, J.M., Galvez Moya, M., Liang, L., Delong, D., and Friedman, H.: Correlation of T1-weighted relative permeability and rCBV values in brain neoplasms. Presentation: American Society of Neuroradiology, Washington, D.C., 2003.

359. Sampson, J.H., Akabani, G., Archer, G., Berger, M., Coleman, R.E., Friedman, A., Friedman, H., Herndon, J., Kunwar, S., Marcus, S., McLendon, R., Provenzale, J., Quinn, J., Reardon, D., Rich, J., Wong, T., Williams, R., Yuan, F., Zalutsky, M., Bigner, D., and Pastan, I.: Response and convection-enhanced delivery imaging results of a Phase I trial of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated *Pseudomonas* exotoxin termed PE-38 (TP-38) for the direct intracerebral treatment of malignant brain tumors. 15th International Conference on Brain Tumor Research, Sorrento, Italy, May 24-27, 2003.

360. Sampson, J.H., Akabani, G., Reardon, D.A., Coleman, R.E., Friedman, H.S., Provenzale, J., Friedman, A.H., Pedain, C., Brady, M., Raghavan, R., Pastan, I., and Bigner, D.D.: Imaging and predicting the extensive intracerebral distribution of macromolecules after direct infusion. Presentation, Fifteenth International Conference on Brain Tumor Research and Therapy, May 24-27, 2003, Sorrento, Italy. *Neuro-Oncology* 5:397, 2003.

100

361. Learn, C.A., Hartzell, T.L., Archer, G.E., Riggins, G.J., Friedman, H.S., Friedman, A.H., Bigner, D.D., and Sampson, J.H.: Inhibition of cell cycle progression and invasion of cells

expressing epidermal growth factor receptor (EGFR) but not mutant EGFR variant III (EGFRvIII) by tyrosine kinase inhibition (TKI). Presentation, Fifteenth International Conference on Brain Tumor Research and Therapy, May 24-27, 2003, Sorrento, Italy. *Neuro-Oncology* 5:388, 2003.

362. Rich, J.N., Peery, T., Reardon, D., Quinn, J.A., Dancey, J., Wikstrand, C., Stenzel, T.T., McLendon, R.E., Friedman, A., Sampson, J., Bigner, D.D., and Friedman, H.S.: Phase I/II trial of ZD1839 (*Iressa*) in patients with first relapse glioblastoma. 15th International Conference on Brain Tumor Research, Sorrento, Italy, May 24-27, 2003. *Neuro-Oncology* 5:396, 2003.

363. Wiltshire, R.N., Herndon, J., Lloyd, A., Friedman, H., Bigner, D., Bigner, S., and McLendon, R.: Comparative genomic hybridization (CGH) characterization of high grade astrocytomas. Presentation, Fifteenth International Conference on Brain Tumor Research and Therapy, May 24-27, 2003, Sorrento, Italy. *Neuro-Oncology* 5:402, 2003.

364. Archer, G., Bigner, D., Friedman, A., Friedman, H., Heimberger, A., and Sampson, J.: Induction of CD4 and CD8 T-cells to the tumor specific antigen EGFRvIII. Presentation, Fifteenth International Conference on Brain Tumor Research and Therapy, May 24-27, 2003, Sorrento, Italy. *Neuro-Oncology* 5:375, 2003.

365. Reardon, D., Akabani, G., Friedman, A., Friedman, H., Herndon, J., McLendon, R., Quinn, J., Rich, J., Penne, K., Sampson, J., Shafman, T., Vredenburgh, J., Wong, T., Zalutsky, M., and Bigner, D.: Phase I trial results using iodine 131-labeled human-mouse chimeric antitenascin monoclonal antibody 81C6 via surgically created resection cavities in the treatment of patients with malignant gliomas. 15th International Conference on Brain Tumor Research, Sorrento, Italy, May 24-27, 2003. *Neuro-Oncology* 5:395, 2003.

366. Vaidyanathan, G., Friedman, H., Wester, H.-J., Schottelium, M., and Zalutsky, M.R.: A peptide based targeted radiotherapeutic for medulloblastoma. 15th International Conference

on Brain Tumor Research, Sorrento, Italy, May 24-27, 2003.

367. Ali-Osman, F., Akande, O., Antoun, G., and Friedman, H.: Transcriptional activation of the GSTP1 gene by wild-type p53 results in DNA mismatch repair dependent NER: a novel p53-GSTP1 mediated mechanism of alkylator resistance in human gliomas. 15th International Conference on Brain Tumor Research, Sorrento, Italy, May 24-27, 2003.

368. Rich, J.N., Keir, S.T., Wheeler, C., Reardon, D.A., Bigner, D.D., and Friedman, H.S.: ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, inhibits central nervous system tumor growth following oral administration. 15th International Conference on Brain Tumor Research, Sorrento, Italy, May 24-27, 2003. *Neuro-Oncology* 5:396, 2003.

101

369. Reardon, D., Akabani, G., Friedman, A., Friedman, H., Herndon, J., McLendon, R., Quinn, J., Rich, J., Penne, K., Sampson, J., Shafman, T., Vredenburgh, J., Wong, T., Zalutsky, M., and Bigner, D.: Phase I trial results using iodine 131-labeled human-mouse chimeric antitenascin monoclonal antibody 81C6 via surgically created resection cavities in the treatment of patients with malignant gliomas. Presentation, SPORE Investigators Workshop, July 8-10, 2003, Baltimore, Maryland.

370. Sampson, J.H., Akabani, G., Archer, G., Berger, M., Coleman, R.E., Friedman, A., Friedman, H., Herndon, J., Kunwar, S., Marcus, S., McLendon, R., Provenzale, J., Quinn, J., Reardon, D., Rich, J., Wong, T., Williams, R., Yuan, F., Zalutsky, M., Pastan, I., and Bigner, D.: Response and convection-enhanced delivery imaging results of a Phase I trial of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated *Pseudomonas* exotoxin termed PE-38 (Tp-38) for the direct intracerebral treatment of malignant brain tumors. Presentation, SPORE Investigators Workshop, July 8-10, 2003, Baltimore, Maryland.

371. Sampson, J.H., Akabani, G., Archer, G., Berger, M., Coleman, R.E., Friedman, A., Friedman, H.S., Herndon, J., Kunwar, S., Marcus, S., McLendon, R., Provenzale, J., Quinn, J., Reardon, D., Rich, J., Wong, T., Williams, R., Yuan, F., Zalutsky, M., Bigner, D., and Pastan, I.: Response and convection-enhanced delivery imaging results of a Phase I trial of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated Pseudomonas exotoxin termed PE-38 (TP-38) for the direct intracerebral treatment of malignant brain tumors. Abstract #4004. Presented at the AACR 94th Annual Meeting, July 11-14, 2003, Washington D.C. Proc. Am. Assoc. Cancer Res. 44:916, 2003.

372. Rich, J.N., Keir, S.T., Wheeler, C., Reardon, D.A., Bigner, D.D., and Friedman, H.S.: ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, inhibits central nervous system tumor growth following oral administration. Abstract #48. Presentation, AACR 94th Annual Meeting, July 11-14, 2003, Washington, D.C. Proc. Am. Assoc. Cancer Res. 44:11, 2003.

373. Learn, C.A., Archer, G.E., Riggins, G.J., Friedman, H.S., Bigner, D.D., and Sampson, J.H.: Inhibition of cell cycle progression and invasion of cells expressing epidermal growth factor receptor (EGFR) but not mutant EGFR variant III (EGFRVIII) by the specific EGFR tyrosine kinase inhibitor (TKI) gefitinib (Iressa, ZD1839). Abstract #6199. Presentation, AACR 94th Annual Meeting, July 11-14, 2003, Washington, D.C. Proc. Am. Assoc. Cancer Res. 44:1420, 2003.

374. Sebastian, S., Lister, D., Rasheed, B.K.A., McLendon, R.E., Friedman, H.S., Bigner, D.D., and Stenzel, T.T.: Validation of a semi-automated loss of heterozygosity assay for chromosomes 1 and 19 in human gliomas using commercially available fluorescent-labeled human MapPairs® and capillary electrophoresis. Abstract #3534. Presentation, AACR 94th Annual Meeting, July 11-14, 2003, Washington, D.C. Proc. Am. Assoc. Cancer Res. 44:807, 2003.

375. Rich, J.N., Keir, S.T., Goudar, R.K., Hjelmeland, M.D., Wheeler, C.D., Reardon, D.A., Bigner, D.D., and Friedman, H.S.: ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, inhibits central nervous system tumor growth following oral administration. Presentation: American Neurological Association 128th Annual Meeting and the 6th Annual Neurology Outcomes Symposium, 2003.

376. Rich, J.N., Hjelmeland, M.D., Keir, S.T., Goudar, R.K., Traxler, P., Lane, H., Reardon, D.A., Bigner, D.D., and Friedman, H.S.: Combination of AEE788, an epidermal growth factor/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, and RAD001, an inhibitor of the mammalian target of rapamycin, inhibits glioblastoma tumor growth following oral administration. Presentation: American Neurological Association 128th Annual Meeting and the 6th Annual Neurology Outcomes Symposium, 2003.

377. Rich, J.N., Van Duyn, L., Peery, T., Reardon, D., Quinn, J.A., Wikstrand, C., Dancey, J., Stenzel, T., Friedman, A.H., Sampson, J., Bigner, D.D., and Friedman, H.S.: Phase I/II trial of ZD1839 (*Iressa*) in patients with first relapse glioblastoma. Presentation: American Neurological Association 128th Annual Meeting and the 6th Annual Neurology Outcomes Symposium, 2003.

378. Peery, T.S., Reardon, D.A., Quinn, J., Ochs, J., Wikstrand, C., Stenzel, T.T., Bigner, D.D., Friedman, H.S., Rich, J.N., and Dancey, J.: Phase II trial of ZD1839 for patients with first relapse glioblastoma. Abstract #396. Presentation: ASCO Annual Meeting, 2003. Proc. Am. Soc. Clin. Oncol. 22:99, 2003.

379. Yung, W.K.A., Friedman, H., Conrad, C., Reardon, D., Provenzale, J., Jackson, E., Leeds, N., Serajuddin, H., Laurent, D., and Reitsma, D.: A phase I trial of single-agent PTK 787/ZK 222584 (PTH/ZK), an oral VEGFR tyrosine kinase inhibitor, in patients with recurrent glioblastoma multiforme. Abstract #395. Presentation: ASCO Annual Meeting,

2003. Proc. Am. Soc. Clin. Oncol. 22:99, 2003.

380. Sampson, J.H., Akabani, G., Archer, G., Merger, M., Friedman, A., Friedman, H.S., Marcus, S., Reardon, D., Bigner, D.D., and Pastan, I.: Clinical outcome and distribution measure of a recombinant chimeric protein composed of transforming growth factor alpha and a mutated Pseudomonas exotoxin (TP-38) via convection-enhanced microinfusion on a phase I study for malignant brain tumor. Abstract #397. Presentation: ASCO Annual Meeting, 2003. Proc. Am. Soc. Clin. Oncol. 22:99, 2003.

381. Friedman, H.S., Evans, B., Reardon, D., Quinn, J., Rich, J., Gururangan, S., Stafford-Fox, V., Chen, C., Pati, A., and Schmidt, W.: Phase II trial of temozolomide for patients with progressive brain metastases. Abstract #408. Presentation: ASCO Annual Meeting, 2003. Proc. Am. Soc. Clin. Oncol. 22:102, 2003.

382. Badruddoia, M.A., Reardon, D., Beason, R., Friedman, A., Quinn, J.A., Rich, J., Sampson, J., Stafford-Fox, V., Bigner, D.D., and Friedman, H.S.: Phase I study of temozolomide plus irinotecan (CPT-11) in adults with recurrent malignant glioma. Abstract #409. Presentation: ASCO Annual Meeting, 2003. Proc. Am. Soc. Clin. Oncol. 22:102, 2003.

103

383. Reardon, D., Friedman, H.S., Yung, W.K.A., Brada, M., Conrad, C., Provenzale, J., Jackson, E.F., Serajuddin, H., Laurent, D., and Reitsma, D.: A phase I trial of PTK787/ZK 222584 (PTH/ZK), an oral VEGF tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Abstract #412. Presentation: ASCO Annual Meeting, 2003. Proc. Am. Soc. Clin. Oncol. 22:410, 2003.

384. Quinn, J.A., Weingart, J., Brem, H., Rich, J., Reardon, D., Sampson, J., Friedman, A., Friedman, H.S., Colvin, O.M., and Dolan, E.: Phase I trial of temozolomide plus O6-benzylguanine in the treatment of patients with recurrent or progressive cerebral anaplastic

gliomas. Abstract #411. Presentation: ASCO Annual Meeting, 2003. Proc. Am. Soc.

Clin. Oncol. 22:103, 2003.

385. Evans, B., Quinn, J., Reardon, D., Rich, J., Gururangan, S., Friedman, A., McLendon, R., Tourt-Uhlig, S., Stafford-Fox, V., and Friedman, H.S.: Phase II treatment of adults with newly diagnosed, progressive or recurrent primary central nervous system lymphoma with temozolomide. Abstract #438. Presentation: ASCO Annual Meeting, 2003. Proc. Am.

Soc. Clin. Oncol. 22:110, 2003.

386. Korones, D., Benita-Weiss, M., Coyle, T.E., Bushunow, P., Mechtler, L., and Friedman, H.S.: A phase II trial of temozolomide and oral VP-16 for adults with recurrent malignant glioma. Abstract #447. Presentation: ASCO Annual Meeting, 2003. Proc. Am. Soc. Clin.

Oncol. 22:112, 2003.

387. Gururangan, S., Friedman, H.S., Phillips, P.C., Petros, W., Blaney, S.M., Hunt, D., and Kun, L.E.: Phase I study of intrathecal (i.t.) Spartaject busulfan (Bu) in children with neoplastic meningitis (NM): A Pediatric Brain Tumor Consortium Trial. Abstract #456.

Presentation: ASCO Annual Meeting, 2003. Proc. Am. Soc. Clin. Oncol. 22:114, 2003.

388. Shafman, T., Reardon, D.A., Akabani, G., Friedman, A., Friedman, H.S., Sampson, J., Wong, T., Zhao, X.-G., Zalutsky, M., and Bigner, D.D.: Delivering a targeted radiation boost dose of 44Gy to the resection cavity perimeter of patients with newly diagnosed malignant brain tumors via an individualized dose of 131-iodine labeled murine

antitenascin monoclonal antibody 81C6: Preliminary results of a phase II trial. Abstract #466. Presentation: ASCO Annual Meeting, 2003. Proc. Am. Soc. Clin. Oncol. 22:117, 2003.

389. Hjelmeland, M.D., Sathornsumetee, S., Friedman, H.S., Laping, N.J., Bigner, D.D., Wang, X.F., and Rich, J.N.: Small molecule inhibitor of transforming growth factor beta (TGFbeta)

receptors blocks TGF-beta-mediated signal transduction and inhibits cellular

proliferation. Abstract ET-17. Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003. *Neuro-Oncology* 5:301, 2003.

104

390. Rich, J.N., Goudar, R.K., Hjelmeland, M.D., Keir, S.T., Traxler, P., Lane, H., Reardon, D.A., Bigner, D.D., and Friedman, H.S.: Combination of AEE788, an epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, and RAD001, an inhibitor of the mammalian target of rapamycin, inhibits glioblastoma tumor growth following oral administration. Abstract ET-39. Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003. *Neuro-Oncology* 5:307, 2003.

391. Rich, J.N., Keir, S., Goudar, R.K., Hjelmeland, M.D., Wheeler, C., Reardon, D.A., Bigner, D.D., and Friedman, H.S.: ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, inhibits central nervous system tumor growth following oral administration. Abstract ET-40. Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003. *Neuro-Oncology* 5:307, 2003.

392. Badruddoja, M.A., Reardon, D.A., Beason, R., Friedman, A., Quinn, J.A., Rich, J., Sampson, J., Stafford-Fox, V., Bigner, D.D., and Friedman, H.S.: Phase I study of temozolomide plus irinotecan (CPT-11) in adults with recurrent malignant glioma. Abstract TA-04. Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003. *Neuro-Oncology* 5:348, 2003.

393. Quinn, J., Bigner, D., Friedman, A., Herndon, J., McLendon, R., Provenzale, J., Rich, J., Reardon, D., Vredenburgh, J., Tourt-Uhlig, S., Walker, W., Stafford-Fox, V., Coover, C., and Friedman, H.: Phase II trial of Temodar plus O6-benzylguanine (O6-BG) in the treatment of patients with Temodar-resistant malignant glioma. Abstract TA-29. Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16,

2003. *Neuro-Oncology* 5:354-355, 2003.

394. Reardon, D., Affronti, M., Allen, D., Baddrudoja, M., Beason, R., Friedman, A., Gururangan, S., Jackson, S., Quinn, J., Rich, J., Sampson, J., Vredenburgh, J., Walker, A., Ziegler, K., Bigner, D., and Friedman, H.: A phase II study of CPT-11 plus celecoxib for adults with recurrent malignant glioma. Abstract TA-31. Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003. *Neuro-Oncology* 5:355, 2003.

395. Reardon, D., Akabani, G., Friedman, A., Friedman, H., Herndon, J., McLendon, R., Quinn, J., Rich, J., Vredenburgh, J., Penne, K., Sampson, J., Shafman, T., Wong, T., Coleman, R., Zalutsky, M., and Bigner, D.: Phase II trial of iodine 131-labeled murine antitenascin monoclonal antibody 81C6 (m81C6) via surgically created resection cavities in the treatment of patients with recurrent malignant brain tumors. Abstract TA-32. Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003. *Neuro-Oncology* 5:355, 2003.

105

396. Rich, J.N., Peery, T., Reardon, D.A., Quinn, J.A., Van Duyn, L., Dancey, J., Wikstrand, C., Stenzel, T., McLendon, R., Herndon, J., Friedman, A.H., Sampson, J., Bigner, D.D., and Friedman, H.S.: Phase I/II trial of the epidermal growth factor receptor small molecule inhibitor ZD1839 (GEFITINIB) in patients with first relapse glioblastoma. Abstract TA-34. Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003. *Neuro-Oncology* 5:356, 2003.

397. Conrad, C., Friedman, H., Reardon, D., Provenzale, J., Jackson, E., Serajuddin, H., Laurent, D., Chen, B., and Yung, W.K.A.: A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). Abstract #1512. Presentation: ASCO Annual Meeting, 2004. *Proc.*

Am. Soc. Clin. Oncol. 22:110S, 2004.

398. Reardon, D., Friedman, H., Yung, W.K.A., Brada, M., Conrad, C., Provenzale, J., Jackson, E., Serajuddin, H., Chen, B., and Laurent, D.: A phase I/II trial of PTK787/XK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Abstract #1513.

Presentation: ASCO Annual Meeting, 2004. Proc. Am. Soc. Clin. Oncol. 22:110S, 2004.

399. Desjardins, A., Quinn, J.A., Reardon, D.A., Rich, J.N., Vredenburgh, J.J., Efird, C., and Friedman, H.S.: Phase II study of thalidomide and daily Cyclophosphamide for adults with malignant glioma. Abstract #1554. Presentation: ASCO Annual Meeting, 2004. Proc.

Am. Soc. Clin. Oncol. 22:120S, 2004.

400. Badruddoja, M.A., Reardon, D.A., Akabani, G., Friedman, A.H., Friedman, H.S., Rich, J.N., Quinn, J.A., Penne, K., Vredenburgh, J.J., and Bigner, D.D.: Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors.

Abstract #1569. Presentation: ASCO Annual Meeting, 2004. Proc. Am. Soc. Clin. Oncol. 22:124S, 2004.

401. Reardon, D.A., Akabani, G., Dowell, J., Friedman, A., Friedman, H., Herndon, J., McLendon, R., Quinn, J., Rich, J., Vredenburgh, J., Penne, K., Sampson, J., Shafman, T., Wong, T., Coleman, R., Zalutsky, M., and Bigner, D.: Results of a phase II trial with iodine 131-labeled murine antitenascin monoclonal antibody 81C6 (m81C6) via surgically created resection cavities in the treatment of patients with recurrent malignant brain tumors.

Abstract #5237. Presented at the AACR 95th Annual Meeting, March 27-31, 2004, Orlando, Florida. Proc. Am. Assoc. Cancer Res. 45:1208, 2004.

402. Ueno, T., Grubbs, E., Ko, S.H., Cheng, T.Y., Abdel-Wahab, Z., Pruitt, S., Friedman, H.S., and Tyler, D.: Temozolomide; a novel regional perfusion agent for the treatment of

advanced extremity melanoma. Abstract #5129. Presented at the AACR 95th Annual Meeting, March 27-31, 2004, Orlando, Florida. Proc. Am. Assoc. Cancer Res. 45:1183, 2004.

106

403. Goudar, R.K., Keir, S.T., Bigner, D.D., and Friedman, H.S.: NMDA and AMPA glutamate receptor antagonists in the treatment of human malignant glioma xenografts. Abstract #4562. Presented at the AACR 95th Annual Meeting, March 27-31, 2004, Orlando, Florida. Proc. Am. Assoc. Cancer Res. 45:1053, 2004.

404. Archer, G.E., Bigner, D.D., Friedman, A., Friedman, H.S., Penne, K., Lally-Batts, D., Paolino, A., Tourt-Uhlig, S., Reardon, D., and Sampson, J.: Dendritic cell vaccine for intracranial tumors I (DC VICTORI trial). Abstract IM-02. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. Neuro-Oncology 6:341, 2004.

405. Badruddoja, M.A., Reardon, D.A., Vredenburgh, J.J., Quinn, J.A., Rich, J.N., Desjardins, A., Friedman, A., Walker, A., Bailey, P., Jex, R., and Friedman, H.S.: Phase II upfront CPT-11 plus celecoxib for adults with glioblastoma multiforme. Abstract TA-01. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. Neuro-Oncology 6:369-370, 2004.

406. Desjardins, A., Quinn, J., Reardon, D., Rich, J., Vredenburgh, J., Friedman, A., Tourt-Uhlig, S., Badruddoja, M., Efird, C., and Friedman, H.S.: Phase II study of thalidomide and daily low-dose cyclophosphamide for adults with anaplastic gliomas. Abstract TA-16. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. Neuro-Oncology 6:373, 2004.

407. Desjardins, A., Reardon, D., Vredenburgh, J., Rich, J., Gururangan, S., Friedman, A., Sampson, J., Provenzale, J., McLendon, R., Herndon II, J., Badruddoja, M., Amara, J.,

Tourt-Uhlig, S., Newton, H., Friedman, H.S., and Quinn, J.A.: Phase I trial of adults with primary malignant glioma with irinotecan (CPT-11) plus temozolomide (Temodar).

Abstract TA-17. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. *Neuro-Oncology* 6:373-374, 2004.

408. Quinn, J.A., Desjardins, A., Reardon, D., Vredenburgh, J., Rich, J., Gururangan, S., Friedman, A., Sampson, J., Provenzale, J., McLendon, R., Herndon II, J., Dolan, M.E., Badruddoja, M., Walker, A., Tourt-Uhlig, S., and Friedman, H.S.: Phase I trial of temozolomide (Temodar) plus irinotecan (CPT-11) plus O6-benzylguanine (O6-BG) in the treatment of recurrent or progressive cerebral anaplastic gliomas. Abstract TA-44.

Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. *Neuro-Oncology* 6:380, 2004.

409. Quinn, J.A., Desjardins, A., Reardon, D., Vredenburgh, J., Rich, J., Gururangan, S., Friedman, A., Sampson, J., Provenzale, J., McLendon, R., Herndon, II, J., Dolan, M.E., Badruddoja, M., Walker, A., Tourt-Uhlig, S., and Friedman, H.S.: Phase II trial of temozolomide (Temodar) plus O6-benzylguanine (O6-BG) in the treatment of patients with temodar-resistant malignant glioma. Abstract TA-45. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. *Neuro-Oncology* 6:380, 2004.

107

410. Reardon, D., Akabani, G., Friedman, A., Friedman, H.S., Herndon, J., McLendon, R., Quinn, J., Rich, J., Vredenburgh, J., Penne, K., Sampson, J., Gururangan, S., Shafman, T., Wong, T., Dowell, J., Dunn, R., Badruddoja, M., Desjardins, A., Affronti, M., Allen, D., Jackson, S., Zeigler, K., Silverman, S., Tourt-Uhlig, S., Coleman, R., Zalutsky, M., and Bigner, D.D.: Phase II study of 131-iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to

the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors. Abstract TA-46. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. *Neuro-Oncology* 6:381, 2004.

411. Reardon, D., Friedman, A., Herndon, J., Quinn, J., Rich, J., Vredenburgh, J., Badruddoja, M., Desjardins, A., Sampson, J., Gururangan, S., Dowell, J., Affronti, M., Allen, D., Jackson, S., Zeigler, K., Silverman, S., Tourt-Uhlig, S., Silverman, S., Salvado, A., Nikolova, Z., Bigner, D.D., and Friedman, H.S.: Phase II trial of imatinib mesylate plus hydroxyurea in the treatment of patients with malignant glioma. Abstract TA-47. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. *Neuro-Oncology* 6:381, 2004.

412. Reardon, D., Friedman, H.S., Brada, M., Conrad, C., Provenzale, J., Jackson, E., Serajuddin, H., and Chen, B.: A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a multi-VEGF receptor tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Abstract TA-48. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. *Neuro-Oncology* 6:381, 2004.

413. Sampson, J.H., Friedman, A.H., Reardon, D.A., Friedman, H.S., Provenzale, J.M., Bigner, D.D., Brady, M., Raghavan, R., Pedain, C., Archer, G., Lally-Batts, D., McGehee, S., Tourt-Uhlig, S., Grahn, A., Dul, J.L., Croteau, D., Sherman, J.W., and Puri, R.K.: Convection-enhanced delivery of IL13-PE38QQR in malignant glioma: Comparison of observed and predicted drug distribution. Abstract TA-49. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. *Neuro-Oncology* 6:381, 2004.

414. Akabani, G., Reardon, D.A., Coleman, R.E., Wong, T.Z., Metzler, S.D., Bowsher, J.E.,

Borboriak, D.P., Provenzale, J.M., Friedman, H.S., Friedman, A.H., McLendon, R.E., Zalutsky, M.R., and Bigner, D.D.: A phase II study of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: dosimetry and radiographic analysis. Presentation: Society of Nuclear Medicine Annual Meeting, June 2005.

415. Vredenburgh, J.J., Reardon, D., Akabani, G., Friedman, A., Friedman, H., McLendon, R., Quinn, J., Rich, J., Zalutsky, M., and Bigner, D.: Results of a phase II study of 131 iodinelabeled anti-tenascin murine monoclonal antibody 81C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimenter in the treatment of patients with newly diagnosed primary and metastatic brain tumors. Abstract #1510. Presentation: ASCO Annual Meeting 2005. Proc. Am. Soc. Clin. Oncol. 23:116a, 2005.

108

416. Friedman, H.S., Quinn, J., Rich, J., Vredenburgh, J., Desjardins, A., Sathornsumetee, S., Salvado, A., Nikolova, Z., Bigner, D., and Reardon, D.: Efficacy of imatinib mesylate plus hydroxyurea regimen in the treatment of recurrent malignant glioma: Phase II study results. Abstract #1513. Presentation: ASCO Annual Meeting 2005. Proc. Am. Soc. Clin. Oncol. 23:117a, 2005.

417. Friedman, H.S., Quinn, J., Rich, J., Vredenburgh, J., Desjardins, A., Sathornsumetee, S., Salvado, A., Nikolova, Z., Bigner, D., and Reardon, D.: Imatinib mesylate (gleevec) plus hydroxyurea is an effective regimen in the treatment of recurrent malignant glioma. Phase 2 study results. Abstract #1515. Presentation: ASCO Annual Meeting 2005. Proc. Am. Soc. Clin. Oncol. 23:117a, 2005.

418. Reardon, D., Cloughesy, T., Conrad, C., Prados, M., Xia, J., Miettowski, W., Dugan, M., Mischel, P., Friedman, H., and Yung, A.: A phase I study of AEE788, a novel

multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients. Abstract #3063. Presentation: ASCO Annual Meeting 2005. Proc. Am. Soc. Clin. Oncol. 23:207s, 2005.

419. Sathornsumetee, S., Reardon, D.A., Quinn, J., Rich, J.N., Vredenburgh, J.J., Desjardins, A., Gururangan, S., Lyons, P., Salvado, A., and Friedman, H.S.: A phase I dose escalation study of imatinib mesylate plus standard-doses temozolomide in the treatment of patients with malignant glioma. Abstract #1540. Presentation: ASCO Annual Meeting 2005. Proc. Am. Soc. Clin. Oncol. 23:124s, 2005.

420. Rich, J.N., Reardon, D.A., Quinn, J.A., Vredenburgh, J.J., Desjardins, A., Sathornsumetee, S., Gururangan, S., Lyons, P., Bigner, D.D., and Friedman, H.S.: A phase I trial of gefitinib (ZD1839) plus repamycin for patients with recurrent malignant glioma. Abstract #1565. Presentation: ASCO Annual Meeting 2005. Proc. Am. Soc. Clin. Oncol. 23:130s, 2005.

421. Badruddoja, M.A., Penne, K., Desjardins, A., Reardon, A.D., Rich, J.N., Quinn, J., Sznol, M., Cahill, A., Friedman, H.S., and Vredenburgh, J.: Phase II study of VNP40101M for adults with recurrent malignant glioma. Abstract #3128. Presentation: ASCO Annual Meeting 2005. Proc. Am. Soc. Clin. Oncol. 23:223s, 2005.

422. Ueno, T., Ko, S.H., Grubbs, E., Abdel-Wahab, Z., Cheng, T.-Y., Abdel-Wahab, O., Pruitt, S., Friedman, H., and Tyler, D.: A novel regional therapeutic strategy for melanoma using chemotherapy resistance modulation: temozolomide in combination with O6-benzylguanine. Abstract #5111. Presented at the AACR 96th Annual Meeting, April 16-20, 2005, Anaheim, CA.

423. Ali-Osman, F., Antoun, G., Akande, O., Koh, J., Friedman, H., and Bigner, D.: Transcriptional activation of the DNA mismatch repair gene, hMLH1, and enhanced TCNER following over-expression of the GSTP1 gene in glioblastoma cells. Abstract #5000. Presented at the AACR 96th Annual Meeting, April 16-20, 2005, Anaheim, CA.

424. Sathornsumetee, S., Batt, D., Kieran, M., Keir, S., Ramsey, T., Yusuff, N., Reardon, D., Bigner, D.D., Friedman, H.S., and Rich, J.N.: AAL881, a novel small molecule inhibitor of RAF and VEGFR activities, blocks growth of malignant gliomas. Abstract #5838. Presented at the AACR 96th Annual Meeting, April 16-20, 2005, Anaheim, CA.
425. Houghton, P.J., Gorlick, R., Friedman, H., Maris, J.M., Lock, R., Reynolds, C.P., Khan, J., Hewitt, S.M., Whiteford, C., and Smith, M.A.: Pediatric preclinical testing program (PPTP) – a molecularly characterized panel of childhood cancer models for new agent testing. Abstract #4731. Presented at the AACR 96th Annual Meeting, April 16-20, 2005, Anaheim, CA.
426. Rich, J.N., Keir, S.T., Sathornsumetee, S., Reardon, D.A., Bigner, D.D., and Friedman, H.S.: Imatinib mesylate (STI-571, Gleevec®) offers combinatorial benefit with temozolomide (Temodar®) against gliomas. Abstract #5979. Presented at the AACR 96th Annual Meeting, April 16-20, 2005, Anaheim, CA.
427. Cheng, C.L., Johnson, S.P., Keir, S.T., Ali-Osman, F., Szabo, C., Salzman, A.L., Bigner, D.D., and Friedman, H.S.: Overcoming temozolomide resistance in a mismatch repair deficient malignant glioma xenograft. Abstract #5003. Presented at the AACR 96th Annual Meeting, April 16-20, 2005, Anaheim, CA.
428. Reardon, D.A., Quinn, J., Rich, J., Vredenburgh, J., Desjardins, A., Sathornsumetee, S., Salvado, A., Nikolova, Z., Bigner, D., and Friedman, H.: Imatinib mesylate (Gleevec) plus hydroxyurea: An effective regimen in the treatment of recurrent malignant glioma: Phase 2 study results. Abstract 35. Oral Poster Presentation for the WFNO II/EANO VI meeting, May 5-8, 2005, Edinburgh, Scotland. *Neuro-Oncol.* 7(3):291, 2005.
429. Reardon, D., Akabani, G., Friedman, A., Friedman, H., McLendon, R., Quinn, J., Rich, J., Vredenburgh, J., Zalutsky, M., and Bigner, D.: An update of phase 2 trial results: Patients

with recurrent malignant glioma treated with iodine 131-labeled murine antitenascin monoclonal antibody 81C6 into the resection cavity. Abstract 117. Presentation for the WFNO II/EANO VI meeting, May 5-8, 2005, Edinburgh, Scotland. *Neuro-Oncol.* 7(3):311, 2005.

430. Reardon, A., Rich, J., Quinn, J., Vredenburgh, J., Desjardins, A., Sathornsumetee, S., Gururangan, S., Lyons, P., Bigner, D., and Friedman, H.: Phase 1 study results of gefitinib (IRESSA; ZD1839) plus rapamycin in the treatment of patients with recurrent malignant glioma. Abstract 119. Presentation for the WFNO II/EANO VI meeting, May 5-8, 2005, Edinburgh, Scotland. *Neuro-Oncol.* 7(3):312, 2005.

431. Desjardins, A., Vredenburgh, J., Badruddoja, M., Quinn, J., Reardon, D., Rich, J., Sathornsumetee, S., Penne, K., Bigner, D., and Friedman, H.: Phase II study of cloretazine for the treatment of adults with recurrent malignant glioma. Abstract 141. Presentation for the WFNO II/EANO VI meeting, May 5-8, 2005, Edinburgh, Scotland. *Neuro-Oncol.* 7(3):317, 2005.

110

432. Sathornsumetee, S., Batt, D., Kieran, M., Kier, S., Ramsey, T., Yusuff, N., Reardon, D., Bigner, D., Friedman, H., and Rich, J.: Targeting malignant gliomas with a low-molecularweight Raf/vascular endothelial growth factor receptor inhibitor. Abstract 381. Presentation for the WFNO II/EANO VI meeting, May 5-8, 2005, Edinburgh, Scotland. *Neuro-Oncol.* 7(3):379, 2005.

433. Desjardins, A., Quinn, J., Reardon, D., Rich, J., Sathornsumetee, S., Vredenburgh, J., Walker, A., Tourt-Uhlig, Bigner, S., and Friedman, H.: Temozolomide (TMZ) with O6-benzylguanine (BG) plus CPT-11 in the treatment of recurrent malignant glioma: a phase I trial. Abstract 152. Presentation for the WFNO II/EANO VI meeting, May 5-8, 2005, Edinburgh, Scotland. *Neuro-Oncol.* 7(3):320, 2005.

434. Desjardins, A., Quinn, J., Reardon, D., Rich, J., Sathornsumetee, S., Vredenburgh, J., Walker, A., Tourt-Uhlig, S., Bigner, D., and Friedman, H.: Temozolomide (TMZ) with O6-benzylguanine (BG) for TMZ-resistant malignant glioma: a phase 2 trial. Abstract 471. Presentation for the WFNO II/EANO VI meeting, May 5-8, 2005, Edinburgh, Scotland. *Neuro-Oncol.* 7(3):401, 2005.
435. Keir, S.T., Guill, A.B., Carter, K.E., Friedman, H.S.: Levels of stress and intervention preferences of brain cancer patient's caregivers. American Psycho-Oncology Society. February, 2006.
436. Keir, S.T., Guill, A.B., Carter, K.E., and Friedman, H.S.: Levels of stress and intervention preferences of brain cancer patients. American Psycho-Oncology Society. February, 2006.
437. Pollack, I.F., Jakacki, R.I., Blaney, S., Hancock, M.L., Kieran, M.W., Phillips, P., Kun, L., Friedman, H.S., Packer, R., Prados, M., Geyer, J.R., Goldman, S., Young-Poussaint, T., Hayes, M., and Boyett, J.M.: A Phase I trial of STI571 (Imatinib Mesylate) in children with newly diagnosed poor prognosis brainstem gliomas and recurrent intracranial malignant gliomas: A pediatric brain tumor consortium (PBTC) report. Presentation for the International Society of Pediatric Neuro-Oncology, Nara, Japan. 2006.
438. Houghton, P.J., Maris, J.M., Friedman, H.S., Keir, S.T., Lock, R.B., Gorlick, R., Kolb, E.A., Reynolds, C.P., Morton, C., and Smith, M.A.: Evaluation of Bortezomib against childhood tumor models by the Pediatric Preclinical Testing Program (PPTP). Presentation for the NCI-AACR-EORTC meeting. 2006.
439. Tano, R., Yoo, J.S., Tyler, D.S., Augustine, C., Ali-Osman, F., Friedman, H.S., Stinnett, S.S., Jaffe, G.J., and Mruthyunjaya, P.: The in vitro efficacy of combining Temozolomide with O6-Benzylguanine in human choroidal melanoma cell lines. Presentation for the Association of Vision and Research in Ophthalmology, Ft. Lauderdale, Florida. Annual Meeting, 2006.

440. Kirkpatrick, J., Desjardins, A., Vredenburgh, J.J., Quinn, J.A., Rich, J.N., Sathornsumetee, S., Gururangan, S., Friedman, A.H., Friedman, H.S., and Reardon, D.A.: Combination of 111

bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and temozolomide: Study of cases. Abstract 11522. Presentation for the 2006 ASCO Annual Meeting Proceedings. *Journal of Clinical Oncology* 24(18S), 2006.

441. Rich, J.N., Shi, Q., Hjelmeland, A.B., Keir, S.T., Wickman, S., Wu, G., Jackson, D., Ohmori, O., Bigner, D.D., and Friedman, H.S.: A novel low molecular weight inhibitor of focal adhesion kinase and insulin-like growth factor-1 receptor, TAE226, inhibits glioma growth. Abstract 11505. Presentation for the 2006 ASCO Annual Meeting Proceedings. *Journal of Clinical Oncology* 24(18S), 2006.

442. Heery, C.R., Desjardins, A., Quinn, J.A., Rich, J.N., Gururangan, S., Vredenburgh, J.J., Friedman, A.H., Reardon, D.A., and Friedman, H.S.: Acute toxicity analysis of patients receiving surgery, Gliadel wafer implantation, and postoperative daily temozolomide with radiation therapy for primary high-grade glioma. Abstract 11504. Presentation for the 2006 ASCO Annual Meeting Proceedings. *Journal of Clinical Oncology* 24(18S), 2006.

443. Vredenburgh, J.J., Desjardins, A., Herndon II, J.E., Quinn, J., Rich, J., Sathornsumetee, S., Friedman, H.S., Reardon, D., Gururangan, S., and Friedman, A.: Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. Abstract 1506. Presentation for the 2006 ASCO Annual Meeting Proceedings. *Journal of Clinical Oncology* 24(18S):59s, 2006.

444. Vredenburgh, J.J., Bohlin, C., Reardon, D.A., Desjardins, A., Quinn, J., Rich, J., Sathornsumetee, S., Marks, L.B., Friedman, A.H., and Friedman, H.S.: Tinzaparin prophylaxis against thromboembolic complications in brain tumor patients. Abstract 1539. Presentation for the 2006 ASCO Annual Meeting Proceedings. *Journal of Clinical*

Oncology 24(18S):67s, 2006.

445. Heimberger, A.B., Hussain, S.F., Aldape, K., Sawaya, R., Archer, G.A., Friedman, H.S., Reardon, D., Friedman, A.H., Bigner, D.D., and Sampson, J.H.: Tumor-specific peptide vaccination in newly-diagnosed patients with GBM. Abstract 2529. Presentation for the 2006 ASCO Annual Meeting Proceedings. *Journal of Clinical Oncology* 24(18S):107s, 2006.

446. Sathornsumetee, S., Reardon, D.A., Quinn, J.A., Rich, J.N., Vredenburgh, J.J., Desjardins, A., Gururangan, S., Egorin, M., Salvado, A., and Friedman, H.S.: An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma. Abstract 1560. Presentation for the 2006 ASCO Annual Meeting Proceedings. *Journal of Clinical Oncology* 24(18S):72s, 2006.

447. Korones, D.N., Benita-Weiss, M., Coyle, T., Bushunow, P., Mechtler, L., and Friedman, H.S.: A phase II study of temozolomide and oral VP-16 for adults with recurrent glioma-Final results. Abstract 1565. Presentation for the 2006 ASCO Annual Meeting Proceedings. *Journal of Clinical Oncology* 24(18S):74s, 2006.

112

448. Quinn, J.A., Vredenburgh, J.J., Rich, J.N., Reardon, D.A., Desjardins, A., Gururangan, S., Friedman, A.H., Lavin, K., Sathornsumetee, S., Threath, S., and Friedman, H.S.: Phase II trial of Gliadel plus O6-benzylguanine (O6-BG) for patients with recurrent glioblastoma multiforme. Abstract 1568. Presentation for the 2006 ASCO Annual Meeting Proceedings. *Journal of Clinical Oncology* 24(18S):74s, 2006.

449. Desjardins, A., Reardon, D.A., Quinn, J.A., Rich, J.N., Vredenburgh, J.J., Sathornsumetee, S., Salvado, A., and Friedman, H.S.: Phase II trial of imatinib mesylate and hydroxyurea for grade III malignant gliomas. Abstract 1573. Presentation for the 2006 ASCO Annual Meeting Proceedings. *Journal of Clinical Oncology* 24(18S):76s, 2006.

450. Reardon, D., Quinn, J.A., Rich, J.N., Vredenburgh, J.J., Desjardins, A., Sathornsumetee, S., Gururangan, S., Egorin, M.J., Salvado, A., and Friedman, H.S.: A phase I trial of imatinib, hydroxyurea and RAD001 for patients with recurrent malignant glioma. Abstract 1580. Presentation for the 2006 ASCO Annual Meeting Proceedings. *Journal of Clinical Oncology* 24(18S):77s, 2006.
451. Johnson, P., McLendon, R.E., Ali-Osman, F., Quinn, J.A., Friedman, A.H., Herndon, J.E., Bierau, K., Bigley, J., Bigner, D.D., and Friedman, H.S.: O6-alkylguanine-DNA alkyltransferase (AGT) and microsatellite instability (MSI) analyses in malignant glioma. Abstract 4492. Presentation for the American Association for Cancer Research (AACR), Washington, DC. April 1-5, 2006.
452. Cui, B., Johnson, S.P., Ali-Osman, F., Bigner, D.D., and Friedman, H.S.: Constitutive phosphorylation of Chk1 at serine 317 in a medulloblastoma cell line is sensitive to the inhibition of the phosphatidylinositol-3kinase-related kinase (PIKK) pathway. Abstract 4254. Presentation for the American Association for Cancer Research (AACR), Washington, DC. April 1-5, 2006.
453. Maxwell, J.A., Johnson, S.P., McLendon, R.E., Ali-Osman, F., Quinn, J.A., Friedman, A.H., Herndon, J.E., Bierau, K., Bigley, J., Bigner, D.D., and Friedman, H.S.: O6-alkylguanine-DNA alkyltransferase (AGT) and microsatellite instability (MSI) analyses in malignant glioma. Abstract 4492. Presentation for the American Association for Cancer Research (AACR), Washington, DC. April 1-5, 2006.
454. Ali-Osman, F., Herndon II, J.E., Adams, B., Antoun, G., Friedman, H., Friedman, A., Reardon, D., McClendon, R., and Bigner, D.D.: Genetic polymorphism of the Epidermal Growth Factor (EGF) gene in glioma patients: Distribution and correlation with survival. Presented at the 97th AACR Annual Meeting, April 1-5, 2006, Washington, DC.
455. Antoun, G., Gasdaska, P., Parker, A., Adams, B., Friedman, H., McLendon, R., Bigner,

D.D., and Ali-Osman, F.: Identification of methylation hotspots in the GSTP1 promoter associated with transcriptional silencing of the GSTP1 gene in human gliomas. Presented at the 97th AACR Annual Meeting, April 1-5, 2006, Washington, DC.

113

456. Houghton, P.J., Maris, J., Friedman, H.S., Kier, S.T., Lock, R.B., Gorlick, R., Kolb, E.A., Reynolds, C.P., Morton, C., and Smith, M.A.: Evaluation of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, KOS-1022) against childhood cancer models by the pediatric preclinical testing program (PPTP). Abstract #1021. Presented at the 97th AACR Annual Meeting, April 1-5, 2006, Washington, DC.

457. Johnson, S.P., Kamen, B.A., Mochel, R.C., and Friedman, H.S.: Characterization of membrane transport of the novel O6-alkylguanine-DNA alkyltransferase inactivator, O4-benzylfolic acid. Abstract #127. Presented at the 97th AACR Annual Meeting, April 1-5, 2006, Washington, DC.

458. Jones, L.W., Guill, A.B., Keir, S.T., Carter, K., Friedman, H.S., Bigner, D.D., and Reardon, D.A.: Patterns of exercise across the cancer trajectory in brain tumor patients: A populationbased survey. Presented at 42nd American Society of Clinical Oncology Annual Meeting, Atlanta, GA, June, 2006.

459. Reardon, D.A., Zalutsky, M.R., Akaban, G., Coleman, R.E., Friedman, A.H., Herndon II, J.E., McLendon, R.E., Kirkpatrick, J., Pegram, C.N., Provenzale, J.M., Quinn, J.A., Rich, J.N., Vredenburgh, J.J., Desjardins, A., Guruangan, S., Boulton, S., Dowell, J.D., Wong, T.Z., Zhao, X., Friedman, H.S., and Bigner, D.D. Patient-specific murine 131I-labeled antitenascin monoclonal antibody 81C6 radioimmunotherapy for delivering a 44 Gy boost to the resection cavity periphery of patients with newly diagnosed primary malignant brain tumors: A feasibility pilot study. Abstract #201. Presentation. 14th SPORE Investigators Workshop in Baltimore, MD. July 16-19, 2006.

460. Houghton, P.J., Maris, J.M., Friedman, H.S., Keir, S.T., Lock, R.B., Gorlick, R., Kolb, E.A., Reynolds, C.P., Morton, C., and Smith, M.A.: Pediatric Preclinical Testing Program (PPTP) evaluation of the KSP inhibitor Ispinesib (SP-715992). *European Journal of Cancer Supplements* 4:98, 2006.

461. Smith, M.A., Maris, J.M., Keir, S.T., Friedman, H.S., Lock, R.B., Kolb, E.A., Keshelava, N., Reynolds, C.P., Morton, C., and Houghton, P.J.: Pediatric Preclinical Testing Program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825). *European Journal of Cancer Supplements* 4:100, 2006.

462. Smith, M.A., Maris, J.M., Keir, S.T., Lock, R.B., Gorlick, R., Kolb, E.A., Keshelava, N., Reynolds, C.P., Morton, C., and Houghton, P.J.: Pediatric Preclinical Testing Program (PPTP) evaluation of the VEGFR-2 inhibitor AZD2171. *European Journal of Cancer Supplements* 3:34, 2006.

463. Keir, S.T., Guill, A.B., Carter, K.E., Boole, L.C., Gonzalos, L., and Friedman, H.S.: Differential levels of stress in caregivers of brain tumor patients – Observations from a pilot study. *Psycho-Oncology Society*, October, 2006.

464. Hjelmeland, A.B., Lattimore, K., Fee, B., Wickman, S., Keir, S.T., Hjelmeland, M.D., Batt, D., Lane, H., Bigner, D.D., Friedman, H.S., and Rich, J.N.: The combination of novel lowmolecular-weight inhibitors of Raf (LBT 613) and TOR (RAD001, Everolimus) decreases

114

glioma proliferation and invasion. Abstract ET-13. Presented at Society for Neuro-Oncology 11th Annual Meeting, Orlando, Florida, November 16-19, 2006.

465. Sathornsumetee, S., Hjelmeland, A.B., Keir, S.T., McLendon, R.E., Batt, D., Ramsey, T., Yusuff, N., Rasheed, B.K.A., Kieran, M.W., Laforme, A., Bigner, D.D., Friedman, H.S., and Rich, J.N.: AAL881, A novel small molecule inhibitor of RAF and VEGFR activities, blocks growth of malignant glioma. Abstract ET-31. Presented at Society for Neuro-

Oncology 11th Annual Meeting, Orlando, Florida, November 16-19, 2006.

466. Shi, Q., Hjelmeland, A.B., Keir, S.T., Wickman, S.K., Wu, Guanghong, Jackson, D., Ohmori, O., Bigner, D.D., Friedman, H.S., and Rich, J.N.: TAE226, A novel lowmolecular-weight inhibitor of focal adhesion kinase, inhibits glioma growth. Abstract ET-34. Presented at Society for Neuro-Oncology 11th Annual Meeting, Orlando, Florida, November 16-19, 2006.

467. Brigidi, B.D., Raynor, R.H., Bonner, M., Schweitzer, H., Carter, K., Guill, B., and Friedman, H.S.: Development of the Duke Cancer Cognitions Inventory – Brain Tumor Version (DCCI-BT). Abstract QL-08. Presented at Society for Neuro-Oncology 11th Annual Meeting, Orlando, Florida, November 16-19, 2006.

468. Brigidi, B.D., Raynor, R.H., and Friedman, H.S.: Neurocognitive deficits according to hemisphere and diagnosis among patients with high-grade CNS tumors. Abstract QL-09. Presented at Society for Neuro-Oncology 11th Annual Meeting, Orlando, Florida, November 16-19, 2006.

469. Reardon, D., Akabani, G., Friedman, A., Friedman, H., Herndon, J., McLendon, R., Quinn, J., Rich, J., Vredenburgh, J., Desjardins, A., Sampson, J., Gururangan, S., Kirkpatrick, J., Wong, T., Dowell, J., Dunn, R., Sathronsumettee, S., Boulton, S., Coleman, R., Zalutsky, M., and Bigner, D.D.: Patient-specific murine 131I-labeled anti-tenascin monoclonal antibody 81C6 radioimmunotherapy for delivering a 44-Gy boost to the resection cavity periphery of patients with newly diagnosed primary malignant brain tumors: A feasibility pilot study. Abstract RO-23. Presented at Society for Neuro-Oncology 11th Annual Meeting, Orlando, Florida, November 16-19, 2006.

470. Affronti, M.L., Dowell, J.M., Herndon II, J.E., Cahill, J., Rich, J.N., Quinn, J.A., Reardon, D.A., Vredenburgh, J.J., Desjardins, A., Gururangan, and Friedman, H.S.: Overall survival of primary glioblastoma (GBM) patients receiving radiation and concurrent temozolomide

followed by rotational multi-agent chemotherapy. Abstract TA-01. Presented at Society for Neuro-Oncology 11th Annual Meeting, Orlando, Florida, November 16-19, 2006.

471. Desjardins, A., Vredenburgh, J., Quinn, J., Rich, J., Sathronsumetee, S., Gururangan, S., Friedman, A., Reardon, D., and Friedman, H.: Combination of Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and chemotherapy for recurrent malignant glioma patients: Series of cases. Abstract TA-12. Presented at Society for Neuro-Oncology 11th Annual Meeting, Orlando, Florida, November 16-19, 2006.

115

472. Desjardins, A., Vredenburgh, J., Quinn, J., Rich, J., Sathronsumetee, S., Friedman, A., Reardon, D., and Friedman, H.: Combination of Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and temozolomide or irinotecan as an upfront treatment in patients with malignant glioma: Study of cases. Abstract TA-13. Presented at Society for Neuro-Oncology 11th Annual Meeting, Orlando, Florida, November 16-19, 2006.

473. Desjardins, A., Quinn, J.A., Rich, J.N., Vredenburgh, J.J., Sathornsumetee, S., Gururangan, S., Friedman, A.H., Berg, W., Egorin, M.J., Salvado, A., Friedman, H.S., and Reardon, A.A.: A Phase I trial of imatinib (Gleevec), hydroxyurea and RAD001 for patients with recurrent malignant glioma. Abstract TA-14. Presented at Society for Neuro-Oncology 11th Annual Meeting, Orlando, Florida, November 16-19, 2006.

474. Quinn, J.A., Desjardins, A., Rich, J.N., Vredenburgh, J.J., Reardon, D.A., Gururangan, S., Sathornsumetee, S., Walker, A., Lavin, K.N., Birch, R., Friedman, A.H., and Friedman, H.S.: Phase I trial of temodar plus *O*6-Benzylguanine 5-day regimen for patients with progressive glioblastoma multiforme. Abstract TA-48. Presented at Society for Neuro-Oncology 11th Annual Meeting, Orlando, Florida, November 16-19, 2006.

475. Sathornsumetee, S., Rich, J.N., Vredenburgh, J.J., Desjardins, A., Quinn, J.A., Gururangan,

S., Friedman, A.H., Egorin, M.J., Salvado, A., Friedman, A.S., and Reardon, D.A.: Phase I trial of temozolomide plus dose-escalating imatinib mesylate for patients with malignant glioma. Abstract TA-50. Presented at Society for Neuro-Oncology 11th Annual Meeting, Orlando, Florida, November 16-19, 2006.

476. Vredenburgh, J., Desjardins, A., Herndon II, J.E., Reardon, D., Quinn, J., Sathornsumetee, S., Gururangana, S., Friedman, A., Bigner, D.D., and Friedman, H.: Bevacizumab and irinotecan is an effective treatment for malignant gliomas. Abstract TA-64. Presented at Society for Neuro-Oncology 11th Annual Meeting, Orlando, Florida, November 16-19, 2006.

477. Jones, L.W., Guill, B., Keir, S.T., Carter, K., Friedman, H.S., Bigner, D.D., and Reardon, M.D.: Exercise interest and preferences among a population-based cohort of patients diagnosed with primary brain cancer. Presentation for the 9th International Congress of Behavioral Medicine, Bangkok, Thailand. December, 2006.

478. Wu, D.S., Cui, B., Johnson, S.P., Keir, S.T., and Friedman, H.S.: Mechanisms of temozolomide resistance in pediatric glioblastoma multiforme. Abstract LB-324. Presentation for the 2007 98th Annual Meeting of the American Association of Cancer Research (AACR). Proc. Am. Assoc. Cancer Res., 2007.

479. Morton, C., Houghton, P.J., Maris, J.M., Friedman, H.S., Keir, S.T., Lock, R.B., Carol, H., Tajbakhsh, M., Gorlick, M., Kolb, E.A., Keshelava, N., Reynolds, C.P., and Smith, M.A.: Pediatric Preclinical Testing Program (PPTP) evaluation of the mTOR inhibitor Rapamycin. Abstract 4064. Presentation for the 2007 98th Annual Meeting of the American Association of Cancer Research (AACR). Proc. Am. Assoc. Cancer Res. 48:962, 2007.

116

480. Smith, M.A., Maris, J.M., Keir, S.T., Friedman, H.S., Lock, R.B., Carol, H., Tajbakhsh, M., Gorlick, M., Kolb, E.A., Keshelava, N., Reynolds, C.P., Morton, C., and Houghton, P.J.:

Pediatric Preclinical Testing Program (PPTP) evaluation of the Bcl-2 inhibitor ABT-263.

Abstract 4951. Presentation for the 2007 98th Annual Meeting of the American Association of Cancer Research (AACR). Proc. Am. Assoc. Cancer Res. 48:1172, 2007.

481. Houghton, P.J., Maris, J.M., Friedman, H.S., Keir, S.T., Lock, R.B., Carol, H., Tajbakhsh, M., Gorlick, M., Kolb, E.A., Keshelava, N., Reynolds, C.P., Morton, C., and Smith, M.A.:

Pediatric Preclinical Testing Program (PPTP) evaluation of multitargeted kinase inhibitor Sunitinib. Abstract 527. Presentation for the 2007 98th Annual Meeting of the American Association of Cancer Research (AACR). Proc. Am. Assoc. Cancer Res. 48:126, 2007.

482. Cui, B., Johnson, S.P., Ali-Osman, F., Bigner, D.D., and Friedman, H.S.: The chloroethylnitrosourea, BCNU, activates the ATR-Chk1 pathway in medulloblastomas independent of the DNA mismatch repair pathway. Abstract 1069. Presentation for the 2007 98th Annual Meeting of the American Association of Cancer Research (AACR). Proc. Am. Assoc. Cancer Res. 48:257, 2007.

483. Keir, S.T., Swartz, J.J., and Friedman, H.S.: Stress levels and sources of stress in an adult brain tumor population. IPOS – Psycho Oncology, September 2007.

484. Keir, S.T., Carter, K.E., and Friedman, H.S.: Barriers and facilitators to participation in stress reduction programs for patients with brain tumors. APOS – Psycho Oncology, March, 2007.

485. Bohlin, C.W., Reardon, D.A., Desjardins, A., Quinn, J.A., Rich, J.N., Bota, D.A., Goli, K., Friedman, H.S., and Vredenburgh, J.J.: Tinzaparin prophylaxis in brain tumor patients. Abstract 12506. Presentation for the 2007 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 25(18S):605s, 2007.

486. Jones, L., Affronti, M.L., Bohlin, C.W., Herndon, II, J.E. Quinn, J.A., Reardon, D.A., Rich, J.N., Friedman, H.S., and Vredenburgh, J.J.: Prevalence of osteoporosis in glioma patients on enzyme inducing anticonvulsants (EIAC) and/or glucocorticoids. Abstract 19527.

Presentation for the 2007 ASCO Annual Meeting Proceedings. J. Clin. Oncol.

25(18S):709s, 2007.

487. Vredenburgh, J.J., Bohlin, C.H., Reardon, D.A., Desjardins, A., Quinn, J.A., Rich, J.N., Bota, D.A., Goli, K.J., Friedman, H.S., and Allen, D.H.: Pilot study of dronabinol for adult patients with primary malignant gliomas. Abstract 19607. Presentation for the 2007 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 25(18S), 2007.

488. Goli, K.J., Desjardins, A., Herndon, II, J.E., Rich, J.N., Reardon, D.A., Quinn, J.A., Sathronsumetee, S., Bota, D.A., Friedman, H.S., and Vredenburgh, J.J.: Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas. Abstract 2003.

117

Presentation for the 2007 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 25(18S):75s, 2007.

489. Sathronsumetee, S., Rich, J.N., Vredenburgh, J.J., Desjardins, A., Quinn, J.A., Gururangan, S., Egorin, M., Salvado, A.J., Friedman, H.S., and Reardon, D.A.: Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM). Abstract 2027. Presentation for the 2007 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 25(18S):81s, 2007.

490. Desjardins, A., Barboriak, D.P., Herndon, II, J.E., Reardon, D.A., Quinn, J.A., Rich, J.N., Sathronsumetee, S., Gururangan, S., Friedman, H.S., and Vredenburgh, J.J.: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11). Abstract 2029. Presentation for the 2007 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 25(18S):82s, 2007.

491. Quinn, J.A., Vredenburgh, J.J., Rich, J.N., Reardon, D.A., Desjardins, A., Gururangan, S., Friedman, A.H., Carter, J.H., Threatt, S., and Friedman, H.S.: Phase II trial of gliadel plus

O6-benzylguanin (O6-BG) for patients with recurrent glioblastoma multiforme. Abstract 2036. Presentation for the 2007 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 25(18S):84s, 2007.

492. Bota, D.A., Desjardins, A., Quinn, J.A., Rich, J.N., Vredenburgh, J.J., Sathronsumetee, S., Goli, K., Salvado, A., Friedman, H.S., and Reardon, D.A.: Phase II trial of imatinib mesylate and hydroxyurea for adults with recurrent/progressive low-grade glioma. Abstract 2053. Presentation for the 2007 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 25(18S):88s, 2007.

493. Gururangan, S. Turner, C., Stewart, C.F., Kocak, M., Poussaint, T.Y., Boyett, J.M., Kun, L.E., Karsten, V., Gerson, S.L., and Friedman, H.S.: Phase I trial of VNP40101M in children with recurrent brain tumors – A Pediatric Brain Tumor Consortium (PBTC) study. Abstract 2059. Presentation for the 2007 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 25(18S), 2007.

494. Kirkpatrick, J., Desjardins, A., Quinn, J., Rich, J., Vredenburgh, J., Sathronsumetee, S., Gururangan, S., Sidor, C., Friedman, H., and Reardon, D.: Phase II open-label, safety, pharmacokinetic and efficacy study of 2-methoxyestradiol nanocrystal colloidal dispersion administered orally to patients with recurrent glioblastoma multiforme. Abstract 2065. Presentation for the 2007 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 25(18S), 2007.

495. Affronti, M.L., Day, J.M., Herndon, II, J.E., Rich, J.N., Quinn, J.A., Reardon, D.A., Vredenburgh, J.J., Desjardins, A., McLendon, R.E., and Friedman, H.S.: Radiation and concurrent temozolomide followed by rotational multi-agent chemotherapy for glioblastoma (GBM) patients. Abstract 2068. Presentation for the 2007 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 25(18S), 2007.

496. Rich, J.N., Affronti, M.L., Day, J.M., Herndon, II, J.E., Quinn, J.A., Reardon, D.A., Vredenburgh, J.J., Desjardins, A., and Friedman, H.S.: Overall survival of primary glioblastoma (GBM) patients (pts) receiving carmustine (BCNU) wafers followed by radiation (RT) and concurrent temozolomide (TMZ) plus rotational multi-agent chemotherapy. Abstract 2070. Presentation for the 2007 ASCO Annual Meeting Proceedings. *J. Clin. Oncol.* 25(18S), 2007.

497. Bota, D., Maxwell, J., Keir, S., Bullock, N., Horne, K., Vredenburgh, J., and Friedman, H.: Preclinical study of bevacizumab and bortezomib combination in malignant glioma. Abstract ET-48. Presentation for the 2007 Twelfth Annual Meeting of the Society for Neuro-Oncology (SNO). *Neuro-Onc.* 9(4):495, 2007.

498. Mitchell, D., Cui, X., Chewning, T., Friedman, H., and Sampson, J.: Induction of enhanced immunologic responses during hematopoietic recovery from temozolomide-induced lymphopenia. Abstract IM-19. Presentation for the 2007 Twelfth Annual Meeting of the Society for Neuro-Oncology (SNO). *Neuro-Onc.* 9(4):506, 2007.

499. Archer, G., Mitchell, D., Heimberger, A., Friedman, H., Reardon, D., Vredenburgh, J., Gilbert, M., Friedman, A., Sawaya, R., Aldape, K., Bigner, D., and Sampson, J.: Temozolomide therapy induces an increase in regulatory t-cells without abrogating a specific tumor antigen immune response in patients with GBM. Abstract IM-29. Presentation for the 2007 Twelfth Annual Meeting of the Society for Neuro-Oncology (SNO). *Neuro-Onc.* 9(4):509, 2007.

500. Mitchell, D., Archer, G., Bigner, D., Friedman, A., Friedman, H., Reardon, D., Vredenburgh, J., Herndon, J., McLendon, R., and Sampson, J.: RNA-loaded dendritic cells targeting cytomegalovirus in patients with malignant glioma. Abstract IM-31. Presentation for the 2007 Twelfth Annual Meeting of the Society for Neuro-Oncology (SNO). *Neuro-Onc.* 9(4):509, 2007.

501. Sathornsumetee, S., Vredenburgh, J., Rich, J., Desjardins, A., Quinn, J., Bota, D., Goli, K., Mathe, A., Gururangan, S., Friedman, A., Friedman, H., and Reardon, D.: Phase II trial of bevacizumab and erlotinib in recurrent glioblastoma multiforme (GBM). Abstract MA-06. Presentation for the 2007 Twelfth Annual Meeting of the Society for Neuro-Oncology (SNO). *Neuro-Onc.* 9(4):516, 2007.

502. Bota, D., Desjardins, A., Rich, J., Vredenburgh, J., Quinn, J., Sathornsumetee, S., Goli, K., Salvado, A., Friedman, H., and Reardon, D.: Update on Phase II trial of imatinib mesylate (Gleevec) and hydroxyurea for adults with recurrent/progressive low-grade glioma. Abstract MA-16. Presentation for the 2007 Twelfth Annual Meeting of the Society for Neuro-Oncology (SNO). *Neuro-Onc.* 9(4):519, 2007.

503. Goli, K., Bota, D., Desjardins, A., Rich, J., Vredenburgh, J., Quinn, J., Sathornsumetee, S., Salvado, A., Friedman, H., and Reardon, D.: A phase II trial of imatinib mesylate (Gleevec) and hydroxyurea for adults with recurrent/progressive meningioma. Abstract MA-18.

119

Presentation for the 2007 Twelfth Annual Meeting of the Society for Neuro-Oncology (SNO). *Neuro-Onc.* 9(4):519, 2007.

504. Desjardins, A., Sathornsumetee, S., Reardon, D., Goli, K., Bota, D., Quinn, J., Rich, J., Gururangan, S., Threath, S., Friedman, A., Friedman, H., and Vredenburgh, J.: A phase I trial of the addition of the farnesyl transferase inhibitor SCH 66336 to temozolomide for patients with grade 3 or 4 malignant glioma. Abstract MA-35. Presentation for the 2007 Twelfth Annual Meeting of the Society for Neuro-Oncology (SNO). *Neuro-Onc.* 9(4):524, 2007.

505. Gururangan, S., Krauser, J., Watral, M., Driscoll, T., Larrier, N., Fuchs, H., Reardon, D., Vredenburgh, J., Quinn, J., Desjardins, A., Rich, J., and Friedman, H.: Evaluation of the efficacy of high-dose chemotherapy (HDC) + autologous stem cell rescue (ASCR) +/-

radiotherapy (RT) or standard salvage therapy in children with recurrent medulloblastoma (MBL). Abstract MP-15. Presentation for the 2007 Twelfth Annual Meeting of the Society for Neuro-Oncology (SNO). *Neuro-Onc.* 9(4):540, 2007.

506. Keir, S. and Friedman, H.: Familial appraisal of providing care to patients with brain cancer. Abstract QL-09. Presentation for the 2007 Twelfth Annual Meeting of the Society for Neuro-Oncology (SNO). *Neuro-Onc.* 9(4):565, 2007.

507. Affronti, M.L., Bohlin, C., Bronson, K., Jones, L. Herndon, J., Quinn, J., Reardon, D., Desjardins, A., Rich, J., Friedman, H., and Vredenburgh, J.: Phase II trial of zoledronic acid (ZA) for bone loss prevention in glioma patients. Abstract QL-10. Presentation for the 2007 Twelfth Annual Meeting of the Society for Neuro-Oncology (SNO). *Neuro-Onc.* 9(4):566, 2007.

508. Brigidi, B., Friedman, H., and Raynor, R.: Cognitive rehabilitation in patients with primary malignant brain tumors: A case study series using an acceptance-based cognitive training approach (N=10). Abstract QL-19. Presentation for the 2007 Twelfth Annual Meeting of the Society for Neuro-Oncology (SNO). *Neuro-Onc.* 9(4):568, 2007.

509. Desjardins, A., Barboriak, D., Herndon, II., J.E., Reardon, D., Quinn, J., Rich, J., Sathornsumetee, S., Friedman, H., and Vredenburgh, J.: Evaluation of tumor response by dynamic contrast-enhanced magnetic resonance imaging in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11). Abstract RA-03. Presentation for the 2007 Twelfth Annual Meeting of the Society for Neuro-Oncology (SNO). *Neuro-Onc.* 9(4):573, 2007.

510. Barboriak, D.P., Desjardins, A., Rich, J., Phadke, D., Friedman, H.S., and Vredenburgh, J.J.: Treatment of recurrent glioblastoma multiforme with bevacizumab and irinotecan leads to rapid decreases in tumor plasma volume and ktrans. Presentation for the Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA),

2007.

120

511. Moghrabi, A., Hershon, L., Rousseau, P., Decarie, J-C., Friedman, H., Zhou, T., Holmes, E., and Pollack, I. A phase I/II feasibility study of oral etoposide given concurrently with radiotherapy followed with dose-intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma COG P9631. Abstract PNET/MED 2. 13th International Symposium on Pediatric Neuro-Oncology, June 30–July 2, Chicago, Illinois. Published online May 29. *Neuro-Oncology* 10 (3):476, 2008.

512. Gururangan, S., Driscoll, T., and Friedman, H. A retrospective study of high-dose chemotherapy (HDC) with autologous stem cell rescue (ASCR) in children and adults with supratentorial primitive neuroectodermal tumors (S-PNET): The Duke experience 1991–2004. Abstract PNET/MED 3. 13th International Symposium on Pediatric Neuro-Oncology, June 30–July 2, Chicago, Illinois. Published online May 29. *Neuro-Oncology* 10 (3):476, 2008.

513. Sampson, J.H., Archer, G.E., Bigner, D.D., Davis, T., Friedman, H.S., Keler, T., Mitchell, D.A., Reardon, D.A., Sawaya, R., and Heimberger, A.B. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. Abstract 2011. ASCO 44th Annual Meeting, May 30–June 3, Chicago, Illinois. *J. Clin. Oncol.* 26, Suppl. (15S, Part I): 92s, 2008.

514. Wagner, S.A., Desjardins, A., Reardon, D.A., Marcello, J., Herndon, J.E., II, Quinn, J.A., Rich, J.N., Sathornsumetee, S., Friedman, H.S., and Vredenburgh, J.J. Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas. Abstract 2021, 2008 ASCO Annual Meeting. *J. Clin. Oncol.* 26, Suppl. (15S, Part I): 94s, 2008.

515. Rich, J.N., Desjardins, A., Sathornsumetee, S., Vredenburgh, J.J., Quinn, J.A., Gururangan, S., Friedman, A.H., Friedman, H.S., and Reardon, D.A. Phase II study of bevacizumab and etoposide in patients with recurrent malignant glioma. Abstract 2022. 2008 ASCO Annual Meeting. J. Clin. Oncol. 26, Suppl. (15S, Part I): 94s, 2008.

516. Desjardins, A., Barboriak, D.P., Herndon, J.E., II, Marcello, J., Reardon, D.A., Quinn, J.A., Rich, J.N., Sathornsumetee, S., Friedman, H.S., and Vredenburgh, J.J. Effect of bevacizumab (BEV) and irinotecan (CPT-11) on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in glioblastoma (GBM) patients. Abstract 2026. 2008 ASCO Annual Meeting. J. Clin. Oncol. 26, Suppl. (15S, Part I): 95s, 2008.

517. Mitchell, D., Archer, G.E., Bigner, D.D., Friedman, H.S., Lally-Goss, D., Herndon, J.E., II, McGehee, S., McLendon, R., Reardon, D.A., and Sampson, J.H. Efficacy of a phase II vaccine targeting *Cytomegalovirus* antigens in newly diagnosed GBM. Abstract 2042. 2008 ASCO Annual Meeting. J. Clin. Oncol. 26, Suppl. (15S, Part I): 99s, 2008.

518. Kirkpatrick, J.P., Rich, J.N., Vredenburgh, J.J., Desjardins, A., Quinn, J.A., Gururangan, S., Sathornsumetee, S., Egorin, M.J., Friedman, H.S., and Reardon, D.A.. Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant

121
glioma (MG). Abstract 2057. 2008 ASCO Annual Meeting. J. Clin. Oncol. 26, Suppl. (15S, Part I): 103s, 2008.

519. Friedman, H.S., Desjardins, A., Vredenburgh, J.J., Rich, J.N., Sathornsumetee, S., Gururangan, S., Quinn, J.A., and Reardon, D.A. Phase II trial of erlotinib plus sirolimus for recurrent glioblastoma multiforme (GBM). Abstract 2062. 2008 ASCO Annual Meeting. J. Clin. Oncol. 26, Suppl. (15S, Part I): 104s, 2008.

520. Salacz, M.E., Desjardins, A., Quinn, J.A., Rich, J.N., Vredenburgh, J.J., Sathornsumetee, S., Goli, K., Friedman, H.S., and Reardon, D.A. Treatment of adults with recurrent progressive

low-grade glioma using imatinib mesylate and hydroxyurea. Abstract 2071. 2008 ASCO Annual Meeting. J. Clin. Oncol. 26, Suppl. (15S, Part I): 106s, 2008.

521. Maron, R., Vredenburgh, J.J., Desjardins, A., Reardon, D.A., Quinn, J.A., Rich, J.N., Gururangan, S., Wagner, S.A., Salacz, M.E., and Friedman, H.S. Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM). Abstract 2074. 2008 ASCO Annual Meeting. J. Clin. Oncol. 26, Suppl. (15S, Part I): 107s, 2008.

522. Quinn, J.A., Jiang, X.S., Rich, J.N., Desjardins, A., Vredenburgh, J.J., Reardon, D.A., Gururangan, S., Walker, A.R., Birch, R., Friedman, A.H., and Friedman, H.S.. Phase I trial of temozolomide plus O6-benzylguanine on three different 5-day temozolomide regimens for patients with progressive glioblastoma multiforme. Abstract 2084. 2008 ASCO Annual Meeting. J. Clin. Oncol. 26, Suppl. (15S, Part I): 110s, 2008.

523. Sathornsumetee, S., Vredenburgh, J.J., Rich, J.N., Desjardins, A., Quinn, J.A., Mathe, A.E., Gururangan, S., Friedman, A.H., Friedman, H.S., and Reardon, D.A. Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme. Abstract 13008. 2008 ASCO Annual Meeting. J. Clin. Oncol. 26, Suppl. (15S, Part I): 619s (online at http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34631), 2008.

524. Mitchell, D.A., Archer, G.E., Bigner, D.D., Desjardins, A., Friedman, A.H., Friedman, H.S., Lally-Goss, D., Herndon, J.E., II, McGehee, S., McLendon, R.E., Perry, B., Reardon, D., Rich, J., Silverman, S., Vredenburgh, J., and Sampson, J.H.. Efficacy and immunologic effects of RNA-pulsed dendritic cell vaccines targeting human cytomegalovirus antigens in patients with glioblastoma. Abstract LB-73. 2008 AACR Annual Meeting, April 12-16, San Diego, CA. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (<http://www.aacr.org/home/scientists/meetings--workshops/annualmeeting-2008/abstracts.aspx>), 2008.

525. Archer, G.E., Heimberger, A.B., Bigner, D.D., Davis, T., Friedman, A.H., Friedman, H.S., Keler, T., Mitchell, D.A., Reardon, D., Sawaya, R., Vredenberg, J., and Sampson, J.H. Humoral and cell mediated responses to the EGFRvIII-targeted vaccine (CDX-110) are enhanced with continuous temozolomide in patients with GBM. Abstract LB-310. 2008 AACR Annual Meeting, April 12-16, San Diego, CA. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research

122

(<http://www.aacr.org/home/scientists/meetings--workshops/annual-meeting-2008/abstracts.aspx>), 2008.

526. Cui, B., Johnson, S.P., Bullock, N.H., Horne, K.S., Ali-Osman, F., Bigner, D.D., and Friedman, H.S. Lack of DNA damage signalling underlies temozolomide resistance in a human glioblastoma multiforme cell line. Abstract 665. 2008 AACR Annual Meeting, April 12-16, 2008, San Diego, CA. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (<http://www.aacr.org/home/scientists/meetings--workshops/annual-meeting-2008/abstracts.aspx>), 2008.

527. Neale, G., Su, X., Morton, C.L., Phelps, D., Gorlick, R., Lock, R.B., C. Reynolds, P., Maris, J.M., Friedman, H.S., Dome, J., Khoury, J., Triche, T.J., Seeger, R.C., Gilbertson, R., Khan, J., Smith, M.A., and Houghton, P.J. Molecular characterization of the Pediatric Preclinical Testing Program (PPTP) models. Abstract 1629. 2008 AACR Annual Meeting, April 12-16, 2008, San Diego, CA. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (<http://www.aacr.org/home/scientists/meetings--workshops/annual-meeting-2008/abstracts.aspx>), 2008.

528. Carol, H., Morton, C.L., Houghton, P.J., Maris, J.M., Friedman, H.S., Keir, S.T., Gorlick, R., Kolb, E.A., Smith, M.A., and Lock, R.B. Pediatric Preclinical Testing Program (PPTP) evaluation of the topoisomerase I inhibitor topotecan. Abstract 2996. 2008 AACR Annual

Meeting, April 12-16, 2008, San Diego, CA. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (<http://www.aacr.org/home/scientists/meetings--workshops/annual-meeting-2008/abstracts.aspx>), 2008.

529. Houghton, P.J., Morton, C.L., Maris, J.M., Courtright, J., Carol, H., Lock, R.B., Friedman, H.S., Keir, S.T., Gorlick, R., E. Kolb, E.A., Reynolds, C.P., Kang, M., and Smith, M.A.

Pediatric preclinical testing program (PPTP) evaluation of the Aurora A kinase inhibitor MLN8237. Abstract #2997. 2008 AACR Annual Meeting, April 12-16, 2008, San Diego, CA. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (<http://www.aacr.org/home/scientists/meetings--workshops/annual-meeting-2008/abstracts.aspx>), 2008.

530. Smith, M.A., Morton, C., Maris, J.M., Courtright, J., Kolb, E.A., Gorlick, R., Carol, H., Lock, R.B., Friedman, H.S., Keir, S.T., Kang, M., Reynolds, C.P., and Houghton, P.J.

Pediatric preclinical testing program (PPTP) evaluation of the MEK1/2 inhibitor AZD6244 (ARRY-142886) Abstract 2998. 2008 AACR Annual Meeting, April 12-16, 2008, San Diego, CA. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (<http://www.aacr.org/home/scientists/meetings--workshops/annualmeeting-2008/abstracts.aspx>), 2008.

531. Mitchell, D.A., Archer, G.E., Bigner, D.D., Friedman, H.S., Lally-Goss, D., Perry, B., Herndon, J.E., II, McGehee, S., McLendon, R.E., Reardon, D., and Sampson, J.H.: Efficacy and immunologic effects of RNA-pulsed dendritic cell vaccines targeting human

cytomegalovirus antigens in patients with glioblastoma. Abstract IM-25, presented at

123

Society for Neuro-Oncology 13th Annual Meeting, November 20-23, 2008, Lake Las Vegas, Nevada. *Neuro-Oncol.* 10:814.

532. Archer, G., Heimberger, A, Bigner, D, Davis, T., Friedman, H., Friedman, A., Keler, T.,

Mitchell, D., Reardon, D., Sawaya, R., Vredenburgh, J., Yung, A., Rich, J., Gilbert, M.R., Desjardins, A., and Sampson, J.H.: The positive influence of temozolomide on the humoral and cell-mediated (DTH) responses to the EGFRvIII-targeted vaccine (CDX-110) in patients with GBM. Abstract IM-12, presented at Society for Neuro-Oncology 13th Annual Meeting, November 20-23, 2008, Lake Las Vegas, Nevada. *Neuro-Oncol.* 10:810.

533. Vredenburgh, J., Desjardins, A., Reardon, D., Rich, J., Kirkpatrick, J., Gururangan, Bailey, L., Friedman, A., Bigner, D., and Friedman, H.: Bevacizumab in combination with temozolomide and radiation therapy followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma multiforme. Abstract MA-73, presented at Society for Neuro-Oncology 13th Annual Meeting, November 20-23, 2008, Lake Las Vegas, Nevada. *Neuro-Oncol.* 10:836.

534. Bota, D., Keir, S., Albert, K., Normant, E., and Friedman, H.S.: Preclinical study of the HSP-90 inhibitor IPI-504 in malignant glioma. Abstract ET-32, presented at Society for Neuro-Oncology 13th Annual Meeting, November 20-23, 2008, Lake Las Vegas, Nevada. *Neuro-Oncol.* 10:791.

535. Sathornsumetee, S., Desjardins, A., Vredenburgh, J., Rich, J., Gururangan, S., Friedman, A., Friedman, H., and Reardon, D.: Safety and efficacy of bevacizumab and erlotinib for recurrent glioblastoma patients in a phase II study. Abstract MA-41, presented at Society for Neuro-Oncology 13th Annual Meeting, November 20-23, 2008, Lake Las Vegas, Nevada. *Neuro-Oncol.* 10:827.

536. Gururangan, S., Chi, S., Onar, A., Packer, R., Boyett, Poussaint, T.Y., Gilbertson, R., Friedman, H., Kun, L., and Boyett, J.: Phase II study of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma—a Pediatric Brain Tumor Consortium study (PBTC-022). Abstract MA-63, presented at Society for Neuro-Oncology 13th Annual Meeting, November 20-23, 2008, Lake Las Vegas, Nevada. *Neuro-*

Oncol. 10:833.

537. Reardon, D., Desjardins, A., Vredenburgh, J., Friedman, A., Sampson, J., Gururangan, S., Rich, J., and Friedman, H.: A phase II trial of sorafenib (Nexavar) and protracted temozolomide for patients with recurrent glioblastoma. Abstract MA-82, presented at Society for Neuro-Oncology 13th Annual Meeting, November 20-23, 2008, Lake Las Vegas, Nevada. Neuro-Oncol. 10:839.

538. Reardon, D., Desjardins, A., Vredenburgh, J., Rich, J., Gururangan, S., Sathornsumetee, S., Friedman, A., and Friedman, H.: Safety and efficacy of bevacizumab and metronomic, oral etoposide for recurrent glioblastoma patients in a phase II study. Abstract MA-83, presented at Society for Neuro-Oncology 13th Annual Meeting, November 20-23, 2008, Lake Las Vegas, Nevada. Neuro-Oncol. 10:839.

124

539. Reardon, D., Desjardins, A., Vredenburgh, J., Friedman, A., Gururangan, S., Rich, J., and Friedman, H.: A phase I trial of dasatinib (Sprycel) and erlotinib (Tarceva) for patients with recurrent malignant glioma. Abstract MA-85, presented at Society for Neuro-Oncology 13th Annual Meeting, November 20-23, 2008, Lake Las Vegas, Nevada. Neuro-Oncol. 10:840.

540. Desjardins, A., Reardon, D., Rich, J., Gururangan, S., Threatt, S., Friedman, A., Friedman, H., and Vredenburgh, J.: Addition of the farnesyl transfer inhibitor SCH 66336 to temozolomide for patients with grade 3 or 4 malignant gliomas: a phase I trial. Abstract MA-88, presented at Society for Neuro-Oncology 13th Annual Meeting, November 20-23, 2008, Lake Las Vegas, Nevada. Neuro-Oncol. 10:840.

541. Paldino, M.J., Desjardins, A., Friedman, H.S., Vredenburgh, J.J. and Barboriak, D.P.: Treatment of patients with recurrent glioblastoma multiforme with bevacizumab results in a rapid increase in fractional anisotropy. Abstract ID: 6007427, presented at RSNA 94th

Scientific Assembly and Annual Meeting November 30-December 5, 2008, McCormick Plaza, Chicago, IL.

542. Paldino, M.J., Desjardins, A., Friedman, H.S., Vredenburgh, J.J. and Barboriak, D.P.: A change in the apparent diffusion coefficient after therapy is associated with decreased survival in patients with recurrent glioblastoma multiforme treated with bevacizumab.

Abstract ID: 6007431, presented at RSNA 94th Scientific Assembly and Annual Meeting November 30-December 5, 2008, McCormick Plaza, Chicago, IL.

543. Reardon, D.A., Vredenburgh, J.J., Desjardins, A., Janney, D.E., Peters, K.B., Friedman, A.H., Gururangan, S., Friedman, H.S.: A phase I study of sunitinib plus irinotecan in the treatment of patients with recurrent malignant glioma. The 3rd Quadrennial meeting of the WFNO, Yokohama, Japan, May 11-14, 2009. Programs and Abstracts

544. Reardon, D.A., Vredenburgh, J.J., Desjardins, A., Gururangan, S., Peters, K.B., Boulton, S.T.: Phase I study of vandetanib, imatinib mesylate and hydroxyurea for recurrent malignant glioma. Presented at The 3rd Quadrennial Meeting of the WFNO, Pacifico Yokohama, Japan, (P182) 192, 2009.

545. Reardon, D.A., Vredenburgh, J.J., Desjardins, A., Janney, D.E., Peters, K.B., Friedman, A.H., Gururangan, S., Friedman, H.S.: A phase I study of sunitinib plus irinotecan in the treatment of patients with recurrent malignant glioma. Presented at The 3rd Quadrennial Meeting of the WFNO, Pacifico Yokohama, Japan, (P183) 193, 2009.

546. Reardon, D.A., Desjardins, A., Vredenburgh, J.J., Gururangan, S., Peters, K.B., Norfleet, J.A., Friedman, A.H., Friedman, H.S.: Phase II study of bevacizumab plus etoposide among recurrent malignant glioma patients: Final study results. Presented at The 3rd Quadrennial Meeting of the WFNO, Pacifico Yokohama, Japan, (O129) 110, 2009.

547. Vredenburgh, J.J., Desjardins, A., Reardon, D.A., Peters, K., Herndon, J.E., II, Kirkpatrick, J., Gururangan, S., Bailey, L., Friedman, A.H., and Friedman, H.S.: Safety and efficacy of

the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT)

125

followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM). Abstract 2015. 2009 ASCO Annual Meeting, May 29-June 2, 2009, Orange County Convention Center, Orlando, FL. *J. Clin. Oncol.* 27, Suppl. (15S, Part I): 90s, 2009.

548. Heimberger, A.B., Archer, G.E., Mitchell, D.A., Bigner, D.D., Schmittling, R.J., Herndon, J.E., II, Davis, T., Friedman, H.S., Keler, T., Reardon, D.A., and Sampson, J.H.: Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM. Abstract 2021. 2009 ASCO Annual Meeting, May 29-June 2, 2009, Orange County Convention Center, Orlando, FL. *J. Clin. Oncol.* 27, Suppl. (15S, Part I): 92s, 2009.

549. Sampson, J.H., Archer, G.E., Bigner, D.D., Schmittling, R.J., Herndon, J.E., II, Davis, T., Friedman, H.S., Keler, T., Reardon, D.A., and Mitchell, D.A.: Effect of daclizumab on TReg counts and EGFRvIII-specific immune responses in GBM. Abstract 2034. 2009 ASCO Annual Meeting, May 29-June 2, 2009, Orange County Convention Center, Orlando, FL. *J. Clin. Oncol.* 27, Suppl. (15S, Part I): 95s, 2009.

550. Sathornsumetee, S., Desjardins, A., Vredenburgh, J.J., Rich, J.N., Gururangan, S., Friedman, A.H., Friedman, H.S., and Reardon, D.A.: Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas. Abstract 2045. 2009 ASCO Annual Meeting, May 29-June 2, 2009, Orange County Convention Center, Orlando, FL. *J. Clin. Oncol.* 27, Suppl. (15S, Part I): 98s, 2009.

551. Wefel, J.S., Cloughesy, T., Zazzali, J., Yi, J., Friedman, H.S., for the BRAIN Investigators: Neurocognitive function in patients with glioblastoma multiforme in first or second relapse treated with bevacizumab in the BRAIN study. Abstract 2056. 2009 ASCO Annual Meeting, May 29-June 2, 2009, Orange County Convention Center, Orlando, FL. *J. Clin.*

Oncol. 27, Suppl. (15S, Part I): 101s, 2009.

552. Paldino, M., Desjardins, A., Friedman, H.S., Vredenburgh, J.J., and Barboriak, D.P.: Prognostic significance of early changes in the apparent diffusion coefficient that occurs after treatment of patients with glioblastoma multiforme with bevacizumab. Abstract 2058. 2009 ASCO Annual Meeting, May 29-June 2, 2009, Orange County Convention Center, Orlando, FL. J. Clin. Oncol. 27, Suppl. (15S, Part I): 101s, 2009.

553. Jones, L., Friedman, A., West, M., Mabe, S., Fraser, J., Kraus, W., Friedman, H., Major, N., and Reardon, D.: Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma. Abstract e13002. 2009 ASCO Annual Meeting, May 29-June 2, 2009, Orange County Convention Center, Orlando, FL. J. Clin. Oncol. (http://www.abstract.asco.org/AbstView_65_31089.html), 2009.

554. Desjardins, A., Reardon, D.A., Gururangan, S., Peters, K., Threatt, S., Friedman, A., Friedman, H., and Vredenburgh, J.: Phase I trial of combining SCH66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG). Abstract e13004. 2009 ASCO Annual Meeting, May 29-June 2, 2009, Orange County Convention Center, Orlando, FL. J. Clin. Oncol. (http://www.abstract.asco.org/AbstView_65_34915.html), 2009.

126

555. Kirkpatrick, J.P., Vredenburgh, J.J., Desjardins, A., Gururangan, S., Peters, K.B., Boulton, S.T., Friedman, A.H., Friedman, H.S., and Reardon, D.A.: Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma. Abstract e13007. 2009 ASCO Annual Meeting, May 29-June 2, 2009, Orange County Convention Center, Orlando, FL. J. Clin. Oncol. (http://www.abstract.asco.org/AbstView_65_34400.html), 2009.

556. Herndon, J.E., II, Vredenburgh, J., Reardon, D., Desjardins, A., Peters, K., Gururangan, S., Norfleet, J., Friedman, A., Bigner, D., and Friedman, H.S.: Phase I trial of vandetanib and

oral etoposide for recurrent malignant gliomas. Abstract e13016. 2009 ASCO Annual Meeting, May 29-June 2, 2009, Orange County Convention Center, Orlando, FL. *J. Clin. Oncol.* (http://www.abstract.asco.org/AbstView_65_34653.html), 2009.

557. Friedman, H.S., Vredenburgh, J.J., Desjardins, A., Janney, D.E., Peters, K.B., Friedman, A.H., Gururangan, S., and Reardon, D.A.: A phase I study of Sunitinib plus irinotecan in the treatment of patients with recurrent malignant glioma. Abstract e13024. 2009 ASCO Annual Meeting, May 29-June 2, 2009, Orange County Convention Center, Orlando, FL. *J. Clin. Oncol.* (http://www.abstract.asco.org/AbstView_65_34850.html), 2009.

558. Peters, K., Desjardins, A., Reardon, D.A., Perry, S., Herndon, J.E., II, Bailey, L, Friedman, A.H., Friedman, H.S., Bigner, D.D., and Vredenburgh, J.J.: Temozolomide (TMZ) and bevacizumab (BV) as initial treatment for unresectable or multifocal glioblastoma multiforme (GBM). Abstract e13025. 2009 ASCO Annual Meeting, May 29-June 2, 2009, Orange County Convention Center, Orlando, FL. *J. Clin. Oncol.* (http://www.abstract.asco.org/AbstView_65_34954.html), 2009.

559. Yan, H., Parsons, D.W., Jin, G., Reitman, Z.J., McLendon, R.E., Reardon, D.A., Friedman, A.H., Friedman, H.S., Herndon, J., Riggins, G.J., Jones, S., Kinzler, K., Vogelstein, B., Velculescu, V., Rasheed, A.B., Kos, I., Batinic-Haberle, I., and Bigner, D.D.: IDH1 and IDH2 mutations play a fundamental role in glioma development. Abstract 192. Joint Meeting of SNO and AANS/CNS Section on Tumors. October 22-24, 2009, New Orleans, LA. *Neuro-Oncol.* 11(5):608, 2009.

560. Mitchell, D.A., Archer, G.E., Bigner, D.D., Friedman, H., Lally-Goss, D., Perry, B., Herndon, J., McGehee-Norman, S., McLendon, R., Reardon, D.A., Ottinger, J., Weinhold, K., and Sampson, J.H.: Cellular immunotherapy trials targeting human cytomegalovirus antigens in glioblastoma. Abstract 222. Joint Meeting of SNO and AANS/CNS Section on Tumors. October 22-24, 2009, New Orleans, LA. *Neuro-Oncol.* 11(5):615, 2009.

561. Prados, M., Cloughesy, T.F., Samant, M., Fang, L., Das, A., Friedman, H., for the BRAIN Investigators: Evaluation of objective response as a predictor of survival in bevacizumab-treated patients with glioblastoma at first or second relapse in the BRAIN study. Abstract 259. Joint Meeting of SNO and AANS/CNS Section on Tumors. October 22-24, 2009, New Orleans, LA. *Neuro-Oncol.* 11(5):623, 2009.
562. Vredenburgh, J., Cloughesy, T.F., Samant, M., Fang, L., Das, A., Friedman, H., for the BRAIN Investigators: Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Abstract 271. Joint Meeting of SNO and AANS/CNS Section on Tumors. October 22-24, 2009, New Orleans, LA. *Neuro-Oncol.* 11(5):626, 2009.
563. Desjardins, A., Vredenburgh, J.J., Gururangan, S., Peters, K.B., Friedman, A.H., Friedman, H., and Reardon, D.A.: A phase II study of bevacizumab plus etoposide among recurrent malignant glioma patients. Abstract 302. Joint Meeting of SNO and AANS/CNS Section on Tumors. October 22-24, 2009, New Orleans, LA. *Neuro-Oncol.* 11(5):633, 2009.
564. Desjardins, A., Vredenburgh, J.J., Peters, K.B., Friedman, A.H., Gururangan, S., Friedman, H., and Reardon, D.A.: Sunitinib plus irinotecan for patients with recurrent malignant glioma: a phase I trial. Abstract 303. Joint Meeting of SNO and AANS/CNS Section on Tumors. October 22-24, 2009, New Orleans, LA. *Neuro-Oncol.* 11(5):633, 2009.
565. Desjardins, A., Vredenburgh, J.J., Gururangan, S., Peters, K.B., Friedman, A.H., Friedman, H., and Reardon, D.A.: Vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma: a phase I study. Abstract 304. Joint Meeting of SNO and AANS/CNS Section on Tumors. October 22-24, 2009, New Orleans, LA. *Neuro-Oncol.* 11(5):634, 2009.
566. Desjardins, A., Reardon, D.A., Peters, K.B., Herndon, J., Kirkpatrick, J., Gururangan, S.,

Sampson, J.H., Friedman, A.H., Friedman, H.F., and Vredenburgh, J.J.: Bevacizumab (BV) in combination to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM): a phase 2 trial. Abstract 305. Joint Meeting of SNO and AANS/CNS Section on Tumors. October 22-24, 2009, New Orleans, LA. *Neuro-Oncol.* 11(5):634, 2009.

567. Wefel, J.S., Cloughesy, T.F., Zazzali, J., Zheng, M., Samant, M., Das, A., Friedman, H., for the BRAIN investigators. Neurocognitive function in patients with glioblastoma at first or second relapse treated with bevacizumab alone or in combination with irinotecan in the BRAIN study. Abstract 338. Joint Meeting of SNO and AANS/CNS Section on Tumors. October 22-24, 2009, New Orleans, LA. *Neuro-Oncol.* 11(5):641, 2009.

568. Cloughesy, T., Vredenburgh, J.J., Day, B., Das, A., Friedman, H.S., for the BRAIN Investigators: Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. Abstract 2008. 2010 ASCO Annual Meeting, June 4-8, 2010, McCormick Place, Chicago, IL. *J. Clin. Oncol.* 28, Suppl. (15S, Part I): 181s, 2010.

569. Vredenburgh, J.J., Desjardins, A., Reardon, D.A., Peters, K., Kirkpatrick, J., Herndon, J.E., Marcello, J., Bailey, L., Threath, S., and Friedman, H.S.: Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ and irinotecan for newly diagnosed glioblastoma multiforme (GBM). Abstract 2023. 2010 ASCO Annual Meeting, June 4-8, 2010, McCormick Place, Chicago, IL. *J. Clin. Oncol.* 28, Suppl. (15S, Part I): 185s, 2010.

128

570. Brickhouse, A., Vredenburgh, J.J., Gururangan, S., Reardon, D.A., Desjardins, A., Peters, K., Herndon, J.E., Norfleet, J., Marcello, J., and Friedman, H.S.: Phase I trial of vandetanib and oral etoposide (VP-16) for recurrent malignant gliomas (MG). Abstract 2038. 2010

ASCO Annual Meeting, June 4-8, 2010, McCormick Place, Chicago, IL. *J. Clin. Oncol.* 28, Suppl. (15S, Part I): 189s, 2010.

571. Desjardins, A., Vredenburgh, J.J., Reardon, D.A., Herndon, J.E., Marcello, J., Peters, K., Gururangan, S., Sathornsumetee, S., Rich, J.N., and Friedman, H.S.: Long-term survival from the initial trial of bevacizumab and irinotecan. Abstract 2045. 2010 ASCO Annual Meeting, June 4-8, 2010, McCormick Place, Chicago, IL. *J. Clin. Oncol.* 28, Suppl. (15S, Part I): 191s, 2010.

572. Sathornsumetee, S., Desjardins, A., Vredenburgh, J.J., McLendon, R.E., Marcello, J., Herndon, J.E., Norflett, J., Gururangan, S., Friedman, H.S., and Reardon, D.A.: Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results. Abstract 2055. 2010 ASCO Annual Meeting, June 4-8, 2010, McCormick Place, Chicago, IL. *J. Clin. Oncol.* 28, Suppl. (15S, Part I): 193s, 2010.

573. Peters, K., Desjardins, A., Vredenburgh, J.J., Dryman, B., Gururangan, S., Friedman, H.S., and Reardon, D.A.: Imatinib mesylate plus hydroxyurea for adults with recurrent/progressive low-grade gliomas: final phase II study results. Abstract 2060. 2010 ASCO Annual Meeting, June 4-8, 2010, McCormick Place, Chicago, IL. *J. Clin. Oncol.* 28, Suppl. (15S, Part I): 194s, 2010.

574. Kirkpatrick, J., Vredenburgh, J.J., Reardon, D.A., Desjardins, A., Peters, K., Gururangan, S., Herndon, J.E., Marcello, J., Woodring, S., and Friedman, H.S.: Phase I trial of the addition of oral topotecan to standard 5-day temozolomide for malignant gliomas. Abstract 2073. 2010 ASCO Annual Meeting, June 4-8, 2010, McCormick Place, Chicago, IL. *J. Clin. Oncol.* 28, Suppl. (15S, Part I): 198s, 2010.

575. Gururangan, S., Vredenburgh, J.J., Desjardins, A., Peters, K., Herndon, J.E., McLendon, R.E., Janney, D., Friedman, H.S., and Reardon, D.A.: CYP3A-inducing antiepileptics decrease sorafenib exposure: results of a phase II study in adults with recurrent

glioblastoma. Abstract 2089. 2010 ASCO Annual Meeting, June 4-8, 2010, McCormick Place, Chicago, IL. *J. Clin. Oncol.* 28, Suppl. (15S, Part I): 201s, 2010.

576. Desjardins, A., Reardon, D.A., Peters, K.B., Herndon II, J.E., Kirkpatrick, J.P., Friedman, H.S., and Vredenburgh, J.J.: Survival and toxicity update of the phase 2 trial of bevacizumab (BV) in combination with temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM) patients. Abstract OT-34. 15th Annual Meeting of the Society for Neuro-Oncology, November 18-21, 2010, Montreal, Quebec, Canada. *Neuro-Oncol.* 12:iv77, 2010.

577. Keir, S.T., Reardon, D.A., Watson, M., Shore, G.C., Bigner, D.D., and Friedman, H.S.: Activity of GMX1777 against a panel of brain tumor xenografts. Abstract ET-53. 15th Annual Meeting of the Society for Neuro-Oncology, November 18-21, 2010, Montreal, Quebec, Canada. *Neuro-Oncol.* 12:iv99, 2010.

578. Keir, S.T., Gururangan, S., Reardon, D.A., Bigner, D.D., and Friedman, H.S.: Efficacy of LBH589 (Panobinostat) against a panel of pediatric brain tumor xenografts. Abstract ET-54. 15th Annual Meeting of the Society for Neuro-Oncology, November 18-21, 2010, Montreal, Quebec, Canada. *Neuro-Oncol.* 12:iv99, 2010.

579. Peters, K.B., Reardon, D.A., Vredenburgh, J.J., Desjardins, A., and Friedman, H.S.: Characterization of long-term survivors of primary glioblastoma multiforme and their use of psychoactive medications. Abstract NC-09. 15th Annual Meeting of the Society for Neuro-Oncology, November 18-21, 2010, Montreal, Quebec, Canada. *Neuro-Oncol.* 12:iv59, 2010.

580. Reardon, D.A., Peters, K., Desjardins, A., Sampson, J., Vredenburgh, J.J., Gururangan, S., and Friedman, H.S.: Final results of a phase II study of imatinib mesylate (Gleevec) plus

Hydroxyurea for adults with recurrent/progressive low-grade glioma. Abstract NO-58. 15th Annual Meeting of the Society for Neuro-Oncology, November 18-21, 2010, Montreal, Quebec, Canada. Neuro-Oncol. 12:iv49, 2010.

581. Desjardins, A., Peters, K.B., Vredenburgh, J.J., Friedman, H.S., and Reardon, D.A.: Dasatinib (Sprycel) and erlotinib (Tarceva) for patients with recurrent malignant glioma: A phase I trial. Abstract#NO-67. 15th Annual Meeting of the Society for Neuro-Oncology, November 18-21, 2010, Montreal, Quebec, Canada. Neuro-Oncol. 12:iv51, 2010.

582. Reardon, D.A., Vredenburgh, J.J., Desjardins, A., Janney, D.E., Peters, K., Sampson, J., Gururangan, S., and Friedman, H.S.: A phase I/II study of vorinostat plus daily temozolomide and bevacizumab in the treatment of patients with recurrent malignant glioma. Abstract OT-19. 15th Annual Meeting of the Society for Neuro-Oncology, November 18-21, 2010, Montreal, Quebec, Canada. Neuro-Oncol. 12:iv73, 2010.

583. Peters, K.B., Reardon, D.A., Vredenburgh, J.J., Desjardins, A., and Friedman, H.S.: Retrospective analysis of insomnia in recurrent glioma patients and its association with dexamethasone and anti-epileptics. Abstract QL-23. 15th Annual Meeting of the Society for Neuro-Oncology, November 18-21, 2010, Montreal, Quebec, Canada. Neuro-Oncol. 12:iv104, 2010.

584. Gururangan, S., Fangusaro, J. Poussaint, T.Y., Onar, A., Gilbertson, R., Packer, R., McLendon, R., Friedman, H.S., and Boyett, J.: Lack of efficacy of bevacizumab (BVZ) + irinotecan (CPT-11) in children with recurrent ependymoma (EPN) – a Pediatric Brain Tumor Consortium study. Abstract PC-06. 15th Annual Meeting of the Society for Neuro-Oncology, November 18-21, 2010, Montreal, Quebec, Canada. Neuro-Oncol. 12:iv82, 2010.

130

585. Reardon, D.A., Vredenburgh, J.J., Desjardins, A., Peters, K.B., Coan, A.D., Herndon, J.E.,

and Friedman, H.S.: Bevacizumab (BV) continuation following BV progression: metaanalysis of five consecutive recurrent glioblastoma (GBM) trials. Abstract 2030. 2011

ASCO Annual Meeting, June 3-7, 2011, McCormick Place, Chicago, IL. J. Clin. Oncol. 29, Suppl. (15S, Part I): 147s, 2011.

586. Lou, E., Reardon, D.A., Peters, K., Desjardins, A., Herndon, J.E., Coan, A.D., Turner, S.G., Sumrall, A.L., Bailey, L., Friedman, H.S., and Vredenburgh, J.J.: Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma. Abstract 2055. 2011 ASCO Annual Meeting, June 3-7, 2011, McCormick Place, Chicago, IL. J. Clin. Oncol. 29, Suppl. (15S, Part I): 153s, 2011.

587. Bota, D.A., Eroglu, Z., Reardon, D.A., Fu, B.D., Norfleet, J., Desjardins, A., Linskey, M.E., Peters, K., Friedman, H.S., and Vredenburgh, J.J.: Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma. Abstract 2056. 2011 ASCO Annual Meeting, June 3-7, 2011, McCormick Place, Chicago, IL. J. Clin. Oncol. 29, Suppl. (15S, Part I): 154s, 2011.

588. Desjardins, A., Reardon, D.A., Vredenburgh, J.J., Peters, K., Trikha, M., Gardner, J.M., Brickhouse, A., Herndon, J.E., and Friedman, H.S.: A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED). Abstract 2070. 2011 ASCO Annual Meeting, June 3-7, 2011, McCormick Place, Chicago, IL. J. Clin. Oncol. 29, Suppl. (15S, Part I): 157s, 2011.

589. Vredenburgh, J.J., Desjardins, A., Reardon, D.A., Peters, K., Kirkpatrick, J., Coan, A.D., Bailey, L., Janney, D., Lu, C., and Friedman, H.S.: Bevacizumab, temozolomide and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM). Abstract 2098. 2011 ASCO Annual Meeting, June 3-7, 2011, McCormick Place, Chicago, IL. J. Clin. Oncol. 29, Suppl. (15S, Part I):

164s, 2011.

590. Sumrall, A.L., Reardon, D.A., Desjardins, A., Peters, K., Lou, E., Turner, S.G., Bailey, L, Friedman, H.S., and Vredenburgh, J.J.: Venous thromboembolic complications in patients with malignant glioma treated on a bevacizumab clinical trial. Abstract 9090. 2011 ASCO Annual Meeting, June 3-7, 2011, McCormick Place, Chicago, IL. J. Clin. Oncol. 29, Suppl. (15S, Part I): 572s, 2011.

131

132

EDITORIALS, POSITION AND BACKGROUND PAPERS,

AND INVITED LECTURES

1. Friedman, H.S., "Childhood Brain Tumors," Charlotte Memorial Hospital, Charlotte, NC, 5 March 1984.
2. Friedman, H.S., "Experimental Models of Human Medulloblastoma," Association for Brain Tumor Research, 9 October 1984.
3. Friedman, H.S., "Childhood ITP," Children's Memorial Hospital, Chicago, IL, 10 October 1984.
4. Friedman, H.S., "The Use of Experimental Models of Human Medulloblastoma in the Design of Rational Therapy," Evanston Hospital, Evanston, IL, 13 February 1985.
5. Friedman, H.S., "Treatment of Human Medulloblastoma with Classical Alkylators," The Johns Hopkins Cancer Center, Baltimore, MD, 8 July 1985.
6. Friedman, H.S., "Chemotherapy of Pediatric Brain Tumors" (Pediatric Grand Rounds), Children's Memorial Hospital, Chicago, IL, 18 September 1985.
7. Friedman, H.S., "Experimental Chemotherapy of Medulloblastoma" (Neurosurgical Grand Rounds), Visiting Professor of Neurosurgery - Northwestern University, Evanston, IL, 19 September 1985.

8. Friedman, H.S., "Current Approaches to the Chemotherapy of Medulloblastoma," New York Neurological Institute, New York, NY, 8 October 1985.
 9. Friedman, H.S., "Pediatric Brain Tumor Chemotherapy," Sixth International Conference on Brain Tumor Research and Therapy, London, 23 October 1985.
 10. Friedman, H.S., "Laboratory and Clinical Chemotherapy of Human Medulloblastoma," Memorial Sloan Kettering, New York, NY, 12 December 1985.
 11. Friedman, H.S., "Central Nervous System Xenografts and Classical Alkylators," The Johns Hopkins Cancer Center, Baltimore, MD, 8 January 1986.
 12. Friedman, H.S., "Treatment of Human Medulloblastoma with Melphalan," Burroughs-Wellcome, Invited Speaker, Research Triangle Park, NC, 8 July 1986.
 13. Friedman, H.S., "Chemotherapy of Childhood CNS Tumors," American Academy of Neurological Surgery, Sea Island, GA, 8 November 1986.
 14. Friedman, H.S., "Treatment of Pediatric Brain Tumors," American Association of Neurology, New York, NY, 10 April 1987.
 15. Friedman, H.S., "Alkylator Cytotoxicity and Resistance to Human Medulloblastoma," Memorial Sloan Kettering, New York, NY, 31 March 1988.
- 133
16. Friedman, H.S., "Alkylator Therapy of Human Medulloblastoma," Pediatric Branch, National Cancer Institute, Bethesda, MD, 8 June 1988.
 17. Friedman, H.S., "Laboratory Analysis of Pediatric Gliomas," Invited Speaker, Preuss Foundation for Brain Tumor Research, San Francisco, CA, 8 November 1988.
 18. Friedman, H.S., "Treatment of Pediatric Brain Tumors," Florida Association of Pediatric Tumor Programs, Tampa, FL, 18 November 1988.
 19. Friedman, H.S., "Therapy of Childhood Brain Tumors," Children's Hospital, Denver, CO, 22 March 1989.

20. Friedman, H.S., "Laboratory Analysis of Experimental Models of Human Medulloblastoma," ACS Neuro-Oncology Symposium, Children's Hospital, Denver, CO, 23 March 1989.
21. Friedman, H.S., "Genotypic, Phenotypic and Therapeutic Analysis of Experimental Models of Human Medulloblastoma," First Annual Dr. David S. Frommer Memorial Lecture in Neuro-Oncology, Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA, 30 March 1989.
22. Friedman, H.S., "Morphologic, Phenotypic, and Genotypic Analysis of Laboratory Models of Human Medulloblastoma," American Association of Neuropathology, Dallas, TX, 19 June 1989.
23. Friedman, H.S., "Treatment of Medulloblastoma," Consensus Meeting of the European Organization of Research for the Treatment of Cancer (EORTC), Zermatt, Switzerland, 11 September 1989.
24. Friedman, H.S., "Treatment of Low-Grade Glioma," Consensus Meeting of the European Organization of Research for the Treatment of Cancer (EORTC), Zermatt, Switzerland, 11 September 1989.
25. Friedman, H.S., "Approaches to the Design of Chemotherapy Protocols," American Academy of Pediatrics, Neurology Section Scientific Presentation, Chicago, IL, 22 October 1989.
26. Friedman, H.S., "Rationale and Choice of Chemotherapeutic Agents and Clinical Significance," International Symposium on Pediatric Neuro-oncology, Philadelphia, PA, 26 May 1990.
27. Friedman, H.S., "Modulation of Alkylation Therapy by Perturbations of Glutathione Metabolism," Burroughs Wellcome, Invited Speaker, Research Triangle Park, NC, 18 June 1990.

28. Friedman, H.S., "Advances in the Treatment of Pediatric Brain Tumors," Children's Orthopedic Hospital, Seattle, WA, 30 August 1990.

134

29. Friedman, H.S., "Use and Potential of Monoclonal Antibody Conjugates for the Treatment of CNS Neoplasia," Cancer in the Nervous System, M.D. Anderson Cancer Center, Houston, TX, 4-5 November 1990.

30. Friedman, H.S., "Rationale and Difficulties to Deliver Chemotherapy Agents to CNS Tumors," Multidisciplinary Approach to CNS Tumors in Childhood, Genova, Italy, 10 November 1990.

31. Friedman, H.S., "Treatment of Recurrences-Experimental Studies," Multidisciplinary Approach to CNS tumors, Genova, Italy, 10 November 1990.

32. Friedman, H.S., "Novel Approaches to the Treatment of Childhood Brain Tumors," Memorial Medical Center, Savannah, GA, 14 December 1990.

33. Friedman, H.S., "Role of Glutathione in Drug Activity and Toxicity," Invited Speaker, Preuss Foundation for Brain Tumor Research, Durham, NC, 16-17 April 1991.

34. Friedman, H.S., "Glutathione-Mediated Drug Resistance," Gordon Conference, Colby Sawyer College, New Hampshire, 18 July 1991.

35. Friedman, H.S., "Pediatric Oncology Group (POG) Brain Tumor Progress Report," Ninth International Conference on Brain Tumor Research and Therapy, Pacific Grove, CA, 15 October 1991.

36. Friedman, H.S., "Childhood Brain Tumors," Presbyterian Hospital, Carolinas Medical Center, Charlotte, NC, 22 November 1991.

37. Friedman, H.S., "Treatment of Pediatric Brain Tumors," Boston Children's Hospital, Boston, MA, 8 January 1992.

38. Friedman, H.S., "Modulation of Alkylator Therapy of CNS Tumors," Dana-Farber Cancer

Institute, Boston, MA, 8 January 1992.

39. Friedman, H.S., "Current Strategies in the Treatment of Childhood Brain Tumors," The Hospital for Sick Children, Toronto, Canada, 24 February 1992.

40. Friedman, H.S., "Modulation of Alkylator Therapy of Childhood Medulloblastoma and Glioma," The Hospital for Sick Children, Toronto, Canada, 25 February 1992.

41. Friedman, H.S., "Treatment of Children with Brain Tumors," Medical College of Georgia, Augusta, GA, 4 May 1992.

42. Friedman, H.S., "Modulation of Alkylator Therapy of CNS Tumors," Medical College of Georgia, Augusta, GA, 5 May 1992.

43. Friedman, H.S., and Finlay, J.L.: Innovative Chemotherapeutic Strategies for Pediatric Brain Tumors," Position Paper, American Society of Clinical Oncology, 17 May, 1992.

135

44. Friedman, H.S., "Advances in the Treatment of Pediatric Brain Tumors," Greenville Cancer Center, Greenville, SC, 27 May 1992.

45. Friedman, H.S., "Management of Pediatric Brain Tumors," Cape Fear Pediatric Society, Wilmington, NC, 11 November 1992.

46. Friedman, H.S., "Therapeutic Strategies in the Management of Childhood Brain Tumors," Medical City Hospital, Dallas, TX, 18 November 1992.

47. Friedman, H.S., "Medulloblastomas and PNET," Harvard Medical School, Boston, MA, 2 December 1992.

48. Friedman, H.S., "Treatment of Neoplastic Meningitis," Children's Cancer Group National Meeting, St. Louis, MO, 3 April 1993.

49. Friedman, H.S., "Pediatric Treatment Options in the Management of CNS Tumors," American Brain Tumor Association National Symposium, Chicago, IL, 22 May 1993.

50. Friedman, H.S., "Laboratory and Clinical Therapeutics of Pediatric Brain Tumors," Johns

Hopkins Oncology Center, Baltimore, MD, 27 May 1993.

51. Friedman, H.S., "Cyclophosphamide Resistance of Medulloblastoma," Medulloblastoma, 1993, Marseilles, France, 13 June 1993.

52. Friedman, H.S., "O6-Alkylguanine-DNA Alkyltransferase and Brain Tumors," Gordon Conference, Munich, Germany, 8 October 1993.

53. Friedman, H.S., "Pediatric Brain Tumors - Diagnosis and Therapy," Gold Coast Conference on Pediatrics, Good Samaritan Medical Center, West Palm Beach, FL, 19 March 1994.

54. Friedman, H.S., "Chemotherapy Trials for High Grade Gliomas in Children," Sixth International Symposium on Pediatric Neuro-oncology, Houston, TX, 19 May 1994.

55. Friedman, H.S., "Modulation of Drug Resistance in Cancer," Sixth International Symposium on Pediatric Neuro-oncology, Houston, TX, 20 May 1994.

56. Friedman, H.S., "Therapy of Children with Brain Tumors", Holliman Visiting Brain Tumor Professor, University of Mississippi Medical Center, Jackson, MS, 2 June 1994.

57. Friedman, H.S., "Laboratory and Clinical Therapy of Pediatric CNS Neoplasms," Evan and Marion Helfaer Distinguished Lecture, Medical College of Wisconsin, Milwaukee, WI, 21 September 1994.

58. Friedman, H.S., "Laboratory Studies of CNS Tumor Drug Resistance," XII International Congress of Neuropathology, Toronto, Canada, 18 September 1994.

59. Friedman, H.S., "Characterization of Drug Resistance at the Phenotype and Molecular Level in CNS Tumors," Child Neurology Society and International Child Neurology Association, San Francisco, CA, 4 October 1994.

136

60. Friedman, H.S., "Alkylator Resistance in CNS Tumors," Case Western Reserve University, Cleveland, OH, 16 December 1994.

61. Friedman, H.S., "From the Laboratory to the Clinic and Back and Back and Back and Back:

An Investigation of Childhood CNS Tumors," St. Jude Childrens Research Hospital,
Memphis, TN, 17 February 1995.

62. Friedman, H.S., "Laboratory and Clinical Evaluation of Brain Tumors," University of North
Carolina, Chapel Hill, NC, 4 October 1995.

63. Friedman, H.S., "Molecular Determinants of Alkylator Resistance in CNS Tumors," Albert
R. Taxin Brain Tumor Symposium, Wistar Institute, Philadelphia, PA, 30 November 1995.

64. Friedman, H.S., "Treatment of CNS Tumors with ABMT," Keystone Symposium,
Keystone, CO, 16 January 1996.

65. Friedman, H.S., "Treatment of CNS Xenografts with Camptothecins," New York Academy
of Science Conference on Camptothecins, Washington, D.C., 9 February 1996.

66. Friedman, H.S., "Alkylator Therapy with Cytokine Support for CNS Tumors," Amgen,
Thousand Oaks, CA, 12 March 1996.

67. Friedman, H.S., "Bone Marrow Transplantation for CNS Tumors," Seventh International
Symposium on Pediatric Neuro-oncology, Washington, D.C., 17 May 1996.

68. Friedman, H.S., "Advances in the Treatment of CNS Tumors," Annual Symposium on
Advances in Cancer Research, Fox Chase Cancer Center, Philadelphia, PA, 11 October
1996.

69. Friedman, H.S., "Methylation Resistance Mediated by Mismatch Repair Deficiency in a
Glioblastoma Multiforme Xenograft," American Association for Cancer Research, San
Diego, CA, 15 April 1997.

70. Friedman, H.S., "Treatment of Pediatric Brain Tumors with High Dose Chemotherapy and
Autologous Stem Cell Rescue," American Society of Clinical Oncology, Denver, CO, 16
May 1997.

71. Friedman, H.S., "Treatment of Adult Brain Tumors," Rex Cancer Center, Raleigh, NC, 3
June 1997.

72. Friedman, H.S., "Chemotherapy of Pediatric Brain Tumors," American Brain Tumor Association Symposium, Chicago, IL, 19 July 1997.

73. Friedman, H.S., "Chemotherapy of Adult Brain Tumors," American Brain Tumor Association Symposium, Chicago, IL, 19 July 1997.

74. Friedman, H.S., "Pediatric Oncology Group Clinical Trials," American Brain Tumor Association Symposium, Chicago, IL, 19 July 1997.

137

75. Friedman, H.S., "Treatment of a Brain Tumor Means Treating the Whole Family," American Brain Tumor Association Symposium, Chicago, IL, 20 July 1997.

76. Friedman, H.S., "Phase I Trial of O6-BG in Recurrent Glioma," NCI Phase I Meetings, Bethesda, MD, 12 September 1997.

77. Friedman, H.S., "Temodal Therapy of Newly Diagnosed High Grade Glioma," Twelfth International Conference on Brain Tumor Research and Therapy, Oxford, England, 21 September 1997.

78. Friedman, H.S., "Mismatch Repair Deficiency in Glioblastoma," Twelfth International Conference on Brain Tumor Research and Therapy, Oxford, London, 21 September 1997.

79. Friedman, H.S., "Monoclonal Antibody Therapy of CNS Tumors," Twelfth International Conference on Brain Tumor Research and Therapy, Oxford, London, 21 September 1997.

80. Friedman, H.S., "Temodal and CPT-11 Therapy of CNS Tumors," Mt. Sinai Medical Center Chemotherapy Foundation Symposium XIV, New York, NY, 7 November 1997.

81. Friedman, H.S., "CPT-11 Therapy of Malignant Brain Tumors," Glioma Symposium, N.Y.U. Medical Center, New York, NY, 7 November 1997.

82. Friedman, H.S., "Chemotherapy of Malignant Glioma in Adults," Massachusetts General Hospital, Boston, MA, 14 November 1997.

83. Friedman, H.S., "State of the Art Treatment for Brain Tumors," American Brain Tumor

Association, Research Triangle Park, NC, 14 June 1998.

84. Friedman, H.S., "Novel Uses of Gliadel with Systemic Chemotherapy," Gliadel Symposia, Las Vegas, NV, 10 July 1998.

85. Friedman, H.S., "Novel Chemotherapeutic Strategies of Malignant Glioma, University of Chicago, 3 August 1998.

86. Friedman, H.S., "Phase I Trial of O6-BG + BCNU," NCI Phase I Meetings, Bethesda, MD, 15 September 1998.

87. Friedman, H.S., "Temozolomide: Novel Strategies for Newly Diagnosed Glioma," Third Annual European Association of Neuro-oncology Congress, Versailles, France. 11 September 1998.

88. Friedman, H.S., "Temozolomide and CPT-11 plus BCNU Therapy of Malignant Glioma," Mt. Sinai Medical Center Chemotherapy Symposia XV, New York, NY, 13 November 1998.

89. Friedman, H.S., "Temozolomide in Malignant Glioma", Glioma Symposia, NYU Medical Center, New York, NY, 13 November 1998.

138

90. Friedman, H.S., "Temodal® Therapy of GBM and AA", Food and Drug Administration, Washington, DC, 12 January 1999.

91. Friedman, H.S., "Treatment of Childhood Brain Tumors", South Honda Brain Tumor Association Annual Meeting, West Palm Beach, FL, 24 January 1999.

92. Friedman, H.S., "Biochemical Mechanisms of Temozolomide Resistance, American Association of Cancer Research, Philadelphia, PA, 12 April 1999.

93. Friedman, H.S., "Adult Brain Tumors", American Brain Tumor Association, Chicago, IL, 23 July 1999.

94. Friedman, H.S., "Pediatric Brain Tumors", American Brain Tumor Association, Chicago,

IL, 24 July 1999.

95. Friedman, H.S., "Brain Tumor Center at Duke, CPT-11 Trials for CNS Tumors", Investigators Meeting, 18 November 1999.

96. Friedman, H.S., "Brain Tumor Center at Duke, Temodar Trials for CNS Tumors", Investigators Meeting, 18 November 1999.

97. Friedman, H.S., "Duke Brain Tumor Center CPT-11 Trials for Brain Tumors", Society for Neuro-Oncology, Scottsdale, AZ, 19 November 1999.

98. Friedman, H.S., "Duke Brain Tumor Center Temodar Trials for Brain Tumors", Society for Neuro-Oncology, Scottsdale, AZ, 19 November 1999.

99. Friedman, H.S., "Topoisomerase I Inhibitors and CNS Tumors", St. Jude Childrens Research Hospital, Memphis, TN, 23 September 2000.

100. Friedman, H.S., "Temodar Therapy of CNS Tumors", Florida Hospital, Orlando, FL, 29 December 2000.

101. Friedman, H.S., "Treatment of CNS Tumors with Temodar", M.D. Anderson – Jacksonville, Jacksonville, FL, 15 March 2001.

102. Friedman, H.S., "CPT-11 Therapy of CNS Tumors", Vanderbilt University Medical Center, 23 March 2001.

103. Friedman, H.S., "Novel Therapeutic Strategies for Brain Tumors", New York Medical College, Valhalla, NY, 20 April 2001.

104. Friedman, H.S., "Duke Brain Tumor Center Clinical Trials," Asheville, NC, 28 May 2001.

105. Friedman, H.S., "Current Treatment of CNS Tumors," University of Alabama, Birmingham, AL, 12 August 2001.

106. Friedman, H.S., "New Treatment Strategies for CNS Tumors," George Washington University, Washington, D.C., 5 December 2001.

107. Friedman, H.S., "New Treatment Strategies for CNS Tumors," Georgetown University, Washington, D.C., 6 December 2001.
108. Friedman, H.S., "Brain Tumor Therapy 2002," Florida Brain Tumor Association Annual Meeting, Tampa, Florida, 26 January 2002.
109. Friedman, H.S., "Regional Therapy of Malignant Glioma," George Washington University, Washington, D.C., 2 February 2002.
110. Friedman, H.S., "New Therapies for Malignant Glioma," Yale Comprehensive Cancer Center, New Haven, CT, 1 October 2002.
111. Friedman, H.S., "Treatment of Malignant Brain Tumors," St. Francis Hospital, Hartford, CT, 1 October 2002.
112. Friedman, H.S., "New Treatment Strategies for Malignant Glioma," Karmanos Cancer Institute, Detroit, MI, 19 December 2002.
113. Friedman, H.S., "New Strategies for CNS Tumors," Florida Brain Tumor Association, West Palm Beach, 18 January 2003.
114. Friedman, H.S., "Lab to Clinical Therapy of CNS Tumors," Fox Chase Cancer Center, Philadelphia, PA, 30 January 2003.
115. Friedman, H.S., "New Treatments for CNS Tumors," University of Louisville, Louisville, KY, 15 May 2003.
116. Friedman, H.S., "CNS Tumors – Novel Approaches to Therapy," Massachusetts General Hospital, Boston, MA, 25 June 2003.
117. Friedman, H.S., "Treatment of CNS Tumors," Washington University, St. Louis, MO, 12 December 2003.
118. Friedman, H.S., "Treatment of Malignant Glioma: Bench to Bedside," University of Tennessee, Knoxville, TN, 27 July 2004.
119. Friedman, H.S., "Temozolomide Therapy of CNS Lymphoma," Massachusetts General

Hospital, Boston, MA, 7 September 2004.

120. Friedman, H.S., "Treatment of Glioma," Grand Rapids Medical Center, Grand Rapids, MI, 9 September 2004.

121. Friedman, H.S., "Treatment of CNS Tumors," Mayfield Clinic, Cincinnati, OH, 9 September 2004.

122. Friedman, H.S., "Treatment of Brain Tumors," Virtual Trials Review (Al Musella), 12 September 2004.

123. Friedman, H.S., "Brain Tumor Strategies," Geisinger Clinic, Danville, PA, 5 October 2004.
140

124. Friedman, H.S., "Brain Tumors – Treatment Strategies," Western North Carolina Oncology Symposium, Asheville, NC, 22 October 2004.

125. Friedman, H.S., "Brain Tumor Volleyball," Brain Tumor Society Annual Meeting, Boston, MA, 30 October 2004.

126. Friedman, H.S., "Gliomas," Neuro-oncology 2005 – Current Concepts, Lake Buena Vista, FL, 30 January 2005.

127. Friedman, H.S., "Malignant Gliomas," Medical College of Georgia, Augusta, GA, 1 September 2005.

128. Friedman, H.S., "New Hope for Patients with Brain Tumors," West Virginia University School of Medicine, Morgantown, West Virginia, 7 October 2005.

129. Friedman, H.S., "New Brain Tumor Strategies for Malignant Glioma," Hackensack, University Medical Center, Hackensack, NJ, 11 November 2005.

130. Friedman, H.S., "Therapy of CNS Tumors," University of Florida, Gainesville, FL, 24 October 2006.

131. Friedman, H.S., "Treatment of CNS Tumors," University of Kansas, Kansas City, MO, 10 November 2006.

132. Friedman, H.S., "Treatment of Recurrent Malignant Glioma," Society of Neuro-Oncology, Orlando, FL, 17 November 2006.
133. Friedman, H.S., "AGT/MGMT-related Methylator/Alkylator Resistance in Malignant Glioma," Society of Neuro-Oncology, Orlando, FL, 17 November 2006.
134. Friedman, H.S., "New therapy for primary brain tumors," University of Mississippi Medical Center, Jackson, MS, 17 April 2007.
135. Friedman, H.S., "Treatment options for malignant glioma", Rush Medical Center, Chicago, IL, 21 June 2007.
136. Friedman, H.S., "Malignant Glioma", Indiana University Neurosurgery, Grand Rounds, Indianapolis, IN, 17 July 2007.
137. Friedman, H.S., "Treatment of Primary Brain Tumors", New England Medical Center, Boston, MA, 6 September 2007.
138. Friedman, H.S., "New Treatment Strategies for Malignant Brain Tumors", Piedmont Hospital, Atlanta, GA, 24 September 2007.
139. Friedman, H.S., "Brain Tumor Therapy", Western Carolina Oncology Society, Asheville, NC, 19 October, 2007.
- 141
140. Friedman, H.S., "New Treatment Strategies for Brain Tumors", Columbus, OH, 30 October, 2007.
141. Friedman, H.S., "Malignant Glioma: New Strategies", Stanford, CA, 10 January, 2008.
142. Friedman, H.S., "Brain Tumor Update", Helen Graham Cancer Center, Newark, DE, 17 January 2008.
143. Friedman, H.S., "Brain Tumor Therapy", North Carolina Neurological Society, Greensboro, NC, 15 February 2008.
144. Friedman, H.S., "New Hope for Brain Tumor Patients", Toledo, OH, 23 April 2008.

145. Friedman, H.S., "New Treatments for Brain Tumors", West Jefferson Medical Center, Marrero, LA, 15 May 2008.
146. Friedman, H.S., "New Hope for GBM", Albany Medical Center, Albany, NY, 27 August 2008.
147. Friedman, H.S., "Advances in the Treatment of Malignant Glioma," JFK Medical Center, Edison, NJ, 29 October 2008.
148. Friedman, H.S., "Glioma Resistance and MGMT", GBM Awareness Day, New York, NY, 13 November 2008.
149. Friedman, H.S., "Treatment of Malignant Glioma", Duke Raleigh Hospital, Raleigh, NC, 4 May 2010.
150. Friedman, H.S., "Therapy of Malignant Glioma with Avastin", Cooper University Hospital, Camden, NJ, 6 June 2010.
151. Friedman, H.S., "Avastin Therapy of Malignant Glioma", Raleigh Regional Cancer Center, Beckley, WV, 7, July 2010.
152. Friedman, H.S., "Treatment of Glioblastoma Multiforme", Dent Neurological Institute, Buffalo, NY, 5, May 2011.
153. Friedman, H.S. and Buckner, J., "Current State of Neuro-Oncology: Successes, Failures and the Future," American Society of Clinical Oncology, Chicago, IL, 6, June 2011.
154. Friedman, H.S., "New Hope for Patients With Brain Tumors," Montreal Neurological Institute, Montreal, Canada, 21, September 2011.

143

CONSULTATIVE APPOINTMENTS/JOURNAL REVIEWER

National Cancer Institute - Developmental Therapeutics Program

"*In Vitro* Screening"

10 January 1985

National Cancer Institute - Organ Site Program (CNS)

"Classical Alkylator Cytotoxicity and Resistance in Medulloblastoma"

25 June 1987

NIH - Study Section Reviewer (Tissue Culture)

Small Business Research Grants

4 March 1988

American Association of Cancer Research

Chairman, Clinical Investigations I

25 May 1988

Association for Brain Tumor Research

Medical Advisory Council

1989-Present

Medical Care Ombudsman Program

Candlelighters Childhood Cancer Foundation

1991-Present

National Cancer Institute - Special Review Committee

RFA-DCBDC Small Research Grants on Animal Models of Solid Tumors

25-26 March 1991

National Cancer Institute - Experimental Therapeutics-2

Ad Hoc Reviewer

28-30 October 1991

National Institute for Neurologic Diseases and Stroke - Special Review Committee

RFA - Brain Tumor Research Center Feasibility Grant

25-27 March 1992

National Cancer Institute - Experimental Therapeutics-2

Ad Hoc Reviewer

23-25 June 1992

National Cancer Institute - Experimental Therapeutics-2

Study Section Member

1 July 1992 - 30 June 1996

National Childrens Cancer Society

Medical Advisory Board

1993 - Present

144

National Cancer Institute - Experimental Therapeutics-2

Ad Hoc Reviewer

30 October - 1 November 1996

National Cancer Institute - Experimental Therapeutics-2

Ad Hoc Reviewer

26-28 February 1997

National Cancer Institute - Experimental Therapeutics-2

Ad Hoc Reviewer

25-27 June 1997

National Cancer Institute - Experimental Therapeutics-2

Study Section Member

1 July 1997 - 30 June 2001

Editorial Board

Neuro-oncology

July 1997 - present

Editorial Board

Journal of Clinical Oncology

January 1999 - 31 December 2002

Editorial Board

Clinical Cancer Research

January 2000 – present

Editorial Board

Cancer (Associate Editor of Neuro-oncology)

January 2000 – present

Oncologic Drugs Advisory Committee (Peds Subcommittee)

Food and Drug Agency

January 2001-present

National Cancer Institute – Z CA-1 RTRB-A (Manpower and Training)

Ad Hoc Reviewer

27-28 February, 2006

National Cancer Institute – Z CA-11 RTRB-A (Manpower and Training)

Ad Hoc Reviewer

12-13 February, 2008.

National Cancer Institute – Z CA-11 RTRB-A (Manpower and Training)

Study Section Member

1 July 2008 – 30 June 2012

145

Manuscripts Reviewed for the Following Journals:

Acta Neuropathologica

American Journal of Pathology

Biochemical Pharmacology

Cancer – Associate Editor for Neuro-Oncology

Cancer Chemotherapy and Pharmacology

Cancer Communications

Cancer Research

Chemico-Biological Interactions

Clinical Cancer Research

International Journal of Radiation Oncology, Biology, Physics

Investigational New Drugs

Journal of Clinical Oncology

Journal of the National Cancer Institute

Journal of Neurosurgery

Journal of Neuropathology and Experimental Neurology

Journal of Neuro-Oncology

Journal of Pediatrics

Molecular Cancer Research

Molecular Cancer Therapy

Neuro-oncology

Neurosurgery

New England Journal of Medicine

Pediatrics

Proceedings of the National Academy of Science

PROFESSIONAL AWARDS AND SPECIAL RECOGNITIONS

Citation, Upstate Medical Center, 1977

F. Wayne Rundles Award for Outstanding Cancer Research, Duke University

Comprehensive Cancer Center, 1990

Gary Lichtenstein Humanitarian Award, Voices Against Brain Cancer, 2010

Visionary Award, Tug McGraw Foundation, 2010

ORGANIZATIONS AND PARTICIPATIONS

Fellow, American Academy of Pediatrics, 1982-Present

North Carolina Pediatric Society, 1982-Present

Pediatric Oncology Group, 1982-Present

Pediatric Oncology Group: Brain Tumor Core Committee, 1983-Present

Pediatric Oncology Group: Vice-Chairperson, Brain Tumor Core Committee, 1988-1991

Southern Society for Pediatric Research, 1983-Present

American Society of Clinical Oncology, 1985-Present

American Association of Neuropathology, 1985-Present

American Association for Advancement of Science, 1985-Present

American Association for Cancer Research, 1986-Present

Society for Pediatric Research, 1986-Present

146

American Cancer Society: Professional Education Committee, 1990-1994

American Cancer Society (NC Division): Board of Directors, 1991-1994

Pediatric Oncology Group: Chairperson, Brain Tumor Core Committee, 1991-2000

Society for Neuro-Oncology, 1994-present

American Society for Clinical Investigation, 1994-Present

American Society of Clinical Oncology: Cancer Education Committee, 2000-present

Tug McGraw Foundation, Chairperson, Medical Advisory Council, 2006-present

147

(Prepared by Chairman)

Teaching Responsibilities Including Continuing Education:

Medical Student Lectures:

Dr. Friedman presents lectures to the medical students enrolled on the Neurooncology elective.

Teaching Conferences:

Dr. Friedman presents lectures in the Pediatrics, Medicine and Neurosurgical Housestaff Conference Series.

Individual Medical Student and Resident Teaching:

As an integral part of his clinical responsibilities, Dr. Friedman is involved in individual medical student and resident teaching in neuro-oncology.

Continuing Education:

Within the institution, Dr. Friedman regularly attends and participates in the departmental conferences listed above, as well as grand rounds and clinical conferences in other departments (including the Pathology Brain Cutting, Neuro-Radiology, and Neuroscience conferences). He regularly attends the annual meeting of the American Association for Cancer Research, the Society for Neuro-Oncology, and the American Society of Clinical Oncology, where he presents papers, attends scientific sessions, and chairs sessions as listed under "Selected Abstracts" and "Consultative Appointments."

Areas of Research Interests (Basic and Applied) - List:

1. Biology and Therapeutic Profile of Central Nervous System Tumors

Dr. Friedman has established the most rigorously studied models of human medulloblastoma, ependymoma and childhood and adult glioma extant. He has had longstanding collaborative relationships with Dr. O. Michael Colvin studying alkylator cytotoxicity and resistance in medulloblastoma; with Dr. Owen Griffith of the Medical College of Milwaukee studying central nervous system metabolism of glutathione, with Dr. Eileen Dolan of the University of Chicago and Dr. Tony Pegg of Penn State University

studying modulation of CNS tumor alkyltransferase activity, and with Dr. Paul Modrich and Dr. Francis Ali-Osman studying mismatch repair deficiency and methylator resistance..

As a member of the Duke Comprehensive Cancer Center, Dr. Friedman functions as the senior investigator in charge of Module 1 of the CCIF, as well as conducting his studies in medulloblastomas, ependymomas and childhood gliomas grown in athymic nude mice.

148

2. Clinical Investigation

Dr. Friedman's major area of clinical investigation is in the therapy of children and adults with newly diagnosed and recurrent brain tumors. He is the co-Deputy Director of The Preston Robert Tisch Brain Tumor Center at Duke and the Associate Director of Clinical Research, Neuro-Oncology Program, Duke Cancer Institute and designs clinical trials for children and adults with brain tumors seen at Duke (seeing 70-100 new patients per month).

External Support (Past and Present) - Gifts, Grants, and Contracts:

Purpose Duration Present Year Total

1. Junior Faculty Clinical 1983-86 \$ 27,000

Fellowship from the

American Cancer Society

2. Association for Brain 1983-86 \$ 60,000

Tumor Research

3. Duke Medical Center 1984 \$ 30,000

Institutional ACS Award

4. Duke Comprehensive Cancer 1982-84 \$ 30,000

Center Development Funds

(CA-14236)

5. Project Leader in Specialized 1984-89 \$201,000

Center of Research on Malignant

Gliomas and Medulloblastoma

(NS20023) Project 3C

6. NINCDS T-I Research 1985-90 \$261,600

Career Development Award

(#NS00958)

7. Principal Investigator 1987-89 \$127,000

on American Cancer Society

Grant (CH-403)

8. Principal Investigator 1987-91 \$201,500

on National Cancer

Institute RO1 Grant CA 44640

9. Project Leader in Specialized 1989-94 \$72,080 \$401,000

149

Center of Research on Malignant

Gliomas and Medulloblastoma

(NS20023) Project 4B

10. Principal Investigator 1990-92 \$175,000

on American Cancer Society

Grant (CH-403B)

11. Principal Investigator 1992-1993 \$202,000

on American Cancer Society

Grant (CH-403C)

12. Principal Investigator 1992-1995 \$101,633 \$351,426

on NINDS

RO1 Grant NS 30245

13. Project Leader in 1992-1996 \$ 95,219 \$416,540

National Cooperative

Drug Discovery Group

(U 01 CA 57725)

14. Principal Investigator 1991-1993 \$ 60,000

on Melphalan and Cyclophosphamide

with Autologous BMT for

Supratentorial Glioma or

Recurrent Brain Tumors

(Burroughs Wellcome Co.)

15. Principal Investigator 1993-1994 \$ 50,000

on Phase II Therapy of

Cyclophosphamide plus GM-CSF

for Recurrent, Persistent,

or Progressive Brain Tumors

(Imunex Co.)

16. Principal Investigator 1993-1995 \$100,000

on Phase I Therapy of Intrathecal

Melphalan for Patients

with Neoplastic Meningitis

(Burroughs Wellcome Co.)

150

17. Principal Investigator 1993-1994 \$ 90,000

on Phase I Dose Escalation

Trial of Carboplatin in the

Treatment of Malignant

CNS Tumors

(Amgen Co.)

18. Chairman, Pediatric Oncology 1993-1995 \$75,000

Group Brain Tumor Committee

(U5 CA 15525)

19. Institutional P.I. 1993-1996 \$ 7,500

US Army DAND

17-93-V 3016

20. Principal Investigator 1994-1996 \$254,000

on American Cancer Society

Grant (DHP-67E)

21. Project Leader in Specialized 1994-1999

Center of Research on Malignant Project 4 \$107,835 \$539,175

Glioma and Medulloblastoma Project 5 \$157,310 \$786,550

(NS20023)

22. Principal Investigator 1995-1997 \$160,000

on Phase II Trial of

Temozolomide in Treatment

of Recurrent Glioblastoma

Multiforme (Schering-Plough Co.)

23. Principal Investigator on 1995-1997 \$120,000

Phase II Trial of Temozolomide

in Treatment of Recurrent

Anaplastic Astrocytoma

(Schering-Plough Co.)

24. Brain Tumor Foundation 1995-1996 \$ 50,000

of the U.S.

25. Principal Investigator 1995-1999 \$150,000 \$460,000

on NINDS

RO1 Grant NS 30245

26. Principal Investigator on Phase I 1995-1997 \$122,308 \$245,571

Trial of O6-Benzylguanine Plus

BCNU in Glioma (CA67266)

151

27. Principal Investigator 1996-1997 \$103,000

on Rapamycin Therapy of

Brain Tumors

(Wyeth-Ayerst Co.)

28. Principal Investigator on 1996-1997 \$100,000

Therapy of Neoplastic

Meningitis in Athymic Nude

Rats with Busulfan

(Sparta)

29. Principal Investigator on 1996-1997 \$133,000

Therapy of Neoplastic Meningitis

in Athymic Nude Rats with

Temozolomide

(Schering Plough Co.)

30. Principal Investigator on American 1996-1997 \$126,000

Cancer Society Grant

(DHP-67H)

31. Project Leader in National 1996-01 \$ 97,403 \$527,345

Cooperative Drug Discovery

Group (UO1 CA95020)

32. Principal Investigator on 1996-1997 \$150,000

Phase II Trial of Temozolomide

in Treatment of Newly Diagnosed

High Grade Glioma

(Schering-Plough Co.)

33. Principal Investigator on 1997-1998 \$ 40,000

Phase I Trial of Topotecan +

BCNU for Recurrent High

Grade Glioma (Smith-Kline-Beecham)

34. Principal Investigator on 1997-2000 \$ 50,000

Phase I Trial of CPT-11 + BCNU

for Recurrent High Grade Glioma

(Pharmacia and Upjohn)

35. Principal Investigator on 1997-1998 \$ 40,000

Phase I Trial of Intrathecal

Topotecan for Patients with

Neoplastic Meningitis

(Smith-Kline-Beecham)

152

36. Principal Investigator on 1997-1998 \$ 123,000

Phase II Trial of CPT-11 for Adults

and Children with Malignant

Brain Tumors (Pharmacia

and Upjohn)

37. Principal Investigator on 1997-1999 \$ 170,000

Phase II Trial with Laboratory

Correlates of Temozolomide in

Treatment of Newly Diagnosed GBM

(Schering-Plough Co.)

38. Principal Investigator on 1997-1999 \$ 247,000

Phase II Trial of Gliadel

Wafers for Adults with

Recurrent Low Grade Glioma

(Rhone-Poulenc-Rorer)

39. Principal Investigator on 1997-1999 \$ 150,000

Phase II Trial of Temozolomide

for Patients with Progressive Low

Grade Glioma (Schering-Plough Co.)

40. Principal Investigator on Phase II 1997-1999 \$ 150,000

Trial of Temozolomide for Adults

with Newly Diagnosed or Recurrent

Anaplastic Oligodendroglioma

(Schering-Plough Co.)

41. Principal Investigator on Phase I 1997-1999 \$ 72,000

Trial of Gliadel Wafers Plus

Temozolomide for Adults with

Progressive High Grade Glioma

(Schering-Plough Co. and Rhone-

Poulenc-Rorer)

42. Principal Investigator on Phase I 1998-1999 \$ 72,000

Trial of Gliadel Wafers Plus

CPT-11 for Adults with Progressive

High Grade Glioma

(Schering-Plough Co. and Rhone-

Poulenc-Rorer)

43. Principal Investigator on Phase II 1998-1999 \$ 140,000

Trial of L-Alanosine for Adults

with Recurrent High Grade Glioma

(Triangle Pharmaceuticals)

153

44. Principal Investigator on FDA Grant: 1998-2001 \$ 300,000

Phase I Trial of Intrathecal Busulfan

for Patients with Neoplastic

Meningitis (FDA)

FD-R-001519-01

45. Principal Investigator on NCI Grant 1998-2005 \$215,696 \$1,157,756

T32 CA74736 – Research Training

In Neuro-Oncology

46. Principal Investigator on NINDS 1999-2004 \$225,000 \$ 1,203,058

R01 Grant NS 30245: DNA Repair

Mediated Resistance in CNS Tumors

47. Principal Investigator on Phase II 1999-2000 \$ 250,000

Trial of Temozolomide for

Brain Metastases

(Schering-Plough Co.)

48. Principal Investigator on Phase II 1999-2000 \$ 360,000

Trial of Temozolomide for

Children with Newly Diagnosed

Brain Tumors

(Schering-Plough Co.)

49. Principal Investigator on Phase I 1999-2000 \$ 150,000

Trial of Anti-angiogenesis Agent

PXY in Patients with Recurrent

Malignant Brain Tumors

(Novartis)

50. Principal Investigator on Phase I 1999-2000 \$ 150,000

Trial of CPT-11 plus Temozolomide

For Patients with Recurrent

Malignant Glioma (Schering-

Plough Co. and Pharmacia and

Upjohn)

51. Principal Investigator on NCI Grant 1999-2001 \$150,000 \$ 300,000

R21 CA81651 – Temozolomide

Resistance in CNS Tumors

154

52. Principal Investigator on Phase II 2000-2002 \$ 50,000

Trial of Temozolomide for Patients

with Newly Diagnosed or

Progressive CNS Lymphoma

(Schering-Plough Co.)

53. Principal Investigator on Phase II 2000-2002 \$ 525,000

Trial of CPT-11 for Patients with

Brain Metastases (Pharmacia and

Upjohn)

54. Principal Investigator on Phase II 2000-2002 \$ 40,000

Trial of Temodar plus Gliadel

Wafers for Patients with Recurrent

Malignant Glioma (Aventis Co. and

Schering-Plough Co.)

55. Principal Investigator on Phase II 2000-2002 \$ 100,000

Trial of O6-Benzylguanine Plus

BCNU for Patients with Nitrosourea

Resistant Malignant Glioma

56. Principal Investigator on Phase I 2000-2002 \$ 90,000

Trial of CPT-11 Plus Temodar for

Patients with Recurrent Malignant

Glioma (Pharmacia,

and Schering-Plough Co.)

57. Principal Investigator on Phase I 2000-2002 \$ 30,000

Trial of Temozolomide Plus

VP-16 for Patients with Recurrent

Malignant Glioma (Schering-Plough

Co.)

58. Principal Investigator on Phase I Trial 2000-2002 \$ 100,000

of SCH66636 for Patients with

Recurrent Malignant Glioma

(Schering-Plough Co.)

59. Principal Investigator on Phase II 2001-2003 \$ 250,000

Trial of CPT-11 Plus BCNU for

Patients with Malignant Glioma

(Pharmacia Co.)

60. Principal Investigator on NCI Grant 1999-2004 \$125,000 \$ 625,000

U01 CA81474 – Pediatric Brain

Tumor Consortium

155

61. Principal Investigator on Phase II 2001-2003 \$ 150,000

Trial of Thalidomide Plus

Cyclophosphamide for Newly Diagnosed

or Recurrent Malignant Glioma

(Celgene)

62. Principal Investigator on NCI Grant: 2001-2003 \$225,000 \$ 450,000

R21 CA091548) – Phase II Trial of

ZD1839 for First Relapse Glioblastoma

63. Principal Investigator on Phase II Trial 2001-2003 \$ 100,000

of Irofulven for Patients with

Recurrent Malignant

Glioma (MGI Pharma)

64. Principal Investigator on 2001-2002 \$ 100,000

Phase II Trial of Karenitecin for

Patients with Newly Diagnosed or

Recurrent Malignant Glioma

(BioNumerik)

65. Principal Investigator on 2001-2005 \$225,000 \$ 900,000

NCI RO1 CA 94231:

Regional AGT Depletion of CNS

and Leptomeningeal Tumors

66. Principal Investigator on 2002-2003 \$ 125,000

Phase II Trial of CPT-11/Celebrex

for Newly Diagnosed or

Recurrent Malignant Glioma

67. Principal Investigator on 2003-2004 \$ 50,000

Phase I Trial of CPT-11/Temodar/

O6-BG for Recurrent Malignant

Glioma

68. Principal Investigator on 2004-2009 \$125,000 \$ 675,000

NCI Grant UO1 CA 81457:

Pediatric Brain Tumor Consortium

69. Principal Investigator on 2005-2010 \$250,000 \$ 1,250,000

NCI RO1 NS 30245: Temozolomide

Resistance in CNS Tumors

70. Principal Investigator on NCI Grant 2005-2010 \$300,571 \$ 1,501,855

T32 CA 74736: Research Training

156

in Neuro-Oncology

71. Principal Investigator on 2006-2007 \$ 350,000

Phase II Trial of Avastin vs. Avastin

plus CPT-11 for First or Second Relapse

GBM (Genentech)

72. Principal Investigator on Voices 2009-2011 \$50,000 \$ 100,000

Against Brain Tumors Grant: Stem

Cell Models to Stimulate Neuro-

Regeneration Following Whole Brain

Radiation Therapy in a Mouse Model

of Malignant Glioma

73. Principal Investigator on NCI Grant 2010-2015 \$296,172 \$ 1,480,860

T32 CA 74736: Research Training in

Neuro-Oncology

157

Clinical Activity - Type of Practice and Estimate of Time Commitment:

Laboratory Research: 20%

Clinical Research/Service: 80%

Participation and Academic and Administrative Activities of the University and Medical

Center:

Co-Director, Collegiate Athlete Premedical Experience (CAPE), 1999-present

Executive Admissions Committee, Duke Medical School, 2008-present